

Financial news for GILD dated on 2020-06-10: Gilead Sciences: Co. Said To Refinance \$2.5B Loan Facility

Financial news for GILD dated on 2020-06-10: Gilead Sciences Option Alert: Jun 19 \$80 Calls Sweep (2) near the Ask: 300 @ \$1.121 vs 22172 OI; Earnings 7/28 After Close [est] Ref=\$78.32

Financial news for GILD dated on 2020-06-10: A Peek Into The Markets: US Stock Futures Mixed; All Eyes On Fed Decision

Financial news for GILD dated on 2020-06-10: Singapore Approves Gilead's Remdesivir as COVID-19 Treatment

Financial news for GILD dated on 2020-06-09: A Look Into Gilead Sciences' Price Over Earnings

Financial news for GILD dated on 2020-06-09: Gilead's Remdesivir Slows Disease Progression in Monkeys with COVID-19

Financial news for GILD dated on 2020-06-08: 4 Analysts On Why The Rumored AstraZeneca-Gilead Deal Is Unlikely To Materialize

Financial news for GILD dated on 2020-06-08: Astrazeneca CEO Soriot Said To Have Called Gilead CEO On May 9; Proposed Exploring Merger On A Call

Financial news for GILD dated on 2020-06-08: PreMarket Prep Stock Of The Day: Gilead Sciences

Financial news for GILD dated on 2020-06-08: 3 Gilead-Heavy ETFs To Watch Amid The AstraZeneca-Gilead Rumor

Financial news for GILD dated on 2020-06-08: EMA Receives Application For Conditional Authorization Of First COVID-19 Treatment In EU

Financial news for GILD dated on 2020-06-08: 'Gilead, AstraZeneca not in merger talks' CNBC's Faber Reports

Financial news for GILD dated on 2020-06-08: Gilead Sciences shares are trading higher following a Bloomberg article suggesting AstraZeneca has approached the company regarding a merger.

Financial news for GILD dated on 2020-06-08: A Peek Into The Markets: US Stock Futures Up; OPEC+ Agrees To Extend Output Cuts

Financial news for GILD dated on 2020-06-08: AstraZeneca Approached Gilead With A Deal That Could Be The Biggest On Record: Report

Financial news for GILD dated on 2020-06-07: AstraZeneca Approaches Gilead Regarding Potential Record Health-Care Merger

Financial news for GILD dated on 2020-06-06: Bulls And Bears Of The Week: Gilead, Shopify, Tesla And More

Financial news for GILD dated on 2020-06-05: Galapagos And Gilead Highlight Presentation Of Analyses From Phase 2 EQUATOR Clinical Program Of Efficacy Of Filgotinib In Psoriatic Arthritis

Financial news for GILD dated on 2020-06-04: The Daily Biotech Pulse: Positive Readout For Kezar, AstraZeneca Stitches Oncology Partnership, D-Day For Merck's Triple Combo Antibiotic

Financial news for GILD dated on 2020-06-04: Gilead Says Indian Licensees are Free to Set Price of Remdesivir

Financial news for GILD dated on 2020-06-04: Gilead, Galapagos Announce Filgotinib Demonstrates Durable Efficacy and Consistent Safety Profile at 52 Weeks in Finch 1 and 3 Studies in Rheumatoid Arthritis

Financial news for GILD dated on 2020-06-03: Gilead Analyst: Coronavirus Drug, Arcus Collaboration Make Biopharma A Buy

Financial news for GILD dated on 2020-06-03: STAT News' Adam Feuerstein Retweets Tweet From Memorial Sloan-Kettering Doctor, Peter Bach, On Gilead Remdesivir Reanalysis Data

Financial news for GILD dated on 2020-06-03: SVB Leerink Upgrades Gilead From Market Perform To Outperform, Raises PT From \$85 To \$94

Financial news for GILD dated on 2020-06-02: Gilead shares are trading lower on

continued momentum after the company reported data from its Phase 3 Trial of Remdesivir showing odds of improvement in clinical status with 10-day course were trending toward but not reaching statistical significance.

Financial news for GILD dated on 2020-06-02: 'Gilead Drug Remdesivir's Use Against Coronavirus Could Become Obsolete, Analyst Says' -Barrons Report

Financial news for GILD dated on 2020-06-02: 'Gilead's next step on coronavirus: inhaled remdesivir, other easier-to-use versions' -Reuters

Financial news for GILD dated on 2020-06-02: Gilead's Remdesivir Cleared for Use in India for Severe Covid Cases

Financial news for GILD dated on 2020-06-01: Mark Genovese Joins Gilead to Lead Clinical Development of Company's Inflammation Programs

Financial news for GILD dated on 2020-06-01: BioSig Shares Spike To Session High On Volume; 8-K Filing Shows Co. Subsidiary ViralClear Filed Protocol Of Planned Study To Evaluate Safety, Efficacy Of Merimepodib In Combo With Remdesivir For Patients With Advanced Coronavirus To ClinicalTrials.gov

Financial news for GILD dated on 2020-06-01: Gilead Falls On Mixed Results From Late-Stage Remdesivir Study In Moderate COVID-19

Financial news for GILD dated on 2020-06-01: Gilead shares are trading lower after the company reported data from its Phase 3 Trial of Remdesivir showing odds of improvement in clinical status with 10-day course were trending toward but not reaching statistical significance.

Financial news for GILD dated on 2020-06-01: 'Gilead study of remdesivir in moderate #COVID19 patients out: patients on 5-day course were 65% more likely to have clinical improvement at Day 11 vs standard of care, but effect for those on 10-day course was not statistically significant' -Tweet

Financial news for GILD dated on 2020-06-01: Gilead Says Odds Of Improvement In Clinical Status With 10-day Course Of Remdesivir Were Trending Toward But Not Reaching Statistical Significance

Financial news for GILD dated on 2020-06-01: UPDATE: Gilead Study Demonstrated That Patients In The 5-day Remdesivir Treatment Group Were 65 Percent More Likely To Have Clinical Improvement At Day 11 Compared With Those In The Standard Of Care Group

Financial news for GILD dated on 2020-06-01: Gilead Announces Results From Phase 3 Trial of Remdesivir in Patients With Moderate COVID-19; Study Demonstrates 5-Day Treatment Course of Remdesivir Resulted in Significantly Greater Clinical Improvement Versus Treatment with Standard of Care Alone

Financial news for GILD dated on 2020-05-31: Mylan's Pakistan Partner AGP to Sell Remdesivir to Treat Covid-19 Within Two Months

Financial news for GILD dated on 2020-05-29: Gilead Seeks Marketing Authorization From India

Financial news for GILD dated on 2020-05-29: Gilead's Kite Pharma Reports Yescarta Data Showing Response Rates In Relapsed, Refractory Indolent Non-Hodgkin Lymphoma To Be Presented At ASCO

Financial news for GILD dated on 2020-05-29: Gilead Reports Updated Results From Single-Arm, Open-Label Phase 1b Trial Of Magrolimab In Combo With Azacitidine In Previously Untreated Patients With Higher-Risk Myelodysplastic Syndrome

Financial news for GILD dated on 2020-05-28: Tigress Financial's Ivan Feinseth Notes Many Co.'s Working To Produce Coronavirus Vaccines/Treatments; Says If Remdesivir Is Ramped Up, Gilead May Need To Work With Others To License And Produce It, And It May Not Be As Profitable

Financial news for GILD dated on 2020-05-28: The Daily Biotech Pulse: PhaseBio To Start Potential Pivotal COVID-19 Trial, Immunomedics CEO Quits, Tetrphase Receives Sweetened Offer

Financial news for GILD dated on 2020-05-28: BDR Pharmaceuticals Sought India Approval to Manufacture Remdesivir Without Gilead Agreement

Financial news for GILD dated on 2020-05-28: Roche Initiates Phase III Clinical Trial of Actemra/Roactemra Plus Remdesivir in Hospitalised Patients With Severe Covid-19 Pneumonia in collaboration with Gilead

Financial news for GILD dated on 2020-05-27: Gilead And Arcus Biosciences Establish 10-Year Partnership To Co-Develop And Co-Commercialize Next-Generation Cancer

Immunotherapies; Arcus To Receive \$175M Up Front And \$200M Equity Investment Plus Up To \$1.6B In Potential R&D Funding+Milestones

Financial news for GILD dated on 2020-05-26: UK Clears Gilead's Remdesivir For Some Coronavirus Patients

Financial news for GILD dated on 2020-05-26: CORRECTION: UK Health Minister Hancock Says Anti-Viral Drug Remdesivir Is Probably Biggest Step Forward In Treatment Since Crisis Began; Prior Headline Named Hancock US Health Minister, This Was Incorrect

Financial news for GILD dated on 2020-05-26: 'Gilead Could Sell \$1.1 Billion of Remdesivir This Year, Analyst Writes' -Barrons Report

Financial news for GILD dated on 2020-05-26: UK Health Minister Hancock Says Anti-Viral Drug Remdesivir Is Probably Biggest Step Forward In Treatment Since Crisis Began

Financial news for GILD dated on 2020-05-26: Benzinga's Top Upgrades, Downgrades For May 26, 2020

Financial news for GILD dated on 2020-05-26: 10 Biggest Price Target Changes For Tuesday

Financial news for GILD dated on 2020-05-26: SunTrust Robinson Humphrey Upgrades Gilead Sciences to Hold, Raises Price Target of \$73

Financial news for GILD dated on 2020-05-26: UK Health Ministry Says Selected NHS Patients to Access Gilead's Coronavirus Treatment Remdesivir

Financial news for GILD dated on 2020-05-22: Investigators Found Remdesivir Was Most Beneficial for Hospitalized Patients With Severe Disease Requiring Supplemental Oxygen; Findings Less Conclusive in Other Patient Subgroups

Financial news for GILD dated on 2020-05-22: NIH Says Peer-reviewed Data Shows Gilead's Remdesivir for Covid-19 Improves Time to Recovery; Says Remdesivir is Superior to Standard of Care for Treatment of Covid-19, According to Report Published in New England Journal of Medicine

Financial news for GILD dated on 2020-05-22: Fauci On Remdesivir Study: Study Showed Advantage Of Diminishing Time Of Recovering From COVID-19

Financial news for GILD dated on 2020-05-22: Gilead Sciences Option Alert: Jun 19 \$75 Calls Sweep (39) near the Ask: 854 @ \$2.185 vs 17286 OI; Ref=\$72.88

Financial news for GILD dated on 2020-05-21: The Daily Biotech Pulse: Mixed Filgotinib Readout For Gilead-Galapagos, Akorn To File For Chapter 11, D-Day For Aquestive

Financial news for GILD dated on 2020-05-20: Gilead, Galapagos Report Topline Results From Phase 2b/3 Trial Of Filgotinib In Moderate To Severe Active Ulcerative Colitis

Financial news for GILD dated on 2020-05-20: Gilead Sciences Option Alert: Jul 17 \$80 Calls Sweep (32) near the Ask: 508 @ \$2.09 vs 5144 OI; Ref=\$73.8899

Financial news for GILD dated on 2020-05-20: Gilead Sciences Option Alert: May 29 \$75 Calls Sweep (2) near the Ask: 300 @ \$1.45 vs 2555 OI; Ref=\$73.31

Financial news for GILD dated on 2020-05-20: 'Gov. Abbott announced El Paso hospitals would receive 12 cases of Remdesivir...' -Tweet From El Paso, Texas' KVIA ABC 7 News

Financial news for GILD dated on 2020-05-19: In The Midst Of Pandemic, Traders Pin Their Hopes On These Healthcare ETFs

Financial news for GILD dated on 2020-05-18: RBC Analyst Earlier Warned Gilead's Remdesivir Is Unlikely To Yield Monetary Results Co. Hoped, Notes Co. Planning To Give Away 1.5M Doses For Free

Financial news for GILD dated on 2020-05-18: Gilead Sciences Option Alert: Jan 15 \$125 Calls Sweep (26) above Ask!: 300 @ \$0.686 vs 2223 OI; Ref=\$74.881

Financial news for GILD dated on 2020-05-17: Barron's Picks And Pans: Cisco, Gilead, Netflix, Wayfair And More

Financial news for GILD dated on 2020-05-15: Gilead Sciences Option Alert: Jan 15 \$90 Calls Sweep (3) near the Ask: 350 @ \$4.651 vs 8065 OI; Ref=\$75.96

Financial news for GILD dated on 2020-05-14: VBI Vaccines Shares At Session Highs; 'Why Big Investors Aren't Betting It All on a Coronavirus Cure' -WSJ Article; Mentions Gilead, VBI Vaccines, INOVIO

Financial news for GILD dated on 2020-05-14: '#COVID19 No data disclosed for #remdesivir #hydroxychloroquine in the DISCOVERY trial in France.' -Tweet From Andy Biotech. BZ NOTE: Content In Tweet From ~2 Hours Ago

Financial news for GILD dated on 2020-05-13: Gilead, Co.'s Kite Pharma Highlight Acceptance Of 9 Abstracts During ASCO 2020

Financial news for GILD dated on 2020-05-13: Gilead Sees Some Results On Remdesivir In 'Few Weeks'

Financial news for GILD dated on 2020-05-13: Hetero Enters Into a Licensing Agreement With Gilead Sciences, Inc. for the Manufacturing and Distribution of "Remdesivir" in 127 Countries, Including India, for COVID-19

Financial news for GILD dated on 2020-05-13: Roivant Sciences Says Breathe Trial Participants Will Be Permitted To Use Investigational Antivirals Including Remdesivir

Financial news for GILD dated on 2020-05-13: The Daily Biotech Pulse: Gilead Signs Manufacturing Deal For Remdesivir, Bristol-Myers Gets Refuse-To-File Letter

Financial news for GILD dated on 2020-05-13: 4 Key Takeaways From Senate's Online Hearing On US Coronavirus Strategy, Reopening Economy

Financial news for GILD dated on 2020-05-13: Gilead Shares Drop As It Agrees To 'Royalty-Free' Coronavirus Drug Licence With Generic Drugmakers In 127 Countries

Financial news for GILD dated on 2020-05-12: UPDATE: Under The Terms Of The License Agreement Signed With Gilead, Mylan Has Rights To Manufacture And Distribute Remdesivir In 127 Low- And Middle-Income Countries, Including India.

Financial news for GILD dated on 2020-05-12: Mylan To Supply Investigational Antiviral Remdesivir For The Potential Treatment Of Coronavirus/COVID-19

Financial news for GILD dated on 2020-05-12: Gilead Confirms Non-Exclusive Voluntary License Deal For Distribution Of Remdesivir With 5 Generic Makers In 127 Countries

Financial news for GILD dated on 2020-05-12: Here's A Bullish Options Play On Gilead

Financial news for GILD dated on 2020-05-12: 'Gilead strikes licensing agreements w 5 cos (Cipla Ltd., Ferozsons Laboratories, Hetero Labs Ltd., Jubilant Lifesciences and Mylan) to manufacture remdesivir in 127 countries, royalty-free until WHO declares end of global public health emergency' -Tweet

Financial news for GILD dated on 2020-05-12: Jubilant Life Sciences Signs Non-Exclusive License Deal For Selling Gilead's Remdesivir In 127 Countries Including India; BZ NOTE: Jubilant Not Publicly Traded In US

Financial news for GILD dated on 2020-05-12: FDA Commissioner: We've Learned A Lot Of Lessons From The 'Remdesivir Situation'

Financial news for GILD dated on 2020-05-12: Fauci: Remdesivir Study Was Statistically Significant But Modest Success

Financial news for GILD dated on 2020-05-12: 'Distribution of Key Drug Was Flawed, Says White House Official' -Yesterday WSJ Report

Financial news for GILD dated on 2020-05-11: UPDATE: European Medicines Authority Says Has Added Treatment Duration Of 5 Days For Gilead's Remdesivir Alongside 10-Day Course

Financial news for GILD dated on 2020-05-11: European Medicine Authority Recommends Expanding Gilead's Remdesivir Compassionate Use To Patients Not On Mechanical Ventilation

Financial news for GILD dated on 2020-05-11: Gilead shares are trading higher. Strength potentially due to optimism surrounding the company's Remdesivir, which is being evaluated as a potential coronavirus treatment candidate.

Financial news for GILD dated on 2020-05-11: Biotech Stock Rally Is Crushing Short Sellers

Financial news for GILD dated on 2020-05-10: The Week Ahead In Biotech: Virtual Conference Presentations, Clovis PDUFA Date In The Spotlight

Financial news for GILD dated on 2020-05-10: NYC Mayor Bill de Blasio Tweets: This week the FDA approved the use of Remdesivir to treat severely ill COVID-19 patients. The initial clinical trials shows it decreased hospital stays from 15 to 11 days. That's promising.

Financial news for GILD dated on 2020-05-09: HHS Announces Shipments of Donated Remdesivir for Hospitalized Patients With Covid-19 from a Donation by Gilead Sciences to the U.S. Which Was Finalized on May 3, 2020

Financial news for GILD dated on 2020-05-08: UPDATE: NIAID Says Investigators Currently Expect Enrolling 1K+ Patients In Remdesivir Plus Baricitinib Trial

Financial news for GILD dated on 2020-05-08: UPDATE: NIH's National Institute Of Allergy And Infectious Diseases Says Remdesivir Trial Is Expected To Open At ~100 US, Int'l. Sites

Financial news for GILD dated on 2020-05-08: US National Health Institutes Clinical Trial Testing Remdesivir Plus Anti-Inflammatory Adults With Coronavirus In US

Financial news for GILD dated on 2020-05-08: Iranian Linked Hackers Attacked Gilead

Financial news for GILD dated on 2020-05-08: White House Says Task Force's Birx Will Offer Consultation Regarding Gilead's Coronavirus Drug

Financial news for GILD dated on 2020-05-07: Gilead Issues Press Release Highlighting Approval Of Veklury In Japan For Patients With Severe Coronavirus Infection

Financial news for GILD dated on 2020-05-07: 3 Biotech ETFs Up 10% Or More Over The Last Month

Financial news for GILD dated on 2020-05-07: Gilead Sciences Option Alert: May 15 \$80 Calls Sweep (4) near the Ask: 725 @ \$0.96 vs 14381 OI; Ref=\$77.35

Financial news for GILD dated on 2020-05-07: Japan Health Ministry Official: Remdesivir Will Be Used For Coronavirus/Covid-19 Patients With Severe Conditions

Financial news for GILD dated on 2020-05-07: Japan Approves Gilead Sciences' Drug Remdesivir As Coronavirus/COVID-19 Treatment

Financial news for GILD dated on 2020-05-06: EXUMA Biotech Is 'Revolutionizing CAR-T Therapy,' Increasing Patient Access, CEO Says

Financial news for GILD dated on 2020-05-06: Gilead Works To 'Maximize Global Supply' Of Coronavirus Candidate Remdesivir Amid Threat Of Patent Loss

Financial news for GILD dated on 2020-05-06: Gilead Says Possibility That Co May Experience Delays With NDA for Filgotinib for Treatment of RA Filed With FDA and With NDA, MAA for Kte-x19 for Treatment of Relapsed or Refractory Mantle Cell Lymphoma

Financial news for GILD dated on 2020-05-06: Gilead Says Anticipate Accelerating Remdesivir Investments in Future Quarters

Financial news for GILD dated on 2020-05-06: Gilead Sciences Says Incurred ~\$50M of Manufacturing Scale-up, Clinical Trial Costs for Remdesivir During Q1

Financial news for GILD dated on 2020-05-06: Coronavirus Has Been Circulating Since Late 2019, UK Research Says

Financial news for GILD dated on 2020-05-05: Gilead In Talks With Some Chemicals, Pharma Companies About Ability To Produce Remdesivir For Europe, Asia, Developing World Through At Least 2022

Financial news for GILD dated on 2020-05-05: UPDATE: Gilead Negotiating Long-Term Voluntary Licenses With Several Generic Drugmakers In India, Pakistan To Produce Remdesivir For Developing Countries

Financial news for GILD dated on 2020-05-05: Gilead Will Further Accelerate, Maximize Access To Remdesivir, Negotiating On Long-Term Voluntary Licenses With Drugmakers

Financial news for GILD dated on 2020-05-05: Japanese Health Minister Says Gilead's Remdesivir May Be Approved In Japan On Thursday

Financial news for GILD dated on 2020-05-05: 'With remdesivir, Gilead finds itself at strategic crossroads, with its reputation (and far more) at stake' -STAT News \$

Financial news for GILD dated on 2020-05-04: WHO Expert Says It Has Not Received Any Data From The US Relevant To The Purported Origin Of The Virus, Need To Understand More About Virus

Financial news for GILD dated on 2020-05-04: WHO Says We Welcome The Recent Data From Randomized Control Trial Done In US With Gilead's Remdesivir Says 'There Are Signals Of Hope There For The Potential Use Of The Drug'

Financial news for GILD dated on 2020-05-04: 4 Sector ETFs For May: 2 To Buy, 2 To Avoid

Financial news for GILD dated on 2020-05-04: A Peek Into The Markets: US Stock Futures Down; Dow Futures Fall Over 300 Points

Financial news for GILD dated on 2020-05-04: 7 Stocks To Watch For May 4, 2020

Financial news for GILD dated on 2020-05-03: Remdesivir To Be Available For Coronavirus Patients This Week, Gilead CEO Says

Financial news for GILD dated on 2020-05-03: Trump Says Gilead is Pushing Fast on Coronavirus Drug

Financial news for GILD dated on 2020-05-03: Gilead CEO O'Day Says Co Has Donated Its Remdesivir Supplies to Federal Government' Says Government to Determine Where Treatments Go, Based on Need

Financial news for GILD dated on 2020-05-03: Benzinga's Bulls And Bears Of The Week: Ford, Gilead, Microsoft, Intel And More

Financial news for GILD dated on 2020-05-02: Barron's Picks And Pans: Berkshire Hathaway, Carvana, Madison Square Garden And More

Financial news for GILD dated on 2020-05-01: Reuters Issues Correction: Says Vice President Pence Says The 1.5 Million (Not 1 Million) Vials Of Remdesivir Will Start Being Distributed To Hospitals On Monday

Financial news for GILD dated on 2020-05-01: Markets Have Best Month Since 1987, But End Week On Low Note

Financial news for GILD dated on 2020-05-01: Gilead's Remdesivir Granted FDA Emergency Use To Treat COVID-19

Financial news for GILD dated on 2020-05-01: Gilead Says Set A Goal Of Producing At Least 500,000 Treatment Courses By October, 1M Treatment Courses By December 2020 And 'Millions More In 2021'

Financial news for GILD dated on 2020-05-01: Gilead Says Authorization Allows 5-Day And 10-Day Treatment Durations

Financial news for GILD dated on 2020-05-01: Gilead Clarifies: 'Remdesivir remains an investigational drug and has not been approved by FDA'; Notes 'The authorization is temporary and does not take the place of the formal new drug application submission, review and approval process'

Financial news for GILD dated on 2020-05-01: Gilead PR Highlights FDA Emergency Authorization For Remdesivir; Says 'Authorization Enables Broader Use of Remdesivir to Treat Hospitalized Patients with Severe COVID-19 Disease in the United States'

Financial news for GILD dated on 2020-05-01: Vice President Pence Says 1M Vials Of Remdesivir Will Start Being Distributed To Hospitals On Monday

Financial news for GILD dated on 2020-05-01: FDA Letter To Gilead Authorizing Emergency Use For Remdesivir (Full Letter)

Financial news for GILD dated on 2020-05-01: (PDF) FDA Fact Sheet For Remdesivir

Financial news for GILD dated on 2020-05-01: Gilead Shares Spike On Reports Of FDA Emergency Use Authorization For Remdesivir; Down ~4.3% For The Session

Financial news for GILD dated on 2020-05-01: FDA's Hahn Says 'This Is An Important Clinical Advance'

Financial news for GILD dated on 2020-05-01: FDA Commissioner Hahn: Gilead Drug Authorized For Use In Hospitalized Patients

Financial news for GILD dated on 2020-05-01: Trump Says Gilead CEO Calls It An Important First Step And Is Donating 1 Million Vials Of Remdesivir

Financial news for GILD dated on 2020-05-01: Trump Says Gilead Has Emergency Use Authorization From FDA

Financial news for GILD dated on 2020-05-01: Gilead Analysts See Questionable Commercial Opportunity For Coronavirus Candidate Remdesivir

Financial news for GILD dated on 2020-05-01: UPDATE: Morgan Stanley Maintains Equal-Weight On Gilead Sciences, Raises Target To \$77 Notes 'Base business stable, we continue to expect near-term updates on remdesivir'

Financial news for GILD dated on 2020-05-01: UPDATE: SunTrust Robinson Humphrey Downgrades Gilead Sciences To Sell, Maintains \$70 Target On 'Lack of visibility to growth'; Notes 'We don't know what a sustainable revenue stream from remdesivir will look like'

Financial news for GILD dated on 2020-05-01: UPDATE: Raymond James Downgrades Gilead Sciences To Market Perform 'Because We Aren't Going to Wild Guess Remdesivir NPV'

Financial news for GILD dated on 2020-05-01: Benzinga's Top Upgrades, Downgrades For May 1, 2020

Financial news for GILD dated on 2020-05-01: SVB Leerink Maintains Market Perform on Gilead Sciences, Raises Price Target to \$85

Financial news for GILD dated on 2020-05-01: Oppenheimer Maintains Outperform on Gilead Sciences, Raises Price Target to \$90

Financial news for GILD dated on 2020-05-01: Morgan Stanley Maintains Equal-Weight on Gilead Sciences, Raises Price Target to \$77

Financial news for GILD dated on 2020-05-01: The Daily Biotech Pulse: Gilead Slips Despite Forecast-Beating Q1, Moderna Partners With Lonza For Coronavirus Vaccine Production, Lyra Therapeutics IPO

Financial news for GILD dated on 2020-05-01: Gilead CEO Says Company Will Continue to Try to Make New Drug Accessible and Affordable to Patients Around the World

Financial news for GILD dated on 2020-05-01: 20 Healthcare Stocks Moving In Friday's Pre-Market Session

Financial news for GILD dated on 2020-05-01: Gilead Sciences shares are trading lower after several firms downgraded the company's stock following the company's Q1 earnings results. The company also sees its business in the short term will be impacted by coronavirus due to fewer patients accessing treatment.

Financial news for GILD dated on 2020-05-01: Gilead Says It Will Produce 1M Courses Of Coronavirus Experimental Drug 'Remdesivir' By December

Financial news for GILD dated on 2020-05-01: JP Morgan Downgrades Gilead Sciences to Neutral

Financial news for GILD dated on 2020-05-01: SunTrust Robinson Humphrey Downgrades Gilead Sciences to Sell

Financial news for GILD dated on 2020-05-01: Raymond James Downgrades Gilead Sciences to Market Perform

Financial news for GILD dated on 2020-04-30: Gilead Sciences Announces Plans To Be Able To Produce Several Million Remdesivir Treatment Courses In 2021

Financial news for GILD dated on 2020-04-30: Gilead Announced Number Of Treatment Courses Expected To Be Available May Actually Be Higher Based On Recent Topline Results From First Simple Study

Financial news for GILD dated on 2020-04-30: Gilead Announced It Anticipates More Than 1M Treatment Courses Will Be Manufactured By December 2020; Treatment Courses Projections Assume A 10-day Dosing Duration

Financial news for GILD dated on 2020-04-30: Gilead Sciences Commits ~\$50M Of Spending To Combat Coronavirus

Financial news for GILD dated on 2020-04-30: Gilead Reports Q1 Earnings Beat, Anticipates Short-Term Impact From Coronavirus

Financial news for GILD dated on 2020-04-30: After Hours Stocks We're Watching: AMZN, WDC, AMGN, GILD, V, SKY, LOCO

Financial news for GILD dated on 2020-04-30: Gilead Says While Coronavirus Did Not Impact Its First Quarter Results in It Anticipates That Its Business In The Short Term Will Be Impacted Due To Fewer Patients Accessing Treatment For Conditions Such As HIV And HCV

Financial news for GILD dated on 2020-04-30: Gilead Sciences Q1 EPS \$1.680 Beats \$1.570 Estimate, Sales \$5.548B Beat \$5.450B Estimate

Financial news for GILD dated on 2020-04-30: Gilead Sciences Option Alert: May 15 \$70 Puts at the Bid: 2500 @ \$0.521 vs 15919 OI; Earnings 4/30 After Close Ref=\$81.95

Financial news for GILD dated on 2020-04-30: UK's Vallance: Remdesivir Has Shown Promise In Studies, Says Total Number Of Infections Coming Down

Financial news for GILD dated on 2020-04-30: Gilead Sciences Option Alert: Jun 19 \$95 Calls at the Bid: 1500 @ \$3.17 vs 7992 OI; Earnings 4/30 After Close Ref=\$82.61

Financial news for GILD dated on 2020-04-30: Apple And Amazon Up To Bat this Afternoon As Investors Ponder Microsoft, Facebook Results

Financial news for GILD dated on 2020-04-30: FDA Commissioner Hahn Says Is Moving At 'Lightning Speed' On Gilead's Remdesivir, Says Wants To Have 'Totality Of Data' To Target Drug

Financial news for GILD dated on 2020-04-30: The Daily Biotech Pulse: FDA Nod For GlaxoSmithKline, Hologic To Launch Coronavirus Test, Amarin's Strong Q1

Financial news for GILD dated on 2020-04-30: Earnings Scheduled For April 30, 2020

Financial news for GILD dated on 2020-04-29: Trump Says He Wants FDA To Go As Quickly As Possible To Approve Gilead's Remdesivir

Financial news for GILD dated on 2020-04-29: Fed Has Market's Back As It Pledges To Keep Rates Low Until Economy Can Swim On Its Own

Financial news for GILD dated on 2020-04-29: FDA Announcement Allowing Emergency Use Of Gilead's Experimental Coronavirus Drug Remdesivir Could Come As Soon As Wednesday

Financial news for GILD dated on 2020-04-29: CFRA Maintains Sell on Gilead Sciences, Raises Price Target to \$74

Financial news for GILD dated on 2020-04-29: NIH Reports Median Time To Recovery Was 11 Days For Patients Treated With Remdesivir Compared With 15 Days For Those Who Received Placebo

Financial news for GILD dated on 2020-04-29: NIH Reports Prelim Results Suggested A Survival Benefit, With A Mortality Rate Of 8.0% For Group Receiving Remdesivir Versus 11.6% For Placebo Group

Financial news for GILD dated on 2020-04-29: NIH Clinical Trial Shows Remdesivir Accelerates Recovery From Advanced Coronavirus; Preliminary Results Indicate That Patients Who Received Remdesivir Had A 31% Faster Time To Recovery Than Those Who Received Placebo

Financial news for GILD dated on 2020-04-29: Fauci: FDA 'Working As We Speak' To Get Remdesivir To Market

Financial news for GILD dated on 2020-04-29: Fauci Says China Study On Remdesivir Was Not Adequate, Underpowered

Financial news for GILD dated on 2020-04-29: Here's How Much Investing \$100 In Gilead Sciences Stock Back In 2010 Would Be Worth Today

Financial news for GILD dated on 2020-04-29: Fauci Says Has No Timeline On Gilead Working With FDA For Remdesivir Approval

Financial news for GILD dated on 2020-04-29: 'Fauci says Gilead reports the anti-viral reduced duration of COVID-19 from 15 to 11 days. "A drug can block this virus," said Fauci about the results of the drug trial. He says the mortality rate also fell from 11% to 8%' -Tweet From CBS White House

Financial news for GILD dated on 2020-04-29: 'Fauci says Gilead reports the anti-viral reduced duration of COVID-19 from 15 to 11 days. "A drug can block this virus," said Fauci about the results of the drug trial. He says the mortality rate also fell from 11% to 8%' -Tweet From CBS White House

Financial news for GILD dated on 2020-04-29: Fauci: Data Shows Remdesivir 'Clear Cut' Positive Effect

Financial news for GILD dated on 2020-04-29: SVBLeerink On Gilead Expects 'to learn more about these results during Gilead's earnings call tomorrow and we believe the focus of the discussion with primarily revolve around timelines for further clinical readouts as well as supply and manufacturing'

Financial news for GILD dated on 2020-04-29: SVBLeerink Maintains Market Perform, \$68 Target On Gilead Notes 'We remain optimistic about the potential for remdesivir to provide meaningful clinical benefit across a relatively broad spectrum of moderate to severe COVID-19 illness'

Financial news for GILD dated on 2020-04-29: Why Gilead Stock Is Trading Higher Today



Financial news for GILD dated on 2020-04-29: STAT News Reporter Adam Feuerstein Responds To Tweet On Lancet Report On Remdesivir Trial, Says 'This Is The Negative China Study...We Reported On Last Week;' Lancet Study Suggests Drug Not Associated With Significant Clinical Benefits

Financial news for GILD dated on 2020-04-29: UPDATE: JMP Reiterates Market Outperform Rating, \$10 Price Target On BioCryst Pharma; BZ NOTE: BioCryst Shares Currently Trading At \$3.72

Financial news for GILD dated on 2020-04-29: BioCryst Pharma Shares At Intraday High As Traders Circulate JMP Research Note Highlighting 'expect BCRX shares to trade up on [remdesivir] news'

Financial news for GILD dated on 2020-04-29: Hearing Gilead Drug Results Will Likely Be Discussed At White House Coronavirus Briefing, National Institutes For Health Will Release Results Later Today

Financial news for GILD dated on 2020-04-29: P/E Ratio Insights for Gilead Sciences

Financial news for GILD dated on 2020-04-29: Alphabet, Boeing Shares Get A Lift Following Earnings, While GE Falls Short

Financial news for GILD dated on 2020-04-29: Gilead Sciences Option Alert: Fri \$80 Calls at the Ask: 1000 @ \$3.32 vs 6362 OI; Earnings 4/30 After Close Ref=\$81.245

Financial news for GILD dated on 2020-04-29: UPDATE: Jefferies Says While Gilead Data Positive 'on balance there are a couple of factors to fill out the picture that are important to know in detail'

Financial news for GILD dated on 2020-04-29: Jefferies Says Gilead News On Remdesivir Will Be Taken As Good News Over Short Term, Sees FDA Probably Accelerating Some Sort Of Approval, Expanded Use For Drug

Financial news for GILD dated on 2020-04-29: Gilead shares are trading higher after a study of the company's remdesivir by the National Institute of Allergy and Infectious Diseases met its primary endpoint. Remdesivir is being evaluated as a potential coronavirus treatment candidate.

Financial news for GILD dated on 2020-04-29: Gilead's Remdesivir Reaches Goal In NIAID-Sponsored Coronavirus Trial

Financial news for GILD dated on 2020-04-29: 'Today, the world gets the first real sign that a new medicine, remdesivir from Gilead Sciences, will help the world emerge from the Covid-19 pandemic...' -Tweet From STAT News' Adam Feuerstein

Financial news for GILD dated on 2020-04-29: UPDATE: Gilead Says 'At Day 14, 64.5% (n=129/200) of patients in the 5-day treatment group and 53.8% (n=106/197) of patients in the 10-day treatment group achieved clinical recovery'

Financial news for GILD dated on 2020-04-29: Gilead Says Plans To Submit Full Data For Remdesivir In Peer-Reviewed Journal In Coming Weeks

Financial news for GILD dated on 2020-04-29: UPDATE: Gilead Says No New Safety Signals Were Identified With Remdesivir

Financial news for GILD dated on 2020-04-29: UPDATE: Gilead Says Phase 3 Trial Of Remdesivir Showed Patients Receiving 10-Day Treatment Course Achieved Similar Improvement In Clinical Status vs Those Taking 5-Day Treatment Course

Financial news for GILD dated on 2020-04-29: Gilead Shares To Resume Trade At 9 a.m. EDT

Financial news for GILD dated on 2020-04-29: S&P 500 Futures Spike ~15 Points Following Positive Gilead Data On Remdesivir

Financial news for GILD dated on 2020-04-29: Gilead Reports Data From National Institute of Allergy and Infectious Diseases, Says 'We understand that the trial has met its primary endpoint and that NIAID will provide detailed information at an upcoming briefing'

Financial news for GILD dated on 2020-04-29: REMINDER: Results From Gilead's Coronavirus Anti-Viral, Remdesivir, Expected This Week

Financial news for GILD dated on 2020-04-29: Gilead Shares Halted News Pending

Financial news for GILD dated on 2020-04-28: Gilead Sciences Option Alert: Aug 21 \$115 Calls Sweep (55) near the Ask: 320 @ \$2.074 vs 8159 OI; Earnings 4/30 After Close Ref=\$79.3902

Financial news for GILD dated on 2020-04-27: 'Experts worry next studies of Gilead Covid-19 drug may add uncertainty' -STAT

Financial news for GILD dated on 2020-04-27: Japan PM Abe Says Approval For Remdesivir Expected 'Soon'

Financial news for GILD dated on 2020-04-27: UPDATE: UBS Downgrades Gilead Sciences To Neutral, Raises Price Target From \$77 To \$80 'on valuation & as risk/reward into remdesivir (RDV) phase 3 readout appears balanced'

Financial news for GILD dated on 2020-04-27: Benzinga's Top Upgrades, Downgrades For April 27, 2020

Financial news for GILD dated on 2020-04-27: UBS Downgrades Gilead Sciences to Neutral

Financial news for GILD dated on 2020-04-27: Hearing Japan May Approve Gilead's Remdesivir for Coronavirus in May

Financial news for GILD dated on 2020-04-27: Japan PM Abe Says Gilead's Coronavirus Drug Candidate Remdesivir May Soon Get Approval

Financial news for GILD dated on 2020-04-26: Gilead Sues U.S., Claiming It Secretly Obtained Patents on HIV Research That Led to Truvada

Financial news for GILD dated on 2020-04-26: The Week Ahead In Biotech (April 26-May 2): Cancer Conference, Earnings News Flow In The Spotlight

Financial news for GILD dated on 2020-04-26: China Tried to Patent Potential Coronavirus Drug Remsvidir the Day After Beijing Confirmed Virus Was Transmissible Between Humans

Financial news for GILD dated on 2020-04-25: Bulls And Bears Of The Week: Amazon, Boeing, Disney, Netflix And More

Financial news for GILD dated on 2020-04-24: CORRECTION: Lead Researcher For Gilead Remdesivir Trial Says Sees Trial Results Possibly By Mid May; Initial Headline Incorrectly Suggested 'Mid Day'

Financial news for GILD dated on 2020-04-24: Gilead Sciences Option Alert: Fri \$76.5 Calls at the Ask: 994 @ \$2.701 vs 218 OI; Earnings 4/30 After Close Ref=\$79.12

Financial news for GILD dated on 2020-04-24: UPDATE: Lead Researcher For Gilead Remdesivir Trial Says Sees Trial Results Possibly By Mid May, Prelim. Results Could Come Earlier

Financial news for GILD dated on 2020-04-24: Gilead Shares Spike To Session High; Report A Lead Researcher Has Said US Gov't. Trial Of Remdesivir Is 'Running Ahead Of Schedule'

Financial news for GILD dated on 2020-04-24: Crude Oil Bounce Gives Energy Stock A Lift As Market Volatility Ebbs

Financial news for GILD dated on 2020-04-24: Baird Analyst Says 'Don't Give Up' Yet On Gilead's Remdesivir

Financial news for GILD dated on 2020-04-24: Benzinga Pro's Top 5 Stocks To Watch For Fri., Apr. 24, 2020: GILD, DKNQ, FFIV, ADC, SGMS

Financial news for GILD dated on 2020-04-23: Why Gilead Stock Is Trading Lower Today

Financial news for GILD dated on 2020-04-23: Gilead Sciences Option Alert: May 1 \$64 Puts Sweep (7) near the Bid: 350 @ \$0.585 vs 61 OI; Earnings 4/30 After Close Ref=\$75.99

Financial news for GILD dated on 2020-04-23: Hearing SunTrust Defending Gilead, Says Remdesivir Could Still Work In Patients With Moderate Severity Coronavirus Infection

Financial news for GILD dated on 2020-04-23: Hearing Author Of Gilead Study Disputes Characterization Drug 'Flopped'

Financial news for GILD dated on 2020-04-23: WHO Says Draft Document On Gilead's Remdesivir Was Inadvertently Posted On Website, Says Manuscript Undergoing Peer Review, WHO Is Waiting For Final Version Before Commenting

Financial news for GILD dated on 2020-04-23: Gilead Sciences Option Alert: Fri \$85 Calls Sweep (11) near the Ask: 969 @ \$0.29 vs 4919 OI; Earnings 4/30 After Close Ref=\$75.9249

Financial news for GILD dated on 2020-04-23: Gilead shares are trading lower after the company reportedly ended its Remdesivir study due to low enrollment and said study results were inconclusive.

Financial news for GILD dated on 2020-04-23: UPDATE: Gilead Calls Study Results 'Inconclusive,' Says Trends In Data Suggest Potential Benefit Via Remdesivir

Financial news for GILD dated on 2020-04-23: UPDATE: Gilead Says Remdesivir Study Was 'Underpowered' To Enable Statistically Meaningful Conclusions

Financial news for GILD dated on 2020-04-23: UPDATE: Gilead Says Investigators In Remdesivir Study Did Not Provide Permission For Publication Of Results, Confirms Study Terminated Early Due To Low Enrollment

Financial news for GILD dated on 2020-04-23: Gilead Confirms Remdesivir Data Was Prematurely Posted, Says Has Been REMoved

Financial news for GILD dated on 2020-04-23: Gilead Sciences Option Alert: Jun 19 \$110 Calls Sweep (4) near the Ask: 863 @ \$1.601 vs 14400 OI; Earnings 4/30 After Close Ref=\$78.0397

Financial news for GILD dated on 2020-04-23: Gilead Sciences Option Alert: May 15 \$80 Calls Sweep (11) near the Ask: 550 @ \$5.0 vs 15829 OI; Earnings 4/30 After Close Ref=\$77.81

Financial news for GILD dated on 2020-04-23: 'I do not believe this gilead news. It is from the chinese trials ...This is not from Gilead' -Tweet From CNBC's Jim Cramer

Financial news for GILD dated on 2020-04-23: Gilead Shares Resume Following Circuit Breaker Halt, Shares Have Rebounded ~4.6% From Session Low, Down 1.9% For Session

Financial news for GILD dated on 2020-04-23: 'Data on Gilead's remdesivir, released by accident, show no benefit for coronavirus patients' -STAT News

Financial news for GILD dated on 2020-04-23: UPDATE: FT Report On Gilead's Remdesivir Says Study Was Ended Due To Low Enrollment, Results Didn't Given Meaningful Conclusions

Financial news for GILD dated on 2020-04-23: S&P 500 Futures Plunge ~30 Points Following Report Gilead's Remdesivir 'Flops' In First Trial

Financial news for GILD dated on 2020-04-23: Gilead Shares Plunge As Hearing Co.'s Remdesivir 'Flops' In First Trial

Financial news for GILD dated on 2020-04-23: Gilead Sciences Option Alert: Fri \$80 Calls Sweep (6) near the Ask: 500 @ \$3.0 vs 3935 OI; Earnings 4/30 After Close Ref=\$82.365

Financial news for GILD dated on 2020-04-22: Gilead Sciences Option Alert: Jun 19 \$110 Calls Sweep (27) near the Ask: 1095 @ \$2.046 vs 2252 OI; Earnings 4/30 After Close Ref=\$81.06

Financial news for GILD dated on 2020-04-22: The Daily Biotech Pulse: Immunic To Develop COVID Treatment, Gilead Strikes IO Partnership

Financial news for GILD dated on 2020-04-21: Gilead, Kite And oNKO-innate Announce Research Collaboration To Discover Cancer Immunotherapies Focused On Natural Killer (NK) Cells

Financial news for GILD dated on 2020-04-20: How The COVID-19 Pandemic Could End

Financial news for GILD dated on 2020-04-20: Gilead Sciences Option Alert: Fri \$90 Calls Sweep (6) near the Ask: 428 @ \$1.85 vs 7491 OI; Earnings 4/30 After Close Ref=\$84.33

Financial news for GILD dated on 2020-04-20: Gilead Sciences Option Alert: May 15 \$90 Calls at the Ask: 398 @ \$4.201 vs 10729 OI; Earnings 4/30 After Close Ref=\$83.15

Financial news for GILD dated on 2020-04-20: Benzinga's Top Upgrades, Downgrades For April 20, 2020

Financial news for GILD dated on 2020-04-20: A Peek Into The Markets: US Stock Futures Down Ahead Of Earnings

Financial news for GILD dated on 2020-04-20: Wells Fargo Downgrades Gilead Sciences to Equal-Weight, Announces \$87 Price Target

Financial news for GILD dated on 2020-04-20: BMO Capital Downgrades Gilead Sciences

to Market Perform, Announces \$79 Price Target

Financial news for GILD dated on 2020-04-20: 95 Biggest Movers From Friday

Financial news for GILD dated on 2020-04-19: The Week Ahead In Biotech (April 19-25): Eli Lilly, Biogen Earnings On Tap, Sanofi Awaits FDA Decision

Financial news for GILD dated on 2020-04-18: Indexes End Week Higher As White House Rolls Out State-By-State Coronavirus Strategy, Investors Digest First Round Of Earnings Reports

Financial news for GILD dated on 2020-04-17: Why Peloton Stock Lost Ground Friday

Financial news for GILD dated on 2020-04-17: Ross Gerber Says Tesla Is Pushing Ahead Of Competitors During COVID-19 Pandemic

Financial news for GILD dated on 2020-04-17: National Institutes Of Health Gives Formal Statement On Gilead's Remdesivir In Monkeys

Financial news for GILD dated on 2020-04-17: Gilead Shares Relatively Quiet As Hearing National Institutes For Health Suggest Co.'s Remdesivir Coronavirus Anti-Viral Treatment Prevent COVID-19 Progression In Monkeys

Financial news for GILD dated on 2020-04-17: A Strong But Cautious Start To The Second Quarter

Financial news for GILD dated on 2020-04-17: CFRA Downgrades Gilead Sciences to Sell

Financial news for GILD dated on 2020-04-17: Why Amazon Is Trading Down Friday

Financial news for GILD dated on 2020-04-17: Gilead Analysts Tackle Early Results From Remdesivir Study In COVID-19, Morgan Stanley Says Stock Move Looks Overdone

Financial news for GILD dated on 2020-04-17: 58 Stocks Moving In Friday's Mid-Day Session

Financial news for GILD dated on 2020-04-17: Big Earnings Day As Honeywell, Procter & Gamble, Schlumberger Among Those Reporting

Financial news for GILD dated on 2020-04-17: Gilead Sciences Option Alert: May 15 \$80 Puts Sweep (6) near the Bid: 577 @ \$4.542 vs 1435 OI; Earnings 4/30 After Close Ref=\$84.38

Financial news for GILD dated on 2020-04-17: Former FDA Commissioner Says Gilead's Remdesivir Could Have Enough Data For Emergency Use Authorization

Financial news for GILD dated on 2020-04-17: Benzinga Pro's Top 5 Stocks To Watch For Fri., Apr. 17, 2020: GILD, NOK, INVH, THMO, LOGM

Financial news for GILD dated on 2020-04-17: The Daily Biotech Pulse: Moderna Secures \$483M In BARDA Funding, Gilead Remdesivir Data, Veracyte's Positive Pre-Announcement

Financial news for GILD dated on 2020-04-17: Gilead Sciences shares are trading higher after a report noted that data from a clinical trial on the company's remdesivir drug suggests coronavirus patients are responding to treatment.

Financial news for GILD dated on 2020-04-17: '"My hunch is that it's going to work earlier in the disease so if it's introduced early in the disease it can be an effective drug. It's not a slam dunk by any means. I don't think it's a cure for the virus," says @ScottGottliebMD...'

Financial news for GILD dated on 2020-04-17: Hearing Raymond James Downplaying Gilead Data On Remdesivir, Says Recent Comments On Data Congruent With Prior New England Journal Of Medicine Cohort Which Implied Potential Modest To No Benefit Compared Historically

Financial news for GILD dated on 2020-04-17: 36 Stocks Moving in Friday's Pre-Market Session

Financial news for GILD dated on 2020-04-17: S&P Futures Rise 2.5%; Report Suggests Gilead's Remdesivir Shows Promise in Treating Covid-19; President Trump Unveils Plan for U.S. Economy Restart; Boeing to Reopen Next Week

Financial news for GILD dated on 2020-04-16: Gilead Says Expect Data From Phase 3 Study in Patients With Severe Covid-19 Infection to Be Available at End of April

Financial news for GILD dated on 2020-04-16: Gilead Says Understand the Urgent Need for a Covid-19 Treatment and the Resulting Interest in Data on Our Investigational Antiviral Drug Remdesivir; Says Anecdotal Reports Do Not Provide Statistical Power

Necessary to Determine Safety, Efficacy Profile of Remdesivir as Treatment for Covid-19

Financial news for GILD dated on 2020-04-16: Big Stocks Moving After Hours As Market Cheers Gilead, 'Reopening' Updates

Financial news for GILD dated on 2020-04-16: Gilead's Encouraging Remdesivir Data: Rapid Reaction On The Stock

Financial news for GILD dated on 2020-04-16: 7 Stocks Moving In Thursday's After-Hours Session

Financial news for GILD dated on 2020-04-16: Gilead Sciences shares are trading higher after a report noted that data from a clinical trial on the company's remdesivir drug suggests coronavirus patients are responding to treatment.

Financial news for GILD dated on 2020-04-16: 'Early peek at data on Gilead coronavirus drug suggests patients are responding to treatment' -STAT News

Financial news for GILD dated on 2020-04-16: Gilead Sciences Option Alert: Aug 21 \$110 Calls Sweep (7) near the Ask: 321 @ \$1.772 vs 10932 OI; Earnings 4/30 After Close [est] Ref=\$76.2501

Financial news for GILD dated on 2020-04-16: Gilead Sciences Option Alert: Aug 21 \$80 Calls Sweep (33) near the Ask: 530 @ \$5.947 vs 6241 OI; Earnings 4/30 After Close [est] Ref=\$74.66

Financial news for GILD dated on 2020-04-15: Arcus Bio Shares Volatile After Hours Amid Report Gilead To Hold Talks To Take Stake In Co.

Financial news for GILD dated on 2020-04-15: Why Gilead's Stock Is Trading Lower Today

Financial news for GILD dated on 2020-04-15: Gilead's Spokesperson Confirms Remdesivir Trial In China In Patients With Severe Disease Was 'Terminated Early Due To Low Enrollment'; Trial In China In Patients With Moderate Disease Now Listed On Clinicaltrials.gov As Suspended

Financial news for GILD dated on 2020-04-15: Every Member Of Trump's 'Great American Economic Revival' Industry Groups

Financial news for GILD dated on 2020-04-15: Gilead Sciences shares are trading lower after trials of the company's potential coronavirus candidate Remdesivir were suspended in China due to low enrollment.

Financial news for GILD dated on 2020-04-15: Gilead Shares Fall To Pre-Market Low As Hearing Co. Trial For Remdesivir In China Has Been Suspended

Financial news for GILD dated on 2020-04-14: Gilead Shares Spike To Session High, Quickly Pare Gain, Following Comment From Trump Co.'s Remdesivir Is Showing 'Good Progress'

Financial news for GILD dated on 2020-04-14: Gilead Sciences Option Alert: Jun 19 \$90 Calls Sweep (2) near the Ask: 344 @ \$2.42 vs 5076 OI; Earnings 4/30 After Close [est] Ref=\$76.3

Financial news for GILD dated on 2020-04-13: Gilead Analysts Break Down Remdesivir Data Readout From Compassionate Use

Financial news for GILD dated on 2020-04-13: Gilead Sciences Option Alert: Fri \$71 Calls Sweep (9) near the Ask: 384 @ \$3.9 vs 337 OI; Earnings 4/30 After Close [est] Ref=\$74.39

Financial news for GILD dated on 2020-04-13: Gilead Sciences Option Alert: Fri \$85 Calls Sweep (3) near the Ask: 7494 @ \$0.12 vs 15594 OI; Earnings 4/30 After Close [est] Ref=\$74.42

Financial news for GILD dated on 2020-04-13: India Today Journalist Tweets: '2 out of 3 #COVID19 patients have benefitted from Remdesivir drug - an observational study has found @ICMRDELHI director Dr Raman GangaKhedkar,' Says Need For Ventilator/Oxygen Was Found To Have Reduced After Administration

Financial news for GILD dated on 2020-04-13: Gilead shares are trading higher after the company said its coronavirus treatment showed an improvement in 68% of cases.

Financial news for GILD dated on 2020-04-12: The Week Ahead In Biotech: Urogen FDA Decision, Amarin, J&J Earnings And More COVID-19 Updates

Financial news for GILD dated on 2020-04-09: Gilead Canada Reports Submission Of

Supplemental New Drug Submission To Health Canada For Descovy For HIV Pre-Exposure Prophylaxis

Financial news for GILD dated on 2020-04-08: UPDATE: RBC Issues Report On Gilead: 'New Remdesivir Trial Changes Aim To Maximize Odds, Though Suggests Dramatic Effects Unlikely'

Financial news for GILD dated on 2020-04-08: Gilead Shares Tick Lower As Traders Circulate Comment From RBC Suggesting co. Updated Its ClinicalTrials.gov Listing For 2 Trials For Remdesivir For Coronavirus Treatment To Increase Enrollment, Revise Primary, Secondary Endpoints

Financial news for GILD dated on 2020-04-07: Gilead Analyst Sees Over 50% Chance Of Success For Remdesivir In Mild-To-Moderate COVID-19

Financial news for GILD dated on 2020-04-07: 10 Short Squeeze Candidates If The Market Rally Continues

Financial news for GILD dated on 2020-04-07: Gilead Sees Volume Spike As Traders Circulate German Website Suggesting Spokesperson For Federal Institute For Drugs And Medical Devices Confirmed 'Corona patients who are particularly seriously ill may...be treated with not yet approved remdesivir'

Financial news for GILD dated on 2020-04-07: Jim Cramer, On CNBC's 'Squawk On The Street,' Says He Is More Bullish On Regeneron Than Gilead

Financial news for GILD dated on 2020-04-07: Cantor Fitzgerald Reiterates Overweight on Gilead Sciences, Raises Price Target to \$86

Financial news for GILD dated on 2020-04-06: Trump Says Spoke With Pharmaceutical Companies; Says 10 Different Therapeutic Agents Are In Active Trials, Says Will Be 'Fairly Quick Process' And Says A Second Company Was Approved To Start Vaccine Trials

Financial news for GILD dated on 2020-04-06: STAT News Reporter Says CEOs Of Amgen, Genentech, Gilead And Regeneron Were Involved In Call With Trump

Financial news for GILD dated on 2020-04-06: Gilead Analyst Sees Catalyst Ahead In Data Readout For Potential Coronavirus Treatment

Financial news for GILD dated on 2020-04-06: 'Data for Gilead's potential coronavirus therapy are coming soon. Here's what you need to know' -Article From STAT News

Financial news for GILD dated on 2020-04-06: Gilead Sciences and Second Genome Announce Strategic Collaboration in Biomarker and Inflammatory Bowel Disease Drug Discovery

Financial news for GILD dated on 2020-04-05: Gilead To Donate 1.5M Doses Of Experimental Coronavirus Treatment: 'The Right Thing To Do'

Financial news for GILD dated on 2020-04-04: Barron's Picks And Pans: Post-Pandemic Ideas, Safe Dividends And More

Financial news for GILD dated on 2020-04-03: What's The Difference Between Coronavirus, SARS-CoV-2 and COVID-19?

Financial news for GILD dated on 2020-04-03: UPDATE: EMA Gives Recommendations On Compassionate Use Of Gilead's Remdesivir For COVID-19 Coronavirus Infection

Financial news for GILD dated on 2020-04-03: European Medicines Agency (European Equivalent Of FDA) Says Gilead's Remdesivir Shown To Be Active Against COVID-19, 2 SARS-, MERS-Coronavirus Infections, But Notes 'Currently Only Limited Data On Use' in COVID-19 Patients

Financial news for GILD dated on 2020-04-02: Gilead Sciences Option Alert: Fri \$81 Calls Sweep (16) near the Ask: 356 @ \$0.283 vs 9594 OI; Earnings 4/30 After Close [est] Ref=\$75.59

Financial news for GILD dated on 2020-04-02: Gilead Sciences shares are trading higher. The company on Wednesday announced it is initiating two phase 3 randomized studies as a potential coronavirus treatment.

Financial news for GILD dated on 2020-04-02: RNC Genter Capital CEO Likes Tech, Health Care, Financials In Volatile Market

Financial news for GILD dated on 2020-04-01: Gilead Initiates Two Phase 3 Randomised Studies To Evaluate The Safety And Efficacy Of Its Investigational Treatment Remdesivir For Coronavirus

Financial news for GILD dated on 2020-04-01: '\$GILD says it's starting two more

remdesivir studies vs Covid-19, in 15 UK hospitals.' -Jacob Plieth

Financial news for GILD dated on 2020-03-31: Gilead Sciences Option Alert: Apr 9 \$85 Calls Sweep (24) near the Ask: 1031 @ \$0.653 vs 571 OI; Earnings 4/30 After Close [est] Ref=\$75.37

Financial news for GILD dated on 2020-03-30: Gilead shares are trading higher after the company said it would expand access to its experimental coronavirus treatment, Remdesivir.

Financial news for GILD dated on 2020-03-30: Gilead Reports HSR Waiting Period For Forty Seven Deal Expired; Sees Tender Offer Closing Beginning In Apr. 2020

Financial news for GILD dated on 2020-03-29: Ex-FDA Chief Gottlieb Expects Coronavirus Therapeutic Option By Summer

Financial news for GILD dated on 2020-03-29: Barron's Picks And Pans: Tech Picks, SoftBank, REITs, Tesla And More

Financial news for GILD dated on 2020-03-27: Veeva Systems' CRM Product Is Seeing Ten Times More Usage During Coronavirus Pandemic

Financial news for GILD dated on 2020-03-26: Gilead shares are trading higher as the global coronavirus outbreak continues. The company's drug remdesivir is being evaluated as a potential coronavirus treatment candidate.

Financial news for GILD dated on 2020-03-25: Gilead Asks FDA To Rescind Orphan Drug Designation For Remdesivir, Says It Is Confident It Can Maintain Expedited Timeline

Financial news for GILD dated on 2020-03-25: Zoom Video, Teladoc Lead The Coronavirus Short Squeeze Candidates

Financial news for GILD dated on 2020-03-25: Gilead Sciences shares are trading lower, not currently seeing company-specific news. Movement appears market related as equities experience volatility amid US stimulus progress.

Financial news for GILD dated on 2020-03-23: 5 Stocks Moving In Monday's After-Hours Session

Financial news for GILD dated on 2020-03-23: Gilead Sciences shares are trading higher as traders circulate word the company received FDA Orphan Drug Designation for Remdesivir as a treatment for the coronavirus.

Financial news for GILD dated on 2020-03-23: Traders Circulate Word Gilead Receives FDA Orphan Drug Designation For Remdesivir As Treatment For Coronavirus

Financial news for GILD dated on 2020-03-23: Shares of several healthcare companies are trading lower amid market volatility. Sunday's fiscal stimulus bill failed a procedural senate vote while the Fed Monday morning announced further stimulus measures to support liquidity.

Financial news for GILD dated on 2020-03-23: Gilead shares are trading higher amid continued coronavirus concerns, as the company's drug remdesivir is being evaluated as a potential coronavirus treatment candidate. UPDAE Shares have since reversed and are now trading lower.

Financial news for GILD dated on 2020-03-20: Why BofA Has Low Expectations For Gilead's Remdesivir As Potential Coronavirus Treatment

Financial news for GILD dated on 2020-03-20: The Daily Biotech Pulse: Mylan Ramps Up Manufacturing Of Potential COVID-19 Drug, Lexicon Stops Study Early, Masimo To Buy German Ventilation Company

Financial news for GILD dated on 2020-03-20: Piper Sandler Upgrades Gilead Sciences to Overweight

Financial news for GILD dated on 2020-03-19: '250 patients have received \$GILD's remdesivir through expanded access, new FDA info says' -Tweet From Pharma Pink Sheet Reporter

Financial news for GILD dated on 2020-03-19: FDA Approves EPCLUSA For Pediatric Patients With Any Strain Of Hepatitis C

Financial news for GILD dated on 2020-03-19: UPDATE: Jefferies Notes Trumps Public Announcement Of Fast Track Potential For New Coronavirus Therapies For Compassionate Use Only, Calls 'Not Material,' And 'A Relatively Minor Disappointment Vs Growing Investor Expectations' For Gilead

Financial news for GILD dated on 2020-03-19: Hearing Jefferies Has Called Trump's

Coronavirus Fast Track 'Somewhat Disappointing' For Gilead

Financial news for GILD dated on 2020-03-19: Gilead Sciences Option Alert: Apr 17 \$82.5 Calls Sweep (25) near the Ask: 331 @ \$8.643 vs 1043 OI; Earnings 4/30 After Close [est] Ref=\$81.9

Financial news for GILD dated on 2020-03-19: FDA's Hahn Clarifies Remdesivir Is Going Through Normal FDA Process

Financial news for GILD dated on 2020-03-19: Gilead shares are trading higher amid continued coronavirus concerns, as the company's drug remdesivir is being evaluated as a potential coronavirus treatment candidate. Piper Sandler analysts said they believe the drug could soon receive approval.

Financial news for GILD dated on 2020-03-19: Analyst Says Gilead's Remdesivir Could Be Approved 'Within Months' For COVID-19 Treatment

Financial news for GILD dated on 2020-03-18: Tweet From STAT News' Adam Feuerstein Includes Some Details Of Piper Sandler Note On Gilead's Remdesivir Potentially Being Approved For Broad Use In 'Coming Months'

Financial news for GILD dated on 2020-03-18: Hearing Piper Analyst Suggesting Gilead's Remdesivir Could Be Approved For Coronavirus Infection 'Very Soon'

Financial news for GILD dated on 2020-03-18: DZ Bank Upgrades Gilead Sciences to Buy

Financial news for GILD dated on 2020-03-18: Gilead Sciences shares are trading higher amid continued global coronavirus concerns, as the company's experimental drug remdesivir is being evaluated as a potential coronavirus treatment candidate.

Financial news for GILD dated on 2020-03-13: Shares of several healthcare companies are trading higher as the market rebounds following Thursday's selloff. NOTE: Since the coronavirus outbreak the healthcare sector has been extremely volatile.

Financial news for GILD dated on 2020-03-12: Shares of several healthcare companies are trading lower as equities sell off amid continued global coronavirus concerns. The virus has caused global economic disruption and negatively impacted stocks across sectors.

Financial news for GILD dated on 2020-03-11: Gilead Highlights New Clinical Study Data For GS-6207 Presented At CROI 2020

Financial news for GILD dated on 2020-03-10: How Close Are Biotechs To Bringing A COVID-19 Treatment To Market?

Financial news for GILD dated on 2020-03-10: Treatment With Gilead's Vesatolimod Is Evaluated For Safety And Virologic And Immunologic Response Versus Placebo In Phase 1B HIV Functional Cure Study

Financial news for GILD dated on 2020-03-10: Gilead Presents 96-Week DISCOVER Trial Data Demonstrating 'Favorable Renal and Bone Safety Profile of Descovy for HIV PrEP in At-Risk Populations'

Financial news for GILD dated on 2020-03-10: Gilead Sciences shares are trading lower, not currently seeing company-specific news. Weakness potentially related to profit taking, as the company is working on a coronavirus treatment and has performed well amid the outbreak.

Financial news for GILD dated on 2020-03-09: Gilead Shares Unaffected Amid Co. Press Release Highlighting New Data On Biktarvy Presented At CROI 2020

Financial news for GILD dated on 2020-03-09: TD Ameritrade Index Shows Retail Investors Were Pessimistic In February

Financial news for GILD dated on 2020-03-09: Investor Movement Index Summary: February 2020

Financial news for GILD dated on 2020-03-09: Gilead Sciences shares are trading lower after RBC Capital downgraded the stock from Top Pick to Outperform.

Financial news for GILD dated on 2020-03-09: Benzinga's Top Upgrades, Downgrades For March 9, 2020

Financial news for GILD dated on 2020-03-09: RBC Capital Downgrades Gilead Sciences to Outperform, Announces \$86 Price Target

Financial news for GILD dated on 2020-03-06: Gilead Sciences Option Alert: May 15 \$90 Calls Sweep (66) near the Ask: 1794 @ \$4.846 vs 7861 OI; Earnings 4/30 After Close [est] Ref=\$79.01



Financial news for GILD dated on 2020-03-06: Gilead Sciences Option Alert: Mar 20 \$79 Calls Sweep (25) near the Ask: 1668 @ \$3.937 vs 599 OI; Earnings 4/30 After Close [est] Ref=\$79.175

Financial news for GILD dated on 2020-03-06: Gilead Sciences shares are trading higher after hearing that Evercore said data from Gilead China on the coronavirus could arrive this month.

Financial news for GILD dated on 2020-03-06: Hearing Evercore Saying Data From Gilead China On Coronavirus Could Arrive This Month

Financial news for GILD dated on 2020-03-05: Gilead Sciences Option Alert: Jan 15 \$110 Calls Sweep (18) near the Ask: 535 @ \$2.08 vs 2732 OI; Earnings 4/30 After Close [est] Ref=\$76.93

Financial news for GILD dated on 2020-03-04: Gilead Sciences Option Alert: May 15 \$80 Calls Sweep (2) near the Ask: 503 @ \$4.0 vs 12396 OI; Earnings 4/30 After Close [est] Ref=\$75.56

Financial news for GILD dated on 2020-03-03: National Institutes For Health Head Fauci Says We Should Know Within Several Months Whether Gilead's Antiviral Coronavirus Treatment Works, Sees Implementation 'Imminent' Afterward

Financial news for GILD dated on 2020-03-03: Gilead Sciences shares are trading lower. NOTE: The company on Monday announced it will acquire Immuno-oncology therapy developer Forty Seven for \$95.50/share in cash, or around \$4.9 billion total.

Financial news for GILD dated on 2020-03-03: The Daily Biotech Pulse: GenMark Diagnostics Ships COVID-19 Test Kits, Karyopharm To Offer Shares, And More

Financial news for GILD dated on 2020-03-03: Pfizer Works On Compounds That May Help Stop Coronaviruses

Financial news for GILD dated on 2020-03-02: How The COVID-19 Outbreak Is Benefiting Biotech Investors

Financial news for GILD dated on 2020-03-02: Mid-Afternoon Market Update: Dow Jumps 800 Points; China Pharma Shares Spike Higher

Financial news for GILD dated on 2020-03-02: How To Approach The Market This Week: PreMarket Prep Recap For March 2, 2020

Financial news for GILD dated on 2020-03-02: Mid-Day Market Update: Crude Oil Rises Over 3%; Novavax Shares Plunge

Financial news for GILD dated on 2020-03-02: Shares of several healthcare companies are trading higher in sympathy with the overall market as it rebounds from a selloff caused by coronavirus fears.

Financial news for GILD dated on 2020-03-02: Mid-Morning Market Update: Markets Open Higher; Gilead To Buy Forty Seven For \$4.9B

Financial news for GILD dated on 2020-03-02: Gilead Confirms Deal To Buy Biotech Forty Seven For \$4.9B

Financial news for GILD dated on 2020-03-02: Benzinga Pro's Top 5 Stocks To Watch For Mon., Mar. 2, 2020: GILD, BIDU, CODX, MRKR, APDN

Financial news for GILD dated on 2020-03-02: Gilead to Acquire Forty Seven for \$95.50/Share Cash

Financial news for GILD dated on 2020-03-01: Barron's Picks And Pans: COVID-19 Stocks, Intel, Tesla And More

Financial news for GILD dated on 2020-02-28: Gilead Sciences shares are trading lower after DZ Bank downgraded the stock from Buy to Hold. NOTE: Many stocks in the healthcare sector are trading lower with the overall market amid continued coronavirus fears.

Financial news for GILD dated on 2020-02-28: Gilead Sciences Option Alert: Jun 19 \$80 Calls Sweep (4) near the Ask: 1000 @ \$2.5 vs 8423 OI; Ref=\$68.2

Financial news for GILD dated on 2020-02-28: Gilead Eyes Takeover Of Cancer Biotech Forty Seven: Report

Financial news for GILD dated on 2020-02-28: The Daily Biotech Pulse: Sangamo In Genome-Editing Therapy Deal With Biogen, FDA Nod For Biohaven, Passage Bio IPO

Financial news for GILD dated on 2020-02-28: DZ Bank Downgrades Gilead Sciences to Hold

Financial news for GILD dated on 2020-02-27: Forty Seven Shares Spike Sharply Higher After Hours As Hearing Co. Had Discussions About Various Options With Gilead

Financial news for GILD dated on 2020-02-27: Stocks That Hit 52-Week Highs On Thursday

Financial news for GILD dated on 2020-02-27: Benzinga's Top Upgrades, Downgrades For February 27, 2020

Financial news for GILD dated on 2020-02-27: Barclays Initiates Coverage On Gilead Sciences with Underweight Rating, Announces \$62 Price Target

Financial news for GILD dated on 2020-02-27: 28 Healthcare Stocks Moving In Thursday's Pre-Market Session

Financial news for GILD dated on 2020-02-27: The Daily Biotech Pulse: Gilead Kicks Off Coronavirus Drug Trials, Adcom Nod For Lily, FDA Approves Esperion's Lipid-Lowering Adjunctive Combo Therapy

Financial news for GILD dated on 2020-02-27: Gilead Sciences shares are trading higher after the company announced it has initiated 2 Phase 3 studies of remdesivir in adults diagnosed with the Coronavirus.

Financial news for GILD dated on 2020-02-27: Gilead to Widen Testing of Antiviral Drug in Hong Kong, South Korea, other Asian Markets

Financial news for GILD dated on 2020-02-26: Gilead Reports Initiation Of 2 Phase 3 Studies Of Remdesivir For Coronavirus

Financial news for GILD dated on 2020-02-26: Shares of several healthcare and biotech companies are trading higher. Not seeing any news to justify the price action.

Financial news for GILD dated on 2020-02-26: Gilead Sciences Option Alert: Mar 20 \$80 Calls Sweep (9) near the Ask: 1000 @ \$1.301 vs 23681 OI; Ref=\$72.32

Financial news for GILD dated on 2020-02-26: Gilead Sciences Option Alert: Mar 20 \$72.5 Calls Sweep (78) near the Ask: 1382 @ \$3.116 vs 9226 OI; Ref=\$72.16

Financial news for GILD dated on 2020-02-26: Shares of several healthcare and biotech companies are trading higher. Movement appears market related as equities have rebounded this session following recent selloffs.

Financial news for GILD dated on 2020-02-26: 24 Healthcare Stocks Moving In Wednesday's Pre-Market Session

Financial news for GILD dated on 2020-02-25: NIAID's Fauci Says The Earliest A Coronavirus Vaccine Could Be Tested And Available To Public Would Be A Year Or A Year And A Half

Financial news for GILD dated on 2020-02-25: Gilead Shares On Watch As NIAID's Fauci Discusses Trials For Co.'s Candidate

Financial news for GILD dated on 2020-02-25: National Institutes Of Health Says Those With Confirmed Coronavirus Infection With Mild, Cold-Like Symptoms Or No Apparent Symptoms Will Not Be Included In Remdesivir Trial; Must Have Laboratory-Confirmed Coronavirus Infection

Financial news for GILD dated on 2020-02-25: Clinical Trial of Remdesivir To Treat Coronavirus Begins Study; Enrolling Hospitalized Adults With Coronavirus In Nebraska

Financial news for GILD dated on 2020-02-25: Gilead Sciences shares are trading lower, potentially selling off from Monday strength. Shares gained on Monday after the WHO said the company's experimental drug may be a coronavirus treatment candidate.

Financial news for GILD dated on 2020-02-25: Gilead Sciences Option Alert: Mar 20 \$70 Calls Sweep (3) near the Ask: 506 @ \$4.394 vs 19554 OI; Ref=\$73.0738

Financial news for GILD dated on 2020-02-25: Hearing US Will Start Testing Gilead's Remdesivir To Treat Coronavirus

Financial news for GILD dated on 2020-02-25: Gilead Shares Volatile But Largely Unaffected Following Earlier Bloomberg Article 'Gilead's Drug Leads Global Race for Coronavirus Treatment'

Financial news for GILD dated on 2020-02-25: The Daily Biotech Pulse: Moderna Ships

COVID-19 Vaccine For Clinics, Mallinckrodt Strikes \$1.6B Opioid Settlement

Financial news for GILD dated on 2020-02-24: Chip Stocks, Apple, Airlines Among Hardest Hit As Stocks Plunge On Coronavirus Spread

Financial news for GILD dated on 2020-02-24: PreMarket Prep Stock Of The Day: Gilead Sciences

Financial news for GILD dated on 2020-02-24: Gilead Sciences Option Alert: Jan, 2022 \$100 Calls Sweep (2) near the Ask: 500 @ \$2.8 vs 4912 OI; Ref=\$72.95

Financial news for GILD dated on 2020-02-24: Gilead Sciences Option Alert: Mar 20 \$70 Calls Sweep (2) near the Ask: 500 @ \$4.5 vs 18026 OI; Ref=\$72.8664

Financial news for GILD dated on 2020-02-24: Gilead Sciences Option Alert: Mar 20 \$80 Calls at the Ask: 1000 @ \$1.4 vs 20677 OI; Ref=\$73.93

Financial news for GILD dated on 2020-02-24: Shares of Gilead Sciences are trading higher amid the non-Chinese spread of coronavirus due to the company's ongoing trial to treat coronavirus.

Financial news for GILD dated on 2020-02-21: Gilead Sciences Option Alert: Mar 20 \$80 Calls Sweep (44) near the Ask: 528 @ \$0.62 vs 23628 OI; Ref=\$69.25

Financial news for GILD dated on 2020-02-21: Gilead shares are trading higher. The company's collaboration partner Galapagos said it expects Filgotinib approval in the US, Europe and Japan.

Financial news for GILD dated on 2020-02-21: Gilead Sciences Option Alert: Mar 20 \$65 Calls Sweep (2) near the Ask: 1014 @ \$4.5 vs 8617 OI; Ref=\$68.6795

Financial news for GILD dated on 2020-02-21: Gilead Sciences Option Alert: Mar 20 \$70 Calls Sweep (3) near the Ask: 500 @ \$1.861 vs 14420 OI; Ref=\$68.63

Financial news for GILD dated on 2020-02-21: Gilead Shares Rise 1.5% Premarket; Galapagos Announced Co, Gilead Expect Approval of First Product Candidate, Filgotinib, in RA in the U.s., Europe, and Japan

Financial news for GILD dated on 2020-02-19: Gilead Sciences Option Alert: Mar 20 \$75 Calls Sweep (28) near the Ask: 500 @ \$0.52 vs 14425 OI; Ref=\$67.3588

Financial news for GILD dated on 2020-02-19: Gilead to Present at the Cowen and Company 40th Annual Health Care Conference on Monday, March 2, 2020

Financial news for GILD dated on 2020-02-12: Gilead Sciences Option Alert: Feb 21 \$72.5 Calls Sweep (47) near the Ask: 970 @ \$0.242 vs 13430 OI; Ref=\$66.425

Financial news for GILD dated on 2020-02-11: The Daily Biotech Pulse: LogicBio Slapped With Clinical Hold, Agile Inks Debt Deal Ahead of Twirla Approval, Gilead Builds Stake In Sierra Oncology

Financial news for GILD dated on 2020-02-10: U.S. FDA Grants Priority Review For Kite's KTE-X19 Biologics License Application In Relapsed Or Refractory Mantle Cell Lymphoma; NOTE: Kite Is A Gilead Co.

Financial news for GILD dated on 2020-02-09: The Week Ahead In Biotech: SMID-Cap Earnings In The Spotlight

Financial news for GILD dated on 2020-02-07: Gilead Sciences shares are trading higher on reports suggesting China has started enrolling coronavirus patients in a clinical trial of the company's Remdesivir.

Financial news for GILD dated on 2020-02-07: GileadSciences Said it Will make Remdesivir Available to More 2019nCoV Patients via Proper Channels if Drug Proves Potentially Safe and Effective in Preliminary Trials

Financial news for GILD dated on 2020-02-07: China Began Enrolling CoronavirusPatients in Clinical Trial of Remdesivir on Thursday

Financial news for GILD dated on 2020-02-06: 74 Stocks Moving In Thursday's Mid-Day Session

Financial news for GILD dated on 2020-02-06: Gilead Sciences shares are trading higher after Chinese scientists applied to patent the company's remdesivir to help treat the coronavirus.

Financial news for GILD dated on 2020-02-06: Benzinga's Top Upgrades, Downgrades For February 6, 2020

Financial news for GILD dated on 2020-02-06: Bernstein Downgrades Gilead Sciences to Market Perform, Lowers Price Target to \$70

Financial news for GILD dated on 2020-02-05: 13 Key NASH Drug Candidates To Watch For In A Potential \$30-Billion Market

Financial news for GILD dated on 2020-02-05: 'We are aware of reports of the Wuhan Institute for Virology's patent application. Our focus at this time, is on rapidly determining the potential for remdesivir as a treatment for 2019-nCoV and accelerating manufacturing'

Financial news for GILD dated on 2020-02-05: UPDATE: B of A Maintains Neutral On Gilead, Raises Target To \$72 Notes 'Overall, we believe that 2020 guidance looks conservative, but we remain concerned over the lack of clear growth drivers that could meaningfully accelerate product sales'

Financial news for GILD dated on 2020-02-05: Benzinga's Top Upgrades, Downgrades For February 5, 2020

Financial news for GILD dated on 2020-02-05: Gilead shares are trading lower after the company reported worse-than-expected Q4 EPS and issued soft FY20 guidance.

Financial news for GILD dated on 2020-02-05: Credit Suisse Maintains Underperform on Gilead Sciences, Raises Price Target to \$60

Financial news for GILD dated on 2020-02-05: B of A Securities Maintains Neutral on Gilead Sciences, Raises Price Target to \$72

Financial news for GILD dated on 2020-02-05: The Daily Biotech Pulse: Merck Spins Off Slow-Growth Businesses, ZioPharm Announces Offering, PhaseBio Data

Financial news for GILD dated on 2020-02-05: Raymond James Downgrades Gilead Sciences to Outperform, Lowers Price Target to \$80

Financial news for GILD dated on 2020-02-04: Remdesivir & Chloroquine were Found Effective in Inhibiting Recently Emerged Coronavirus (2019-nCoV) in Vitro; Result was Published in Cell Research, said Wuhan Institute of Virology on its website Tue

Financial news for GILD dated on 2020-02-04: '\$GILD on call: No knowledge of additional #coronavirus responses to remdesivir. Waiting for clinical data. On manufacturing capacity: "We are investing heavily to be prepared as best we can."' -Tweet From STAT's Adam Feuerstein

Financial news for GILD dated on 2020-02-04: Gilead Raises Quarterly Dividend From \$0.63 To \$0.68/Share

Financial news for GILD dated on 2020-02-04: Gilead Sees FY20 Product Sales \$21.8B-\$22.2B, Adj. EPS \$6.05-\$6.45 vs \$7.01 Estimate

Financial news for GILD dated on 2020-02-04: Gilead Sciences Q4 Adj. EPS \$1.3 Misses \$1.67 Estimate, Sales \$5.796B Beat \$5.71B Estimate

Financial news for GILD dated on 2020-02-04: Gilead Sciences Option Alert: Feb 21 \$72.5 Calls Sweep (37) near the Ask: 531 @ \$0.513 vs 10294 OI; Earnings 2/4 After Close Ref=\$67.39

Financial news for GILD dated on 2020-02-04: The Daily Biotech Pulse: EyePoint In-Licenses Eye Disorder Drug, BioMarin CFO Quits, Rockwell Medical To Offer Shares

Financial news for GILD dated on 2020-02-04: First Shipment of Gilead's Remdesivir May Arrive in China on Tuesday

Financial news for GILD dated on 2020-02-04: 85 Biggest Movers From Yesterday

Financial news for GILD dated on 2020-02-04: Earnings Scheduled For February 4, 2020

Financial news for GILD dated on 2020-02-03: Gilead Sciences Option Alert: Mar 20 \$67.5 Calls Sweep (35) near the Ask: 692 @ \$2.297 vs 11796 OI; Earnings 2/4 After Close Ref=\$66.66

Financial news for GILD dated on 2020-02-03: Gilead Sciences Option Alert: Mar 20 \$75 Calls Sweep (35) near the Ask: 719 @ \$0.5 vs 244 OI; Earnings 2/4 After Close Ref=\$66.8

Financial news for GILD dated on 2020-02-03: PreMarket Prep Recap: Bulls Regain Early Control Of The Markets

Financial news for GILD dated on 2020-02-03: 61 Stocks Moving In Monday's Mid-Day Session

Financial news for GILD dated on 2020-02-03: 'Gilead Sciences says remdesivir not yet approved to treat coronavirus' -China's Global Times

Financial news for GILD dated on 2020-02-03: Gilead Sciences Option Alert: May 15 \$75 Calls at the Ask: 500 @ \$0.761 vs 914 OI; Earnings 2/4 After Close Ref=\$65.7449

Financial news for GILD dated on 2020-02-03: Gilead Sciences Option Alert: Feb 21 \$70 Calls Sweep (4) near the Ask: 721 @ \$1.061 vs 27477 OI; Earnings 2/4 After Close Ref=\$67.245

Financial news for GILD dated on 2020-02-03: Gilead Sciences Option Alert: Feb 21 \$70 Calls Sweep (119) above Ask!: 1094 @ \$0.594 vs 27477 OI; Earnings 2/4 After Close Ref=\$68.2778

Financial news for GILD dated on 2020-02-03: Gilead's Experimental Antiviral Drug To Be Screened In Human Trials In China For Coronavirus

Financial news for GILD dated on 2020-02-03: 18 Healthcare Stocks Moving In Monday's Pre-Market Session

Financial news for GILD dated on 2020-02-03: 30 Stocks Moving in Monday's Pre-Market Session

Financial news for GILD dated on 2020-02-03: Gilead Sciences shares are trading higher following reports the company's Remdesivir will undergo a trial for treatment of Coronavirus.

Financial news for GILD dated on 2020-02-03: Gilead Shares Selling Off Over the Last 30 Minutes, the Stock Traded Higher Early Monday Following a Weekend Report the Company's Remdesivir Would Undergo a Trial for Coronavirus

Financial news for GILD dated on 2020-02-02: The Week Ahead In Biotech: Merck, Bristol-Myers Earnings, Conference Presentations In Focus

Financial news for GILD dated on 2020-02-02: Beijing's China-Japan Friendship Hospital will Lead a Clinical Trial on the Treatment of Coronavirus Gilead's Remdesivir in Wuhan

Financial news for GILD dated on 2020-02-02: Coronavirus Case Treated With Gilead Drug May Spur Wider Tests

Financial news for GILD dated on 2020-01-31: Hearing Gilead Working with China to Determine if its Remdesivir Can be Used to Treat Corona Virus

Financial news for GILD dated on 2020-01-28: Gilead Sciences Option Alert: Fri \$64.5 Calls at the Ask: 3770 @ \$0.451 vs 6889 OI; Earnings 2/4 After Close Ref=\$64.205

Financial news for GILD dated on 2020-01-27: Gilead Sciences Option Alert: Mar 20 \$62.5 Calls Sweep (50) near the Ask: 984 @ \$3.051 vs 1043 OI; Earnings 2/4 After Close Ref=\$63.61

Financial news for GILD dated on 2020-01-27: Gilead Sciences Option Alert: Fri \$64.5 Calls Sweep (15) near the Ask: 505 @ \$0.461 vs 3302 OI; Earnings 2/4 After Close Ref=\$63.69

Financial news for GILD dated on 2020-01-23: Gilead Says There Are Currently No Antiviral Data For Remdesivir That Show Activity Against Wuhan Coronavirus

Financial news for GILD dated on 2020-01-23: Gilead Says Co Is In Discussions Regarding Potential Use Of Remdesivir As An Investigational Treatment For Ongoing Wuhan Coronavirus Outbreak

Financial news for GILD dated on 2020-01-23: Gilead Says Co Is In Active Discussions With Researchers, Clinicians In U.S. And China Regarding Ongoing Wuhan Coronavirus Outbreak

Financial news for GILD dated on 2020-01-23: Gilead Shares Spike To Session High Hearing Company Assessing Its Ebola Drug As A Coronavirus Treatment

Financial news for GILD dated on 2020-01-21: Guggenheim Securities Downgrades Gilead Sciences to Neutral

Financial news for GILD dated on 2020-01-20: 7 Blockbuster Drugs Expected To Be Launched In 2020

Financial news for GILD dated on 2020-01-17: Gilead Sciences Option Alert: Fri \$63 Calls Sweep (52) above Ask!: 1040 @ \$0.3 vs 232 OI; Earnings 2/3 After Close [est] Ref=\$63.09

Financial news for GILD dated on 2020-01-13: Gilead Sciences CEO Says To Focus On Small To Medium Sized Bolt-On Acquisitions

Financial news for GILD dated on 2020-01-10: A Preview Of JPMorgan's Healthcare Conference: Focus On Value-Creating Themes, 2020 Expectations

Financial news for GILD dated on 2020-01-09: Gilead Sciences Licenses Portfolio Of HIV Antibodies From The Rockefeller University

Financial news for GILD dated on 2020-01-08: Xencor And Gilead Enter License Agreement For Use Of XmAb Antibody Technologies In Investigational Agents For HIV

Financial news for GILD dated on 2020-01-07: Investor Movement Index Summary: December 2019

Financial news for GILD dated on 2020-01-06: HOOKIPA Says it has Made Strong Progress in its Collaboration with Gilead for Cures to Hepatitis B and HIV

Financial news for GILD dated on 2020-01-03: Gilead Sciences Option Alert: Jan 17 \$65 Calls at the Ask: 1500 @ \$1.311 vs 32458 OI; Earnings 2/3 After Close [est] Ref=\$65.1002

Financial news for GILD dated on 2020-01-03: Benzinga's Top Upgrades, Downgrades For January 3, 2020

Financial news for GILD dated on 2020-01-02: Drugmakers Kick Off 2020 With Margin-Expanding Price Hikes

Financial news for GILD dated on 2020-01-01: Bristol-Myers Squibb, Gilead Sciences, Biogen Raised U.S. List Prices on 50+ Drugs on Wednesday an Average of 5%

Financial news for GILD dated on 2019-12-31: Gilead Sciences Option Alert: Feb 21 \$70 Calls at the Ask: 5863 @ \$0.761 vs 14359 OI; Earnings 2/3 After Close [est] Ref=\$64.5295

Financial news for GILD dated on 2019-12-29: Week Ahead In Biotech: PDUFA Date Ahead For Astra Zeneca, Merck's Lynparza, Pending Clinical Readouts In Focus

Financial news for GILD dated on 2019-12-24: The Daily Biotech Pulse: NewLink Genetics Licenses Ovarian Cancer Dug, Correvio Awaits FDA Verdict

Financial news for GILD dated on 2019-12-24: Gilead and Eisai Enter Into Agreement in Japan for the Co-Promotion of the Investigational Rheumatoid Arthritis Therapy Filgotinib, Pending Regulatory Approval

Financial news for GILD dated on 2019-12-20: Gilead Reports China's National Medical Products Admin. Approved Vosevi For Treatment Of Chronic Hep C Infection Who Require Re-Treatment

Financial news for GILD dated on 2019-12-20: The Daily Biotech Pulse: Axovant Surges On Gene Therapy Study Results, FDA Approves Merck's Ebola Vaccine, Abeona Announces Offering

Financial news for GILD dated on 2019-12-19: Gilead Reports Submission Of Filgotinib New Drug Application Under Priority Review For Rheumatoid Arthritis Treatment

Financial news for GILD dated on 2019-12-19: Micron Yesterday, Nike Today: Earnings Keep Rolling In As Week Winds Down

Financial news for GILD dated on 2019-12-16: Gilead Sciences Option Alert: Jan 17 \$70 Calls Sweep (21) near the Ask: 514 @ \$0.693 vs 65480 OI; Earnings 2/3 After Close [est] Ref=\$66.4952

Financial news for GILD dated on 2019-12-16: Gilead's Phase 2 ATLAS Study in Patients with Bridging Fibrosis and Compensated Cirrhosis Missed its Primary Endpoint

Financial news for GILD dated on 2019-12-14: Bernie Sanders Tweet: We could eradicate HIV/AIDS in America. What's standing in the way? The greed of the pharmaceutical industry. An \$8 HIV drug in Australia costs \$2,000 in America. That is immoral. We need affordable, generic HIV medicine. Now

Financial news for GILD dated on 2019-12-13: Bristol-Myers Squibb Wins Patent Royalty Fight Against Gilead; Co. Awarded \$585M In Damages Plus Royalty

Financial news for GILD dated on 2019-12-13: Gilead Sciences shares are trading lower after Credit Suisse downgraded the stock from Neutral to Underperform and lowered the price target from \$67 to \$63.

Financial news for GILD dated on 2019-12-13: Credit Suisse Downgrades Gilead Sciences to Underperform, Lowers Price Target to \$63

Financial news for GILD dated on 2019-12-12: Gilead Sciences Option Alert: Jan 17 \$70 Calls Sweep (41) above Ask!: 864 @ \$1.087 vs 44382 OI; Earnings 2/3 After Close [est] Ref=\$67.575

Financial news for GILD dated on 2019-12-12: Gilead Sciences Option Alert: Jan 17 \$70 Calls Sweep (21) near the Ask: 608 @ \$1.048 vs 44382 OI; Earnings 2/3 After Close [est] Ref=\$67.535

Financial news for GILD dated on 2019-12-12: 'Activists Say A Patent Office Lawyer's Tweets Showed 'Bias' In Favor Of Gilead In HIV Drug Case' - STAT

Financial news for GILD dated on 2019-12-12: Gilead Sciences Option Alert: Feb 21 \$70 Calls at the Ask: 4230 @ \$2.351 vs 10716 OI; Earnings 2/3 After Close [est] Ref=\$67.6259

Financial news for GILD dated on 2019-12-12: The Daily Biotech Pulse: European Nod For Amgen, miRagen Overhauls Clinical Pipeline, Tonix Snags Patent Win

Financial news for GILD dated on 2019-12-11: Kite Submits Biologics License Application to U.S. Food and Drug Administration for Company's Second CAR T Cell Therapy

Financial news for GILD dated on 2019-12-11: Gilead's Kite And Kiniksa Pharmaceuticals Announce Clinical Collaboration Evaluating Investigational Combination Of Yescarta And Mavrilimumab In Relapsed Or Refractory Large B-Cell Lymphoma

Financial news for GILD dated on 2019-12-09: Gilead's Kite Presents Results From Pivotal ZUMA-2 Trial In Relapsed Or Refractory Mantle Cell Lymphoma; Results Showed 93 Percent of Patients Treated With Investigational KTE-X19 Achieved Response

Financial news for GILD dated on 2019-12-09: Gilead's Kite Presents Findings From Real-World Use Of Yescarta Study

Financial news for GILD dated on 2019-12-09: Gilead Shares Unaffected Following Earlier Article From UK's Guardian 'Sanders and Ocasio-Cortez say company seeking HIV patent extension 'deceitful and immoral''

Financial news for GILD dated on 2019-12-07: Kite Announces Long-term Data From ZUMA-1 Showing Approximately Half of Refractory Large B-cell Lymphoma Patients Were Alive Three Years After Yescarta Treatment at ASH 2019

Financial news for GILD dated on 2019-12-01: The Week Ahead In Biotech: ASH 2019 Gets Underway, Biogen's Aducanumab Data And More

Financial news for GILD dated on 2019-11-25: Gilead Sciences shares are trading higher. Currently not seeing any news to justify the price action.

Financial news for GILD dated on 2019-11-14: Gilead Sciences Option Alert: Jan 17 \$65 Calls Sweep (87) near the Ask: 4354 @ \$1.248 vs 47976 OI; Ref=\$62.565

Financial news for GILD dated on 2019-11-14: Galapagos Says Received Transparency Notice from Gilead; Gilead Holds 25.10% of Galapagos Shares

Financial news for GILD dated on 2019-11-12: Benzinga's Top Upgrades, Downgrades For November 12, 2019

Financial news for GILD dated on 2019-11-12: SunTrust Robinson Humphrey Initiates Coverage On Gilead Sciences with Hold Rating, Announces \$70 Price Target

Financial news for GILD dated on 2019-11-09: Gilead, Galapagos Announce New Data on Filgotinib in Rheumatoid Arthritis Demonstrate Durable Efficacy and Safety Profile

Financial news for GILD dated on 2019-11-08: Gilead Highlights Presentation Of Data On GS-6207 As Potential Component Of Long-Acting HIV Therapy

Financial news for GILD dated on 2019-11-08: Gilead To Present New Data From Viral Hepatitis Research Programs At The Liver Meeting 2019

Financial news for GILD dated on 2019-11-07: Former Google, Pharma Execs Start Ritual-Based Cannabis Company

Financial news for GILD dated on 2019-11-07: Gilead Sciences shares are trading lower after the company exercised warrants for 2.62 million shares of Galapagos.

Financial news for GILD dated on 2019-11-06: Gilead Therapeutics Exercises Warrants

for 2.62M Shares of Galapagos

Financial news for GILD dated on 2019-11-06: Gilead Presents 96-Week Discover Trial Data Supporting Non-inferior Efficacy And Key Safety Differences Of Descovy For PrEP Compared With Truvada For PrEP

Financial news for GILD dated on 2019-10-30: US Appeals Court Upholds Lower Court Ruling That Tossed \$2.54B Jury Verdict For Merck In Patent Case Against Gilead

Financial news for GILD dated on 2019-10-28: Gilead Sciences Option Alert: Jan 17 \$65 Calls Sweep (22) near the Ask: 12532 @ \$1.638 vs 31930 OI; Ref=\$63.015

Financial news for GILD dated on 2019-10-28: Gilead and Glympse Bio Announce the Companies Enter Strategic Collaboration for Use of Biomarker Technology in NASH Clinical Development

Financial news for GILD dated on 2019-10-25: Benzinga's Top Upgrades, Downgrades For October 25, 2019

Financial news for GILD dated on 2019-10-25: Gilead Falls On Uninspiring Q3 Print: 3 Analyst Takes

Financial news for GILD dated on 2019-10-25: UPDATE: Raymond James On Gilead Notes 'therefore filgotinib and M&A will need to be the main growth drivers going forward'; 'both can be and while the base business doesn't look like a major growth business to us anymore on net, it is still stable', Huge

Financial news for GILD dated on 2019-10-25: UPDATE: Raymond James Maintains Strong Buy On Gilead, Lowers Target To \$81 Notes 'our investment thesis is admittedly drifting'; Doesn't 'think Biktarvy + PrEP + Yescarta are enough anymore to drive growth in the face of continued pressure on HCV'

Financial news for GILD dated on 2019-10-25: Hearing Dealreporter Says Gilead Could Be Eyeing Intercept Pharma

Financial news for GILD dated on 2019-10-25: Oppenheimer Maintains Outperform on Gilead Sciences, Lowers Price Target to \$80

Financial news for GILD dated on 2019-10-25: 10 Biggest Price Target Changes For Friday

Financial news for GILD dated on 2019-10-25: Maxim Group Downgrades Gilead Sciences to Hold

Financial news for GILD dated on 2019-10-25: BMO Capital Maintains Outperform on Gilead Sciences, Lowers Price Target to \$81

Financial news for GILD dated on 2019-10-25: Gilead Sciences shares are trading lower after the company reported worse-than-expected Q3 sales results. The company also narrowed its FY19 sales guidance below analyst estimates.

Financial news for GILD dated on 2019-10-25: Raymond James Maintains Strong Buy on Gilead Sciences, Lowers Price Target to \$81

Financial news for GILD dated on 2019-10-25: Maxim Downgrades Gilead To Hold, Lowers Price Target To \$66

Financial news for GILD dated on 2019-10-25: The Daily Biotech Pulse: Melinta Crosses FDA Hurdle But Sees Liquidity Pushback, Positive Readout For Aclaris Wart Drug

Financial news for GILD dated on 2019-10-24: Gilead Sciences shares are trading lower after the company reported worse-than-expected Q3 sales results. The company also narrowed its FY19 sales guidance below analyst estimates.

Financial news for GILD dated on 2019-10-24: Gilead Narrows FY19 Sales Guidance From \$21.6B-\$22.1B To \$21.8B-\$22.1B vs \$22.32B Estimate, Reaffirms EPS At \$3.90-\$4

Financial news for GILD dated on 2019-10-24: Gilead Sciences Q3 Adj. EPS \$1.75 Beats \$1.74 Estimate, Sales \$5.604B Miss \$5.61B Estimate

Financial news for GILD dated on 2019-10-24: The Daily Biotech Pulse: Acorda To Trim Jobs, GlaxoSmithKline Gets FDA Nod, Edward Lifesciences Posts Q3 Beat-And-Raise

Financial news for GILD dated on 2019-10-24: Earnings Scheduled For October 24, 2019

Financial news for GILD dated on 2019-10-21: Earnings Season Kicks Into Full Gear In Round 3 Of The WeTrader Competition

Financial news for GILD dated on 2019-10-20: The Week Ahead In Biotech: Earnings



Trickle In, While Glaxo, Melinta, Foamix And Eton Await FDA Verdict

Financial news for GILD dated on 2019-10-17: Bank of America Reinstates Neutral on Gilead Sciences, Announces \$70 Price Target

Financial news for GILD dated on 2019-10-15: Gilead Sciences Appoints Andrew Dickinson As CEO Effective November 1, 2019

Financial news for GILD dated on 2019-10-11: Shares of several healthcare companies are trading higher after President Trump made positive remarks on the U.S.-China trade talks as traders grew more optimistic over the possibility of a limited trade deal. Trump is scheduled to meet with Chinese Vice Premier Liu He at the White House today.

Financial news for GILD dated on 2019-10-11: The Daily Biotech Pulse: Therapix Extends Merger Deadline, Five Prime Restructures, Gilead-Galapagos Rheumatism Drug Readout

Financial news for GILD dated on 2019-10-10: Gilead, Galapagos Report Efficacy, Safety Results Of Filgotinib Through 52 Weeks In FINCH 1, 3 Studies In RA

Financial news for GILD dated on 2019-10-10: Gilead To Report Q3 Earnings On Thurs., Oct. 24, 2019 After Market Close

Financial news for GILD dated on 2019-10-10: Gilead Sciences Option Alert: Fri \$62.5 Calls Sweep (91) near the Ask: 983 @ \$0.391 vs 359 OI; Earnings 10/24 After Close Ref=\$62.4786

Financial news for GILD dated on 2019-10-09: Jim Cramer Shares His Thoughts On Roku, Gilead And More

Financial news for GILD dated on 2019-10-08: Shares of several healthcare companies are trading lower with the broader market after the US expanded its trade blacklist to include China's top AI firms. The US also will increase its tariffs on \$250 billion worth of goods from 25% to 30% on Oct 15.

Financial news for GILD dated on 2019-10-08: The Daily Biotech Pulse: D-Day For Clinuvel, Qiagen Warns Of Q3 Shortfall, Prevail Announces Gene Therapy Collaboration

Financial news for GILD dated on 2019-10-08: Gilead Submits NDA for Filgotinib for the Treatment of Adults With Rheumatoid Arthritis in Japan

Financial news for GILD dated on 2019-10-04: Gilead Highlights New Data From HIV Clinical Development Program At IDWeek

Financial news for GILD dated on 2019-10-03: Gilead Receives FDA Approval For Descovy In HIV Pre-Exposure Prophylaxis

Financial news for GILD dated on 2019-10-02: Shares of several healthcare companies are trading lower in sympathy with the overall market on continued fears of a recession amid a weak ADP jobs report. There is also uncertainty in the market over the upcoming U.S.-China meeting next week.

Financial news for GILD dated on 2019-09-30: Attention Biotech Investors: Mark Your Calendar For These October PDUFA Dates

Financial news for GILD dated on 2019-09-29: The Week Ahead In Biotech (Sept. 29-Oct. 5): Conference Presentations, IPOs Hit Top Gear

Financial news for GILD dated on 2019-09-26: 'Fast Money Halftime Report' Picks For September 26

Financial news for GILD dated on 2019-09-20: Shares of several drug companies are trading higher after Senate Majority Leader McConnell suggested a new Democratic drug price reform proposal would be dead on arrival.

Financial news for GILD dated on 2019-09-09: Gilead Sciences and Elton John AIDS Foundation to Partner to Positively Impact People Affected with HIV

Financial news for GILD dated on 2019-08-26: Alberta Provides Access To Biktarvy For The Treatment Of HIV

Financial news for GILD dated on 2019-08-23: Gilead And Galapagos Complete Closing Of Transformative Research And Development Collaboration

Financial news for GILD dated on 2019-08-21: Gilead Sciences Says "Strongly Believe" That The Patents Granted To Hhs Since 2015 For Prep And Pep Are Not Valid

Financial news for GILD dated on 2019-08-21: Gilead Statement On Petitions To U.S.

Patent And Trademark Office On Hiv Prep Patents; Will Continue To Invest In Programs To Accelerate Access To Prep

Financial news for GILD dated on 2019-08-15: Gilead Reports EMA Validated Marketing Application For Filgotinib For Treatment Of RA

Financial news for GILD dated on 2019-08-15: Gilead Reports Its Canada Unit Reported Quebec Public Drug Insurance Plan Will Be Provided For Eligible Patients With Access To Biktarvy Tablets

Financial news for GILD dated on 2019-08-13: Shares of several healthcare companies are trading higher with the overall market after the U.S. announced it is excluding and delaying the additional 10% tariff on certain products.

Financial news for GILD dated on 2019-08-09: Gilead Reports China National Medical Products Admin. Approved Biktarvy For Treatment Of HIV-1 Infection

Financial news for GILD dated on 2019-08-08: Agenus Reports \$7.5M Payment Triggered Following Acceptance Of Investigational New Drug Application Filing For AGEN2373

Financial news for GILD dated on 2019-08-08: The Daily Biotech Pulse: Glaukos To Buy Avedro, Mixed Adcom Vote For Gilead, Dynavax Offering

Financial news for GILD dated on 2019-08-07: Gilead Sciences Statement on FDA Advisory Committee's Recommendation on Descovy for PrEP

Financial news for GILD dated on 2019-08-07: Gilead Shares Unaffected As FDA Panel Has Voted 16-2 In Favor Of co.'s Descovy For Pre-Exposure Prep Of HIV In Men, Transgender Women

Financial news for GILD dated on 2019-08-07: The Daily Biotech Pulse: Novartis Stands By Zolgensma, GW Pharma Q2 Propelled By Epidiolex Sales, Ionis-Akcea Clinical Readout

Financial news for GILD dated on 2019-08-06: Gilead Sciences Option Alert: Sep 20 \$65 Calls Sweep (2) near the Ask: 527 @ \$1.5 vs 3258 OI; Ref=\$63.23

Financial news for GILD dated on 2019-08-06: Gilead's Sciences Canada Unit Highlights Ontario Drug Benefit Program Will Provide Eligible Patients With Access To Biktarvy Tablets

Financial news for GILD dated on 2019-08-05: Shares of several drug/pharma/medical equipment companies trading lower given weakness in broader stock market following concerns with China trade tensions.

Financial news for GILD dated on 2019-07-31: Gilead Sciences Option Alert: Aug 9 \$67.5 Calls Sweep (2) near the Ask: 700 @ \$0.401 vs 536 OI; Ref=\$65.71

Financial news for GILD dated on 2019-07-31: Gilead Sciences shares are trading lower despite better-than-expected Q2 results and raised guidance.

Financial news for GILD dated on 2019-07-31: Credit Suisse Maintains Neutral on Gilead Sciences, Lowers Price Target to \$67

Financial news for GILD dated on 2019-07-31: Raymond James Maintains Strong Buy on Gilead Sciences, Raises Price Target to \$86

Financial news for GILD dated on 2019-07-30: Gilead Ticks Higher After Q2 Earnings Beat

Financial news for GILD dated on 2019-07-30: Gilead Raises FY19 Product Sales Guidance From \$21.3B-\$21.8B To \$21.6B-\$22.1B

Financial news for GILD dated on 2019-07-30: Gilead Sciences Q2 Adj. EPS \$1.82 Beats \$1.72 Estimate, Sales \$5.685B Beat \$5.51B Estimate

Financial news for GILD dated on 2019-07-30: The Daily Biotech Pulse: European Cheer For Merck, Legal Victory For Coherus, Medpace Picks Up On Earnings

Financial news for GILD dated on 2019-07-30: 15 Stocks To Watch For July 30, 2019

Financial news for GILD dated on 2019-07-30: Earnings Scheduled For July 30, 2019

Financial news for GILD dated on 2019-07-29: RBC On Gilead: 'A Compelling Opportunity To Build A Long-Term Position'

Financial news for GILD dated on 2019-07-29: UPDATE: RBC On Gilead Also Notes 'high conviction that with new leadership and many overhangs out of the way, shares will begin to better reflect the value of future cash flows from their marketed products and pipeline, which we believe is worth \$91'

Financial news for GILD dated on 2019-07-29: UPDATE: RBC Upgrades Gilead To Top Pick, Announces \$91 Target As Firm Notes 'We have increasingly high confidence GILD's HIV franchise will provide steady annual revenues of ~\$16B/year over the medium term'

Financial news for GILD dated on 2019-07-29: Benzinga's Top Upgrades, Downgrades For July 29, 2019

Financial news for GILD dated on 2019-07-29: RBC Capital Upgrades Gilead Sciences to Top Pick

Financial news for GILD dated on 2019-07-27: The Week Ahead In Biotech: Pending Clinical Readouts, Earnings Dominate

Financial news for GILD dated on 2019-07-23: Gilead Highlights Presentation Of Data In Ongoing HIV Cure Research Program

Financial news for GILD dated on 2019-07-23: Gilead Reports Presented Added Results From DISCOVER Trial Of Descovy At International AIDS Society Conference on HIV Science

Financial news for GILD dated on 2019-07-22: Gilead Presents New Data On Biktarvy For The Treatment Of HIV In Women And In Virologically Suppressed Patients With Known Resistance

Financial news for GILD dated on 2019-07-22: STAT News Article Highlights CAR-T Therapy Innovations

Financial news for GILD dated on 2019-07-22: Gilead Highlights Presentation Of Proof-Of-Concept Data For GS-6207 Capsid Inhibitor In People Living With HIV

Financial news for GILD dated on 2019-07-22: DURECT Soars On Out-Licensing Deal With Gilead For Up To \$170M

Financial news for GILD dated on 2019-07-22: DURECT And Gilead Enter Into License Agreement For Long-Acting Injectable HIV Investigational Product; DURECT To Receive Upfront Payment Of \$25M With Potential For Up To \$75M In Development And Regulatory Milestones

Financial news for GILD dated on 2019-07-19: Gilead Will Buy Exclusive Global Rights To Develop, Commercialize Novel Small Molecules Against 3 Undisclosed Targets From Novartis, Novartis Will Receive Upfront Payment, Eligible For Added \$291M

Financial news for GILD dated on 2019-07-16: Gilead To Report Q2 Earnings On Tue., Jul. 30, 2019 After Market Close

Financial news for GILD dated on 2019-07-16: 52 Biggest Movers From Yesterday

Financial news for GILD dated on 2019-07-15: Mid-Afternoon Market Update: Carolina Trust BancShares Rises On Acquisition News; Callon Petroleum Shares Tumble

Financial news for GILD dated on 2019-07-15: Mid-Day Market Update: Crude Oil Down 1%; Galapagos Shares Spike Higher

Financial news for GILD dated on 2019-07-15: 42 Stocks Moving In Monday's Mid-Day Session

Financial news for GILD dated on 2019-07-15: Mid-Morning Market Update: Markets Edge Lower; Citigroup Beats Q2 Estimates

Financial news for GILD dated on 2019-07-15: Galapagos Notches \$3.95B Upfront Investment From Gilead

Financial news for GILD dated on 2019-07-15: Gilead Sciences shares are trading higher after Wells Fargo upgraded the stock from Market Perform to Outperform and raised the price target from \$68 to \$88.

Financial news for GILD dated on 2019-07-15: 10 Biggest Price Target Changes For Monday

Financial news for GILD dated on 2019-07-15: Benzinga's Top Upgrades, Downgrades For July 15, 2019

Financial news for GILD dated on 2019-07-15: Wells Fargo Upgrades Gilead Sciences to Outperform, Raises Price Target to \$88

Financial news for GILD dated on 2019-07-15: Galapagos Shares Rise \$23 Premarket Following Announcement of \$1.1B Equity Investment from Gilead

Financial news for GILD dated on 2019-07-14: Gilead, Galapagos Announce 10-year Global R&D Collaboration

Financial news for GILD dated on 2019-07-11: Shares of several drug manufacturing companies are trading lower. The Trump Administration earlier rolled back a proposal to eliminate rebates from government drug plans and commented on continued efforts to lower drug prices.

Financial news for GILD dated on 2019-07-11: Gilead Reports Strategic Collaboration With Renown Institute For Health Innovation For Collection, Analyzing Of Genetic, Electronic Health Data

Financial news for GILD dated on 2019-07-09: Gilead, Lyndra Therapeutics Partner On Ultra-Long-Acting HIV Drugs

Financial news for GILD dated on 2019-07-09: Lyndra Therapeutics, Gilead Sciences to Collaborate on Development of Ultra-Long-Acting HIV Therapeutics

Financial news for GILD dated on 2019-07-08: Shares of several healthcare companies are trading lower after Trump on Friday said he was preparing an executive order declaring a 'favored nations clause' for drug prices, lowering the price that consumers will pay prescription drugs.

Financial news for GILD dated on 2019-07-05: Gilead Sciences Option Alert: Jul 26 \$71.5 Calls Sweep (28) near the Ask: 596 @ \$0.339 vs 1144 OI; Earnings 7/24 After Close [est] Ref=\$68.65

Financial news for GILD dated on 2019-07-02: The Daily Biotech Pulse: Celyad To Advance Leukemia Drug To Clinical Trial, Positive Data For Teva's Migraine Drug

Financial news for GILD dated on 2019-07-01: Gilead Announces Intent to Submit NDA to FDA for Filgotinib This Year

Financial news for GILD dated on 2019-06-29: The Week Ahead In Biotech: Pending Clinical Readouts In Focus

Financial news for GILD dated on 2019-06-25: The Daily Biotech Pulse: Genfit NASH Drug In China, Conatus Explores Sale, Gilead Stitches Up Immuno-Oncology Partnership

Financial news for GILD dated on 2019-06-24: Gilead, Carina Biosciences Announce Research and Development Collaboration to Develop Novel Immuno-Oncology Therapies

Financial news for GILD dated on 2019-06-19: Gilead Reports Strategic Collaboration With Nurix To Develop Novel Therapies For Cancer, Other Diseases

Financial news for GILD dated on 2019-06-13: Abcellera Reports Therapeutic Antibody Discovery Collaboration With Gilead, Will Receive Upfront, Research Payments

Financial news for GILD dated on 2019-06-12: WHO Emergency Committee Meeting To Decide If Ebola Outbreak Constitutes An Int'l. Emergency Will Begin Jun. 14, 2019

Financial news for GILD dated on 2019-06-12: Gilead Sciences Option Alert: Jun 28 \$66 Calls Sweep (3) near the Ask: 500 @ \$1.301 vs 838 OI; Earnings 7/24 After Close [est] Ref=\$66.67

Financial news for GILD dated on 2019-06-12: The Daily Biotech Pulse: Nuvecetra Files For Expanded Label For Algovita SCS, Axovant Earnings, FDA Nod For Aratana

Financial news for GILD dated on 2019-06-11: Why Low-Float, Thinly Traded ContraVir Pharma's Rally Is Continuing

Financial news for GILD dated on 2019-06-08: The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trial Readouts

Financial news for GILD dated on 2019-06-07: Many US-traded stocks are trading higher as recent economic signals have raised the potential for a Federal Reserve rate cut.

Financial news for GILD dated on 2019-06-06: ContraVir Rallies As NASH Drug Shows Efficacy In Preclinical Study

Financial news for GILD dated on 2019-06-04: Shares of several healthcare companies are trading higher with the overall US market. Recent comments out of China and Mexico has renewed trade optimism and lifted economic outlook.

Financial news for GILD dated on 2019-06-03: Gilead Sciences shares are trading higher after Kite, a Gilead company, announced positive data from the ZUMA-1 trial of Yescarta.

Financial news for GILD dated on 2019-06-03: Gilead's Kite Highlights New Yescarta

Data From ZUMA-1, Showed 'High Rates of Durable Response and Overall Survival Regardless of Age at Two Years Post-Treatment'

Financial news for GILD dated on 2019-06-01: Biocartis, Kite Sign Agreement for Development of Assays Supporting Kite's Therapies; Financial Terms Not Disclosed

Financial news for GILD dated on 2019-05-31: Gilead's Kite Reports Clinical Collaboration With Humanigen To Evaluate Investigational Combination of Yescarta(r) with Lenzilumab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Financial news for GILD dated on 2019-05-29: Gilead, Galapagos Highlights Will Present Latest Data From Filgotinib At EULAR 2019

Financial news for GILD dated on 2019-05-28: Goldman Downgrades Gilead Sciences: 'We Find It Difficult To See The Stock's Multiple Expanding'

Financial news for GILD dated on 2019-05-28: UPDATE: Goldman Downgrades Gilead To Sell, Lowers Target To \$60 As Firm Notes 'Nearer-term we expect the company's top line growth to decelerate'

Financial news for GILD dated on 2019-05-28: 10 Biggest Price Target Changes For Tuesday

Financial news for GILD dated on 2019-05-28: Gilead Sciences shares are trading lower after Goldman Sachs downgraded the stock from Neutral to Sell and lowered the price target from \$70 to \$60.

Financial news for GILD dated on 2019-05-28: Benzinga's Top Upgrades, Downgrades For May 28, 2019

Financial news for GILD dated on 2019-05-28: A Peek Into The Markets: US Stock Futures Edge Lower Ahead Of Economic Data

Financial news for GILD dated on 2019-05-28: Goldman Sachs Downgrades Gilead Sciences to Sell, Lowers Price Target to \$60 Price Target

Financial news for GILD dated on 2019-05-24: Alpine Immune Sciences 8-K Shows Gilead's Kite Pharma Provided Co. Notice Of Termination Of License, Research Deal

Financial news for GILD dated on 2019-05-23: Gilead And Kratos Defense: 'Fast Money Halftime Report' Picks From May 23

Financial news for GILD dated on 2019-05-23: Benzinga's Top Upgrades, Downgrades For May 23, 2019

Financial news for GILD dated on 2019-05-23: Citigroup Upgrades Gilead Sciences, Inc. - Common Stock to Buy

Financial news for GILD dated on 2019-05-21: Credit Suisse Initiates Coverage On Gilead Sciences, Inc. - Common Stock with Neutral Rating, Announces \$70 Price Target

Financial news for GILD dated on 2019-05-20: Hearing Credit Suisse Initiates Coverage On Gilead With Neutral Rating, \$70 Price Target

Financial news for GILD dated on 2019-05-15: Temasek Liquidates Positions In Boeing, Tencent Music, Gilead, Takes Small Stake In Microsoft

Financial news for GILD dated on 2019-05-14: Shares of several healthcare companies are trading higher as the US market rebounds from recent weakness, driven by renewed cautious optimism surrounding US-China trade talks.

Financial news for GILD dated on 2019-05-13: Shares of several healthcare companies are trading lower amid continued trade dispute between the US and China. Also, the United States filed a lawsuit against drug manufacturers alleging price fixing.

Financial news for GILD dated on 2019-05-10: Shares of several healthcare companies are trading lower in sympathy with the overall market. The S&P 500 is trading lower 1%

Financial news for GILD dated on 2019-05-10: 'Drugmaker Gilead reaches multiyear agreement with White House to donate HIV prevention med PrEP' -CNBC

Financial news for GILD dated on 2019-05-08: Gilead To Invest \$109M In Goldfinch Bio For Kidney Drug Collaboration

Financial news for GILD dated on 2019-05-08: UPDATE: Goldfinch To Receive \$55M In Upfront Payments From Gilead, Added \$54M To Support Development Of KGA Platform For Diabetic Kidney Disease

Financial news for GILD dated on 2019-05-08: Gilead Sciences Reports Strategic Collaboration With Goldfinch Bio To Develop Novel Therapies For Kidney Disease

Financial news for GILD dated on 2019-05-03: Gilead Sciences shares are trading higher after the company reported better-than-expected Q1 EPS and reaffirmed 2019 guidance.

Financial news for GILD dated on 2019-05-03: The Daily Biotech Pulse: Obseva Reports Positive Endometriosis Drug Trial, Assembly Biosciences Execs Depart, Coherus Settles With Amgen

Financial news for GILD dated on 2019-05-02: Gilead Reaffirms FY19 Guidance

Financial news for GILD dated on 2019-05-02: Gilead Sciences Q1 Adj. EPS \$1.76 Beats \$1.61 Estimate, Sales \$5.258B Miss \$5.31B Estimate

Financial news for GILD dated on 2019-05-02: What's The Buzz Around Novartis' Gene Therapy Zolgensma?

Financial news for GILD dated on 2019-05-02: The Daily Biotech Pulse: FDA Nod For Sanofi's Dengue Vaccine, Veracyte Offering, Biogen Reports Positive Data

Financial news for GILD dated on 2019-05-02: Earnings Scheduled For May 2, 2019

Financial news for GILD dated on 2019-05-01: Alphabet's Eric Schmidt, Diane Greene To Leave Board This June

Financial news for GILD dated on 2019-05-01: The Daily Biotech Pulse: Nabriva Stumbles At FDA Hurdle, Gilead CFO To Retire, Eisai Ends Collaboration With Purdue

Financial news for GILD dated on 2019-04-30: Gilead Reports CFO Robin Washington To Step Down; Was Named To Alphabet's Board

Financial news for GILD dated on 2019-04-26: Bernstein Initiates Coverage On Gilead Sciences, Inc. - Common Stock with Outperform Rating

Financial news for GILD dated on 2019-04-26: Bernstein Initiates Coverage On Gilead Sciences, Inc. - Common Stock with Outperform Rating, Announces \$82 Price Target

Financial news for GILD dated on 2019-04-25: Gilead Reiterates Faith In NASH Combination Approach After Another Trial Disappointment

Financial news for GILD dated on 2019-04-25: Gilead Announces Phase 3 STELLAR-3 Study Of Selonsertib In Bridging Fibrosis Due To NASH Did Not MEet PRe-Specified Week 48 Endpoint

Financial news for GILD dated on 2019-04-24: 'Gilead defied a government HIV patent. The Justice Department has opened a review.' -Washington Post

Financial news for GILD dated on 2019-04-24: Gilead Reports Its Kite Pharma Co. Planning New Facility In Frederick County On 20-Acre Site, Maryland To Produce Cell Therapies For People With Cancer

Financial news for GILD dated on 2019-04-23: Shares of several healthcare stocks are trading higher in a potential rebound from last week's selloff. In an upgrade of HCA Healthcare, Raymond James analysts noted the selloff was 'based on legislation that has almost no chance of passing'

Financial news for GILD dated on 2019-04-18: Shares of several drug companies are trading lower amid continued efforts from Washington to curb prescription drug prices. The overall healthcare sector has seen weakness recently due to uncertainty over the future of healthcare policy.

Financial news for GILD dated on 2019-04-18: Jim Cramer Shares His Thoughts On AMD, Gilead, Nvidia And More

Financial news for GILD dated on 2019-04-17: Shares of several drug companies are trading lower amid continued efforts from Washington to curb prescription drug prices. The overall healthcare sector has seen weakness recently due to uncertainty over the future of healthcare policy.

Financial news for GILD dated on 2019-04-16: Shares of several drug companies are trading lower. Weakness may be tied to uncertainty over healthcare policy going into the 2020 primaries and Washington's recent efforts to curb prescription drug prices.

Financial news for GILD dated on 2019-04-16: Gilead And Insitro Announce Strategic Collaboration To Discover And Develop Novel Therapies For Nonalcoholic Steatohepatitis

Financial news for GILD dated on 2019-04-12: Gilead Sciences, Novo Nordisk Announce Intent to Initiate a Clinical Collaboration in NASH

Financial news for GILD dated on 2019-04-11: Gilead Highlights Will Present New Data On HBV, Hep C Medicines At The International Liver Congress Thurs.

Financial news for GILD dated on 2019-04-11: The Daily Biotech Pulse: NASH Cheer For Intercept, Gilead Layoffs, BioDelivery Licenses Constipation Drug

Financial news for GILD dated on 2019-04-11: Gilead Presents New Data in NASH at the International Liver Congress 2019

Financial news for GILD dated on 2019-04-10: 'Gilead Sciences to lay off one-fifth of sales force as financial pressures build' -STAT

Financial news for GILD dated on 2019-04-10: UBS Upgrades Gilead, Sees EPS Upside In 2019

Financial news for GILD dated on 2019-04-10: Gilead Sciences shares are trading higher after UBS upgraded the stock from Neutral to Buy and raised the price target from \$75 to \$77.

Financial news for GILD dated on 2019-04-10: 10 Biggest Price Target Changes For Wednesday

Financial news for GILD dated on 2019-04-10: Benzinga's Top Upgrades, Downgrades For April 10, 2019

Financial news for GILD dated on 2019-04-10: A Peek Into The Markets: US Stock Futures Climb Ahead Of CPI, Fed Minutes

Financial news for GILD dated on 2019-04-10: UBS Upgrades Gilead Sciences to Buy, Raises Price Target to \$77

Financial news for GILD dated on 2019-04-05: Gilead Sciences Option Alert: May 17 \$70 Calls Sweep (35) near the Ask: 534 @ \$1.309 vs 7580 OI; Earnings 4/30 After Close [est] Ref=\$67.56

Financial news for GILD dated on 2019-04-05: Gilead Reports Submission Of Supplemental New Drug Application To FDA For Once-Daily Descovy For HIV Pre-Exposure Prophylaxis

Financial news for GILD dated on 2019-03-29: Congo Health Ministry Says Has Recorded 15 New Confirmed Cases Of Ebola

Financial news for GILD dated on 2019-03-29: Gilead Sciences shares are trading higher after the company's filgotinib met its primary and key secondary endpoints in a phase 3 Finch 1 rheumatoid arthritis study.

Financial news for GILD dated on 2019-03-29: The Daily Biotech Pulse: Safety Board Clears Eisai's Alzheimer's Study, Positive Trial Results For Galapagos-Gilead

Financial news for GILD dated on 2019-03-28: Gilead And Galapagos Announce Filgotinib Meets Primary And Key Secondary Endpoints In The Phase 3 Finch 1 Rheumatoid Arthritis Study

Financial news for GILD dated on 2019-03-27: The Precision Biosciences IPO: What You Need To Know

Financial news for GILD dated on 2019-03-27: 6 Gene Therapy M&A Targets On The Radar

Financial news for GILD dated on 2019-03-27: Gilead to Present New Data From Multiple Liver Disease Research and Development Programs at The International Liver Congress 2019

Financial news for GILD dated on 2019-03-26: Gilead Reports Japan's Ministry of Health, Labour, Welfare Approves Co.'s Biktarvy For Treatment Of HIV-1 Infection

Financial news for GILD dated on 2019-03-22: Conatus Shares Fall By More Than 50% After Midstage Study Shows NASH Candidate Lagged Placebo

Financial news for GILD dated on 2019-03-15: Benzinga's Top Upgrades, Downgrades For March 15, 2019

Financial news for GILD dated on 2019-03-15: BMO Capital Initiates Coverage On Gilead Sciences with Outperform Rating, Announces \$78 Price Target

Financial news for GILD dated on 2019-03-13: Gilead Sciences Option Alert: Apr 18 \$70 Calls Sweep (33) near the Ask: 991 @ \$0.301 vs 5924 OI; Earnings 4/30 After Close

[est] Ref=\$65.63

Financial news for GILD dated on 2019-03-13: Agenus Reports Acceptance Of Co.'s IND Filing For AGEN1423 Partnership With Gilead, Triggering Cash Payment Of \$7.5M

Financial news for GILD dated on 2019-03-07: Gilead Highlights Data From Two Studies Supporting Further Development Of GS-6207, A Novel, Investigational HIV-1 Capsid Inhibitor As A Component Of Future Long-Acting HIV Therapies

Financial news for GILD dated on 2019-03-06: UPDATE: Gilead Says Biktarvy Showed No Treatment-Emergent Resistance

Financial news for GILD dated on 2019-03-06: Gilead Reports Presented New Data On Biktarvy, TAF-Based Regimens For Treatment Of HIV-1: Through Week 48, Biktarvy Maintained High Rates Of Virologic Suppression With Low Incidence Of Study Drug-Related Adverse Events,

Financial news for GILD dated on 2019-03-06: Gilead Announces Its DISCOVER Trial Meets Primary And Secondary Endpoints And Will Support Supplemental Regulatory Filing For Descovy For Pre-Exposure Prophylaxis

Financial news for GILD dated on 2019-02-19: Intercept Shares Soar To Multimonth High After NASH Drug Aces Late-Stage Trial

Financial news for GILD dated on 2019-02-19: Gilead Reports Received Approval In Canada For YESCARTA CAR T Therapy For Adults With Relapsed or Refractory Large B-cell Lymphoma After Two or More Lines of Systemic Therapy

Financial news for GILD dated on 2019-02-15: The Week Ahead In Biotech: Conferences, Clinical Trials And Earnings

Financial news for GILD dated on 2019-02-15: Centers For Medicaid, Medicare Has Proposed Coverage With Evidence Development For CAR-T Therapy, Decision Would Provide Nationwide Consistency In CMS Coverage

Financial news for GILD dated on 2019-02-13: Analyst: Intercept's NASH Drug Could Launch Sans Competition After Gilead Trial Failure

Financial news for GILD dated on 2019-02-12: 44 Stocks Moving In Tuesday's Mid-Day Session

Financial news for GILD dated on 2019-02-12: Gilead Analysts React To Failed NASH Trial: Citigroup, Wells Fargo Downgrade Biotech

Financial news for GILD dated on 2019-02-12: 8 Biggest Price Target Changes For Tuesday

Financial news for GILD dated on 2019-02-12: UPDATE: Raymond James Lowers Gilead Target From \$90 To \$85 As Firm Notes 'Gilead's Phase 3 trial in F4 NASH patients (STELLAR4) failed' And Firm Has 'very little reason to suspect STELLAR3 in F3 NASH (data 2Q19E) will be any different'

Financial news for GILD dated on 2019-02-12: Gilead's Failed NASH Drug Trial Drags Stock Lower

Financial news for GILD dated on 2019-02-12: Benzinga's Top Upgrades, Downgrades For February 12, 2019

Financial news for GILD dated on 2019-02-12: 26 Stocks Moving In Tuesday's Pre-Market Session

Financial news for GILD dated on 2019-02-12: Shares of Gilead Sciences are trading lower after the company announced its Phase 3 STELLAR-4 study did not meet its primary endpoint. The stock was subsequently downgraded by several banks.

Financial news for GILD dated on 2019-02-12: The Daily Biotech Pulse: NASH Disappointment For Gilead, Xeris To Offer Shares

Financial news for GILD dated on 2019-02-12: Raymond James Maintains Strong Buy on Gilead Sciences, Lowers Price Target to \$85

Financial news for GILD dated on 2019-02-12: A Peek Into The Markets: US Stock Futures Point To Higher Wall Street Open

Financial news for GILD dated on 2019-02-12: Citigroup Downgrades Gilead Sciences to Neutral, Lowers Price Target to \$75

Financial news for GILD dated on 2019-02-12: Wells Fargo Downgrades Gilead Sciences to Market Perform, Lowers Price Target to \$68



Financial news for GILD dated on 2019-02-11: 7 Stocks Moving In Monday's After-Hours Session

Financial news for GILD dated on 2019-02-11: Gilead Sciences shares are trading lower after the company reported the topline data from its STELLAR-4 Phase 3 study did not meet its primary endpoint.

Financial news for GILD dated on 2019-02-11: Gilead Reports Topline Data From Phase 3 STELLAR-4 Study of Selonsertib in Compensated Cirrhosis Due To NASH Did Not Meet Primary Endpoint

Financial news for GILD dated on 2019-02-07: For Sale: Performance Stocks, Slightly Worn

Financial news for GILD dated on 2019-02-05: January's Market Bounce Resulted In Some Unexpected Retail Trading Trends

Financial news for GILD dated on 2019-02-05: Analysts Focus On Gilead's Late-Stage Data Readouts Following Mixed Q4

Financial news for GILD dated on 2019-02-05: Investor Movement Index January Summary

Financial news for GILD dated on 2019-02-05: 42 Stocks Moving In Tuesday's Mid-Day Session

Financial news for GILD dated on 2019-02-05: Gilead Sciences shares are trading lower after the company reported Q4 EPS of \$1.44 versus \$1.70 estimate; sales declined 3.8% year over year due to weakness in its hepatitis C segment.

Financial news for GILD dated on 2019-02-05: 32 Stocks Moving In Tuesday's Pre-Market Session

Financial news for GILD dated on 2019-02-05: The Daily Biotech Pulse: Gilead Earnings, Codexis Sings Pact With Merck, Eli Lilly Reports Positive Trial Results

Financial news for GILD dated on 2019-02-05: 12 Stocks To Watch For February 5, 2019

Financial news for GILD dated on 2019-02-04: '\$GILD's comment on M&A: late stage opportunities are few and far between.' -Tweet From Notable Biotech Investor Brad Loncar

Financial news for GILD dated on 2019-02-04: Gilead Sciences shares are trading lower after the company reported Q4 EPS of \$1.44 versus the \$1.70 estimate.

Financial news for GILD dated on 2019-02-04: Gilead Raises Qtr. Dividend From \$0.57 To \$0.63/Share

Financial news for GILD dated on 2019-02-04: Gilead Sees FY19 GAAP EPS \$1.40-\$1.50, Product Sales \$21.3B-\$21.8B

Financial news for GILD dated on 2019-02-04: Gilead Sciences Q4 EPS \$1.44 May Not Compare To \$1.70 Estimate, Sales \$5.795B Beat \$5.48B Estimate

Financial news for GILD dated on 2019-02-04: Q4 Earnings Preview For Gilead Sciences

Financial news for GILD dated on 2019-02-04: 8 Stocks To Watch For February 4, 2019

Financial news for GILD dated on 2019-02-04: Earnings Scheduled For February 4, 2019

Financial news for GILD dated on 2019-02-03: The Week Ahead In Biotech: Conferences, Clinical Trials, Earnings And IPOs

Financial news for GILD dated on 2019-01-28: Analysts Cut AbbVie Price Targets After Earnings Miss

Financial news for GILD dated on 2019-01-24: Agenus Closes \$150 Million Immunology Transaction With Gilead

Financial news for GILD dated on 2019-01-18: Searching For A Treatment: NASH Investigational Drugs With Catalysts This Year

Financial news for GILD dated on 2019-01-08: UPDATE: Nektar Says Gilead Will Be Responsible For Preclinical Studies, Costs

Financial news for GILD dated on 2019-01-08: UPDATE: Nektar Research Collab With Gilead Will Be For Exploration Of Combo Between Co.'s NKTR-225 And Gilead's Effector-Memory T Cells With Antiretroviral Therapies

Financial news for GILD dated on 2019-01-08: Nektar Therapeutics 8-K Shows Pres, CEO Will Make Presentation At JP Morgan Healthcare Conference; Will Outline Research Collab With Gilead; Will Show \$1.92B In Cash, Equivalents as Of Dec. 31, 2018

Financial news for GILD dated on 2019-01-08: Gilead Received Approval for Epclusa in Japan

Financial news for GILD dated on 2019-01-07: 5 Top-Selling Drugs With Growth Potential In 2019

Financial news for GILD dated on 2019-01-07: Gilead Sciences at JP Morgan Conference Says To Focus On HIV In 2019

Financial news for GILD dated on 2019-01-06: Gilead. Yuhan Announce Collaboration and License Agreement to Develop Novel Investigational Treatments for Advanced Fibrosis Due to Nonalcoholic Steatohepatitis

Financial news for GILD dated on 2019-01-03: Oppenheimer Upgrades Gilead Sciences to Outperform

Financial news for GILD dated on 2019-01-03: 26 Stocks Moving In Thursday's Pre-Market Session

Financial news for GILD dated on 2019-01-03: Gilead shares are trading up on news that Bristol-Myers will acquire Celgene in a \$74 billion deal.

Financial news for GILD dated on 2019-01-02: Gilead Sciences Option Alert: Feb 15 \$65 Calls Sweep (27) near the Ask: 536 @ \$2.739 vs 4625 OI; Earnings 2/5 After Close [est] Ref=\$63.63

Financial news for GILD dated on 2019-01-02: Gilead Sciences Option Alert: Mar 15 \$65 Calls Sweep (17) near the Ask: 590 @ \$3.25 vs 329 OI; Earnings 2/5 After Close [est] Ref=\$63.4

Financial news for GILD dated on 2019-01-02: Gilead Sciences Option Alert: Mar 15 \$65 Calls Sweep (28) near the Ask: 508 @ \$3.151 vs 329 OI; Earnings 2/5 After Close [est] Ref=\$63.43

Financial news for GILD dated on 2018-12-24: 28 Stocks Moving In Monday's Pre-Market Session

Financial news for GILD dated on 2018-12-23: The Week Ahead In Biotech: Focus Shifts To Year-End Clinical Trial Results

Financial news for GILD dated on 2018-12-20: Raymond James: Gilead In NASH For The Long Haul

Financial news for GILD dated on 2018-12-20: The Daily Biotech Pulse: Tilray Inks Cannabis Drink Pact, Double Delight For Merck, FDA Snub For Spectrum

Financial news for GILD dated on 2018-12-20: Gilead, Agenus Report Collaboration Deal To Develop Immuno-Oncology Therapies; Agenus To Receive \$150M

Financial news for GILD dated on 2018-12-19: Morgan Stanley Maintains Equal-Weight on Gilead Sciences, Raises Price Target to \$86

Financial news for GILD dated on 2018-12-19: Gilead Sciences And Scholar Rock Announce Collaboration To Develop Novel Therapies For Fibrotic Diseases; Scholar Rock Will Receive \$80M Upfront As Well As Up To \$1.425B In Potential Milestones

Financial news for GILD dated on 2018-12-18: Guggenheim Reinstates Buy on Gilead Sciences, Announces \$86

Financial news for GILD dated on 2018-12-17: Gilead Sciences Option Alert: Jan 18 \$75 Calls at the Ask: 600 @ \$0.37 vs 25755 OI; Earnings 2/5 After Close [est] Ref=\$66.87

Financial news for GILD dated on 2018-12-12: Gilead Sciences Option Alert: Jan 18 \$50 Calls Sweep (2) near the Ask: 700 @ \$19.076 vs 2396 OI; Earnings 2/5 After Close [est] Ref=\$69.07

Financial news for GILD dated on 2018-12-12: Stocks That Will Be Trading Ex Dividend Thurs., Dec. 13, 2018

Financial news for GILD dated on 2018-12-11: New Gilead Sciences CEO Has 'Breadth Of Experience' From Time At Roche, Says Bullish Raymond James

Financial news for GILD dated on 2018-12-10: Gilead Shares Down 1.7% To Below \$68 Level Mon.; Co. Announced Late Sun. Roche Exec Daniel O'Day Will Replace John Milligan As CEO, Also Be Named Chair

Financial news for GILD dated on 2018-12-09: Roche Executive Daniel O'Day to Succeed John Milligan as Gilead CEO

Financial news for GILD dated on 2018-12-04: Gilead Reports China National Medical Products Administration Approved Harvoni As Hepatitis C Treatment

Financial news for GILD dated on 2018-12-04: Gilead Reports China National Medical Products Administration Approved Descovy As HIV Treatment

Financial news for GILD dated on 2018-12-04: The Daily Biotech Pulse: ASH Presentations Take The Spotlight, Eiger Gets A New CFO

Financial news for GILD dated on 2018-12-04: Gilead's Kite Announces Updated Data From ZUMA-3 Study of KTE-X19 in Adult Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia at ASH 2018

Financial news for GILD dated on 2018-12-03: Kite Announces Encouraging Updated Data From ZUMA-3 Study of KTE-X19 in Adult Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia at ASH 2018

Financial news for GILD dated on 2018-12-02: Gilead's Kite Announces Two-Year Data for Yescarta in Patients With Refractory Large B-Cell Lymphoma at ASH 2018; Median Duration Of Complete Response Was Not Reached; Median Overall Survival Was Not Reached

Financial news for GILD dated on 2018-12-02: The Week Ahead In Biotech: ASH Presentations Pick Up Pace, PDUFA Dates, Clinical Trials And IPOs

Financial news for GILD dated on 2018-11-30: Gilead Sciences shares are trading higher amid reports of an Ebola outbreak in The Congo; Gilead developed the Remdesivir antiviral which is undergoing clinical trials to treat Ebola.

Financial news for GILD dated on 2018-11-29: Japan Tobacco Terminates Agreements With Gilead Sciences Under Which Gilead Grants An Exclusive License To JT To Develop And Commercialize Six Anti-HIV Drugs In Japan

Financial news for GILD dated on 2018-11-25: 9 Policy Catalysts For Health Care Investors To Watch Before Year's End

Financial news for GILD dated on 2018-11-19: Gilead Announces China National Medical Products Administration (NMPA) Approves Vemlidy for Chronic Hepatitis B Virus Infection

Financial news for GILD dated on 2018-11-09: Gilead Reports Phase 2 Results For GS-9674 In Primary Sclerosing Cholangitis At The Liver Meeting

Financial news for GILD dated on 2018-11-06: IMX Dips In October, But Investors Remain Bullish

Financial news for GILD dated on 2018-11-06: Investor Movement Index October Summary

Financial news for GILD dated on 2018-10-31: Gilead Sciences shares are down 6.0% after the company announced partnership with Tango Therapeutics; Gilead will pay \$50M upfront.

Financial news for GILD dated on 2018-10-31: Gilead Sciences and Tango Therapeutics Announce Collaboration to Develop Immuno-Oncology Therapies, Gilead to Make a \$50M Upfront Payment

Financial news for GILD dated on 2018-10-30: Gilead Reports 96-Week Results From Phase 3 Study Of Biktarvy For Treatment Of HIV-1 In Adults New To HIV Therapy: 'Showed High Efficacy and High Barrier to Resistance'

Financial news for GILD dated on 2018-10-26: Raymond James Maintains Strong Buy on Gilead Sciences, Lowers Price Target to \$94

Financial news for GILD dated on 2018-10-26: Cantor Fitzgerald Maintains Overweight on Gilead Sciences, Raises Price Target to \$88

Financial news for GILD dated on 2018-10-26: 10 Biggest Price Target Changes For Friday

Financial news for GILD dated on 2018-10-26: Benzinga's Top Upgrades, Downgrades For October 26, 2018

Financial news for GILD dated on 2018-10-26: The Daily Biotech Pulse: Gilead's Q2, Syndax Breast Cancer Drug Setback, Synergy Pharma On Brink Of Default

Financial news for GILD dated on 2018-10-26: PiperJaffray Downgrades Gilead Sciences to Neutral, Lowers Price Target to \$75

Financial news for GILD dated on 2018-10-25: Gilead Sciences Raises FY18 Sales Guidance From \$20B-\$21B To \$20.8B-\$21.3B vs \$21.43B Est.

Financial news for GILD dated on 2018-10-25: Gilead Sciences, Inc. Q3 Adj. EPS \$1.84 Beats \$1.63 Estimate, Sales \$5.5B Beat \$5.38B Estimate

Financial news for GILD dated on 2018-10-25: A Preview Of Gilead's Q3 Earnings

Financial news for GILD dated on 2018-10-25: The Daily Biotech Pulse: AbbVie Takes Full Control Of Cystic Fibrosis Program, Amgen Slashes Cholesterol Drug Price

Financial news for GILD dated on 2018-10-25: Earnings Scheduled For October 25, 2018

Financial news for GILD dated on 2018-10-21: The Week Ahead In Biotech: ESMO Conference, PDUFA Dates, Clinical Trial Results, Large-Cap Pharma Earnings And IPOs

Financial news for GILD dated on 2018-10-20: Gilead, Galapagos Announce FINCH 2 Study Results Demonstrate Significant Improvement in Rheumatoid Arthritis Signs, Symptoms and Health-Related Quality of Life

Financial news for GILD dated on 2018-10-04: Gilead Sciences Option Alert: Oct 19 \$77.5 Calls Sweep (19) near the Ask: 539 @ \$0.986 vs 4073 OI; Earnings 10/25 After Close Ref=\$76.18

Financial news for GILD dated on 2018-10-03: Gilead Reports 96-Week Results From Phase 3 Study Of Biktarvy For Treatment Of HIV-1 In Adults New To HIV Therapy: 'Showed High Efficacy and a Demonstrated Tolerability Profile'

Financial news for GILD dated on 2018-10-02: Gilead Subsidiary, Kite, And HiFiBio Therapeutics Announce Research Collaboration o Develop Technology For The Potential Discovery Of Neoantigen-Reactive T Cell Receptors (TCRs) Cancer Treatment; HiFiBio Will Receive \$10M Upfront Payment

Financial news for GILD dated on 2018-10-01: Cantor Fitzgerald Initiates Coverage On Gilead Sciences with Overweight Rating, Announces \$87 Price Target

Financial news for GILD dated on 2018-09-26: Traders Circulating FDA.gov Adverse Event Reporting System Doc Showing Case For Multiple Instances Of Co.'s HIV Treatment Potentially Causing Transplacental Defects; Gilead Shares Move Lower

Financial news for GILD dated on 2018-09-24: Gilead Subsidiary to Launch Authorized Generics of Epclusa and Harvoni for the Treatment of Chronic Hepatitis C

Financial news for GILD dated on 2018-09-14: Stocks Trading Ex Dividend For Thurs., Sep. 13, 2018

Financial news for GILD dated on 2018-09-13: Stocks Trading Ex Dividend For Thurs., Sep. 13, 2018

Financial news for GILD dated on 2018-09-12: Why Gilead, Galapagos Shares Are Trading Higher

Financial news for GILD dated on 2018-09-12: Fast Money Picks For September 12

Financial news for GILD dated on 2018-09-12: Gilead Reports Collaboration With Precision BioSciences For Development Of Therapies Against Hep B Virus Using ARCUS Genome Editing

Financial news for GILD dated on 2018-09-12: The Daily Biotech Pulse: Foamix Jumps on Data, Positive Results for Galapagos-Gilead's Rheumatoid Arthritis Drug, Bausch Health Trims Debt

Financial news for GILD dated on 2018-09-12: 30 Stocks Moving In Wednesday's Pre-Market Session

Financial news for GILD dated on 2018-09-11: Gilead and Galapagos Announce Filgotinib Meets Primary and 'All Key Secondary' Endpoints In Phase 3 Study In Rheumatoid Arthritis

Financial news for GILD dated on 2018-09-09: The Week Ahead In Biotech: Conferences, Clinical Trial Results, Earnings And IPOs

Financial news for GILD dated on 2018-09-06: The Daily Biotech Pulse: Novartis Divestment, Eyepoint's Drug Gets Coverage, Spectrum's Robust Data

Financial news for GILD dated on 2018-09-06: Gilead, Galapagos Announce Tortuga

## Phase 2 Study of Filgotinib in Ankylosing Spondylitis Achieves Primary Endpoint

Financial news for GILD dated on 2018-09-04: UPDATE: Terms Of Gilead Licensing Deal For Trianni Not Disclosed

Financial news for GILD dated on 2018-09-04: Gilead Reports Licensing Deal With Trianni For Use Of Trianni Transgenic Human Monoclonal Antibody Discovery Platform

Financial news for GILD dated on 2018-09-02: The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials And Earnings

Financial news for GILD dated on 2018-08-27: Gilead's Yescarta Resceives European Marketing Authorization

Financial news for GILD dated on 2018-08-22: Sierra Oncology Acquires Momelotinib, Will Pay Gilead \$3M Upfront With Potential Milestone Payments Of Up To \$195M

Financial news for GILD dated on 2018-08-07: The Highs And Lows Of Earnings Season Dominate July's IMX Results

Financial news for GILD dated on 2018-08-07: Investor Movement Index July Summary

Financial news for GILD dated on 2018-08-06: Gilead Sciences' Genvoya for the Treatment of HIV-1 is Approved by the China National Drug Administration

Financial news for GILD dated on 2018-07-28: The Week Ahead In Biotech: Conferences, PDUFA Dates, Earnings And IPOs

Financial news for GILD dated on 2018-07-27: Stifel Doubles Down On MEI Pharma, Considers ME-401 'Best-In-Class'

Financial news for GILD dated on 2018-07-26: Gilead Sciences Option Alert: Sep 21 \$82.5 Calls Sweep (32) near the Ask: 863 @ \$1.15 vs 3235 OI; Ref=\$77.79

Financial news for GILD dated on 2018-07-26: Benzinga's Top Upgrades, Downgrades For July 26, 2018

Financial news for GILD dated on 2018-07-26: Benzinga's Daily Biotech Pulse: Biogen, AC Immune Slip Despite Positive Trials, Sarepta Slapped With Clinical Hold

Financial news for GILD dated on 2018-07-26: Morgan Stanley Maintains Equal-Weight on Gilead Sciences, Raises Price Target to \$85

Financial news for GILD dated on 2018-07-26: Baird Downgrades Gilead Sciences to Neutral

Financial news for GILD dated on 2018-07-25: Gilead Reaffirms FY18 Net Product Sales Guidance \$20B-\$21B vs \$20.81B Estimate

Financial news for GILD dated on 2018-07-25: UPDATE: Gilead Raises FY18 GAAP EPS From \$1.41-\$1.51 To \$1.50-\$1.60

Financial news for GILD dated on 2018-07-25: Gilead Raises FY18 Outlook

Financial news for GILD dated on 2018-07-25: Gilead Sciences Q2 Adj. EPS \$1.91 Beats \$1.56 Estimate, Sales \$5.5B Beat \$5.21B Estimate

Financial news for GILD dated on 2018-07-25: Gilead Sciences Announces CEO John F. Milligan to Step Down

Financial news for GILD dated on 2018-07-25: Benzinga's Daily Biotech Pulse: Merck's Keytruda Found Effective, Nabriva To Acquire Zavante, FDA Denies Agile

Financial news for GILD dated on 2018-07-25: Gilead Sciences Q2 Earnings Preview

Financial news for GILD dated on 2018-07-25: Earnings Scheduled For July 25, 2018

Financial news for GILD dated on 2018-07-24: Gilead Highlights New Data On Impact Of Truvada For Pre-Exposure Prophylaxis on the Number of HIV Diagnoses in the United States At Int'l. AIDS Conference: Prevalence Increased From 7 To 68.5 Per 1K People

Financial news for GILD dated on 2018-07-23: The Week Ahead: FANG Earnings Continue, Fox Vote On Disney Deal, More IPOs

Financial news for GILD dated on 2018-07-22: The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Results, Earnings And IPOs

Financial news for GILD dated on 2018-07-20: Celgene Shares Spike ~0.6% Following

Trader Circulation Of Questionable Chatter Of Interest From Gilead

Financial news for GILD dated on 2018-07-19: Gilead Reports Kite Pharma And Gadeta Entered Strategic Collaboration To Develop Novel Gamma Delta TCR Therapies In Various Cancers

Financial news for GILD dated on 2018-07-19: Gilead's Kite, Gadeta Report Strategic Partnership to Advance Gamma Delta T Cell Receptor Technology for Solid Tumors

Financial news for GILD dated on 2018-07-18: Benzinga's Daily Biotech Pulse: Novartis Earnings, J&J's HIV Combo Clears FDA Hurdle, Cara To Offer Shares

Financial news for GILD dated on 2018-07-12: Gilead Reports Received Approval In Canada For BIKTARVY For Treatment Of HIV-1 Infection

Financial news for GILD dated on 2018-07-11: 3 Stocks With Bullish Setups For The Rest Of The Week

Financial news for GILD dated on 2018-07-10: Novartis, Roche, Gilead Have Cancelled Some Drug Price Increases

Financial news for GILD dated on 2018-07-09: Health Care Sector Outlook: Checking In Ahead Of Q2 Earnings Reports

Financial news for GILD dated on 2018-07-06: Gilead Sciences Option Alert: Jul 20 \$74.5 Calls Sweep (5) near the Ask: 500 @ \$1.371 vs 81 OI; Earnings 7/25 After Close Ref=\$74.4

Financial news for GILD dated on 2018-07-05: A Look At Biotech In 2018 And The Biggest Catalysts Coming Up In The Second Half Of The Year

Financial news for GILD dated on 2018-06-29: EU Recommends Approval Of Novartis Kymriah, Recommends Approval Of Utlragenyx Drug For Treatment Of Sly Syndrome, Recommends Approval Of Yescarta

Financial news for GILD dated on 2018-06-28: Raymond James Reviews Gilead Pipelines, Takes Bullish Stance On Pharma Stock

Financial news for GILD dated on 2018-06-28: Benzinga's Top Upgrades, Downgrades For June 28, 2018

Financial news for GILD dated on 2018-06-28: Raymond James Initiates Coverage On Gilead Sciences with Strong Buy Rating, Announces \$93 Price Target

Financial news for GILD dated on 2018-06-25: European Commission Grants Marketing Authorization for Gilead's Biktarvy

Financial news for GILD dated on 2018-06-19: A Look Back At What's Happened To Each Sector Through The First Half Of 2018 (Part 1)

Financial news for GILD dated on 2018-06-12: Galmed Shares More Than Double As It Hits Bullseye With Fatty Liver Candidate

Financial news for GILD dated on 2018-06-06: Jefferies 2018 Global Healthcare Conference Continues Today, Presenters Include: TherapeuticsMD, Charles River, OSI Systems, Odonate Therapeutics, Syros, Alnylam, Gilead, and Celgene

Financial news for GILD dated on 2018-06-04: Gilead Option Alert: Jul 20 \$70 Calls Sweep (24) near the Ask: 827 @ \$2.05 vs 4507 OI; Earnings 7/25 After Close [est] Ref=\$69.86

Financial news for GILD dated on 2018-06-04: Gilead Shares Spike Higher After the Company Says a Study of an Experimental Therapy Eliminated Woman's Breast Cancer

Financial news for GILD dated on 2018-06-04: Gilead's Kite Reports ZUMA-1 Data Suggest Patient Response To Yescarta At 3 Months Could Be Predictive Of Longer-Term Response In refractory B-Cell Lymphoma

Financial news for GILD dated on 2018-06-04: Gilead's Kite Reports Initial Results From Phase 1 Study Of T-Cell Receptor Cell Therapy In HPV-16-Positive Solid Tumors: NCI Study Shows Investigational Therapy Induces Response In Patients with Epithelial Cancers

Financial news for GILD dated on 2018-06-01: Cramer: Gilead Is Dead Money

Financial news for GILD dated on 2018-05-31: Benzinga's Daily Biotech Pulse: Clinical Hold For Crispr, Gilead Study Meets Endpoint, Akers Gets Grace Time

Financial news for GILD dated on 2018-05-31: PiperJaffray Assumes Gilead Sciences at Overweight, Announces Price Target \$85

Financial news for GILD dated on 2018-05-30: UPDATE: Galapagos Will Receive a \$15M Payment from Gilead For This Progression of Filgotinib From Phase 2 to a Phase 2b/3 SELECTION Study

Financial news for GILD dated on 2018-05-30: Gilead and Galapagos Announce Filgotinib in Phase 2 EQUATOR Study Met Primary Endpoint

Financial news for GILD dated on 2018-05-30: Benzinga's Daily Biotech Pulse: Chinese Cheer For Gilead, ImmuteP Presents Positive Phase 1 Data, FDA Accepts Exelixis sNDA

Financial news for GILD dated on 2018-05-30: Gilead Announces China Drug Administration Approves Epclusa for Chronic Hepatitis C Virus Infection

Financial news for GILD dated on 2018-05-22: Tesaro Shares Spike ~\$0.70 Over Last Min. As Hearing Speculation Gilead Is In Advanced Talks To Buy Co.

Financial news for GILD dated on 2018-05-17: UPDATE: FDA Offers Guidelines, Background For Reference Listed Drug Access Inquiries, Related To Claim Of Blocking Generic Rivals

Financial news for GILD dated on 2018-05-17: Gilead Option Alert: Jun 21, 2019 \$75 Calls Sweep (26) at the Ask: 962 @ \$4.35 vs 383 OI; Ref=\$67.58

Financial news for GILD dated on 2018-05-17: Hearing FDA Names Drugmakers Accused Of Blocking Generic Rivals Including Gilead, Celgene, Novartis

Financial news for GILD dated on 2018-05-15: U.S. Food and Drug Administration Approves Expanded Indication for Truvada for Reducing the Risk of Acquiring HIV-1 in Adolescents

Financial news for GILD dated on 2018-05-15: Gilead's Kite Pharma Reports New Global Facilities, Expanded Collaboration With National Cancer Institute To Support Cell Therapy Pipeline

Financial news for GILD dated on 2018-05-14: Gilead, Match Group, Biotech, Ethereum: 'Fast Money' Picks For May 14

Financial news for GILD dated on 2018-05-03: 55 Biggest Movers From Yesterday

Financial news for GILD dated on 2018-05-02: 43 Stocks Moving In Wednesday's Mid-Day Session

Financial news for GILD dated on 2018-05-02: 21 Stocks Moving In Wednesday's Pre-Market Session

Financial news for GILD dated on 2018-05-02: Benzinga's Daily Biotech Pulse: SIGA Rallies On FDA Panel Backing, Rigel And Gilead React To Earnings

Financial news for GILD dated on 2018-05-02: 16 Stocks To Watch For May 2, 2018

Financial news for GILD dated on 2018-05-01: 9 Stocks Moving In Tuesday's After-Hours Session

Financial news for GILD dated on 2018-05-01: Gilead Reaffirms FY18 Outlook

Financial news for GILD dated on 2018-05-01: Gilead Sciences Q1 EPS \$1.48 Misses \$1.64 Estimate, Sales \$5.088B Miss \$5.38B Estimate

Financial news for GILD dated on 2018-05-01: Benzinga's Daily Biotech Pulse: Karyopharm's STORM Study, Inogen Rallies On Earnings

Financial news for GILD dated on 2018-05-01: 15 Stocks To Watch For May 1, 2018

Financial news for GILD dated on 2018-05-01: Earnings Scheduled For May 1, 2018

Financial news for GILD dated on 2018-04-30: Gilead And Verily Announce Scientific Collaboration To Identify And Understand Immunological And Molecular Drivers Of Inflammatory Diseases

Financial news for GILD dated on 2018-04-30: The Week Ahead: Tesla And Apple Earnings, Dropbox Quiet Period Expires, Fed Rate Decision And More

Financial news for GILD dated on 2018-04-29: The Week Ahead In Biotech: PDUFA Dates, Clinical Trials, Merck And Pfizer Earnings On Tap

Financial news for GILD dated on 2018-04-27: Gilead Sciences Reports European CHMP

Adopted Positive Opinion For Co.'s Biktarvy

Financial news for GILD dated on 2018-04-25: Baird: Biogen A Buy On M&A Prospects, Underappreciated Franchises

Financial news for GILD dated on 2018-04-20: Watching Gilead Shares As Traders Circulating Earlier STAT News Article 'NIH is sued for plans to award license for CAR-T therapy to Gilead'

Financial news for GILD dated on 2018-04-18: Gilead Subsidiary Kite Acquires Certain Facilities From Astellas, No Terms Disclosed

Financial news for GILD dated on 2018-04-13: Gilead Combination Therapy Data Presented from First 12-Week Study, Says Enrollment Complete for Phase 3 STELLAR Trials of ASK1 Inhibitor Selonsertib

Financial news for GILD dated on 2018-03-20: Checking In On The Healthcare Sector Ahead Of Q1 Earnings Season

Financial news for GILD dated on 2018-03-12: Gilead Sciences Tweets: Gilead's Norbert Bischofberger to step down; John McHutchison appointed Chief Scientific Officer and Andrew Cheng appointed Chief Medical Officer

Financial news for GILD dated on 2018-03-09: Don't Bail On Biotech ETFs: 'There Are Several Reasons Why The Sector Took A Breather'

Financial news for GILD dated on 2018-03-07: Height Casts 65% Odds That Congress Rolls Back Pharma Discounts

Financial news for GILD dated on 2018-03-06: An Eventful February Took Its Toll On TD Ameritrade's Investor Index

Financial news for GILD dated on 2018-03-06: Investor Movement Index February Summary

Financial news for GILD dated on 2018-03-05: Gilead Reports Phase 3 Study Data Evaluating Women Who Switched To Biktarvy From a Boosted Protease Inhibitor-Based Regimen or Boosted Elvitegravir-Containing Regimen

Financial news for GILD dated on 2018-03-05: UPDATE: Gilead Says 'No Patients in Biktarvy Treatment Arm Demonstrated Treatment-Emergent Resistance Through 48 Weeks'

Financial news for GILD dated on 2018-03-05: UPDATE: Gilead Says 'Through 48 Weeks, Biktarvy Found to Be Non-Inferior to Abacavir-Containing Regimen in Virologically Suppressed Adults Living With HIV'

Financial news for GILD dated on 2018-03-05: Gilead Highlights Results From Phase 3 Study Of Patients Who Switched To Biktarvy From Abacavir, Dolutegravir, Lamivudine Regimen

Financial news for GILD dated on 2018-03-05: 7 Biotech Stocks With Clinical Trial Outcomes In March

Financial news for GILD dated on 2018-03-04: Gilead Announces Data Support Continued Clinical Investigation of GS-9620 and GS-9722 as Part of an HIV Eradication Strategy

Financial news for GILD dated on 2018-02-27: Teva Pharma and Natco Pharma Submit ANDAs to the FDA Requesting Permission to Manufacture Generic Sovaldi, Argue Gilead's Patents are Not Valid

Financial news for GILD dated on 2018-02-22: Gilead Form 4 Filing Late Wed. Showed Sale Of 14,435 Shares By Exec VP, Corporate & Medical Affairs, Gregg Alton, On Feb. 20

Financial news for GILD dated on 2018-02-22: Gilead's Kite, Sangamo Therapeutics Partner To Develop Generation Engineered Cell Therapies For Cancer Treatment, Sangamo To Receive Upfront Payment Of \$150M With \$3.01B In Potential Milestone Payments

Financial news for GILD dated on 2018-02-21: RBC Capital Global Healthcare Conference Begins Today, Presenters Include: Chemed, Revance, Eagle Pharma, Enanta, Gilead, TransEnterix, Immunogen, and Incyte

Financial news for GILD dated on 2018-02-20: Gilead, Merck Quiet As Traders Circulate Reuters Article From Feb. 17th Titled 'Gilead wins reversal of \$2.54 billion hepatitis C drug patent verdict'

Financial news for GILD dated on 2018-02-15: Gilead Shares Unaffected, AbbVie Shares Move Lower Amid Capitol Forum Report 'Rep. Khanna and Other Democrats Urge HHS to Take Patents, Pave Way for Cheaper HCV Generics'



Financial news for GILD dated on 2018-02-12: Traders Circulating Speculation Gilead Pursuing Galapagos Takeover

Financial news for GILD dated on 2018-02-08: BMO Capital Maintains Market Perform on Gilead Sciences, Raises price target to \$88.00

Financial news for GILD dated on 2018-02-07: Najarian Brothers See Unusual Options Activity In Procter & Gamble And Gilead

Financial news for GILD dated on 2018-02-07: With \$36.7B In Cash, Bank of America Expects Gilead To Shop For Complements To Drug Pipeline

Financial news for GILD dated on 2018-02-07: Gilead Reports FDA Approved Biktarvy For Treatment Of HIV-1 Infection

Financial news for GILD dated on 2018-02-07: Leerink Swann Maintains Market Perform on Gilead Sciences, Lowers price target to \$83.00

Financial news for GILD dated on 2018-02-06: TD Ameritrade Investors Had A Record-Breaking January

Financial news for GILD dated on 2018-02-06: 8 Stocks Moving In Tuesday's After-Hours Session

Financial news for GILD dated on 2018-02-06: Gilead Sciences Shares Up 2.4% After Hours As Company Reports Positive Q1 Earnings, 10% Q1 Dividend Increase

Financial news for GILD dated on 2018-02-06: Gilead Sciences Raises Qtr. Dividend From \$0.52 to \$0.57/Share

Financial news for GILD dated on 2018-02-06: Gilead Sciences Reports Q4 EPS \$1.78 vs \$1.67 Est., Sales \$5.9B vs \$5.73B Est.

Financial news for GILD dated on 2018-02-06: Investor Movement Index January Summary

Financial news for GILD dated on 2018-02-06: Earnings Outlook For Gilead Sciences

Financial news for GILD dated on 2018-02-06: 12 Stocks To Watch For February 6, 2018

Financial news for GILD dated on 2018-02-06: Earnings Scheduled For February 6, 2018

Financial news for GILD dated on 2018-02-05: The Week Ahead: IPOs Ramp Up Just As Earnings Season Fades

Financial news for GILD dated on 2018-02-04: Benzinga's Weekly Bulls & Bears: AbbVie, Kinder Morgan, Paypal, Starbucks, Wynn And More

Financial news for GILD dated on 2018-02-01: Alphabet Earnings Preview: What Might Be Expected For Q4?

Financial news for GILD dated on 2018-01-31: Attention Biotech Investors: February PDUFA Catalysts Come Calling

Financial news for GILD dated on 2018-01-31: FDA Watchlist: Catalysts To Look Out For This February

Financial news for GILD dated on 2018-01-30: Vetr Crowd Downgrades Gilead Sciences

Financial news for GILD dated on 2018-01-30: Gilead Sciences Outlook Brightens; Citi Upgrades

Financial news for GILD dated on 2018-01-30: Benzinga's Top Upgrades, Downgrades For January 30, 2018

Financial news for GILD dated on 2018-01-30: Citigroup Upgrades Gilead Sciences to Buy

Financial news for GILD dated on 2018-01-26: Jefferies On Gilead: 'We See Better Days Ahead'

Financial news for GILD dated on 2018-01-26: Benzinga's Top Upgrades, Downgrades For January 26, 2018

Financial news for GILD dated on 2018-01-26: The Market In 5 Minutes: GDP, Intel's Beat, XFL's Return, Bitcoin And Japan

Financial news for GILD dated on 2018-01-26: Jefferies Upgrades Gilead Sciences to Buy

Financial news for GILD dated on 2018-01-23: Gilead To Report Q4 Earnings On Tues., Feb. 6 After Market Closes

Financial news for GILD dated on 2018-01-23: Pharma M&A Picks Up Momentum

Financial news for GILD dated on 2018-01-23: Bluebird Bio Up On Buyout Speculation After Celgene-Juno Deal

Financial news for GILD dated on 2018-01-23: Biotech M&A Off To A Strong Start In 2018: More Deals To Follow?

Financial news for GILD dated on 2018-01-22: 5 Stocks With Clear Technical Trading Signals Right Now

Financial news for GILD dated on 2018-01-19: The Top 10 Value Stocks In The S&P 500

Financial news for GILD dated on 2018-01-18: Gilead's Kite Pharma Reports Clinical Collaboration To Evaluate Investigational Combo Of Yescarta, Pfizer's Utomilumab In Large B-Cell Lymphoma

Financial news for GILD dated on 2018-01-16: 5 Biggest Price Target Changes For Tuesday

Financial news for GILD dated on 2018-01-16: Benzinga's Top Upgrades, Downgrades For January 16, 2018

Financial news for GILD dated on 2018-01-16: The Market In 5 Minutes: Auto Show Highlights, Bitcoin Tumbles, Northrop Vs. Lockheed

Financial news for GILD dated on 2018-01-16: Wells Fargo Upgrades Gilead Sciences to Outperform

Financial news for GILD dated on 2018-01-16: Wells Fargo Upgrades Gilead Sciences to Outperform; Raises PT to \$96 from \$84 -Reuters

Financial news for GILD dated on 2018-01-09: Pete Najarian Sees Unusual Options Activity In Gilead And KKR & Co.

Financial news for GILD dated on 2018-01-08: JP Morgan Healthcare Conference Begins Today, Presenters Include: Gilead, Illumina, Seattle Genetics, Biogen, Incyte, Baxter, Regeneron, Walgreens, Alnylam, Edwards Lifesciences, Molina, Alexion, Celgene, Pfizer, Neurocrine Biosciences, and Jazz Pharma

Financial news for GILD dated on 2018-01-05: BofA: The Biotech Sector Is In A 'Perfect Storm' For M&A

Financial news for GILD dated on 2018-01-02: Gilead Shares Spike Higher Over \$72, \$73 Levels; Stock Up 2.5%

Financial news for GILD dated on 2017-12-27: 4 Biotech Stocks Ready To Crush The Market In 2018

Financial news for GILD dated on 2017-12-27: Gilead Option Alert: Jan 19 \$73 Calls Sweep (12) at the Ask: 522 @ \$1.68 vs 267 OI; Ref=\$73.13

Financial news for GILD dated on 2017-12-20: 3 Biotech Pipeline Areas To Keep An Eye On In 2018

Financial news for GILD dated on 2017-12-20: Credit Suisse: Street Expectations 'Too High' For Gilead's Hep C Therapy

Financial news for GILD dated on 2017-12-20: Benzinga's Top Upgrades, Downgrades For December 20, 2017

Financial news for GILD dated on 2017-12-20: The Market In 5 Minutes: Historic Tax Bill Looms Large, Bitcoin Cash, Amazon Boxes, And More

Financial news for GILD dated on 2017-12-20: Credit Suisse Downgrades Gilead Sciences to Neutral

Financial news for GILD dated on 2017-12-20: Credit Suisse Downgrades Gilead to Neutral from Outperform; Lowers PT to \$80 from \$82 -Reuters

Financial news for GILD dated on 2017-12-19: Galapagos Shares Briefly Spike Higher, Turn Positive As Traders Circulate Report Gilead Could Be Interested In Co.

Financial news for GILD dated on 2017-12-18: Galapagos Announced Earlier Receipt Of Transparency Notification From Gilead Sciences

Financial news for GILD dated on 2017-12-14: Galapagos Exercises Co-promotion Option for Filgotinib with Collaboration Partner Gilead Sciences in Eight European Countries

Financial news for GILD dated on 2017-12-14: Gilead Sciences Reports Executive Chair John Martin Will Transition To Chair Of Board

Financial news for GILD dated on 2017-12-13: ASH 2017 Highlights: Gilead, Novartis, Juno, Bluebird Bio And More

Financial news for GILD dated on 2017-12-13: Analyst Doubts Bluebird Bio Shares -- Up 200% In 2017 -- Can Fly Much Higher

Financial news for GILD dated on 2017-12-12: Kite Announces Data from ZUMA-3 Study of KTE-C19 in Adult Patients with Relapsed or Refractory ALL at #ASH2017

Financial news for GILD dated on 2017-12-11: 3 Stocks In Focus As Biotech M&A Hopes For 2018 Rise

Financial news for GILD dated on 2017-12-10: Gilead's Kite Announces Long-Term Data From Pivotal ZUMA-1 Study of Yescarta in Patients With Refractory Large B-cell Lymphoma at #ASH2017

Financial news for GILD dated on 2017-12-08: Gilead Option Alert: Dec 15 \$71.5 Calls Sweep (19) at the Ask: 500 @ \$2.281 vs 99 OI; Ref=\$73.62 Signals

Financial news for GILD dated on 2017-12-08: Wall Street's M&A Chatter From December 7: Entellus Medical-Stryker, Sucampo, Silicon Labs-Sigma Designs

Financial news for GILD dated on 2017-12-07: UPDATE: Gilead Says Deal For Cell Design Labs Made Up Of Initial Upfront Payment Of ~\$175M, Added Payments Of Up To \$322M 'upon the occurrence of certain events, including the achievement of development and approval milestones'

Financial news for GILD dated on 2017-12-07: Gilead Sciences Reports Deal With Subsidiary Kite To Acquire Cell Design Labs For ~\$567M

Financial news for GILD dated on 2017-12-04: Gilead Sciences Announces a \$100M Commitment to Fight HIV/AIDS in Southern US

Financial news for GILD dated on 2017-12-01: GlaxoSmithKline Begins Phase III Study On Injection To Prevent HIV

Financial news for GILD dated on 2017-12-01: Maim Upgrades Gilead Sciences to Buy from Hold -Reuters

Financial news for GILD dated on 2017-11-30: CMS Head Verma Says Agency Considering Ways To Curb Costs For Expensive New Medications

Financial news for GILD dated on 2017-11-30: Maxim Explains Why Gilead Sciences Is A Now A Buy

Financial news for GILD dated on 2017-11-30: Benzinga's Top Upgrades, Downgrades For November 30, 2017

Financial news for GILD dated on 2017-11-30: Maxim Group Upgrades Gilead Sciences to Buy

Financial news for GILD dated on 2017-11-28: X-Chem, Gilead Report Drug Discovery Collaboration To Screen Proprietary Dex Libraries To Discover Therapeutic Leads Against Targets In Antiviral, Added Therapeutic Areas

Financial news for GILD dated on 2017-11-28: Amazon, Gilead, Nordstrom: Fast Money Picks For November 28

Financial news for GILD dated on 2017-11-15: Portfolio Manager Says Now Is A Great Time To Buy Biotech

Financial news for GILD dated on 2017-11-13: As Gilead's Outlook Dims, Argus Downgrades

Financial news for GILD dated on 2017-11-13: Argus Downgrades Gilead Sciences to Hold

Financial news for GILD dated on 2017-11-09: Lightning Round: Jim Cramer Advises His Viewers On Gilead, Exxon Mobil And More

Financial news for GILD dated on 2017-11-08: A Big Biotech ETF Is About To Get Cheaper

Financial news for GILD dated on 2017-11-07: Credit Suisse Healthcare Conference

Continues Today, Presenters Include: Walgreens, Vertex Pharmaceuticals, Laboratory Corp, Puma Biotech, Anthem, Alexion Pharma, Celgene, and Gilead

Financial news for GILD dated on 2017-11-07: Gilead Sciences Says In Sept 2017, Post-Trial Motions Judge Denied Idenix's Motion for Enhanced Damages, Attorney's; Says Expects Judge to Rule On Outstanding Motions With Relation to Idenix in Late 2017, Early 2018 -10Q

Financial news for GILD dated on 2017-11-06: FDA Commissioner Tweets: Today, #FDA finalized guidance to help bring more Hepatitis C treatments to the market  
<https://go.usa.gov/xnbNg>

Financial news for GILD dated on 2017-11-06: Federal Register Issues Guidance: Chronic Hepatitis C Virus Infection; Developing Direct-Acting Antiviral Drugs for Treatment

Financial news for GILD dated on 2017-11-01: The Health Care Episode: Reviewing Earnings Season And A CVS/Aetna Merger

Financial news for GILD dated on 2017-10-27: 45 Stocks Moving In Friday's Mid-Day Session

Financial news for GILD dated on 2017-10-27: 32 Stocks Moving In Friday's Pre-Market Session

Financial news for GILD dated on 2017-10-26: 14 Stocks Moving In Thursday's After-Hours Session

Financial news for GILD dated on 2017-10-26: Gilead Sciences Reports Q3 Adj. EPS \$2.27 vs \$2.13 Est., Sales \$6.512B vs \$6.39B Est.

Financial news for GILD dated on 2017-10-26: It's A Bad Day For Biotechs

Financial news for GILD dated on 2017-10-26: Earnings Scheduled For October 26, 2017

Financial news for GILD dated on 2017-10-24: Healthcare ETFs Set To Soar As Q3 Earnings Unfold

Financial news for GILD dated on 2017-10-24: Gilead Announces GS-0976 In Phase 2 Study Showed Statistically Significant Efficacy Compared To Placebo

Financial news for GILD dated on 2017-10-23: The Week Ahead: Earnings Season Starts In Earnest

Financial news for GILD dated on 2017-10-23: Alpine Immune Sciences and Kite Extend Research Term of Collaboration for CAR-T and TCRs

Financial news for GILD dated on 2017-10-20: Gilead Sciences Reports Phase 2 And 3 Studies Of Its Approved HCV And HBV Medicines At The 2017 Liver Meeting

Financial news for GILD dated on 2017-10-19: Senator Bernie Sanders Tweets: Gilead, one of the greediest pharmaceutical corporations in the world, is once again gouging people dealing with life-threatening illness.

Financial news for GILD dated on 2017-10-19: 32 Stocks Moving In Thursday's Mid-Day Session

Financial news for GILD dated on 2017-10-19: Gilead's Yescarta Cancer Treatment Approved, Some Analysts Shrug

Financial news for GILD dated on 2017-10-19: Gilead Volatile After Kite Pharma's Yescarta Gets FDA Approval

Financial news for GILD dated on 2017-10-19: 22 Stocks Moving In Thursday's Pre-Market Session

Financial news for GILD dated on 2017-10-18: Gilead Subsidiary Kite Announces FDA Approval For Yescarta

Financial news for GILD dated on 2017-10-18: 13 Stocks Moving In Wednesday's After-Hours Session

Financial news for GILD dated on 2017-10-12: How To Use Options During Earnings Season

Financial news for GILD dated on 2017-10-11: Barclays Reinstates Overweight on Gilead Sciences, Announces \$90.00

Financial news for GILD dated on 2017-10-10: These Were The Most Bought And Sold

## Stocks In September

Financial news for GILD dated on 2017-10-10: 5 Pharma & Biotech Stocks That Could Be Big Winners in Q3 Earnings

Financial news for GILD dated on 2017-10-09: Health Care Sector Back In Focus In Congress Ahead Of Q3 Earnings Result

Financial news for GILD dated on 2017-10-09: Watch These 7 Huge Put Purchases In Monday Trade

Financial news for GILD dated on 2017-10-06: Gilead Option Alert: Oct 20 \$81.5 Puts Sweep (23) at the Ask: 507 @ \$1.191 vs 329 OI; Ref=\$82.05

Financial news for GILD dated on 2017-10-06: Life (Science) Lessons: The Hows And Whos To Play Biotech

Financial news for GILD dated on 2017-10-05: Benzinga's Top Upgrades, Downgrades For October 5, 2017

Financial news for GILD dated on 2017-10-05: Oppenheimer Initiates Coverage On Gilead Sciences with Perform Rating

Financial news for GILD dated on 2017-10-04: Gilead Report No Patients In bictegravir Treatment Arm Demonstrated Treatment-Emergent Resistance Through 48 Weeks, Was Found To Be Non-Inferior To Boosted Protease Inhibitor Based Regimens

Financial news for GILD dated on 2017-10-04: Jefferies Reinstates Hold on Gilead Sciences, Announces \$93.00 Price Target

Financial news for GILD dated on 2017-10-04: Gilead Announces New License Agreement With UN-Backed Medicines Patent Pool for Access to Bictegravir

Financial news for GILD dated on 2017-09-27: Gilead Sciences COO Kevin Young CBE To Retire Effective Early 2018

Financial news for GILD dated on 2017-09-26: Gilead, Kite Pharma Report Expiration Of HSR Waiting Period

Financial news for GILD dated on 2017-09-25: Gilead's Sovaldi Approved by the China FDA for Treatment of Chronic Hepatitis C Virus Infection

Financial news for GILD dated on 2017-09-19: AMD, Bank Of America, Gilead, Intel: Fast Money Picks For September 19

Financial news for GILD dated on 2017-09-15: RBC Initiated Coverage On 33 Pharma/Biotech Cos.

Financial news for GILD dated on 2017-09-11: Morgan Stanley Healthcare Conference Begins Today, Presenters Include: Veeva Systems, Quorum Health, Neurocrine Biosciences, Vertex Pharma, Merck, Ocular Therapeutix, Biogen, Gilead, and Bristol-Myers

Financial news for GILD dated on 2017-09-07: Najarian Brothers See Unusual Options Activity In Tripadvisor And Gilead

Financial news for GILD dated on 2017-09-07: Pro: Biotech Is The Hottest ETF Of 2017 With Plenty Of Upside Ahead

Financial news for GILD dated on 2017-09-06: Citi Biotech Conference Begins Today, Presenters Include: Gilead, Ligand, Puma Biotech, and Bioverativ

Financial news for GILD dated on 2017-09-05: Why It's Useful To Know A Company's Competitors When Trading

Financial news for GILD dated on 2017-09-02: Vetr Urges Hold On Gilead After Kite Merger

Financial news for GILD dated on 2017-09-01: Attention Biotech Investors: September Ushers In Another Slew Of PDUFA Catalysts

Financial news for GILD dated on 2017-09-01: Sell In May And Go Away? Doing So With These Stocks Was A Mistake

Financial news for GILD dated on 2017-09-01: Watch These 5 Huge Put Purchases In Friday Trade

Financial news for GILD dated on 2017-08-31: A Sign Of Things To Come? Traders Are Betting On More Biotech Mergers

Financial news for GILD dated on 2017-08-31: S-3 From Gilead Shows Registration For Mixed Securities Shelf Offering

Financial news for GILD dated on 2017-08-31: Benzinga's Option Alert Recap From August 31

Financial news for GILD dated on 2017-08-31: Gilead Option Alert: Feb 16 \$80 Puts Sweep (2) at the Bid: 1000 @ \$3.9 vs 111 OI; Ref=\$83.870

Financial news for GILD dated on 2017-08-31: iShares NASDAQ Biotech ETF At Highest Since Level Since December 2015

Financial news for GILD dated on 2017-08-31: Street Puts Stamp Of Approval On Gilead's Kite Pharma Takeover

Financial news for GILD dated on 2017-08-31: 18 Biggest Mid-Day Gainers For Thursday

Financial news for GILD dated on 2017-08-31: Gilead Gets An Upgrade Amid 'Game-Changing' Kite Deal

Financial news for GILD dated on 2017-08-31: Benzinga's Top Upgrades, Downgrades For August 31, 2017

Financial news for GILD dated on 2017-08-31: Argus Upgrades Gilead Sciences to Buy

Financial news for GILD dated on 2017-08-31: Watch These 7 Huge Put Purchases In Thursday Trade

Financial news for GILD dated on 2017-08-31: Watch These 7 Huge Call Purchases In Thursday Trade

Financial news for GILD dated on 2017-08-30: Benzinga's Option Alert Recap From August 30

Financial news for GILD dated on 2017-08-30: Gilead Option Alert: Sep 8 \$81 Calls Sweep (12) at the Ask: 502 @ \$1.221 vs 20 OI; Ref=\$80.93

Financial news for GILD dated on 2017-08-30: Gilead Option Alert: Sep 15 \$77 Puts Sweep (30) at the Ask: 514 @ \$1.078 vs 92 OI; Ref=\$78.11

Financial news for GILD dated on 2017-08-30: The Market In 5 Minutes

Financial news for GILD dated on 2017-08-30: Brian Stutland Sees Unusual Options Activity In Juno Therapeutics

Financial news for GILD dated on 2017-08-29: Analysts Weigh In On Gilead-Kite Pharma Deal

Financial news for GILD dated on 2017-08-29: Juno Therapeutics Adds To Monday's Gain After Wedbush Upgrade

Financial news for GILD dated on 2017-08-29: 5 Biggest Price Target Changes For Tuesday

Financial news for GILD dated on 2017-08-29: Wall Street's M&A Chatter From August 28: Gilead-Kite Pharma, Enzymotec-Frutarom, MaxPoint-Valassis

Financial news for GILD dated on 2017-08-29: Watch These 8 Huge Call Purchases In Tuesday Trade

Financial news for GILD dated on 2017-08-28: Mid-Afternoon Market Update: IXYS Surges On Acquisition News; Uni-Pixel Shares Plunge

Financial news for GILD dated on 2017-08-28: Adam Feuerstein Tweets: \$GILD should be more worried about \$NVS undercutting CAR-T pricing than any NIH-loving ninny.

Financial news for GILD dated on 2017-08-28: 18 Biggest Mid-Day Gainers For Monday

Financial news for GILD dated on 2017-08-28: Mid-Day Market Update: Crude Oil Down 2.5%; MaxPoint Interactive Shares Spike Higher

Financial news for GILD dated on 2017-08-28: Juno Therapeutics Jumps 17% After Gilead's Purchase Of Kite Pharma

Financial news for GILD dated on 2017-08-28: Mid-Morning Market Update: Markets Mostly Higher; Gilead Sciences To Buy Kite Pharma

Financial news for GILD dated on 2017-08-28: Gilead Option Alert: Sep 29 \$76 Calls

Sweep (34) at the Ask: 1751 @ \$1.353 vs 389 OI; Ref=\$75.15

Financial news for GILD dated on 2017-08-28: Gilead Seeks Diversification Into Immuno-oncology Space With \$11.9 Billion Kite Pharma Acquisition

Financial news for GILD dated on 2017-08-28: Gilead CEO On Conf. Call Says Co. Is Not Going Quiet After This Deal, Will Search For More Opportunities

Financial news for GILD dated on 2017-08-28: 25 Stocks Moving In Monday's Pre-Market Session

Financial news for GILD dated on 2017-08-28: A Peek Into The Markets: U.S. Stock Futures Edge Lower Ahead Of International Trade Data

Financial news for GILD dated on 2017-08-28: Gilead to Acquire Kite Pharma for \$11.9B Cash, \$180/Share

Financial news for GILD dated on 2017-08-28: Gilead to Acquire Kite Pharma for \$180/Share According to Dow Jones

Financial news for GILD dated on 2017-08-28: Gilead to Buy Kite Pharma for ~\$11B in Cash -DJ

Financial news for GILD dated on 2017-08-18: 5 Biggest Price Target Changes For Friday

Financial news for GILD dated on 2017-08-17: A Peek Into The Markets: U.S. Stock Futures Down Ahead Of Wal-Mart, Alibaba Earnings

Financial news for GILD dated on 2017-08-17: Gilead Receives Approval For Vosevi

Financial news for GILD dated on 2017-08-10: Gilead Reports FDA Priority Review Designation For Fixed-Dose Combo Of Bictegravir, Emtricitabine, Tenofovir Alafenamide For Treatment Of HIV

Financial news for GILD dated on 2017-08-10: Morgan Stanley Expects Galapagos Shares To Rise 10%

Financial news for GILD dated on 2017-08-09: Gilead Shares Up ~\$0.40 Over Last Min. As Traders Circulating Chatter Of Activist Interest

Financial news for GILD dated on 2017-08-07: Wall Street's M&A Chatter From August 4-7: Acadia Pharma, United Technologies-Rockwell Collins, United Therapeutics

Financial news for GILD dated on 2017-08-04: United Therapeutics Shares Up 7.7% On M&A Chatter; GSK, Gilead, Novartis Said To Be Possibly Considering Deal For Co.

Financial news for GILD dated on 2017-08-04: UK Evening Standard Reports GSK, Gilead, Novartis Could Pay Up to \$200/Share for United Therapeutics

Financial news for GILD dated on 2017-08-01: FDA Approves Expanded Labeling For Gilead's Epclusa

Financial news for GILD dated on 2017-08-01: 3 ETFs To Watch Out For On Biotech Earnings

Financial news for GILD dated on 2017-08-01: August PDUFA Dates: Biotech Investors Stay Tuned To A Month Of Plenty

Financial news for GILD dated on 2017-07-28: EC Grants Marketing Authorization for Gilead's Vosevi for the Treatment of All Genotypes of Chronic Hepatitis C

Financial news for GILD dated on 2017-07-27: Wall Street's M&A Chatter From July 26: Biomarin, Sigma Designs, Colgate-Palmolive, Markel-State National

Financial news for GILD dated on 2017-07-27: Gilead, Juniper, United, Wynn: Fast Money Picks For July 27

Financial news for GILD dated on 2017-07-27: 15 Stocks To Watch For July 17, 2017

Financial news for GILD dated on 2017-07-26: Gilead Sciences, Inc. Reports Q2 Adj. EPS \$2.56 vs \$2.15 Est., Sales \$7.141B vs \$6.35B Est.

Financial news for GILD dated on 2017-07-26: Gilead Sciences, Verizon Communications, And MGM Resorts Report Q2 Results This Week

Financial news for GILD dated on 2017-07-26: Redburn Initiates Coverage On Gilead Sciences with Buy Rating

Financial news for GILD dated on 2017-07-26: 12 Stocks To Watch For July 26, 2017

Financial news for GILD dated on 2017-07-26: Earnings Scheduled For July 26, 2017

Financial news for GILD dated on 2017-07-24: 2 Ways To Trade This Week's Healthcare Earnings

Financial news for GILD dated on 2017-07-24: Adam Feuerstein Tweets: \$GILD -- HIV is the new (old) profit driver, which is why bictegravir (new data today) is so important. --> [statnews.com/2017/07/24/hiv...](http://statnews.com/2017/07/24/hiv...)

Financial news for GILD dated on 2017-07-24: Gilead Presenting Phase 3 Bictegravir Data At Int'l AIDS Society Conf. Today

Financial news for GILD dated on 2017-07-18: Gilead Reports FDA Approved Vosevi For Re-Treatment Of Adults With Chronic Hep C

Financial news for GILD dated on 2017-07-17: Exclusive: Verastem CEO Talks Duvelisib, Pipeline Data, And Further Upside For The Stock

Financial news for GILD dated on 2017-07-14: Jim Cramer Advises His Viewers On Seagate, Centurylink And Gilead

Financial news for GILD dated on 2017-07-13: Shares of Eli Lilly, AstraZeneca, Merck, Gilead, Abbvie, Other Large Cap Biotech Spiking Higher

Financial news for GILD dated on 2017-07-13: EMA Validates Gilead's Marketing Application for Fixed-Dose Combination of Bictegravir, Emtricitabine and Tenofovir Alafenamide for Treatment of HIV

Financial news for GILD dated on 2017-07-12: J&J To Commence Pharma Q2 Earnings Season: What's Up?

Financial news for GILD dated on 2017-07-11: Benzinga's Top Upgrades, Downgrades For July 11, 2017

Financial news for GILD dated on 2017-07-11: Jefferies Assumes Gilead Sciences at Hold, Announces price target \$80.00

Financial news for GILD dated on 2017-07-10: Spring Bank Pharma Reports Collaboration With Gilead For Hep B Phase 2 Study Exploring Combo Treatment Of SB 9200, Vemlidy

Financial news for GILD dated on 2017-06-24: Barron's Picks And Pans: Canadian Stocks, NCR, Gilead And More

Financial news for GILD dated on 2017-06-23: Deutsche Bank's Take On Big Pharma: 3 Buys And A Hold

Financial news for GILD dated on 2017-06-23: Benzinga's Top Upgrades, Downgrades For June 23, 2017

Financial news for GILD dated on 2017-06-23: Gilead Reports European CHMP Adopted Positive Opinion For Co.'s Vosevi For Treatment Of All Chronic Hep C Genotypes

Financial news for GILD dated on 2017-06-23: Deutsche Bank Initiates Coverage On Gilead Sciences with Buy Rating, Announces \$79.00 Price Target

Financial news for GILD dated on 2017-06-21: Wall Street's M&A Chatter From June 20: Calpine, Parexel, Gilead, Spherix-Hoth Therapeutics, Norsat-Hytera

Financial news for GILD dated on 2017-06-20: Gilead Shares Spike ~\$0.45 Off Session Lows As Traders Circulating Takeover Chatter

Financial news for GILD dated on 2017-06-19: A Peek Into The Markets: U.S. Stock Futures Signal Higher Start On Wall Street

Financial news for GILD dated on 2017-06-19: Gilead Receives Approval in Canada for VEMLIDY for the Treatment of Chronic Hepatitis B Virus Infection

Financial news for GILD dated on 2017-06-18: Gilead Sciences Receives FDA Orphan Designation for Tybost in Treatment of HIV-1 Infection in Pediatric Patients

Financial news for GILD dated on 2017-06-15: Goldman Sachs Global Healthcare Conference Concludes Today, Presenters Include: Gilead, Tesaro, Ironwood Pharmaceuticals and Alkermes

Financial news for GILD dated on 2017-06-14: Wall Street's M&A Chatter From June 13: Brookdale, Etsy, Roche-Tesaro



Financial news for GILD dated on 2017-06-13: Tesaro Is A Top Rumor Mill Stock Right Now; Here Is A Timeline Of The Chatter

Financial news for GILD dated on 2017-06-13: Wall Street's M&A Chatter From June 12: Neuroderm, Penn Virginia, Tesaro, Synaptics-Conexant

Financial news for GILD dated on 2017-06-12: Gilead Reports Submission Of NDA For Fixed-Dose Combo Of Bictegravir, Emtricitabine, Tenofovir Alafenamide For HIV

Financial news for GILD dated on 2017-06-12: What Do To With Starbucks, Amgen, Costco, Twilio, Gilead and Kroger?

Financial news for GILD dated on 2017-06-06: Gilead, Roche Shares Largely Unimpacted Following Headlines the World Health Organization Expert Committee Said Could Delete Oseltamivir from Next List of Recommended Medicines as General Treatment for Flu Pandemics

Financial news for GILD dated on 2017-05-30: Gilead Sciences Fixed-Dose Combination of Bictegravir, Emtricitabine and Tenofovir Alafenamide for the Treatment of HIV-1 Meets Primary Endpoint in Four Phase 3 Studies; U.S. NDA Submission Planned For Q2

Financial news for GILD dated on 2017-05-30: Watch These 8 Huge Call Purchases In Tuesday Trade

Financial news for GILD dated on 2017-05-26: Benzinga's Option Alert Recap From May 26

Financial news for GILD dated on 2017-05-18: Bank Of America Health Care Conference Concludes Today; Presenters Include Boston Scientific, Humana, Universal Health, Chemed, Community Health, Eagle Pharma, Alnylam, Gilead, & Illumina

Financial news for GILD dated on 2017-05-11: U.S. Health Officials Say New Cases Of Hep. C Rose ~300% From 2010 to 2015, Fueled By Spike In Heroin and Other Injection Drugs

Financial news for GILD dated on 2017-05-04: Analysts On Gilead: We Think They're Mobilizing For A Deal

Financial news for GILD dated on 2017-05-03: Gilead's Q1 Fails To Impress, But Strength Of Pipeline Not Reflected In Current Share Price

Financial news for GILD dated on 2017-05-03: In Light Of Negative Sentiment, Gilead's Q1 Results Weren't So Bad

Financial news for GILD dated on 2017-05-03: Adam Feuerstein Tweets: No \$GILD M&A Yet, but CEO Offers Hint of Deals to Come --> [thestreet.com/story/14116282...](http://thestreet.com/story/14116282...)

Financial news for GILD dated on 2017-05-03: 25 Stocks Moving In Wednesday's Pre-Market Session

Financial news for GILD dated on 2017-05-03: 15 Stocks To Watch For May 3, 2017

Financial news for GILD dated on 2017-05-02: Meg Tirrell Tweets: \$GILD CEOs says a number of partnerships, acquisitions could play out this year

Financial news for GILD dated on 2017-05-02: Gilead Reaffirms FY17 Outlook

Financial news for GILD dated on 2017-05-02: Gilead Reports Q1 Adj. EPS \$2.23 vs \$2.28 Est., Sales \$6.505B vs \$6.62B Est.

Financial news for GILD dated on 2017-05-02: 12 Stocks To Watch For May 2, 2017

Financial news for GILD dated on 2017-05-02: Earnings Scheduled For May 2, 2017

Financial news for GILD dated on 2017-05-01: Earnings Preview: Q1 Results From Pfizer, Merck, And Gilead Sciences This Week

Financial news for GILD dated on 2017-04-26: Benzinga's Option Alert Recap From April 26

Financial news for GILD dated on 2017-04-26: Option Alert: Gilead May 69.0 Calls Sweep: 1000 @ ASK \$1.57: 2284 traded vs 196 OI: Earnings 5/2 After Close \$68.48 Ref

Financial news for GILD dated on 2017-04-21: Watch These 10 Huge Call Purchases In Friday Trade

Financial news for GILD dated on 2017-04-20: Benzinga's Option Alert Recap From April 20

Financial news for GILD dated on 2017-04-20: Option Alert: Gilead May 65.0 Calls: 979 @ Above Ask! \$2.65: 1086 traded vs 3760 OI: Earnings 5/2 After Close \$66.29 Ref

Financial news for GILD dated on 2017-04-18: Gilead Shares Turn Positive Over Last Few Mins, Now Up 0.1% as Traders Circulating Rumor Mentioning JANA

Financial news for GILD dated on 2017-04-12: Apple Team Working on Secret Diabetes Treatment -CNBC

Financial news for GILD dated on 2017-04-11: Watch These 6 Huge Put Purchases In Tuesday Trade

Financial news for GILD dated on 2017-04-07: Gilead Announces FDA Has Approved New Indications for Harvoni, Sovaldi in Patients 12 Years, Older with Chronic Hep C Infection

Financial news for GILD dated on 2017-04-06: Anthrax And Government Contracts: PharmAthene And Altimmune Ahead Of Merger

Financial news for GILD dated on 2017-04-06: Your Cheat Sheet For Q1 Biotech Earnings

Financial news for GILD dated on 2017-04-05: Feuerstein Throws BioMarin Into Gilead Takeover Speculation

Financial news for GILD dated on 2017-04-05: Feuerstein on Possibilities of Gilead Takeover Interest: Notes A Lot of Sources Have Talked About TESARO as Target, But Feels BioMarin is a Co. Which Has Better Chance to Move the Needle at Gilead

Financial news for GILD dated on 2017-04-05: Feuerstein on Possibilities of Gilead Takeover Interest: Likes BioMarin as a Target

Financial news for GILD dated on 2017-04-04: Galapagos Announces Three New Phase 2 Proof-of-Concept Studies Investigating Filgotinib in Sjogren's Syndrome with Collaboration Partner Gilead

Financial news for GILD dated on 2017-03-31: Option Alert: Gilead Apr 69.5 Calls: 1500 @ ASK \$0.58: 1520 traded vs 942 OI: Earnings 4/27 After Close (est) \$68.22 Ref

Financial news for GILD dated on 2017-03-30: Here's What You Missed On PreMarket Prep Today

Financial news for GILD dated on 2017-03-30: Galectin Shares Upgraded To Buy; NASH-CX Results In December A 'Major Stock Catalyst'

Financial news for GILD dated on 2017-03-29: Option Alert: Gilead May 67.5 Calls: 1500 @ ASK \$2.38: 1955 traded vs 4929 OI: Earnings 4/27 After Close (est) \$67.38 Ref

Financial news for GILD dated on 2017-03-27: STAT News Reporting Gilead Faces European Hepatitis C Drug Patent Challenge Filed By Medecins du Monde and Doctors Without Borders

Financial news for GILD dated on 2017-03-20: Jefferies Says Gilead's GS-0976 Novel Mechanism Has Good Scientific Rationale, May Likely Be Playing Out In Phase 2 Study

Financial news for GILD dated on 2017-03-16: Incyte Shares Spike Over \$148 Level as Hearing Traders Circulating Unconfirmed Chatter of Gilead Interest

Financial news for GILD dated on 2017-03-14: Gilead Looking To Buy Incyte? It Makes Sense

Financial news for GILD dated on 2017-03-14: Barclays Global Healthcare Conference Begins Today; Presenters Include Johnson & Johnson, Alnylam, Axovant, Paraxel, Gilead, bluebird bio, Envision Healthcare, & Tenet Healthcare

Financial news for GILD dated on 2017-03-13: Adam Feuerstein Tweets: Barclays Healthcare Conference: \$GILD CEO John Milligan 9 am Tues. \$INCY CEO Herve Hoppenot 2:30 pm Weds. Both STILL ON SCHEDULE.

Financial news for GILD dated on 2017-03-13: Wall Street's M&A Chatter From March 10-12

Financial news for GILD dated on 2017-03-10: Incyte Spikes to High of \$149.28

Financial news for GILD dated on 2017-03-10: Hearing Unconfirmed Chatter Gilead Near Bid for Incyte

Financial news for GILD dated on 2017-03-10: Adam Feuerstein Weighs In On Novo-GBT Rumors, Undue Sarepta Volatility, Unprofitable Business Of Curing Disease

Financial news for GILD dated on 2017-03-10: Adam Feuerstein Talks Vulnerable Pharmaceuticals, Drug Pricing Under Trump

Financial news for GILD dated on 2017-03-10: Barclays Analyst Pens Open Letter To Gilead Board And Management

Financial news for GILD dated on 2017-03-10: Feuerstein Highlighting Several Points Why Gilead Has Been Struggling Recently

Financial news for GILD dated on 2017-03-10: Feuerstein on Benzinga's PreMarket Prep Discussing Stocks Which Could Be Impacted by Drug Pricing Changes: Believes Worst Case Scenario Would Create Vulnerabilities for Drugs with High Levels of Competition

Financial news for GILD dated on 2017-03-10: Galapagos Announces New Phase 2 Studies with Filgotinib in Small Bowel and Fistulizing Crohn's Disease

Financial news for GILD dated on 2017-03-09: Benzinga's Top Upgrades, Downgrades For March 9, 2017

Financial news for GILD dated on 2017-03-09: UBS Downgrades Gilead Sciences To Neutral

Financial news for GILD dated on 2017-03-06: RBC Hints At Potential M&A For Kite Pharma

Financial news for GILD dated on 2017-03-02: Traders Circulating Rumor Of Icahn Involvement In Gilead

Financial news for GILD dated on 2017-02-28: Hearing Starboard Has Built \$2.6B Activist Stake In Gilead

Financial news for GILD dated on 2017-02-24: EU Medicines Agency Recommends Approval of Gilead's Descovy For HIV Treatment

Financial news for GILD dated on 2017-02-22: Gilead Sciences Canada To List Epclusa On Public Drug Plan To Treat All 6 Genotypes Of Hep. C Infection

Financial news for GILD dated on 2017-02-22: RBC Capital Markets Healthcare Conference Begins Today, Day 1 Of 2; Presenters Include Tesaro, Axovant, Gilead, And Puma Biotechnology

Financial news for GILD dated on 2017-02-21: Icahn Takes Bristol-Myers Stake With M&A In Mind; Who Could Be The Acquirer?

Financial news for GILD dated on 2017-02-16: Gilead Receives Canada Approval For Odefsey For Treatment Of HIV-1 Infection

Financial news for GILD dated on 2017-02-15: Deutsche Bank Casts Doubt On Pfizer's Rumored Takeover Approach To Bristol-Myers

Financial news for GILD dated on 2017-02-15: Gilead Announces Higher Rates of Virologic Suppression in 144-Week Data Evaluating Safety and Efficacy of Genvoya(r) for Treatment of HIV-1 in Treatment-Naive Adults

Financial news for GILD dated on 2017-02-14: Hearing Gilead Will Face New Patent Challenges Related to Hep C Drugs In India; Shares Unaffected

Financial news for GILD dated on 2017-02-14: Curing Disease Is Bad For Business: How Do Big Pharma Companies Continue Their Growth?

Financial news for GILD dated on 2017-02-14: Wall Street's M&A Chatter From February 13

Financial news for GILD dated on 2017-02-13: Gilead Sciences Says Bictegravir in Combination With FTC/TAF Showed 97% Rates of Virologic Suppression in Phase 2 Study

Financial news for GILD dated on 2017-02-13: Hearing Carl Icahn Has Taken Stake In Gilead

Financial news for GILD dated on 2017-02-08: 20 Biggest Mid-Day Losers For Wednesday

Financial news for GILD dated on 2017-02-08: Oil Weakness A Possible Drag On Market As Earnings Season Keeps Rolling

Financial news for GILD dated on 2017-02-08: 8 Biggest Price Target Changes For Wednesday

Financial news for GILD dated on 2017-02-08: Gilead's 2017 Guidance Sank Shares To A New Bottom

Financial news for GILD dated on 2017-02-08: Martin Shkreli: I Would Buy Gilead Shares

Financial news for GILD dated on 2017-02-08: Benzinga's Top Upgrades, Downgrades For February 8, 2017

Financial news for GILD dated on 2017-02-08: The Market In 5 Minutes: Disney, Gilead Investors Not Too Pleased

Financial news for GILD dated on 2017-02-08: Yesterday Night, Martin Shkreli Said He Would Be A Buyer Of Gilead On Weak Quarter Results, Believes Stock Is Worth \$125/Share

Financial news for GILD dated on 2017-02-08: 25 Stocks Moving In Wednesday's Pre-Market Session

Financial news for GILD dated on 2017-02-08: Citigroup Downgrades Gilead Sciences To Neutral, Lowers Price Target To \$76

Financial news for GILD dated on 2017-02-08: 12 Stocks You Should Be Watching Today

Financial news for GILD dated on 2017-02-07: Gilead Touches Lowest Level Since 2014 Following Q4 Report

Financial news for GILD dated on 2017-02-07: Adam Feuerstein @adamfeuerstein Tweet: \$GILD Just Kitchen-Sinked 2017 Guidance, Worse Than Anyone Expected --> [thestreet.com/story/13993572](http://thestreet.com/story/13993572)

Financial news for GILD dated on 2017-02-07: Gilead Raises Qtr Dividend From \$0.47/Share To \$0.52/Share

Financial news for GILD dated on 2017-02-07: Gilead Science Sees FY17 Product Sales \$22.5B-\$24.5B

Financial news for GILD dated on 2017-02-07: Gilead Sciences Reports Q4 Adj EPS \$2.70 vs \$2.61 Est, Revenues \$7.32B vs \$7.15B Est

Financial news for GILD dated on 2017-02-07: Keep an Eye on These 12 Stocks for February 7, 2017

Financial news for GILD dated on 2017-02-07: Earnings Scheduled For February 7, 2017

Financial news for GILD dated on 2017-02-06: Q4 2016 Real-Time Call Brief

Financial news for GILD dated on 2017-02-02: Jim Cramer Gives His Opinion On CSX, JetBlue, Gilead And Burlington Stores

Financial news for GILD dated on 2017-01-27: JJ Kinahan Walks Us Through The Most Traded Stocks Among TDA Clients In 2016: Apple, Bank of America & More

Financial news for GILD dated on 2017-01-26: Gilead Defends Hepatitis C Treatments On Reports Of Side Effects

Financial news for GILD dated on 2017-01-25: Gilead Responds to Report Of Lack Of Efficacy From Harvoni Treatment, Points to Extensive Data Showing Failure Rates 'low but given large numbers of patients treated...not unexpected to see reports of some patients failing these treatments'

Financial news for GILD dated on 2017-01-25: UPDATE: Gilead Says It Has Worked Closely With FDA To Share Data On Liver Failure Cases, Has Found No Suggestion Of Causal Relationship Between Harvoni And Liver Failure, No Product Updates Deemed Necessary

Financial news for GILD dated on 2017-01-25: Gilead Responds To Reports Of Side Effects From Harvoni Hepatitis Treatment, Tells Benzinga Safety Is Highest Priority, Co. Continuously Monitors Safety Information To Inform Appropriate Use

Financial news for GILD dated on 2017-01-25: Traders Circulating Stat News Report Posted 5 Hrs Ago Suggesting Safety Concerns In Gilead's Hepatitis Drugs

Financial news for GILD dated on 2017-01-25: Watch These 10 Huge Call Purchases In Wednesday Trade

Financial news for GILD dated on 2017-01-24: Benzinga's Option Alert Recap From January 24

Financial news for GILD dated on 2017-01-24: Option Alert: Gilead May 70.0 Calls Sweep: 2173 @ ASK \$3.953: 12k traded vs 1798 OI: Earnings 2/7 After Close \$70.12 Ref

Financial news for GILD dated on 2017-01-20: Technical Alert: Gilead Sciences Makes New For Move

Financial news for GILD dated on 2017-01-20: EMA Validates Gilead's Marketing Authorization Application for Investigational Chronic Hepatitis C Therapy Sofosbuvir/Velpatasvir/Voxilaprevir

Financial news for GILD dated on 2017-01-19: Verastem's CEO Talks DYNAMO Study, The Competitive Landscape And Pitch To Investors

Financial news for GILD dated on 2017-01-18: BZ NOTE: Gilead Has Been Mentioned as a Rumor Stock by Traders At Least Twice Over the Last 2 Months

Financial news for GILD dated on 2017-01-18: Hearing Gilead, Pfizer CEOs Currently Meeting At Davos, Traders Speculating M&A Talks

Financial news for GILD dated on 2017-01-18: Orphan Drugs Among 2015's Top 10 Best-Selling Medications

Financial news for GILD dated on 2017-01-11: Adam Feuerstein Tweets: \$GILD told analysts at mtg today they might separate out HCV and/or HIV product guidance for 2017 on upcoming earnings call.

Financial news for GILD dated on 2017-01-11: Watching Weakness In Amgen,Biogen, Gilead, Mylan, Pfizer And Other Biotechs After Pres. Elect Trump Negative Statement On Drug Pricing

Financial news for GILD dated on 2017-01-11: Gilead Granted Marketing Authorization From European Commission for Vemlidy

Financial news for GILD dated on 2017-01-11: GM, Gilead, Barracuda And Freeport-McMoRan: Fast Money Picks For January 11

Financial news for GILD dated on 2017-01-09: Gilead Says Slowdown In Patients Starting Hepatitis C Therapies To Continue Into 2017

Financial news for GILD dated on 2017-01-09: Adam Feuerstein Tweets: \$GILD breakout. The full force of co.'s HIV power is being applied to bictegravir pgm. They sound really confident about this drug. #JPM17

Financial news for GILD dated on 2017-01-09: Gilead CEO Says Planning Phase 3 Trials Of Nash Drug In Patients With Advanced Fibrosis

Financial news for GILD dated on 2017-01-09: The Year's Biggest Healthcare Conference Commences This Week; Here's What You Need To Know

Financial news for GILD dated on 2017-01-06: Hearing Carl Icahn Considering Activist Stake In Gilead

Financial news for GILD dated on 2017-01-05: Jefferies' Picks For 2017's Most And Least Likely Biotech M&A Targets

Financial news for GILD dated on 2017-01-04: Jim Cramer Gives His Opinion On SYSCO And Gilead

Financial news for GILD dated on 2016-12-30: January Will Feature Some Of The Market's Most Influential Events

Financial news for GILD dated on 2016-12-19: Japan to Review Drug Prices Each Year vs Every Two Years Previously -Reuters

Financial news for GILD dated on 2016-12-19: Japan's Ministry of Health, Labour and Welfare Approves Gilead's Vemlidy for Patients With Chronic Hepatitis B Virus Infection

Financial news for GILD dated on 2016-12-15: CNBC Meg Tirrell Tweets: \$GILD says it plans to "vigorously challenge" verdict ordering it to pay \$MRK \$2.54B in hepatitis C royalties

Financial news for GILD dated on 2016-12-15: Gilead To Pay Merck \$2.54B In Hep. C Royalties

Financial news for GILD dated on 2016-12-15: Galapagos Reports Publication of Phase 2 Study with Filgotinib in Crohn's Disease in The Lancet

Financial news for GILD dated on 2016-12-14: Najarian Brothers See Unusually High Options Activity In KeyCorp, Gilead Sciences

Financial news for GILD dated on 2016-12-12: 10 Notable Stocks Trading Ex-Dividend Tuesday, December 13

Financial news for GILD dated on 2016-12-12: Express Scripts Hep. C Cure Program Expands To Cover Treatments To Include Viekira Pak, Harvoni In 2017

Financial news for GILD dated on 2016-12-08: Stocks Hitting 52-Week Lows

Financial news for GILD dated on 2016-12-08: Endeavor Funds' Jerome Dodson Defends 3 Stocks Beaten Down In 2016

Financial news for GILD dated on 2016-12-08: Gilead Submits NDA to FDA for Sofosbuvir

Financial news for GILD dated on 2016-12-07: Gilead Sciences Nears 30-Month Low, Attempts To Rebound

Financial news for GILD dated on 2016-12-02: PRAC Warns Of Risk Of Hepatitis B Re-activation With Direct-acting Antivirals For Hepatitis C

Financial news for GILD dated on 2016-11-29: PiperJaffray Healthcare Conference Begins Today, Day 1 of 2; Presenters Include NantKwest, Ignyta, Gilead Sciences, DexCom, Incyte, bluebird bio

Financial news for GILD dated on 2016-11-22: UPDATE: Galapagos Says Start of DIVERSITY Study Triggers \$50M Milestone Payment from Gilead

Financial news for GILD dated on 2016-11-18: Assessing The Legitimacy Of The Biotech ETF Bounce

Financial news for GILD dated on 2016-11-17: How Incyte Just Became A Major M&A Target

Financial news for GILD dated on 2016-11-17: Incyte Shares Trading Up 5.3%, Traders Attributing Strength To Multiple Analyst Notes Highlighting Gilead's Unlikely Approval Of SIMPLIFY-1 and SIMPLIFY-II, Combined With Repatriation Holiday, Make Incyte More Attractive As M&A Target

Financial news for GILD dated on 2016-11-16: Gilead's Full Top-Line Results From Two Phase 3 Studies

Financial news for GILD dated on 2016-11-16: Gilead Announces SIMPLIFY-1 Study Achieved Its Primary Endpoint In Phase 3 Study

Financial news for GILD dated on 2016-11-16: Gilead Announces SIMPLIFY-2 Did Not Achieve Its Primary Endpoint In Phase 3 Study

Financial news for GILD dated on 2016-11-14: Gilead Responds To CMS Blog Highlighting High Cost Of Harvoni: Most Payers Receive Substantial Discounts Off The List Price

Financial news for GILD dated on 2016-11-14: Gilead Reports Phase 2 Data for Selonsertib in NASH Showed Results Demonstrate Improvement in Fibrosis Stage among NASH Patients with Moderate to Severe Fibrosis

Financial news for GILD dated on 2016-11-14: Gilead Responding To CMS Blog Post Highlighting The Cost Increase For Hep-C Treatment Harvoni Tells Benzinga The VA And Medicaid Currently Receive Discounts Of 50%+ On Harvoni

Financial news for GILD dated on 2016-11-14: Several Key Catalysts Lay Ahead For Gilead Sciences In The Next Year

Financial news for GILD dated on 2016-11-14: CMS Criticizes Gilead's Harvoni Price Increases

Financial news for GILD dated on 2016-11-14: Benzinga's Top Initiations

Financial news for GILD dated on 2016-11-14: The Market In 5 Minutes: A Couple Of Pharma Stocks Move 70% In Opposite Directions

Financial news for GILD dated on 2016-11-14: Stifel Nicolaus Initiates Coverage On Gilead Sciences, Inc. - Common Stock at Buy, Announces \$100.00

Financial news for GILD dated on 2016-11-11: Technical Alert: Gilead Sciences Lower Despite Favorable EU Ruling

Financial news for GILD dated on 2016-11-11: EU Medicines Agency Announces Positive

Opinion from CHMP for Gilead's Chronic Hep B Treatment, Vemlidy

Financial news for GILD dated on 2016-11-10: U.S. Food and Drug Administration Approves Gilead's Vemlidy for the Treatment of Chronic Hepatitis B Virus Infection

Financial news for GILD dated on 2016-11-09: Wednesday's Loser: Hospital Stocks

Financial news for GILD dated on 2016-11-09: Biotech Is Getting A Big Boost Following Clinton's Loss

Financial news for GILD dated on 2016-11-08: UPDATE: Jefferies Comments on Gilead: 'ALXN's actions interpreted by some as suggesting they are in play.'; BZ NOTE: Note is Focused on Gilead, Not Necessarily Alexion; Jefferies Maintains Gilead is 'Undervalued'

Financial news for GILD dated on 2016-11-08: UPDATE: Jefferies Note Highlighting Gilead for Alexion Titled 'Another Look At Our Hypothetical M&A Scenario Analysis'

Financial news for GILD dated on 2016-11-08: Hearing Jefferies Defending Alexion, Says Gilead Could Buy Co.

Financial news for GILD dated on 2016-11-08: The Market In 5 Minutes: Election Day Has Finally Arrived

Financial news for GILD dated on 2016-11-08: Mizuho Initiates Coverage On Gilead Sciences, Inc. - Common Stock at Buy, Announces \$88.00

Financial news for GILD dated on 2016-11-04: Gilead Shares Spike to Session Highs as Traders Passing Around Vague, Unconfirmed Chatter in Name; Shares Up 2% for Session

Financial news for GILD dated on 2016-11-02: Near-Term Headwinds And Long-Term Promise For Gilead Sciences

Financial news for GILD dated on 2016-11-02: Gilead Sciences Price Target Trimmed Following A Sobering Q3

Financial news for GILD dated on 2016-11-02: Benzinga's Top Upgrades

Financial news for GILD dated on 2016-11-02: The Market In 5 Minutes: Alibaba, Brocade And A Game 6

Financial news for GILD dated on 2016-11-02: BMO Capital Upgrades Gilead Sciences, Inc. - Common Stock to Outperform

Financial news for GILD dated on 2016-11-02: 12 Stocks You Should Be Watching Today

Financial news for GILD dated on 2016-11-01: Adam Feuerstein @adamfeuerstein Tweet: Summary of analyst reaction to \$GILD quarter: "Whew, they didn't guide down again." Sad to say, but that is a positive.

Financial news for GILD dated on 2016-11-01: Gilead Ticks Lower On Earnings Miss

Financial news for GILD dated on 2016-11-01: Gilead Reports Q3 Adj. EPS \$2.75 vs \$2.86 Est., Sales \$7.5B vs \$7.45B Est.

Financial news for GILD dated on 2016-11-01: ContraVir CEO Talks Hep. B Treatment's Future

Financial news for GILD dated on 2016-11-01: Nerves Start To Fray Ahead Of Election As Investors Scramble For Protection

Financial news for GILD dated on 2016-11-01: The Election Can't Come Soon Enough For Biotechs

Financial news for GILD dated on 2016-11-01: Earnings Scheduled For November 1, 2016

Financial news for GILD dated on 2016-11-01: Keep an Eye on These 10 Stocks for November 1, 2016

Financial news for GILD dated on 2016-10-26: Option Alert: GILD Feb17 82.5 Calls: 3530 @ Above Ask! \$2.00: 4948 traded vs 774 OI: Earnings 11/1 After Close \$75.25 Ref

Financial news for GILD dated on 2016-10-25: Jefferies Says Gilead's 4997 Data Is Impressive, Underappreciated

Financial news for GILD dated on 2016-10-24: Gilead Reports FTC/TAF-Based Regimens Demonstrate Comparable Efficacy and Improved Renal and Bone Laboratory Parameters Compared to Truvada

Financial news for GILD dated on 2016-10-20: Gilead Announces SVR12 Rates From Four Phase 3 Studies of a Once-Daily, Fixed-Dose Combination of Sofosbuvir, Velpatasvir and Voxilaprevir in Treatment-Naive and Treatment-Experienced Genotype 1-6 Chronic HCV-Infected Patients

Financial news for GILD dated on 2016-10-20: UPDATE: Gilead Says Separate Phase 2 Study of Selonsertib Did Not Meet Primary Endpoint for PAH or DKD; Gilead Will Not Pursue Phase 3 Studies for PAH or DKD at This Time

Financial news for GILD dated on 2016-10-20: UPDATE: Gilead Says Selonsertib Showed 'Anti-Fibrotic Activity in Open-Label Phase 2 NASH Study; Data Support Plans to Advance GS-4997 into Phase 3 Clinical Trials'

Financial news for GILD dated on 2016-10-20: Gilead Reports Top-Line Phase 2 Results from Selonsertib in NASH, PAH, DKD

Financial news for GILD dated on 2016-10-18: Exclusive: SunTrust Top Analysts Explain Fatty Liver Diseases, Galmed's Potential In The Space

Financial news for GILD dated on 2016-10-17: 20-Week Data From Filogtinib Phase 2 "Fitzroy" Study In Crohn's Disease Expected To Be Presented During United European Gastroenterology Week

Financial news for GILD dated on 2016-10-17: Watch These 5 Huge Put Purchases In Monday Trade

Financial news for GILD dated on 2016-10-14: Option Alert: GILD May \$65 Put; 1100 @Bid @\$3.40 vs 275 OI

Financial news for GILD dated on 2016-10-12: Theravance Biopharma's Valuation Has Gotten A Little Carried Away

Financial news for GILD dated on 2016-10-12: Analysts Share Their Low Forward P/E Picks

Financial news for GILD dated on 2016-10-11: Technical Alert: Gilead Sciences Lower For Fourth Day In A Row

Financial news for GILD dated on 2016-10-07: Technical Alert: Gilead Sciences Makes New Low For Move

Financial news for GILD dated on 2016-09-28: Gilead, Bank Of America, Costco: Fast Money Picks For September 28

Financial news for GILD dated on 2016-09-27: Gilead Sciences, WHO Report 5 Year Leishmaniasis Partnership

Financial news for GILD dated on 2016-09-27: Galapagos Reports Successful Completion Of Discussions With US And European Authorities To Initiate Phase 3 Crohn's Disease Study

Financial news for GILD dated on 2016-09-27: 15 Biggest Mid-Day Losers For Tuesday

Financial news for GILD dated on 2016-09-27: The Drug Price Increase Debate: Separating The Winners From The Losers

Financial news for GILD dated on 2016-09-27: The Market In 5 Minutes: Debates, Oil Keep Stocks Mixed

Financial news for GILD dated on 2016-09-27: Benzinga's Top Downgrades

Financial news for GILD dated on 2016-09-27: Leerink Swann Downgrades Gilead Sciences to Market Perform

Financial news for GILD dated on 2016-09-26: Incyte Could Be A Takeover Target, Argus Lifts Price Target To \$98

Financial news for GILD dated on 2016-09-23: Sell Twitter, Buy Gilead And More Fast Money Picks For September 23

Financial news for GILD dated on 2016-09-23: Cramer Advises His Viewers On Gilead Sciences And Monsanto

Financial news for GILD dated on 2016-09-22: Gilead Valuation Only Minimally Effected By Drug Trial Stoppage

Financial news for GILD dated on 2016-09-22: Will Allergan Buy Gilead? Don't Count On 'The Mother Of All Blockbusters'



Financial news for GILD dated on 2016-09-22: Benzinga's Top Initiations

Financial news for GILD dated on 2016-09-22: The Market In 5 Minutes: No Interest Rate Hike...Yet

Financial news for GILD dated on 2016-09-22: Berenberg Initiates Coverage on Gilead Sciences at Buy

Financial news for GILD dated on 2016-09-22: Can You Guess This Chart?

Financial news for GILD dated on 2016-09-21: Gilead Reports Termination of Phase 2/3 Study of GS-5745 in Patients Ulcerative Colitis

Financial news for GILD dated on 2016-09-21: The Street's Adam Feuerstein Tweets: \$AGN (\$94B) is not buying \$GILD (\$107B) Please shut up.

Financial news for GILD dated on 2016-09-21: Allergan Going After Gilead? Gabelli Says CEO 'Playing Chess While The Market Is Playing Checkers'

Financial news for GILD dated on 2016-09-21: Traders Highlighting Barron's Article On Gabelli Note Speculating Allergan Possibly Preparing Bid For Gilead

Financial news for GILD dated on 2016-09-21: Allergan's Tobira Acquisition Represents The Highest Premium Ever Paid In Biopharma

Financial news for GILD dated on 2016-09-20: Technical Alert: Gilead Sciences Tests Resistance At \$82 Area

Financial news for GILD dated on 2016-09-20: NASH Sympathy Plays On Tobira Therapeutics Deal

Financial news for GILD dated on 2016-09-20: The 5 Top-Selling Drugs In The World

Financial news for GILD dated on 2016-09-16: TESARO Shares Trading Up ~2% in Otherwise Down Tape on No News; Some Traders Getting Anxious Following News of Gilead \$5B Senior Notes Offering Announced Thurs. Evening

Financial news for GILD dated on 2016-09-15: Adam Feuerstein @adamfeuerstein \$GILD Drug Pipeline, Maligned by Investors is Still Packed with Q4 Clinical Trial Readouts thestreet.com/story/13741594... 9 clinical trials in Q4.

Financial news for GILD dated on 2016-09-15: Adam Feuerstein Tweets: \$GILD Drug Pipeline, Maligned by Investors, is Still Packed with Q4 Clinical Trial Readouts thestreet.com/story/13741594... 9 clinical trials in Q4.

Financial news for GILD dated on 2016-09-14: Credit Suisse Cuts Gilead Price Target To \$95

Financial news for GILD dated on 2016-09-14: 7 Biggest Price Target Changes For Wednesday

Financial news for GILD dated on 2016-09-14: The Market In 5 Minutes: Huge FDA News, Major Mid-Week M&A

Financial news for GILD dated on 2016-09-14: Can You Guess This Chart?

Financial news for GILD dated on 2016-09-14: Watch These 7 Huge Put Purchases In Wednesday Trade

Financial news for GILD dated on 2016-09-13: Option Alert: GILD Jun 16 \$72.5 Puts at the bid: 2000 @ 5.651 vs. Open Interest 136

Financial news for GILD dated on 2016-09-13: Recent Strength In TESARO Being Attributed To Gabelli Research Report Of Potential Gilead Interest In TESARO

Financial news for GILD dated on 2016-09-12: Benzinga's Top Initiations

Financial news for GILD dated on 2016-09-12: The Market In 5 Minutes: Hillary Clinton Falls Ill With The Global Stock Markets

Financial news for GILD dated on 2016-09-12: Berenberg Initiates Coverage on Gilead Sciences at Buy

Financial news for GILD dated on 2016-09-08: Traders Attributing Strength in TESARO Shares to Comment from Gilead Exec Mgmt is 'Absolutely Willing' to Take Risk with Right PARP Product

Financial news for GILD dated on 2016-09-08: Hearing Gilead Exec at Wells Fargo

Healthcare Conference Has Said Mgmt is Feeling 'an Urgency to Do Deals,' But is Not Desperate

Financial news for GILD dated on 2016-09-06: Benzinga's Top Upgrades

Financial news for GILD dated on 2016-09-06: The Market In 5 Minutes: Stocks Return Higher From Three-Day Weekend

Financial news for GILD dated on 2016-09-06: Jefferies Upgrades Gilead To Buy Citing Bullish Prospects For HIV Franchise

Financial news for GILD dated on 2016-09-06: Jefferies Upgrades Gilead Sciences to Buy

Financial news for GILD dated on 2016-08-30: Janney Initiates Galapagos At Buy, Sees Fair Value Of Shares At \$64

Financial news for GILD dated on 2016-08-29: Technical Alert: Gilead Sciences Makes New Low For Move And Attempts To Rebound

Financial news for GILD dated on 2016-08-27: Here Are All The Big Biotech Mergers In 2016

Financial news for GILD dated on 2016-08-22: Galapagos NV Reports Initiation of Global Phase 3 Program Investigating filgotinib In Rheumatoid Arthritis

Financial news for GILD dated on 2016-08-22: European Commission Grants Marketing Authorization For Once-Daily Truvada To Reduce Risk Of Sexually Acquired HIV-1

Financial news for GILD dated on 2016-08-22: Must Watch Stocks for August 22, 2016

Financial news for GILD dated on 2016-08-21: Benzinga's Weekend M&A Chatter

Financial news for GILD dated on 2016-08-17: UPDATE: Reuters Says Merck, Sanofi, Pfizer, Gilead, Celgene Have Each Submitted Expressions of Interest for Medivation

Financial news for GILD dated on 2016-08-16: The Least Popular Stocks This 13F Season

Financial news for GILD dated on 2016-08-15: 13F from Soros' Soros Fund Mgmt Shows Liquidated Positions in Apple, Netflix, Gilead, Gap, Synchrony Financial, United Continental

Financial news for GILD dated on 2016-08-15: 13F from Cooperman's Omega Shows Liquidated Stake in Gilead

Financial news for GILD dated on 2016-08-11: Gilead Shares Tick Lower; Traders Circulating Stat News Article "IRS is urged to investigate Gilead for 'dodging' US taxes"

Financial news for GILD dated on 2016-08-05: Gilead Shares Indicated Higher, Up ~0.4%; BZ NOTE: Co. Was Discussed as a Possible Takeover Candidate for Bristol-Myers, as Recently as Aug. 1

Financial news for GILD dated on 2016-08-01: UPDATE: Free Cash-Flow For Bristol-Myers Squibb Has Been Negative For 2 Straight Quarters

Financial news for GILD dated on 2016-08-01: UPDATE: In Early July Citigroup Said Gilead Would Not Seek Mega-Merger, Said Co Was Comfortable With 'their lean size'

Financial news for GILD dated on 2016-08-01: Gilead Spikes to High; Hearing Unconfirmed Market Chatter Co Talking With BMY Regarding Merger

Financial news for GILD dated on 2016-08-01: Jefferies Ponders Whether Gilead Sciences Should Experiment With An HCV Spinoff

Financial news for GILD dated on 2016-07-29: The Market In 5 Minutes: Amazon And Google Continue To Dominate

Financial news for GILD dated on 2016-07-29: Argus Research Downgrades Gilead Sciences to Hold

Financial news for GILD dated on 2016-07-27: Barclays Shares Its Thoughts On Gilead Sciences Post-Earnings

Financial news for GILD dated on 2016-07-26: 15 Biggest Mid-Day Losers For Tuesday

Financial news for GILD dated on 2016-07-26: Technical Alert - Gilead Sciences Falls Into Limited Support Zone After Q2 Report

Financial news for GILD dated on 2016-07-26: Benzinga's Top Downgrades

Financial news for GILD dated on 2016-07-26: The Market In 5 Minutes: Apple And Twitter And McDonald's, Oh My!

Financial news for GILD dated on 2016-07-26: 15 Stocks Moving In Tuesday's Pre-Market Session

Financial news for GILD dated on 2016-07-26: Needham Downgrades Gilead Sciences to Hold

Financial news for GILD dated on 2016-07-26: Wait On The DNC Before Going Long Biotech ETFs

Financial news for GILD dated on 2016-07-26: Keep an Eye on These 12 Stocks for July 26, 2016

Financial news for GILD dated on 2016-07-25: 4 Stocks Moving In Monday's After-Hours Session

Financial news for GILD dated on 2016-07-25: After-Hours Losers: CRME down 14.91%, SANM 9.06%, GBR 4.50%, CMP 2.75%, GILD 3.67, CDNS 2.45%, FCCY 2.50%

Financial news for GILD dated on 2016-07-25: Gilead Misses Revenue Estimates, Cuts Guidance

Financial news for GILD dated on 2016-07-25: Gilead Shares Down 4.5%

Financial news for GILD dated on 2016-07-25: Gilead Cuts FY16 Rev. From \$30-\$31B To \$29.5-\$30.5B

Financial news for GILD dated on 2016-07-25: Gilead Sciences Cuts Sales Guidance

Financial news for GILD dated on 2016-07-25: Gilead Reports Q2 EPS \$3.08 vs. Est. \$3.02, Rev. \$7.776B vs. Est. \$7.79B

Financial news for GILD dated on 2016-07-25: Technical Alert - Gilead Sciences Testing Major Resistance Ahead Of Q2 Report

Financial news for GILD dated on 2016-07-25: The Market In 5 Minutes: Yahoo, Outerwall Highlight Merger Monday

Financial news for GILD dated on 2016-07-25: Earnings Scheduled For July 25, 2016

Financial news for GILD dated on 2016-07-25: 8 Stocks You Should Be Watching Today

Financial news for GILD dated on 2016-07-24: Biotech In The Earnings Spotlight: Amgen, Celgene, Gilead Sciences

Financial news for GILD dated on 2016-07-24: Scott Bauer's Gilead Sciences Trade

Financial news for GILD dated on 2016-07-22: Gilead Gets European CHMP's Positive Opinion On Its Type II Variation Application For Truvada

Financial news for GILD dated on 2016-07-22: Gilead Sciences Reports Position Opinion from CHMP Related to Type II Variation App for Truvada for Reducing Risk of Sexually-Acquired HIV

Financial news for GILD dated on 2016-07-21: Gilead's Odefsey Meets Primary 48-Week Objective in Two Phase 3b Studies

Financial news for GILD dated on 2016-07-19: Here Are The 14 Stocks Morgan Stanley Wants You To Focus On During Q2 Earnings

Financial news for GILD dated on 2016-07-17: Barron's Picks And Pans: Madison Square Garden, Cigna, Kennedy-Wilson And More

Financial news for GILD dated on 2016-07-15: SWEEP (SELL) - GILD Sep \$87.5 Put - 842 @ 3.801 in 37 orders. 907 traded. OI: 449

Financial news for GILD dated on 2016-07-14: Gilead Receives Approval in Canada for Eplclusa for Treatment of Chronic Hepatitis C

Financial news for GILD dated on 2016-07-12: 10 Stocks Cramer's Watching To See If The Market Rebound Is Sustainable

Financial news for GILD dated on 2016-07-08: Ligand Reaches OmniAb Platform License Agreement with Gilead

Financial news for GILD dated on 2016-07-08: Gilead Receives European Commission Marketing Authorization For Epclusa

Financial news for GILD dated on 2016-07-08: Ligand Enters into OmniAb Platform License Agreement with Gilead Sciences

Financial news for GILD dated on 2016-07-08: Gilead Announces European Commission Marketing Authorization For Epclusa For Hepatitis C

Financial news for GILD dated on 2016-07-01: Jim Cramer Shares His Thoughts On Gilead Sciences, Inc. And Citigroup Inc

Financial news for GILD dated on 2016-07-01: Fast Money Traders Share Their Biotech Picks

Financial news for GILD dated on 2016-06-29: Buying Nike, Gilead And PayPal: Fast Money Picks For June 29

Financial news for GILD dated on 2016-06-28: Jefferies Sees Limited Impact To Gilead From Regulus' HCV Candidate's Clinical Hold

Financial news for GILD dated on 2016-06-28: Gilead Rallies Off Epclusa Approval

Financial news for GILD dated on 2016-06-28: Gilead Gets FDA Approval For Epclusa (Sofosbuvir/Velpatasvir) for All Genotypes Of Chronic Hepatitis C Treatment

Financial news for GILD dated on 2016-06-28: Adam Feuerstein @adamfeuerstein Tweet: \$GILD I'm surprised at the Epclusa WAC price of \$74,760 -- a lot lower than I expected.

Financial news for GILD dated on 2016-06-28: FDA Approves Gilead's Epclusa for Treatment of Chronic Hepatitis C Virus Infection

Financial news for GILD dated on 2016-06-24: Option Alert: SWEEP (BUY) - GILD July 8 \$81 Call - 739 @ 1.559 in 18 orders. 753 traded. OI: 11

Financial news for GILD dated on 2016-06-23: Gilead Sciences Get European Commission Grant For Marketing Authorization Of Its Single Tablet Regimen Odefsey

Financial news for GILD dated on 2016-06-23: As Buybacks Soar, Buyback ETF Tries To Get Its Groove Back

Financial news for GILD dated on 2016-06-23: European Commission Grants Marketing Authorization for Gilead's Single Tablet Regimen Odefsey for the Treatment of HIV

Financial news for GILD dated on 2016-06-22: Biotechs Are Ripping Following IPAB Ruling

Financial news for GILD dated on 2016-06-21: Gilead Sciences Approaches Major Support Level

Financial news for GILD dated on 2016-06-20: Gilead Reports Prelim. Data on Bictegravir, Says Now Being Evaluated in Phase 3 Studies

Financial news for GILD dated on 2016-06-16: Arbutus Biopharma Taken Off Of Chardan's Sell List

Financial news for GILD dated on 2016-06-14: At William Blair Growth Conference, Gilead Says They Cured 2 People With Ebola Treated With GS-5734

Financial news for GILD dated on 2016-06-13: Gilead's HCV Franchise Erosion Here To Stay; Leerink Cuts Price Target

Financial news for GILD dated on 2016-06-12: Biogen And Gilead Sciences Buck Biotech Short Interest Trend

Financial news for GILD dated on 2016-06-09: Hold The Phone On Biotech

Financial news for GILD dated on 2016-06-08: Gilead Shares Spiking, Traders Passing Around Comments Of Possible ValueAct Stake

Financial news for GILD dated on 2016-06-07: Merck Says Ruling Reversal in Gilead Case 'Doesn't Reflect the Facts,' Co. Will Appeal Ruling Overturn

Financial news for GILD dated on 2016-06-06: US Judge Rules Gilead Won't have to Pay \$200M Jury Verdict to Merck in Hepatitis C Patent Dispute -Reuters

Financial news for GILD dated on 2016-06-06: TD Ameritrade's IMX Growth Hits Record High In May: Check Out Clients' Picks & Pans

Financial news for GILD dated on 2016-06-06: Gilead Shares Trading HOD, Seeing Sweep Action In The Weekly 87.5 Calls Expiring July 1

Financial news for GILD dated on 2016-06-04: What's The Single Best \$10,000 Investment To Hold For The Next 25 Years?

Financial news for GILD dated on 2016-06-01: Benzinga's Top Initiations

Financial news for GILD dated on 2016-06-01: Gabelli & Co Initiates Coverage on Gilead Sciences at Buy

Financial news for GILD dated on 2016-05-31: Solid Potential For Gilead To Beat Estimates And Raise Guidance: Here's How

Financial news for GILD dated on 2016-05-27: Gilead Gets European CHMP's Positive Opinion For Epclusa For All Genotypes of Chronic Hepatitis C Treatment

Financial news for GILD dated on 2016-05-27: European CHMP Adopts Positive Opinion for Gilead's Epclusa for the Treatment of All Genotypes of Chronic Hepatitis C, Expects Target Action Date Under PDUFA Of June 28th, 2016

Financial news for GILD dated on 2016-05-26: Could Rally Cool Off Ahead Of Friday's GDP Data and Yellen Speech?

Financial news for GILD dated on 2016-05-25: Benzinga's M&A Chatter for Wednesday May 25, 2016

Financial news for GILD dated on 2016-05-25: Celgene, Gilead Said to Bid for Medivation -Bloomberg

Financial news for GILD dated on 2016-05-24: Gilead Names Kevin Young CBE COO

Financial news for GILD dated on 2016-05-19: 5 Reasons Arrowhead Pharma Is A Hepatitis B Leader

Financial news for GILD dated on 2016-05-17: Has A Biotech Recovery Started Yet?

Financial news for GILD dated on 2016-05-16: 13F From George Soros Shows New Stake In Gilead Sciences

Financial news for GILD dated on 2016-05-16: Leon Cooperman Buys 227,000 Apple Shares, Adds More Microsoft

Financial news for GILD dated on 2016-05-04: Jim Cramer Advises Viewers On Schlumberger, Gilead Sciences And Disney

Financial news for GILD dated on 2016-05-03: The Next Sector Rotation Will Be To Biotechs

Financial news for GILD dated on 2016-05-01: Barron's 500: America's Top Companies

Financial news for GILD dated on 2016-04-29: After-Hours Recap: April In Review, Friday Index Movers & After-Hours Runners

Financial news for GILD dated on 2016-04-29: Gilead Says European CHMP Adopts Positive Opinion For Its Odefsey For Treating HIV

Financial news for GILD dated on 2016-04-29: European CHMP Adopts Positive Opinion for Gilead's TAF-Based Single Tablet Regimen Odefsey for Treatment of HIV

Financial news for GILD dated on 2016-04-29: 15 Stocks Moving In Friday's Pre-Market Session

Financial news for GILD dated on 2016-04-29: Maxim Group Downgrades Gilead Sciences to Hold

Financial news for GILD dated on 2016-04-29: 10 Stocks You Should Be Watching Today

Financial news for GILD dated on 2016-04-28: Gilead Reaffirms FY16 Sales \$30B-\$31B vs \$31.8B Est.

Financial news for GILD dated on 2016-04-28: Gilead Sciences Reports Q1 Adj EPS \$3.03 Vs Est \$3.14, Sales \$7.79B Vs Est \$8.11B

Financial news for GILD dated on 2016-04-28: Biotech Boom May Continue Through Earnings Season

Financial news for GILD dated on 2016-04-28: Earnings Scheduled For April 28, 2016

Financial news for GILD dated on 2016-04-27: Amazon Earnings, GDP And Other Key Market Data For Thursday

Financial news for GILD dated on 2016-04-26: Credit Suisse Maintains Outperform on Gilead Sciences, Raises PT to \$120.00

Financial news for GILD dated on 2016-04-26: Big Biotech In The Earnings Spotlight

Financial news for GILD dated on 2016-04-25: Sustainable Investing With A New ETF

Financial news for GILD dated on 2016-04-25: Gilead Gets European Commission Marketing Authorization For HIV-1 Infection Drug

Financial news for GILD dated on 2016-04-25: Gilead Announces European Commission Grants Marketing Authorization For 2 Doses Of Descovy For HIV Treatment

Financial news for GILD dated on 2016-04-16: Gilead Announces Multiple Scientific Presentations Demonstrating Broad Utility of Sofosbuvir-Based Hep C Therapies at ILC

Financial news for GILD dated on 2016-04-16: Gilead Presents New Data Highlighting Progress in Liver Fibrosis at ILC

Financial news for GILD dated on 2016-04-15: Adam Feuerstein @adamfeuersteinTweet: Investor source (long \$GILD) at EASL: "\$RGLS isn't going anywhere. This is the \$GILD show. Literally half the posters are abt GILD's drugs."

Financial news for GILD dated on 2016-04-15: Gilead Sciences' Two Phase Three Trials Meet Primary Endpoints

Financial news for GILD dated on 2016-04-15: Gilead Announces Two Phase 3 Studies Evaluating Tenofovir Alafenamide for Patients With Chronic Hep B Infection Both Met their Primary Endpoints of Non-inferiority to Gilead's Viread

Financial news for GILD dated on 2016-04-13: SunTrust: Medivation M&A Chatter Highlights Value, Company's 'Unique' Industry Position

Financial news for GILD dated on 2016-04-12: Cancer Drug Stocks Are The Picture Of Health

Financial news for GILD dated on 2016-04-12: Baird: Gilead Set For Q1 EPS Miss, But Hep C Trends Still Good Long Term

Financial news for GILD dated on 2016-04-07: How One Analyst Is Playing The Biotech Rebound This Week

Financial news for GILD dated on 2016-04-05: BMO Capital Initiates Coverage on Gilead Sciences at Market Perform, Announces \$102.00 PT

Financial news for GILD dated on 2016-04-04: Gilead Sciences Acquires Nimbus Apollo for \$400M

Financial news for GILD dated on 2016-04-04: Gilead Announces FDA Has Approved Descovy

Financial news for GILD dated on 2016-04-04: Gilead Reports Purchase of Nimbus Therapeutics' ACC Program for NAS, Other Liver Diseases; Made \$400M Upfront Payment, Potential to Receive Added \$800M in Development-Related Milestones Over Time

Financial news for GILD dated on 2016-03-31: IBM, Micron, Gilead: Fast Money Picks For March 31

Financial news for GILD dated on 2016-03-31: Gilead Submits NDA to Japan's Pharmaceutical and Medical Devices Agency for Tenofovir Alafenamide for Patients with Chronic Hepatitis B Infection

Financial news for GILD dated on 2016-03-29: ContraVir Pharma Says Its CMX157 Outperformed Gilead's Drug in Trial

Financial news for GILD dated on 2016-03-28: Data Shows Gilead's HCV Franchise Is Surviving New Competition

Financial news for GILD dated on 2016-03-24: Patent Expert: It's Not Over For Gilead, Still Has Strong Defense Against Merck

Financial news for GILD dated on 2016-03-24: Gilead, FedEx And Other Fast Money Picks For March 24

Financial news for GILD dated on 2016-03-23: Jury Rules Merck Patents Valid...Bad For

Gilead?

Financial news for GILD dated on 2016-03-23: Gilead -2.5% Premarket Following Verdict Tuesday Validating Merck's Hep C Patents

Financial news for GILD dated on 2016-03-23: Credit Suisse Maintains Outperform on Gilead Sciences, Lowers PT to \$116.00

Financial news for GILD dated on 2016-03-22: Wedbush Downgrades Infinity Pharma To Underperform, Slashes Target To \$3

Financial news for GILD dated on 2016-03-18: Potent Value In This Large-Cap ETF

Financial news for GILD dated on 2016-03-17: A Rare Opportunity With A Biotechnology ETF

Financial news for GILD dated on 2016-03-15: Gilead Shares Down 0.7% @\$89.90 Pre-Market After Gilead Decided To Stop Zydelig Trials Due To Serious Adverse Events

Financial news for GILD dated on 2016-03-10: Factor Fun With This ETF

Financial news for GILD dated on 2016-03-08: The Market In 5 Minutes: Tuesday, March 8, 2016

Financial news for GILD dated on 2016-03-08: Leerink Raises Gilead Target To \$130 On New HIV Outlook

Financial news for GILD dated on 2016-03-07: Gilead Vs. Merck: What To Know

Financial news for GILD dated on 2016-03-07: The 5 Most Notable Insider Sells Of The Week

Financial news for GILD dated on 2016-03-03: Gilead Shares Fall to Low of \$87.65 on Volume; May be Attributed to Insider Sales Filings

Financial news for GILD dated on 2016-03-03: Leerink Positive On GILD Outlook, Likes Co's Substantial Cash Generation, Maintains Outperform And \$125 PT

Financial news for GILD dated on 2016-03-03: NY State AG Subpoenas Health Insurers Requesting Documents Explaining How Decide Which Hep C Drugs to Cover -Bloomberg

Financial news for GILD dated on 2016-03-01: Gilead Reports FDA Approval of Second TAF-Based Single Tablet Regimen Odefsey for Treatment of HIV-1 Infection

Financial news for GILD dated on 2016-03-01: Gilead's 'R&D Day' Points To Upside For Shareholders

Financial news for GILD dated on 2016-02-29: 3 Mega Biotechs Leerink Loves

Financial news for GILD dated on 2016-02-29: Health Canada Issues Notice Of Compliance for Gilead's Truvada for Reducing Risk of Sexually Acquired HIV Infection

Financial news for GILD dated on 2016-02-26: European CHMP Adopts Positive Opinion for Gilead's Fixed-Dose Combination Descovy for the Treatment of HIV

Financial news for GILD dated on 2016-02-25: Citi: Buy Celgene, Gilead, Biogen And Regeneron As Biotechs Recover

Financial news for GILD dated on 2016-02-25: Citigroup Initiates Coverage on Gilead Sciences at Buy

Financial news for GILD dated on 2016-02-24: Gilead Offers New Preclinical Study Data Evaluating Investigational TLR7 Agonist in SIV-Infected Monkeys

Financial news for GILD dated on 2016-02-24: Biotech Investors Shouldn't Fear Legislation, Even If Hillary Is President And Dems Win Senate Majority

Financial news for GILD dated on 2016-02-23: Will Merck Encroach On Gilead's Harvoni Territory?

Financial news for GILD dated on 2016-02-23: 8,383 Patients Contacted to Arrange Blood Test Following Possible Exposure to ex-NHS Worker with Hepatitis C -Sky News

Financial news for GILD dated on 2016-02-22: Gilead Launches New Grants Program to Support HIV Cure

Financial news for GILD dated on 2016-02-17: The Stocks That Moved The S&P, Dow And Nasdaq Today

Financial news for GILD dated on 2016-02-16: Gilead Reports FDA Has Approved Two Supplemental Indications for Harvoni in Chronic Hep C Patients with Advanced Liver Disease

Financial news for GILD dated on 2016-02-13: Schroer: Biotech Will Turn Around

Financial news for GILD dated on 2016-02-11: Benzinga's Top Initiations

Financial news for GILD dated on 2016-02-11: Oppenheimer Initiates Coverage on Gilead Sciences at Outperform, Abb \$120.00 PT

Financial news for GILD dated on 2016-02-10: Zika Virus Spreading: Here's How To Play It Again

Financial news for GILD dated on 2016-02-09: Icahn, Gilead, GE Lead Top Insider Trades Of The Week

Financial news for GILD dated on 2016-02-09: Celgene, Gilead Spike to Highs; May be Attributed to CMS Memo

Financial news for GILD dated on 2016-02-09: Rebound For Big Biotech ETF Will Require Some Patience

Financial news for GILD dated on 2016-02-09: Cramer Shares His Thoughts On Chipotle Mexican Grill, Inc. And Gilead Sciences, Inc.

Financial news for GILD dated on 2016-02-08: Most Of Credit Suisse's Top Investment Ideas For 2016...In One Place

Financial news for GILD dated on 2016-02-08: Schoenebaum: Biotech P/Es Show 'Buying Signal' With Caveat; Amgen, Biogen, Celgene & Gilead Have Catalysts

Financial news for GILD dated on 2016-02-08: How To Invest In An Aging World With The 'Live Long & Prosper' ETF

Financial news for GILD dated on 2016-02-07: Barron's: Here Comes \$20 Oil

Financial news for GILD dated on 2016-02-07: Barron's Picks And Pans: Kinder Morgan, Gilead Sciences And More

Financial news for GILD dated on 2016-02-05: Leerink Is Back On Board The Biotech Train

Financial news for GILD dated on 2016-02-05: Leerink Swann Initiates Coverage on Gilead Sciences at Outperform

Financial news for GILD dated on 2016-02-04: 25 Companies That Could Still Buy Back Mountains Of Stock

Financial news for GILD dated on 2016-02-03: Gilead Sciences Rallies Off Q4 Report

Financial news for GILD dated on 2016-02-03: Zika-Related Social Media Chatter Is Picking Up

Financial news for GILD dated on 2016-02-03: Is Big Pharma Hinting At A SMID-Cap Biotech Rally?

Financial news for GILD dated on 2016-02-03: Joe McCann: Here's How To Play Biotech Market In Earnings Season

Financial news for GILD dated on 2016-02-03: Ronnie Moas Initiates Gilead At Buy; Models Show It's A Top 10 S&P Stock

Financial news for GILD dated on 2016-02-03: Benzinga's Top Initiations

Financial news for GILD dated on 2016-02-03: Credit Suisse Not Expecting GILD To Face Significantly Lower HCV Discounts From New Competitor

Financial news for GILD dated on 2016-02-03: Credit Suisse Maintains Outperform on Gilead Sciences, Lowers PT to \$118.00

Financial news for GILD dated on 2016-02-03: Standpoint Research Initiates Coverage on Gilead Sciences at Buy, Announces \$110.00 PT

Financial news for GILD dated on 2016-02-03: Keep an Eye on These 10 Stocks for February 3, 2016

Financial news for GILD dated on 2016-02-02: Gilead Trounces Hep C Estimates; Harvoni International Footprint Nearly Equals U.S.



Financial news for GILD dated on 2016-02-02: Earnings Recap For February 2

Financial news for GILD dated on 2016-02-02: Gilead To Increase Qtr. Dividend From \$0.43 To \$0.47/Share

Financial news for GILD dated on 2016-02-02: Gilead Reports \$12B Additional Buyback

Financial news for GILD dated on 2016-02-02: Gilead Sees FY16 Rev. \$30B-\$31B v.s Est. \$32.26B

Financial news for GILD dated on 2016-02-02: Gilead Sciences Reports Q4 EPS \$3.32 Vs Est \$2.99, Sales \$8.51B Vs Est \$8.13B

Financial news for GILD dated on 2016-02-02: Gilead Faces Its Great Hep C Threat: Will It Change Earnings?

Financial news for GILD dated on 2016-02-02: Hearing Intercept Pharma hires JPM to Handle Interest from Pfizer, Gilead, BristolMyers -Daily Mail

Financial news for GILD dated on 2016-02-02: Must Watch Stocks for Today

Financial news for GILD dated on 2016-02-02: Earnings Scheduled For February 2, 2016

Financial news for GILD dated on 2016-02-01: From GoPro To Gilead: The Week's Most Important Earnings Calls After Google

Financial news for GILD dated on 2016-02-01: UPDATE: STAT News on Gilead Cites Filing Posted on AIDSHealth.org

Financial news for GILD dated on 2016-02-01: Gilead Accused of Manipulating HIV Patents Story, AIDS Healthcare Foundation Files Lawsuit Against Gilead-STAT News

Financial news for GILD dated on 2016-02-01: European Medicines Agency Validates Gilead's Type II Variation Application for Truvada for Reducing the Risk of Sexually Acquired HIV

Financial news for GILD dated on 2016-01-29: Gilead Hits New 52-Week Low; Here Are Two Reasons Why

Financial news for GILD dated on 2016-01-29: Worst Performing Industries For January 29, 2016

Financial news for GILD dated on 2016-01-29: Stocks Hitting 52-Week Lows

Financial news for GILD dated on 2016-01-29: EXCLUSIVE: Colombian Health Minister Says Country Has 16,490 Confirmed Zika Cases, Likely More Unreported

Financial news for GILD dated on 2016-01-29: Maybe Some Good News For A Big Biotech ETF

Financial news for GILD dated on 2016-01-29: 10 Stocks Moving In Friday's Pre-Market Session

Financial news for GILD dated on 2016-01-29: Gilead Names Chair, CEO John Martin Exec Chair; Pres, COO, John Milligan, Promoted to CEO

Financial news for GILD dated on 2016-01-28: 7 Biotech Traders Pick Their Favorite Stocks For 2016

Financial news for GILD dated on 2016-01-28: Stocks To Play In A Zika Virus Pandemic

Financial news for GILD dated on 2016-01-27: Option Alert: GILD Fri 1/29 91.0 Calls (Wkly) Sweep: 4000 @ ASK \$0.58: 4849 traded vs 1183 OI: Earnings 2/2 After Close \$89.61 Ref

Financial news for GILD dated on 2016-01-27: Massachusetts Attorney General To Gilead Sciences: Cost Of Harvoni & Sovaldi Drugs 'May Constitute An Unfair Trade Practice In Violation Of Massachusetts Law'

Financial news for GILD dated on 2016-01-27: Massachusetts AG Tells Gilead to Lower Prices on Hep C Drugs -Boston Globe

Financial news for GILD dated on 2016-01-25: Gilead Sciences Now Holds 14.75% of Galapagos Shares

Financial news for GILD dated on 2016-01-24: Jim Cramer Dishes On Microsoft, Gilead, TG Therapeutics & NY Community Bancorp

Financial news for GILD dated on 2016-01-21: Looking To Healthcare ETFs For Earnings Growth

Financial news for GILD dated on 2016-01-20: Gilead Sciences Tumbles; Unconfirmed Reports Of Drug Pricing Changes In Japan

Financial news for GILD dated on 2016-01-20: Credit Suisse Bullish On Most Big Pharma Names

Financial news for GILD dated on 2016-01-20: Gilead Shares Down Over 2.75%, Pharma Japan Reporting Possible Drug Repricing For Sovaldi, Harvoni, Avastin, And Plavix

Financial news for GILD dated on 2016-01-20: Credit Suisse Sets Outperform Rating, \$125 Target On Gilead Story

Financial news for GILD dated on 2016-01-20: Credit Suisse Initiates GILD At Outperform, Believes Franchise Is Sustainable And Says 'this value stock is no trap'

Financial news for GILD dated on 2016-01-19: Galapagos, Gilead Complete Global filgotinib Collaboration Deal; Triggers \$300M Fee Payment To Galapagos; Gilead Also Now Owns 14.75% Of Galapagos

Financial news for GILD dated on 2016-01-19: Credit Suisse Initiates Coverage on Gilead Sciences at Outperform, Announces \$125.00 PT

Financial news for GILD dated on 2016-01-15: Rethink U.S. Large-Cap Exposure With This ETF

Financial news for GILD dated on 2016-01-15: Write A Prescription For This Healthcare ETF

Financial news for GILD dated on 2016-01-15: Bank of America Upgrades Gilead Sciences to Neutral

Financial news for GILD dated on 2016-01-13: Galapagos, Gilead Cleared FTC to Close Global Partnership on Filgotinib

Financial news for GILD dated on 2016-01-12: Gilead Reports FDA Submission of NDA for TAF for Treatment of Chronic Hep B

Financial news for GILD dated on 2016-01-12: Moving To Momentum With ETFs

Financial news for GILD dated on 2016-01-07: Why Gilead Is 'The Apple Of Biotech'

Financial news for GILD dated on 2016-01-07: Jim Cramer Gives His Opinion On Lockheed Martin And Gilead Sciences

Financial news for GILD dated on 2016-01-05: Gilead Reports Termination of Phase 3 Study of Simtuzumab in Patients with Idiopathic Pulmonary Fibrosis

Financial news for GILD dated on 2016-01-05: UPDATE: Gilead To Submit Regulatory Applications For TAF For Chronic HBV In U.S. And EU In Q1 2016

Financial news for GILD dated on 2016-01-05: Gilead Reports Top-Line Results From Phase 3 Studies With Chronic Hepatitis B Infection, TAF Demonstrated Improved Renal And Bone Safety Parameters Compared To Viread

Financial news for GILD dated on 2016-01-04: Gilead Reports U.S. FDA Priority Review Designation for Sofosbuvir/Velpatasvir for Treatment of All Genotypes of Chronic Hepatitis C Infection, Final FDA Decision Anticipated By June 28th

Financial news for GILD dated on 2016-01-04: Gilead, Other Biotechs Selling Off On Market Weakness

Financial news for GILD dated on 2015-12-31: Looking To Q4 Earnings Season In 6 Charts

Financial news for GILD dated on 2015-12-31: Roth Capital's Joseph Pantginis Reiterates Buy on Ligand Following Captisol Supply Deal with Gilead; 'We believe Ligand is strongly positioned for continued growth.'

Financial news for GILD dated on 2015-12-31: 8-K from Ligand Pharma Shows Co. Entered Supply Deal with Gilead for Captisol

Financial news for GILD dated on 2015-12-30: Option Alert: GILD Feb16 105 Calls: 2000 @ Above Ask! \$2.77: 2056 traded vs 9762 OI: Earnings 2/2 \$102.16 Ref

Financial news for GILD dated on 2015-12-23: Peering Through The Fog To Find The Best Sectors Into Year End

Financial news for GILD dated on 2015-12-23: An Award-Winning Debut For This Goldman ETF

Financial news for GILD dated on 2015-12-22: Argus Like Gilead's Filgotinib Drug, Call It A 'blockbuster product', Says Galapagos 'warrants attention'

Financial news for GILD dated on 2015-12-21: GILD Fri 1/29 110 Calls (Wkly): 5200 @ ASK \$0.89: 5200 traded vs 108 OI: Earnings 2/2 \$102.04 Ref

Financial news for GILD dated on 2015-12-18: Option Alert: GILD Jan16 105 Calls Sweep: 10002 @ ASK \$1.54: 11k traded vs 19k OI: Earnings 2/2 \$101.64 Ref

Financial news for GILD dated on 2015-12-18: Piper Jaffray Makes 15 'Provocative' Predictions For Biopharma Sector In 2016

Financial news for GILD dated on 2015-12-18: Atlantic Equities Initiates Coverage on Gilead Sciences at Neutral, Announces \$111.00 PT

Financial news for GILD dated on 2015-12-17: CT Order Filing from Gilead Shows Co.'s App Under Rule 24b-2 Was Determined (by Division of Corporation Finance) Not to Publicly Disclose

Financial news for GILD dated on 2015-12-17: Benzinga's Volume Movers

Financial news for GILD dated on 2015-12-17: Benzinga's Top #PreMarket Gainers

Financial news for GILD dated on 2015-12-17: Galapagos, Gilead Announce Global Partnership to Develop Filgotinib to Treat Rheumatoid Arthritis, Other Inflammatory Diseases

Financial news for GILD dated on 2015-12-14: M&A In Small-, Mid-Cap Biotechs Isn't Slowing Down

Financial news for GILD dated on 2015-12-08: Phase 3 Results for Zydelig With Bendamustine, Rituximab for Relapsed Chronic Lymphocytic Leukemia Presented at American Society of Hematology Annual Meeting, Study Found 67% Reduction In Disease Progress Or Death

Financial news for GILD dated on 2015-12-07: Achillion Spikes to High; May be Attributed to FT Article on Gilead Seeking Hep C Deal

Financial news for GILD dated on 2015-12-07: Early Global News: PlayStation 4 Sets Records, New Weight Watchers App, And More

Financial news for GILD dated on 2015-12-07: Gilead Canada Reports Health Canada Has Issued Notice of Compliance of Co.'s Single Tablet Regimen Genvoya for Treatment of HIV-1 Infection

Financial news for GILD dated on 2015-12-04: EMA Validates Gilead's Marketing Application for Fixed-Dose Combination of Sofosbuvir/Velpatasvir for Treatment of Hep C

Financial news for GILD dated on 2015-12-02: 5 Things To Consider When Preparing For A Santa Claus Rally

Financial news for GILD dated on 2015-12-02: High Drug Prices Put Gilead Under Fire From Senate Committee

Financial news for GILD dated on 2015-12-02: Early Global News: Instagram Seeing Fast Growth Among U.S. Companies, Cabelas Explores Strategic Options

Financial news for GILD dated on 2015-12-01: 15 Biotechs Making Announcements At The 2015 Piper Jaffray Healthcare Conference

Financial news for GILD dated on 2015-12-01: Gilead Selling Off; CNBC Reports Senate Investigating Co Over Drug Pricing

Financial news for GILD dated on 2015-11-25: Early Global News: Ebola In Liberia, Boeing To Roll Out 737 MAX Next Month, Google Testing SMS Alerts

Financial news for GILD dated on 2015-11-17: Bristol-Myers Squibb Spokesperson Declines Comment on Earlier Chatter of Gilead Interest in Co.

Financial news for GILD dated on 2015-11-17: Hearing Unconfirmed Market Chatter of Gilead Deal to Acquire BMY

Financial news for GILD dated on 2015-11-16: Gilead's Zydelig(r) Combined with Bendamustine and Rituximab Shows Superior Efficacy to Bendamustine/Rituximab in Phase

### 3 Study of Patients with Relapsed Chronic Lymphocytic Leukemia

Financial news for GILD dated on 2015-11-15: Multiple Scientific Presentations at The Liver Meeting 2015 Further Highlight the Utility of Sofosbuvir-Based Hepatitis C Therapies

Financial news for GILD dated on 2015-11-12: U.S. FDA Approves New Indications for Harvoni, Gilead's Once-Daily Single Tablet Regimen for Chronic Hepatitis C

Financial news for GILD dated on 2015-11-11: X-RX Reports Autotaxin Inhibitor Partnership With Gilead

Financial news for GILD dated on 2015-11-09: Early Global News: New Alibaba Chatter, Tesla-GM Size Comparison & What Pamela Anderson And Gilead May Have In Common

Financial news for GILD dated on 2015-11-09: Pamela Anderson And Hepatitis C: Which Drug Makers Are Working On A Cure?

Financial news for GILD dated on 2015-11-05: UPDATE: Gilead's Genvoya Is First TAF-Based Regimen To Receive FDA Approval

Financial news for GILD dated on 2015-11-05: U.S. Food and Drug Administration Approves Gilead's Single Tablet Regimen Genvoya for Treatment of HIV-1 Infection

Financial news for GILD dated on 2015-11-05: FDA Approves Gilead'S Single Tablet Regimen Genvoya for Treatment Of Hiv-1 Infection -Reuters

Financial news for GILD dated on 2015-11-05: ISIS Pharma Called A 'Sleeper Awakening' At Piper Jaffray

Financial news for GILD dated on 2015-11-05: Fast Money Picks For November 5

Financial news for GILD dated on 2015-11-04: Meg Tirrell @megtirrell Tweet: In drug price task force hearing, House Dems take aim at Sovaldi

Financial news for GILD dated on 2015-10-30: Gilead Sciences, WuXi PharmaTech to Collaborate on Dedicated Analytical and Stability Testing Facility

Financial news for GILD dated on 2015-10-28: Gilead Submits New Drug Application to U.S. Food and Drug Administration for Fixed-Dose Combination of Sofosbuvir/Velpatasvir for Treatment of All Six Genotypes of Hepatitis C

Financial news for GILD dated on 2015-10-28: Gilead Stock Whiffs, But One Pro Remains Bullish

Financial news for GILD dated on 2015-10-28: Fast Money Picks For October 28

Financial news for GILD dated on 2015-10-28: Keep an Eye on These 10 Stocks for October 28, 2015

Financial news for GILD dated on 2015-10-27: Tuesday's After-Hours Movers: Apple And Twitter Lead The Way

Financial news for GILD dated on 2015-10-27: Gilead Sciences Posts Upbeat Q3 Earnings, Lifts Outlook

Financial news for GILD dated on 2015-10-27: Gilead shares down ~2% following earnings release

Financial news for GILD dated on 2015-10-27: UPDATE: Gilead Raises FY15 Net Product Sales Guidance from \$29B-\$30B to \$30B-\$31B vs \$31.5B Est.

Financial news for GILD dated on 2015-10-27: Gilead Raises FY15 Net Product Sales Guidance

Financial news for GILD dated on 2015-10-27: Gilead Reports Product Sales \$8.2B; Revises FY15 Net Product Sales Outlook

Financial news for GILD dated on 2015-10-27: Gilead Reports Q3 Adj. EPS \$3.22 vs \$2.89 Est.

Financial news for GILD dated on 2015-10-27: Gilead +1.5% Ahead of Earnings After the Close

Financial news for GILD dated on 2015-10-27: Biotech ETFs: Buy, Buy, Buy?

Financial news for GILD dated on 2015-10-27: Earnings Scheduled For October 27, 2015

Financial news for GILD dated on 2015-10-25: High Hopes For Apple, Alibaba, Other

## Earnings This Week

Financial news for GILD dated on 2015-10-23: Gilead Sciences Finds Resistance

Financial news for GILD dated on 2015-10-22: FDA Ruling Shakes Up Biotech: Gilead, AbbVie And More

Financial news for GILD dated on 2015-10-22: Morgan Stanley Says Viekira Unlikely To Be Pulled From Market, Gilead May Gain Market Share But Not All Of Viekira's Market Share

Financial news for GILD dated on 2015-10-22: UPDATE: FDA Requires Abbvie to Add New Information About Safety Risk To Drug Labels

Financial news for GILD dated on 2015-10-22: UPDATE: FDA Warns Hepatitis C Treatments Viekira Pak And Technivie Can Cause Serious Liver Injury -Reuters

Financial news for GILD dated on 2015-10-22: FDA Warns Of Potential Injury To Livers When Using Viekira Pak, Will Require Manufacture To Include Additional Safety Risk Info

Financial news for GILD dated on 2015-10-22: Gilead Spikes Higher

Financial news for GILD dated on 2015-10-22: UPDATE: Gilead's Phase 3 Genvoya Study Found To Be Non-Inferior To Stribild With Improved Renal, Bone Parameters

Financial news for GILD dated on 2015-10-22: Gilead Reports Phase 3 Results for Genvoya an Investigational Once-Daily Single Tablet Regimen for HIV

Financial news for GILD dated on 2015-10-21: UPDATE: Gilead Said GS-5734 Currently Being Provided to Female Patient in UK

Financial news for GILD dated on 2015-10-21: Gilead Offers Update on GS-5734 for Treatment of Ebola: Fulfilled Request for Compassionate Access

Financial news for GILD dated on 2015-10-20: Oppenheimer Incrementally More Bullish on Gilead, Remains Cautious On Vertex

Financial news for GILD dated on 2015-10-19: Cowen: In Biotech Earnings We Trust

Financial news for GILD dated on 2015-10-12: Watching Volatility In Other Big Pharma Names Amid Eli Lilly Halt

Financial news for GILD dated on 2015-10-06: Biotech Bears Spark Good Vibes For These ETFs

Financial news for GILD dated on 2015-10-06: Social Media Beat: The Three Gs -- GE, Google And Gilead

Financial news for GILD dated on 2015-10-06: Singapore Ministry of Health Convenes Independent Review Committee on Report of Cluster of 22 Acute Cases of Hepatitis C Among Kidney Patients -Reuters

Financial news for GILD dated on 2015-10-05: UPDATE: ContraVir +100% on Positive CMX157 Hepatitis B Data

Financial news for GILD dated on 2015-10-05: ContraVir +30% Premarket as Co Says Data Demonstrate CMX157 to be 60-Fold More Potent vs Hepatitis B Virus than Gilead's Viread

Financial news for GILD dated on 2015-10-02: Morning Market Losers

Financial news for GILD dated on 2015-10-02: Benzinga's Top Downgrades

Financial news for GILD dated on 2015-10-02: Morgan Stanley On Big Biotech: Upgrades, Pfizer, Vertex, Alexion, Cuts Gilead, Valeant

Financial news for GILD dated on 2015-10-02: Benzinga's Top #PreMarket Losers

Financial news for GILD dated on 2015-10-02: Morgan Stanley Downgrades Gilead Sciences to Equal-weight, Maintains \$127.00 PT

Financial news for GILD dated on 2015-10-01: Fast Money Traders Share The Stocks They Would Buy In Fourth Quarter

Financial news for GILD dated on 2015-09-28: In Volatile Markets, Short Sellers Head For Biotechs

Financial news for GILD dated on 2015-09-24: Keep The Quality And The Large Caps With

This New ETF

Financial news for GILD dated on 2015-09-24: Fast Money Traders Share Their Must-Buy Stocks

Financial news for GILD dated on 2015-09-23: Adam Feuerstein And The Price Blowup: Turing Pharmaceuticals' Daraprim Decision

Financial news for GILD dated on 2015-09-21: Adam Feuerstein Agrees With Interviewee That Big Biotech Companies Could Be Shielded From Drug Pricing Issues, "Yea, To Some Extent They Are A Bit Shielded As Long As They Continue To Innovate"

Financial news for GILD dated on 2015-09-21: Adam Feuerstein Believes Turing Pharma. Simply Raising Price Of Older Drug, Whereas Gilead Attempting To Cure Via Research To Develop Drug

Financial news for GILD dated on 2015-09-21: UPDATE: Gilead Says 98% of Patients Achieved Primary Efficacy Endpoint, 13 Patients Showed Virologic Failure, 7 Could Not Complete Visit

Financial news for GILD dated on 2015-09-21: Gilead Reports SVR12 Rates from Four Phase 3 Studies Evaluating a Once-Daily, Fixed-Dose Combination of Sofosbuvir, Velpatasvir for the Treatment of All Six Hepatitis C Genotypes

Financial news for GILD dated on 2015-09-14: Amgen And Biogen Lead Short Interest Surge In Biotechs

Financial news for GILD dated on 2015-09-14: Biotechs Coming Off One Of The Busiest Weeks In Recent Memory

Financial news for GILD dated on 2015-09-14: Barclays Favorite Biotech Names For Year End Balance Are Gilead, Vertex, Medivation

Financial news for GILD dated on 2015-09-14: JMP Analyst Says He Believes Biotech Megacaps Appear To Be Generating A Shopping List After Raising Cash; Implying Possible M&A Activity In Biotech Space After Recent Investor Conference Activity

Financial news for GILD dated on 2015-09-10: Gilead Prices \$10B of Senior Unsecured Notes

Financial news for GILD dated on 2015-09-08: UBS: Biotech Will Continue To Outperform In 2015

Financial news for GILD dated on 2015-09-02: Gilead's Investigational Fixed-Dose Combination of Emtricitabine/Tenofovir Alafenamide Meets Primary 48-Week Objective in Phase 3 Study

Financial news for GILD dated on 2015-09-01: It's Not Shopping, It's Market Research: Talking Investing Trends With TD Ameritrade's Nicole Sherrod

Financial news for GILD dated on 2015-08-27: Benzinga's M&A Chatter for Thursday August 27, 2015

Financial news for GILD dated on 2015-08-27: Biogen And Gilead Sciences Catch The Eye Of Short Sellers

Financial news for GILD dated on 2015-08-27: Hearing Unconfirmed Market Chatter of Gilead Deal to Acquire BMJ

Financial news for GILD dated on 2015-08-26: Results From the AMBITION Study of First-Line Treatment With Letairis and Tadalafil in Pulmonary Arterial Hypertension Published in The New England Journal of Medicine

Financial news for GILD dated on 2015-08-24: Avoid The Temptation To Buy Calls On Anything 'Options' This Week

Financial news for GILD dated on 2015-08-24: Morgan Stanley Lists Stocks With \$5B in Market Cap Possessing Best 1 Year Opportunity

Financial news for GILD dated on 2015-08-21: The Other Bearish Biotech ETF Is Looking Groovy, Too

Financial news for GILD dated on 2015-08-20: European Medicines Agency Validates Gilead's Marketing Application for Single Tablet Regimen Containing Rilpivirine, Emtricitabine and Tenofovir Alafenamide for HIV Treatment

Financial news for GILD dated on 2015-08-19: Option Alert: Gilead Aug \$115 Call Sweep; 1008 Contracts @Ask @\$1.75

Financial news for GILD dated on 2015-08-13: What Are Payors Saying About Managed Care Giants?

Financial news for GILD dated on 2015-08-11: What TD Ameritrade Investors Bought And Sold Last Month

Financial news for GILD dated on 2015-08-07: The Historical Correlation Between Biotech Stocks And Interest Rates

Financial news for GILD dated on 2015-08-02: A Look Ahead: Consumer Discretionary And Greek ETFs To Watch This Week

Financial news for GILD dated on 2015-07-30: Even With Recent Declines, Investors Still Love Biotech ETFs

Financial news for GILD dated on 2015-07-29: Gilead Sciences: Here's What A Bull And A Bear Are Saying

Financial news for GILD dated on 2015-07-29: Morning Market Gainers

Financial news for GILD dated on 2015-07-29: Benzinga's Top #PreMarket Gainers

Financial news for GILD dated on 2015-07-29: Gilead Worth \$125 After Earnings: Morgan Stanley

Financial news for GILD dated on 2015-07-29: Fast Money Picks For July 29

Financial news for GILD dated on 2015-07-29: Deutsche Bank Maintains Buy on Gilead Sciences, Raises PT to \$135.00

Financial news for GILD dated on 2015-07-29: Keep an Eye on These 10 Stocks for July 29, 2015

Financial news for GILD dated on 2015-07-28: Tuesday's After-Hours Movers: Twitter, Gilead, Yelp And Buffalo Wild Wings

Financial news for GILD dated on 2015-07-28: Gilead Sciences Q2 Profit Beats Views, Shares Rise

Financial news for GILD dated on 2015-07-28: Gilead Raises FY15 Sales Guidance from \$26B-\$27B to \$29B-\$30B vs \$30.36B Est.

Financial news for GILD dated on 2015-07-28: Gilead Sciences Reports Q2 EPS \$3.15 Vs Exp \$2.64

Financial news for GILD dated on 2015-07-28: Options Strategist Discusses Activity In Gilead And Wynn Ahead Of Earnings

Financial news for GILD dated on 2015-07-28: Is More M&A On The Way For Large-Cap Biotechs?

Financial news for GILD dated on 2015-07-28: Earnings Scheduled For July 28, 2015

Financial news for GILD dated on 2015-07-28: 10 Stocks You Should Be Watching Today

Financial news for GILD dated on 2015-07-27: Wall Street's Best Think Gilead Will Continue To Outperform The Market

Financial news for GILD dated on 2015-07-27: A Big Day For Biotech And It's Not Going So Well

Financial news for GILD dated on 2015-07-21: New Alzheimer's Trials Could Produce The Most Important Drugs In History

Financial news for GILD dated on 2015-07-21: Gilead Reports Phase 3 Results From the First Study to Evaluate Switching From TDF-Based Regimens to a TAF-Based Regimen Containing Elvitegravir, Cobicistat, Emtricitabine and Tenofovir Alafenamide

Financial news for GILD dated on 2015-07-20: Oppenheimer's 10 'Best Of The Best' Technical Buy Ideas

Financial news for GILD dated on 2015-07-17: Why Big Biotech Could Have Another Leg Up

Financial news for GILD dated on 2015-07-16: Bristol-Myers' HIV-1 Drug Approved In Europe

Financial news for GILD dated on 2015-07-14: Fast Money Picks For July 14

Financial news for GILD dated on 2015-07-13: Short Sellers Shy Away From Biotech Stocks

Financial news for GILD dated on 2015-07-10: CNBC's Meg Tirrel Speculates About Gilead's New Acquisiton

Financial news for GILD dated on 2015-07-09: Large-Cap Biotechs Poised For Second-Half Rally, RBC Says

Financial news for GILD dated on 2015-07-07: Keep An Eye On These 8 After-Hours Movers

Financial news for GILD dated on 2015-07-06: Gilead Still A 'Buy' After Harvoni Approval In Japan, Maxim Proclaims

Financial news for GILD dated on 2015-07-03: Japan's Ministry of Health, Labour and Welfare Approves Gilead's Harvoni

Financial news for GILD dated on 2015-07-01: Gilead Submits New Drug Application to U.S. Food and Drug Administration for Single Tablet Regimen for HIV Containing Rilpivirine, Emtricitabine and Tenofovir Alafenamide

Financial news for GILD dated on 2015-07-01: Fast Money Picks For July 1

Financial news for GILD dated on 2015-06-27: Biotech Short-Sellers Prefer Amgen To Gilead Sciences

Financial news for GILD dated on 2015-06-23: ProShares Releases 2 New Leveraged Biotech ETFs

Financial news for GILD dated on 2015-06-20: China Rejects Gilead's Sovaldi Patent Application

Financial news for GILD dated on 2015-06-18: Biotech ETFs Hit New 2015 Highs

Financial news for GILD dated on 2015-06-12: Big Biotech Stocks See Declining Short Interest

Financial news for GILD dated on 2015-06-11: Gilead's President Spoke At Goldman Sachs' Global Healthcare Conference This Week: Here Are The Highlights

Financial news for GILD dated on 2015-06-09: Benzinga's M&A Chatter for Tuesday June 9, 2015

Financial news for GILD dated on 2015-06-08: Vertex Pharmaceuticals Will Outperform, Has 'Competitive Edge,' JMP Says

Financial news for GILD dated on 2015-05-29: Does This Data Show 2015 Is Finally The Year To 'Sell In May?'

Financial news for GILD dated on 2015-05-28: European Medicines Agency Validates Gilead's Marketing Application for Fixed-Dose Combination of Emtricitabine and Tenofovir Alafenamide for HIV Treatment

Financial news for GILD dated on 2015-05-27: Gilead's Alberta ULC Unit Announces 'cuts ribbon on innovative new laboratory, announces additional \$100m investment in Edmonton'

Financial news for GILD dated on 2015-05-21: What Does The Johnson & Johnson/Achillion Deal Mean For HCV Competitors?

Financial news for GILD dated on 2015-05-20: 5 NASDAQ Healthcare Stocks With The Highest EPS

Financial news for GILD dated on 2015-05-20: Gilead Just Presented 'Interesting' Data, Analysts Say

Financial news for GILD dated on 2015-05-20: Patent Challenges In 5 Countries Dispute Validity Of Gilead's Claims To Hep C Drug Patents That Prevent Treatment For Up To 59 Million People

Financial news for GILD dated on 2015-05-18: Gilead Press Release Confirms Will Present at UBS '15 Global Healthcare Conference Tomorrow (Tues, May 19)

Financial news for GILD dated on 2015-05-18: Top Street Analysts Like Gilead Sciences

Financial news for GILD dated on 2015-05-15: Leon Cooperman's Omega Advisors Sells Apple, Gilead; Buys Humana, GM And IBM



Financial news for GILD dated on 2015-05-15: Omega Advisors 13-F Shows Cooperman Sold Out Of Gilead Stake

Financial news for GILD dated on 2015-05-13: Senator Sanders Asks VA to Break Patent on Gilead's Sovaldi -Firece Pharma

Financial news for GILD dated on 2015-05-09: The Best And Worst ETFs Of The Week Amid Biotech Rebound

Financial news for GILD dated on 2015-05-08: iShares Rolls Out New Smart Beta ETFs

Financial news for GILD dated on 2015-05-08: WHO Says Lower Prices for Hepatitis C Drugs Needed to Make them Affordable in Poorer Countries -Reuters

Financial news for GILD dated on 2015-05-07: Deutsche Sees Cancer Treatment Home Run At Infinity Pharmaceuticals

Financial news for GILD dated on 2015-05-06: Gilead Announces Purchase of EpiTherapeutics for \$65M

Financial news for GILD dated on 2015-05-04: Gilead Sciences Remains Popular Post-Earnings

Financial news for GILD dated on 2015-05-04: Mylan Launches Gilead Sciences' Sovaldi Tablets in India

Financial news for GILD dated on 2015-05-01: Gilead Soothes Price War Worry With Q1 Results

Financial news for GILD dated on 2015-05-01: Gilead Sciences Rallying Off Q1 Beat: A Technical Look

Financial news for GILD dated on 2015-05-01: Does Anyone Care About Gilead's Beat, Guidance Boost?

Financial news for GILD dated on 2015-05-01: Bank Of America Reviews Gilead Earnings

Financial news for GILD dated on 2015-05-01: Morgan Stanley On What 'Should Be Rewarded' At Gilead

Financial news for GILD dated on 2015-05-01: Gilead Still A 'Top Pick' For Barclays

Financial news for GILD dated on 2015-05-01: Keep an Eye on These 10 Stocks for May 1, 2015

Financial news for GILD dated on 2015-04-30: Gilead Sciences Beats Q1 Views, Shares Rise

Financial news for GILD dated on 2015-04-30: Gilead Reports Q1 EPS \$2.94 vs. Est. \$2.32, Rev. \$7.59B vs. Est. \$6.92B

Financial news for GILD dated on 2015-04-30: Is Gilead Sciences About To Buy Vertex For \$45 Billion?

Financial news for GILD dated on 2015-04-30: Earning & Economic Calendar for Thursday April 30, 2015

Financial news for GILD dated on 2015-04-30: Earnings Scheduled For April 30, 2015

Financial news for GILD dated on 2015-04-29: Can Gilead Really Post EPS Growth Above 50%?

Financial news for GILD dated on 2015-04-29: What's Wall Street Been Saying About Gilead Lately?

Financial news for GILD dated on 2015-04-27: All-Star Analysts Discuss GoPro, Apple & Gilead Before They Make Headlines

Financial news for GILD dated on 2015-04-27: This Underrated Twitter Account Is Crushing The Market

Financial news for GILD dated on 2015-04-27: Oppenheimer Assumes Gilead Sciences at Outperform

Financial news for GILD dated on 2015-04-25: Gilead Says Sovaldi in Combination with RBV or with PEG/RBV Demonstrated High Cure Rates across all Patients with Genotypes 2, 3

Financial news for GILD dated on 2015-04-24: 142 HIV Cases Linked to Indiana Outbreak

-DJ

Financial news for GILD dated on 2015-04-24: Morgan Stanley Alert: Gilead Investors Don't Have The Whole Story

Financial news for GILD dated on 2015-04-24: Analyst: Biogen Will Miss On Tecfidera Sales; No Threat To Gilead's Harvoni

Financial news for GILD dated on 2015-04-23: Gilead Announces Data for Investigational, All-Oral, Pan-Genotypic Three-Drug Regimen of Sofosbuvir, GS-5816 and GS-9857 for Chronic Hepatitis C

Financial news for GILD dated on 2015-04-23: Gilead Says Harvoni. Sovaldi Demonstrate Efficacy, Safety Among Chronic Hepatitis C Patients with Advanced Liver Disease

Financial news for GILD dated on 2015-04-21: Benzinga's M&A Chatter for Tuesday April 21, 2015

Financial news for GILD dated on 2015-04-21: Gilead-Vertex Deal Has 'Low Probability' Of Happening, RBC Capital Says

Financial news for GILD dated on 2015-04-21: Adam Feuerstein @adamfeuerstein Tweet: Ackman could be interviewed on @CNBC multiple times across many shows to promote/pump his \$GILD position.

Financial news for GILD dated on 2015-04-21: Should Gilead Buy Vertex?

Financial news for GILD dated on 2015-04-21: Hearing RBC Says Probability of Gilead Buying Vertex is Low

Financial news for GILD dated on 2015-04-21: RBC Analyst Saying Gilead and Vertex Deal Is A 'pretty low probability'

Financial news for GILD dated on 2015-04-21: Tweet, Rumor And Bernstein Fueling Rallies In Gilead Sciences, Vertex Pharmaceuticals

Financial news for GILD dated on 2015-04-21: Hearing Unconfirmed Market Chatter of Ackman \$2B Stake in Gilead; Ackman Said to Push for Acquisition of Vertex

Financial news for GILD dated on 2015-04-21: Bernstein: It's Time For Gilead To Pull The Trigger On This Acquisition

Financial news for GILD dated on 2015-04-21: Adam Feuerstein @adamfeuerstein Tweet: \$GILD Should Buy \$VRTX for \$45B Now, Analyst Says thestreet.com/story/13119465... via @TheStreet

Financial news for GILD dated on 2015-04-19: Why This Trader Likes Gilead Better Than Biogen

Financial news for GILD dated on 2015-04-18: Morningstar: Gilead Sciences To Grow Its Hepatitis C Market

Financial news for GILD dated on 2015-04-18: These Companies Probably Won't Be Acquiring Ariad Pharmaceuticals

Financial news for GILD dated on 2015-04-14: Analyst Wants Proof On Arrowhead Research's Hepatitis B Drug

Financial news for GILD dated on 2015-04-13: 5 Companies The Crowd Is Betting On To Beat Wall Street

Financial news for GILD dated on 2015-04-13: 7 Trends Drug Investors Should Know

Financial news for GILD dated on 2015-04-10: Biotech Investors: Nomura Says To Watch These Dates

Financial news for GILD dated on 2015-04-10: Gilead Shares Pulling Back; May be Attributed to Barron's Blog Post Mentioning Nomura Analyst Concern Regarding Harvoni Pricing

Financial news for GILD dated on 2015-04-09: The Biotech Stocks JMP Is Watching

Financial news for GILD dated on 2015-04-08: This Data Offers Insight Into Gilead Sales

Financial news for GILD dated on 2015-04-08: US Stock Futures Edge Higher Ahead Of Fed Minutes, Alcoa Earnings

Financial news for GILD dated on 2015-04-07: Gilead Submits New Drug Application to

U.S. FDA for Fixed-Dose Combo of Emtricitabine/Tenofovir Alafenamide for HIV Treatment

Financial news for GILD dated on 2015-04-06: What RBC Is Saying About MannKind And Gilead

Financial news for GILD dated on 2015-04-06: Gilead Alert: What Deutsche Bank Is Saying

Financial news for GILD dated on 2015-04-03: Actavis Confirms it Filed NDA To Market Letairis Generic

Financial news for GILD dated on 2015-03-31: Doctor Says Sovaldi Could be Cardiotoxic -Medscape

Financial news for GILD dated on 2015-03-31: Gilead Sciences Hovering Above Major Support Level

Financial news for GILD dated on 2015-03-31: Is Gilead's Latest Japan Win Good News For Shareholders?

Financial news for GILD dated on 2015-03-27: Investors Might Want To Stay Away From This Biotech ETF

Financial news for GILD dated on 2015-03-27: Experts Talking Gilead, Not Bubbles At Detroit's Engage Conference

Financial news for GILD dated on 2015-03-26: Is It Closing Time At The Biotech Bar?

Financial news for GILD dated on 2015-03-26: Japan's MHLW Approves Gilead's Sovaldi for Treatment of Genotype 2 Chronic Hepatitis C

Financial news for GILD dated on 2015-03-24: FDA Recommends Health Care Professionals Not Prescribe Either Harvoni or Sovaldi Combined With Another Direct Acting Antiviral With Amiodarone

Financial news for GILD dated on 2015-03-24: Gilead Safety Warning? No Problem, Says Wall Street

Financial news for GILD dated on 2015-03-24: Gilead Canada Says Multiple Provinces to Provide Public Access to Harvoni for Chronic Hepatitis C Virus Genotype 1 Infection In Adults; Sovaldi Also Listed for Public Reimbursement for Chronic HCV Genotypes 1, 2,3 Infection in Multiple Provinces

Financial news for GILD dated on 2015-03-23: ICYMI: Pharmaceutical Stocks Are Moving Big On Monday

Financial news for GILD dated on 2015-03-23: Gilead Shares Reacting To Death Of Patient

Financial news for GILD dated on 2015-03-23: Why This Analyst Thinks Gilead's Technicals Are Setting Up For A Break

Financial news for GILD dated on 2015-03-23: Morning Market Losers

Financial news for GILD dated on 2015-03-23: Gilead Shares Tumble On Drug Warning; Baird Says Buy

Financial news for GILD dated on 2015-03-23: Benzinga's Top #PreMarket Losers

Financial news for GILD dated on 2015-03-23: Gilead Shares Fall 2.7% Premarket Following Bloomberg Report of Death of Hepatitis Patient on Heart Drug

Financial news for GILD dated on 2015-03-20: The Top 5 Trading Ideas Of The Week By Traffic

Financial news for GILD dated on 2015-03-20: Biotech Stocks Soar Amid Positive News

Financial news for GILD dated on 2015-03-20: Argus Sees 'Strong Prospects' For Gilead Sciences

Financial news for GILD dated on 2015-03-18: Gilead Sciences Stuck In Trading Range: A Technical Look

Financial news for GILD dated on 2015-03-13: Analyst Sees Upside To Outlook At 4 Biotechs

Financial news for GILD dated on 2015-03-12: Hetero Receives Approval for Generic Sofosbuvir Tablets, 400 Mg in India -Reuters

Financial news for GILD dated on 2015-03-11: The 4 Biggest Biotech Stocks In The Market

Financial news for GILD dated on 2015-03-10: TD Ameritrade's IMX for Feb. Showed ~3% Decline to 4.7 Reading

Financial news for GILD dated on 2015-03-09: Copy of Gilead's Sovaldi Appears in Bangladesh for \$10/Pill

Financial news for GILD dated on 2015-02-27: Gilead Confirms Immunovaccine Deal PR Was Fake

Financial news for GILD dated on 2015-02-27: Immunovaccine CEO Says PR on Immunovaccine Signing Deal With Gilead Was a Hoax -Reuters

Financial news for GILD dated on 2015-02-27: Bloomberg Reporting Globe Newswire Confirms Earlier Immunovaccine Release Was Hoax

Financial news for GILD dated on 2015-02-27: Immunovaccine Disclaims Hoax Press Release

Financial news for GILD dated on 2015-02-27: ImmunoVaccine Up 24% On Deal With Gilead Sciences

Financial news for GILD dated on 2015-02-27: Gilead Booking Profits Overseas On A \$1,000 Pill: Hard To Swallow

Financial news for GILD dated on 2015-02-27: Gilead Partners Immunovaccine Announces Fast Track, Phase I Trial Approval for Ebola, Anthrax Vaccine Programs

Financial news for GILD dated on 2015-02-26: Gilead Offers Phase 3 Results for Investigational Once-Daily Single Tablet HIV Regimen Containing TAF

Financial news for GILD dated on 2015-02-26: UPDATE: Gilead Press Release Regarding Phase 3 Harvoni Study

Financial news for GILD dated on 2015-02-26: Gilead Announces SVR12 Rates From Phase 3 Study Evaluating Harvoni(r) for Treatment of Chronic Hepatitis C in Patients Co-Infected With HIV

Financial news for GILD dated on 2015-02-26: Bloomberg Reporting Gilead Will Avoid Billions in Taxes From Its Hep. C Drug By Booking Profits Overseas

Financial news for GILD dated on 2015-02-25: Gilead Says Watson Alleges Patent Associated with Ambrisentan Tablets Is Invalid; Gilead to File Patent Infringement Suit as Necessary -DJ

Financial news for GILD dated on 2015-02-25: UPDATE: Gilead Reports Preclinical Data

Financial news for GILD dated on 2015-02-25: Gilead Announces Preclinical Data for an Investigational TLR7 Agonist in SIV-Infected, Virally Suppressed Monkeys

Financial news for GILD dated on 2015-02-23: Mylan Reports Signing of Exclusive Deal with Gilead Related to Distribution of Sovaldi, Harvoni in India

Financial news for GILD dated on 2015-02-23: Mylan Signs Exclusive Agreement with Gilead Sciences to Distribute Sovaldi, Harvoni in India

Financial news for GILD dated on 2015-02-20: New Potential HIV Vaccine Drug 'Absolutely 100% Effective' In Monkeys

Financial news for GILD dated on 2015-02-18: What Steven Cohen Is Doing With His Personal Wealth

Financial news for GILD dated on 2015-02-18: Hearing Unconfirmed Market Chatter of Potential Gilead Bid for Juno

Financial news for GILD dated on 2015-02-17: Leon Cooperman's Omega Advisors Bought Gilead, Boosted Groupon & Liquidated Alibaba Last Quarter

Financial news for GILD dated on 2015-02-17: 13F: Omega Advisors Reports New Position In Gilead Sciences Totaling 612,500 Shares

Financial news for GILD dated on 2015-02-17: Biotech Performance 'Particularly Impressive,' Says JP Morgan

Financial news for GILD dated on 2015-02-17: Top 5 Biotech Stocks That The Smart Money Doesn't Like

Financial news for GILD dated on 2015-02-16: 4 Stocks Wall Street Loves This Year...And 4 It Doesn't

Financial news for GILD dated on 2015-02-14: Gilead Sciences, Atlas Energy And Others Insiders Have Been Buying

Financial news for GILD dated on 2015-02-12: Gilead, Beryllium Publish Structural Basis for HCV RNA Replication in Science

Financial news for GILD dated on 2015-02-11: Gilead Shares Near High; Presenting at Leerink Conference

Financial news for GILD dated on 2015-02-11: Adam F Says AbbVie Deal with Express Scripts has Backfired

Financial news for GILD dated on 2015-02-11: From Conf Call: Wellcare Says in Last Few Weeks have Reaffirmed Alignment With Gilead as Clinical Choice for Hep C Treatment

Financial news for GILD dated on 2015-02-11: JMP Securities Covers Mostly Good News From Pharma Pending More Visibility

Financial news for GILD dated on 2015-02-10: Obama Just Created New Questions For Drug Makers

Financial news for GILD dated on 2015-02-09: Gilead's Sofosbuvir Just Made Achillion Investors Very Happy

Financial news for GILD dated on 2015-02-09: Jefferies Analyst Says AbbVie Hepatitis C Price-War Fears Overblown

Financial news for GILD dated on 2015-02-09: Top 4 NASDAQ Stocks In The Biotechnology Industry With The Highest Profit Margin

Financial news for GILD dated on 2015-02-06: Credit Suisse Downgrades Gilead Sciences, Sees Declining HCV Revenues

Financial news for GILD dated on 2015-02-06: Benzinga's Top Downgrades

Financial news for GILD dated on 2015-02-06: Credit Suisse Downgrades Gilead Sciences To Neutral

Financial news for GILD dated on 2015-02-06: Credit Suisse Downgrades Gilead Sciences to Neutral, Lowers PT to \$115.00

Financial news for GILD dated on 2015-02-04: The S&P 500 Got A Boost From These Earnings

Financial news for GILD dated on 2015-02-04: Cigna Signs Agreement with Gilead to Include Harvoni as Only Preferred Brand for Customers with Hep C Genotype 1

Financial news for GILD dated on 2015-02-04: UBS Just Boosted Aetna By 8% Because Of This

Financial news for GILD dated on 2015-02-04: J.P. Morgan Is Watching This 'Curve Ball' At Gilead

Financial news for GILD dated on 2015-02-04: Gilead Sciences Getting Crushed On Mixed Results

Financial news for GILD dated on 2015-02-04: 5 Reasons Deutsche Bank Still Likes Gilead Stock

Financial news for GILD dated on 2015-02-04: Morgan Stanley On Gilead: 'It's All About Price (Again)'

Financial news for GILD dated on 2015-02-04: Nomura Just Cut Its Price Target On Gilead

Financial news for GILD dated on 2015-02-04: Morning Market Losers

Financial news for GILD dated on 2015-02-04: Wednesday Morning Movers: Gilead Sciences, Myriad Genetics Tumble Following Earnings

Financial news for GILD dated on 2015-02-04: Benzinga's Top #PreMarket Losers

Financial news for GILD dated on 2015-02-03: Tuesday's After-Hours Movers: Gilead, Wynn Resorts And Chipotle Fall Following Earnings

Financial news for GILD dated on 2015-02-03: Gilead Sciences Beats Q4 Views But Outlook Disappoints, Shares Fall

Financial news for GILD dated on 2015-02-03: Gilead Sciences conference call ends.

Financial news for GILD dated on 2015-02-03: Company has never been in better shape and will continue to look forward and invest in share buybacks, dividends and continued product strength.

Financial news for GILD dated on 2015-02-03: Gilead has a large, sustainable market in Europe that will continue with healthy growth in the coming years.

Financial news for GILD dated on 2015-02-03: The timing of our dividend reflects our confidence in our cash flow and balance sheet. Does not in any way prevent the company from investing in its business pipeline or M&A. We do not feel constrained in any way by issuing this dividend.

Financial news for GILD dated on 2015-02-03: Gilead sales team has been a lot of time securing access in 2014 and will shift to drive demand in 2015.

Financial news for GILD dated on 2015-02-03: Harvoni has proven to be effective on a much wider range of patients than previously thought, we are not concerned about future competition and this represents a very strong category for Gilead based on this profile.

Financial news for GILD dated on 2015-02-03: 70% of patients in 2014 came from the private sector

Financial news for GILD dated on 2015-02-03: We are confident that we will see a large increase in patients across the US based on our goals to achieve greater accessibility.

Financial news for GILD dated on 2015-02-03: Intentions for dividend are to grow over time, but at the moment they will still use share repurchases as the larger portion of the share returns in the near future.

Financial news for GILD dated on 2015-02-03: Gilead conference call Q&A begins

Financial news for GILD dated on 2015-02-03: CFO Washington: Expecting 2015 product sales to be \$26-27B, increase of 6-10% over 2014

Financial news for GILD dated on 2015-02-03: CFO Washington: Repaid \$1B in outstanding debt in Q4

Financial news for GILD dated on 2015-02-03: CFO Washington: HCV product sales \$12.4B for 2014, helped by continued launches of Sovaldi and Harvoni and geographic expansion

Financial news for GILD dated on 2015-02-03: Gilead Estimates 2015 Gross to Net Hepatitis C Drug Adjustments at 46% vs 22% at End of 2014

Financial news for GILD dated on 2015-02-03: CFO Washington: Cash flow will keep company strong and well positioned for any forthcoming M&A opportunities

Financial news for GILD dated on 2015-02-03: CFO Washington: Annual yield of 1.6%, based on Monday's closing stock price

Financial news for GILD dated on 2015-02-03: EVP Carter: HIV: In 2014, Gilead continues clinical and commercial success, \$1.9B in sales in the Q4 and \$6.3B in sales for the whole year, lead by Complera and Stribild

Financial news for GILD dated on 2015-02-03: EVP Carter: 80% of new HIV patients started treatment on a Gilead product, 70% of which were on Truvada

Financial news for GILD dated on 2015-02-03: EVP Carter: We aim to streamline the process of access to treatment and therapy to at least 250,000 patients across all genotypes

Financial news for GILD dated on 2015-02-03: EVP Carter: We expect 2015 gross to net adjustments in product in the US to be 46%, over double in 2014 which was 22%

Financial news for GILD dated on 2015-02-03: EVP Carter: Sovaldi contributed \$1.5B to European sales in 2014

Financial news for GILD dated on 2015-02-03: EVP Carter: 140,000 have started HCV therapy on a Gilead product in the United States.

Financial news for GILD dated on 2015-02-03: CEO Martin: Board has approved quarterly

cash dividend program and \$15B, 5-year repurchase. 2015 will be as busy as 2014, and will continue to provide collaboration and medication to those in need. I am proud of our progress thus far.

Financial news for GILD dated on 2015-02-03: CEO Martin: GS-57945 Phase 2 studies are planned in Crohn's disease

Financial news for GILD dated on 2015-02-03: CEO Martin: Progress continues in oncology and inflammation. Additional hires have been made to oncology, respiratory and inflammatory studies and departments.

Financial news for GILD dated on 2015-02-03: CEO John Martin: Sovaldi has been approved in India and currently has 15,000 under treatment

Financial news for GILD dated on 2015-02-03: Gilead Sciences Announces Initial Dividend Of \$0.43/share

Financial news for GILD dated on 2015-02-03: Gilead Sciences Announces \$15B Buyback Program

Financial news for GILD dated on 2015-02-03: Gilead Reports Q4 Adj. EPS \$2.43 vs \$2.21 Est., Sales \$7.31B vs \$6.74B Est.

Financial news for GILD dated on 2015-02-03: Gilead Sciences Q4 Conference Call Play-By-Play Recap

Financial news for GILD dated on 2015-02-03: Notable Earnings After The Close: GILD, DIS, CMG

Financial news for GILD dated on 2015-02-03: Gilead Sciences Earnings Preview: Hepatitis C Guidance Is Key

Financial news for GILD dated on 2015-02-03: Catamaran Corp Says Gilead's Hepatitis C Treatments, Harvoni, Sovaldi Are Exclusive Options on Cos National, Value Formularies

Financial news for GILD dated on 2015-02-03: Why This Analyst Thinks Gilead Sciences Will 'Handily' Beat Q4 Expectations

Financial news for GILD dated on 2015-02-03: The Key Level In Gilead Sciences You Need To Watch For

Financial news for GILD dated on 2015-02-03: Here's What To Watch At Gilead Sciences, Chipotle & Twitter

Financial news for GILD dated on 2015-02-03: From Conf Call: Aetna CFO Says Part of Increase in 2015 Earnings Outlook Based on Lower Price on Gilead's Hepatitis C Drugs

Financial news for GILD dated on 2015-02-03: Earning & Economic Calendar for Tuesday February 3, 2015

Financial news for GILD dated on 2015-02-03: Earnings Scheduled For February 3, 2015

Financial news for GILD dated on 2015-02-03: Must Watch Stocks for Today

Financial news for GILD dated on 2015-02-02: Gilead Could Miss Earnings (Hint: Watch Drug Sales)

Financial news for GILD dated on 2015-02-02: Energy, TIPS And Biotechnology ETFs To Watch This Week

Financial news for GILD dated on 2015-02-01: Biotech Breakdown: Market Breaks...Gilead, Kite Pharma & Biogen Idec Worth Watching

Financial news for GILD dated on 2015-02-01: Earnings Expectations For The Week Of February 2: Disney, Exxon, GM And More

Financial news for GILD dated on 2015-02-01: Why The Biotech Boom Is Still In The 1st Inning

Financial news for GILD dated on 2015-01-31: Fast Money Halftime Report Final Trade From January 30

Financial news for GILD dated on 2015-01-30: What Investors Are Watching For In Regulus Therapeutics' Next Data Release

Financial news for GILD dated on 2015-01-29: Baird Remains Buyers Of Gilead Before Earnings Release

Financial news for GILD dated on 2015-01-28: Gilead Promotes Andrew Cheng To EVP HIV

Therapeutics and Development Operations; Taiyin Yang To EVP, President Pharmaceutical Development and Manufacturing

Financial news for GILD dated on 2015-01-26: Alibaba Is A Favorite Holding Even For U.S.-Focused Funds

Financial news for GILD dated on 2015-01-26: US Stock Futures Signal Lower Start On Wall Street

Financial news for GILD dated on 2015-01-26: Gilead Expands Hepatitis C Generic Licensing Agreements to Include GS-5816

Financial news for GILD dated on 2015-01-21: Deutsche Bank Comments On Concerns Over Consensus Estimates For AbbVie And Gilead Sciences

Financial news for GILD dated on 2015-01-20: The 5 Biggest Biotech Stocks

Financial news for GILD dated on 2015-01-20: Why Drug Pricing Could Bring Volatility To The Biotech Sector This Year

Financial news for GILD dated on 2015-01-16: From Aetna Newsroom: 'Aetna and Gilead agree to discount pricing for hepatitis C drugs'

Financial news for GILD dated on 2015-01-16: Aetna Says Gilead's Harvoni And Sovaldi Are Preferred Treatment For Its 20 Mln Commercial Customers

Financial news for GILD dated on 2015-01-16: Nomura's Takeaways From Meeting With Gilead Sciences' Management

Financial news for GILD dated on 2015-01-15: Kite CEO Says Learning from Gilead's Pricing Playbook for their Own Experimental Cancer Treatment -Reuters

Financial news for GILD dated on 2015-01-14: Gilead Sciences' Sovaldi Patent Application Rejected In India

Financial news for GILD dated on 2015-01-14: 'India Rejects Gildead Patent Request For Hep C Drug'

Financial news for GILD dated on 2015-01-13: Aetna CEO Bertolini Says Co Has Not Made Decision Regarding Gilead's, Abbvie's Hepatitis C Drugs -Reuters

Financial news for GILD dated on 2015-01-13: Gilead Begins Presentation At JPM Conference

Financial news for GILD dated on 2015-01-12: A Look At 3 Biotech Stocks With Upside Potential

Financial news for GILD dated on 2015-01-12: Prime Therapeutics Enters Agreements With AbbVie, Gilead

Financial news for GILD dated on 2015-01-12: Biotechs Presenting At The J.P. Morgan Healthcare Conference: Day 2

Financial news for GILD dated on 2015-01-09: Adam Feuerstein @adamfeuerstein Tweet: \$GILD Buying \$VRTX Among Bold Biotech Stock Predictions for 2015 thestreet.com/story/13006004... @dsobek peers into his Cajun crystal ball...

Financial news for GILD dated on 2015-01-08: Anthem, Gilead Sign Deal For Hep. C Drug

Financial news for GILD dated on 2015-01-07: Gilead Sciences Just Received Orphan Drug Status For Liver Treatment

Financial news for GILD dated on 2015-01-07: Gilead Receives Orphan Drug Status For Simtuzumab

Financial news for GILD dated on 2015-01-06: J.P Morgan Just Chimed In With Ratings On Biotech Stocks

Financial news for GILD dated on 2015-01-06: Barclays Analyst Sees Biotech FY15 EPS Growth Outstripping Market

Financial news for GILD dated on 2015-01-06: UPDATE: Barclays Initiates Coverage On Gilead Sciences, 'Should Remain Ahead Of Its Peers'

Financial news for GILD dated on 2015-01-06: Gilead Sciences Announces Purchase of Phenex Pharma's Development Program for NASH

Financial news for GILD dated on 2015-01-06: Barclays Initiates Coverage on Gilead Sciences at Overweight, Announces \$125.00 PT



Financial news for GILD dated on 2015-01-05: CNBC's Stock Pops & Drops From January 5

Financial news for GILD dated on 2015-01-05: Gilead Sciences Spikes Amid CVS Formulary Status

Financial news for GILD dated on 2015-01-05: CVS Health Corp. Gives Preferred Formulary Status to Gilead Sciences' Drugs Harvoni and Sovaldi

Financial news for GILD dated on 2015-01-03: These Were The 10 Most Traded Stocks Of 2014

Financial news for GILD dated on 2014-12-31: The Struggles Of Gilead Sciences

Financial news for GILD dated on 2014-12-30: Gilead Spokesperson Says GoodRx Coupon for Harvoni Tablets Was Not Sponsored by Gilead and Co Cannot Comment on Pricing, As they do Not Sell Directly to Consumers

Financial news for GILD dated on 2014-12-30: Discount Coupon for Gilead's Harvoni from GoodRx

Financial news for GILD dated on 2014-12-29: Mid-Afternoon Market Update: Crude Oil Slides 3%; Gilead Sciences Shares Spike Higher

Financial news for GILD dated on 2014-12-29: Morgan Stanley Upgrades Gilead Sciences, Says It Will Maintain 75% Market Share

Financial news for GILD dated on 2014-12-29: Morning Market Movers

Financial news for GILD dated on 2014-12-29: Benzinga's Top Upgrades

Financial news for GILD dated on 2014-12-29: #PreMarket Primer: Monday, December 29: Controversial Film 'The Interview' Makes Millions Online

Financial news for GILD dated on 2014-12-29: Gilead Reports Amended Deals with J&J's Janssen to Develop PREZISTA-Based Single-Tablet Regimen for Treatment of People Living with HIV

Financial news for GILD dated on 2014-12-29: Benzinga's Top #PreMarket Gainers

Financial news for GILD dated on 2014-12-29: Morgan Stanley Upgrades Gilead Sciences To Overweight, Shares Rise

Financial news for GILD dated on 2014-12-29: UPDATE: Gilead Shares Rise ~2% Premarket Following Morgan Stanley Upgrade to Overweight

Financial news for GILD dated on 2014-12-29: US Stock Futures Down; Crude Oil Rises

Financial news for GILD dated on 2014-12-29: Morgan Stanley Upgrades Gilead Sciences to Overweight

Financial news for GILD dated on 2014-12-27: CNBC's Stock Pops & Drops From December 26

Financial news for GILD dated on 2014-12-26: #Premarket Prep Technical Update - Gilead Sciences Higher

Financial news for GILD dated on 2014-12-26: Morning Market Movers

Financial news for GILD dated on 2014-12-26: Why Shares Of Gilead Sciences Are Trading Higher

Financial news for GILD dated on 2014-12-26: RBC: Gilead could launch \$10B+ accelerated buyback

Financial news for GILD dated on 2014-12-24: How Gilead And Johnson & Johnson's Tumble Could've Burned These Hedge Funds

Financial news for GILD dated on 2014-12-24: Benzinga's Top #PreMarket Losers

Financial news for GILD dated on 2014-12-23: 3 Charts That Show Why There's Gilead Sciences...And Then There's Everybody Else

Financial news for GILD dated on 2014-12-23: Evercore ISI Analyst: 160,000 Patients Affected by AbbVie Hepatitis Pact

Financial news for GILD dated on 2014-12-23: Health Care And Biotech Sector Looking Sick

Financial news for GILD dated on 2014-12-23: #Premarket Prep Technical Update - Gilead Sciences Continues Lower

Financial news for GILD dated on 2014-12-23: CNBC's Meg Tirrell Breaks Down The AbbVie/Express Scripts Deal

Financial news for GILD dated on 2014-12-23: Deutsche Bank Analyst Sees Gilead Sciences Vs. AbbVie 'Price War'

Financial news for GILD dated on 2014-12-23: Fast Money Picks For December 23: Gilead Sciences, Starbucks, CVS Health

Financial news for GILD dated on 2014-12-22: AbbVie Takes A Bite Out Of Gilead Sciences' Hepatitis C Market Share

Financial news for GILD dated on 2014-12-22: Bank Of America Downgrades Gilead Sciences, Sees Possible Pricing War

Financial news for GILD dated on 2014-12-22: Option Alert: Gilead Jan \$105 Call; 4,504 Contract Trade Above Ask @\$1.45; Currently \$94.64

Financial news for GILD dated on 2014-12-22: Bank of America Downgrades Gilead Sciences to Underperform, Lowers PT to \$87.00

Financial news for GILD dated on 2014-12-22: Mid-Day Losers From December 22: Gilead, Ocwen Financial And More

Financial news for GILD dated on 2014-12-22: Mid-Morning Market Update: Markets Open Higher; Caesars Entertainment To Buy Caesars Acquisition

Financial news for GILD dated on 2014-12-22: Monday's Biggest Social Media Movers

Financial news for GILD dated on 2014-12-22: Morning Market Losers

Financial news for GILD dated on 2014-12-22: Gilead Sciences Plummets Amid AbbVie Deal With Express Scripts

Financial news for GILD dated on 2014-12-22: Monday's #PreMarket Movers: Caesars, Enta, Twitter And More

Financial news for GILD dated on 2014-12-22: Benzinga's Top #PreMarket Losers

Financial news for GILD dated on 2014-12-22: Express Scripts to Cover AbbVie Hepatitis C Drug Viekira Pak, Drops Coverage on Gilead's Sovaldi Due to Significantly Lower Price of AbbVie Treatment -CNBC

Financial news for GILD dated on 2014-12-19: ONO, Gilead Announce Exclusive License Agreement to Develop ONO-4059 for Treatment of B-cell Malignancies and Other Diseases

Financial news for GILD dated on 2014-12-15: Gilead Sciences Announces Philippe Bishop, MD Will Join Gilead As SVP Hematology, Oncology Therapeutics

Financial news for GILD dated on 2014-12-12: These 2 Biotech Stocks Are Set To Split The \$15 Billion Hepatitis C Market

Financial news for GILD dated on 2014-12-11: Gilead Sciences Bucks Trend In Biotech Short Interest

Financial news for GILD dated on 2014-12-11: 6 Strong Analyst Recommendations That You Should Know

Financial news for GILD dated on 2014-12-10: Septa Lawsuit Seeks Class-Action Status, Monetary Damages From Gilead for Price Gouging on Sovaldi -DJ

Financial news for GILD dated on 2014-12-09: UPDATE: Morgan Stanley Raises PT on Gilead Sciences Following AlphaWise Survey

Financial news for GILD dated on 2014-12-09: Morgan Stanley Maintains Equal-weight on Gilead Sciences, Inc., Raises PT to \$100.00

Financial news for GILD dated on 2014-12-08: 3 Biotech ETFs Rally On Merger News

Financial news for GILD dated on 2014-12-08: Gilead Presents Follow-up Data from Zydelig Registrational Studies At 56th American Society of Hematology Annual Meeting

Financial news for GILD dated on 2014-12-05: Gilead Sciences Spikes Higher As Barron's Suggests Looking Beyond Hepatitis-C

Financial news for GILD dated on 2014-12-04: Earnings Season In Review: Who's

Winning?

Financial news for GILD dated on 2014-12-03: Great News For Biogen, But What's Next For The Stock?

Financial news for GILD dated on 2014-12-01: 8-K from Gilead Sciences Shows UK Court Invalidated Idenix 489 Patent, Trials Will Be Held on Merck's Idenix Patents in Canada in Jan.

Financial news for GILD dated on 2014-12-01: Mylan Reports Deal with Gilead for Enhancement of Access to TAF-Based HIV Treatments in Developing Countries

Financial news for GILD dated on 2014-11-26: #PreMarket Primer: Wednesday, November 26: Big Retailers Gear Up For Black Friday

Financial news for GILD dated on 2014-11-20: Hearing Unconfirmed Market Chatter of Icahn Stake in Gilead

Financial news for GILD dated on 2014-11-20: CNBC's Stock Pops & Drops From November 19

Financial news for GILD dated on 2014-11-20: French Ministry of Health Announces Final Negotiated Price for Gilead's Sovaldi is EUR41,000 for 12 Weeks -Reuters

Financial news for GILD dated on 2014-11-18: Gilead Sciences Announces That The European Commission Has Granted Marketing Authorization for Gilead's Harvoni

Financial news for GILD dated on 2014-11-15: Julian Robertson's Tiger Management 13F Reveals Huge Alibaba Stake

Financial news for GILD dated on 2014-11-14: CNBC's Stock Pops & Drops From November 13: King Digital, Alibaba, SanDisk, Gilead Sciences

Financial news for GILD dated on 2014-11-14: #PreMarket Primer: Friday, November 14: Tensions At All-Time High For G20 Summit

Financial news for GILD dated on 2014-11-13: Gilead Sciences In Correction Mode

Financial news for GILD dated on 2014-11-13: The Top 25 Analysts On Wall Street

Financial news for GILD dated on 2014-11-13: Hearing Cleveland Research Cautious on Gilead

Financial news for GILD dated on 2014-11-12: Gilead Prices \$4B Offering Of Senior Unsecured Notes

Financial news for GILD dated on 2014-11-12: Fast Money Halftime Report Final Trade From November 12: Twitter, Dunkin Brands, Gilead Sciences

Financial news for GILD dated on 2014-11-12: #PreMarket Primer: Wednesday, November 12: Banks Fined More Than \$3 Billion For Role In Forex Manipulation

Financial news for GILD dated on 2014-11-11: Gilead Reports Phase 2 Data for Investigational All-Oral Regimen of Sofosbuvir Plus GS-5816 for Treatment of Chronic Hep C

Financial news for GILD dated on 2014-11-11: Gilead Announces Phase 2 Data For Investigational All-Oral Regimen Of Sofosbuvir Plus GS-5816 For The Treatment Of Chronic Hepatitis C

Financial news for GILD dated on 2014-11-10: RBC Sees Weak Merck Data As Positive For Gilead

Financial news for GILD dated on 2014-11-06: Gilead Submits New Drug Application To FDA For Tenofovir Alafenamide

Financial news for GILD dated on 2014-11-03: CNBC's Stock Pops & Drops From November 3: GoPro, Gilead Sciences And More

Financial news for GILD dated on 2014-11-03: #PreMarket Primer: Monday, November 3: Commercial Space Travel Questioned After Failed Flights

Financial news for GILD dated on 2014-10-31: Edward Jones Initiates Coverage on Gilead Sciences, Inc. at Hold

Financial news for GILD dated on 2014-10-29: Fast Money Traders Comment On Stocks Making Headlines On Wednesday: Panera Bread, Hershey And More

Financial news for GILD dated on 2014-10-29: Express Scripts Says May Change Drug

Formulary in Mid-2015 to Favor Less Expensive Hepatitis C Drugs vs Gilead's Sovaldi -Reuters

Financial news for GILD dated on 2014-10-29: #PreMarket Primer: Wednesday, October 29: Fed Likely To End Bond Purchases

Financial news for GILD dated on 2014-10-28: Gilead Sciences Reports Softer Sovaldi Revenues

Financial news for GILD dated on 2014-10-28: Gilead Boosts FY14 Product Sales Guidance from \$21-\$23B Previously to \$22-\$23B

Financial news for GILD dated on 2014-10-28: Gilead Sciences, Inc. Reports Q3 EPS of \$1.84 vs \$1.92 Est; Revenue of \$6.04B vs \$6.06B Est; Narrowing Guidance

Financial news for GILD dated on 2014-10-28: Gilead Earnings Implied Volatility ~70%; Expecting \$6.30 Move

Financial news for GILD dated on 2014-10-28: #PreMarket Primer: Tuesday, October 28: CDC Warns That Involuntary Quarantines Could Discourage Progress On Ebola

Financial news for GILD dated on 2014-10-28: Earnings Scheduled For October 28, 2014

Financial news for GILD dated on 2014-10-27: #PreMarket Primer: Monday, October 27: ECB Stress Tests In-Line With Expectations

Financial news for GILD dated on 2014-10-20: #PreMarket Primer: Monday, October 20: Fed To Tread Softly At October Meeting

Financial news for GILD dated on 2014-10-16: Gilead Announces Health Canada Has Issued Notice of Compliance Related to Harvoni for Genotype 1 Chronic Hep C

Financial news for GILD dated on 2014-10-15: Barclays: Johnson & Johnson's Q3 Could Be 'High Water Mark'

Financial news for GILD dated on 2014-10-14: Deutsche Bank Says Gilead Sciences Stock Reaction Is Overdone

Financial news for GILD dated on 2014-10-14: Deutsche Bank Just Out with Mid-Day Defense on Gilead, 'weakness on Irish tax, JNJ comments is overdone'

Financial news for GILD dated on 2014-10-13: Markets Debut Week On Negative Note; S&P 500 Falls Through Key Level

Financial news for GILD dated on 2014-10-13: FBR Capital Maintains Outperform on Gilead Sciences, Inc., Raises PT to \$133.00

Financial news for GILD dated on 2014-10-13: Big Swings in Biotech Short Interest

Financial news for GILD dated on 2014-10-13: 5 Companies That Could Develop An Enterovirus Treatment

Financial news for GILD dated on 2014-10-10: Release Confirms Gilead's Approval For Combination Hep C Product

Financial news for GILD dated on 2014-10-10: Gilead Has Won US Approval for Combination Hep C Product

Financial news for GILD dated on 2014-10-08: Shares of Achillion Pharma at Session Highs as Traders Passing Around Mid-Day Note from FBR Showing Indication from Co. (via Abstract) of '100% of Patients Dosed for Eight Weeks Remained Cured'

Financial news for GILD dated on 2014-10-01: #PreMarket Primer: Wednesday, October 1: First Case Of Ebola In The US Confirmed

Financial news for GILD dated on 2014-09-30: AIFA, Gilead Have Agreed to Reimburse Sovaldi for Hep C Treatment

Financial news for GILD dated on 2014-09-29: Gilead Sciences, Inc. Consolidating Gains?

Financial news for GILD dated on 2014-09-27: Agios Pharmaceuticals Inc, Altria Group Inc Highlight CNBC's Stock Pops & Drops From September 26

Financial news for GILD dated on 2014-09-26: Gilead Release Confirms European CHMP Positive Opinion for Harvoni for Treatment of Chronic Hep C Infection in Adults

Financial news for GILD dated on 2014-09-26: EMA Announces Positive Recommendation for Gilead's Harvoni -DJ

Financial news for GILD dated on 2014-09-25: Gilead Shares Volatile This Morning Following FDA Approval of VITEKTA in HIV

Financial news for GILD dated on 2014-09-24: Gilead's Investigational Tenofovir Alafenamide (TAF)-Based Single Tablet HIV Regimen Meets 48-Week Primary Objective in Two Phase 3 Studies

Financial news for GILD dated on 2014-09-24: Gilead Submits NDA in Japan for Fixed-Dose Combination of Ledipasvir/Sofosbuvir for Chronic Hepatitis C Genotype 1 Infection

Financial news for GILD dated on 2014-09-19: US Stock Futures Signal Higher Start On Wall Street

Financial news for GILD dated on 2014-09-19: Gilead Gets EC Approval for Zydelig in Chronic Lymphocytic Leukemia, Follicular Lymphoma

Financial news for GILD dated on 2014-09-18: 2 Columbia Growth Funds Notch Impressive Three-Month Performance

Financial news for GILD dated on 2014-09-17: This Top Growth Fund Leans Heavily On Large-Cap Tech

Financial news for GILD dated on 2014-09-17: Gilead Says Addition of Simtuzumab to Gemcitabine Didn't Significantly Increase Progression-Free Survival

Financial news for GILD dated on 2014-09-16: Deutsche Bank Is Bullish On Gilead Sciences, Inc. And Other Biotech Stocks

Financial news for GILD dated on 2014-09-16: Benzinga's Top #PreMarket Losers

Financial news for GILD dated on 2014-09-15: Morning Market Losers

Financial news for GILD dated on 2014-09-15: Benzinga's Top #PreMarket Losers

Financial news for GILD dated on 2014-09-15: #PreMarket Primer: Monday, September 15: Cameron Vows To Destroy ISIS

Financial news for GILD dated on 2014-09-15: UPDATE: Gilead Announces Licensing Agreements for Generic Sovaldi

Financial news for GILD dated on 2014-09-15: Mylan In Pact With Gilead To Accelerate Access To Hepatitis C

Financial news for GILD dated on 2014-09-15: UPDATE: Gilead Says Licensees to Set Prices for Generic Version of Sovaldi, Will Pay Gilead a Royalty on Sales

Financial news for GILD dated on 2014-09-15: Gilead Licenses Hep C Drug Sovaldi to 7 Companies Including Mylan, Ranbaxy

Financial news for GILD dated on 2014-09-12: #PreMarket Primer: Friday, September 12: US Allies Vague About Participation In Syrian Airstrikes

Financial news for GILD dated on 2014-09-10: Gilead Sciences, Inc. Could Be Taking A Break Before Even More Upside

Financial news for GILD dated on 2014-09-09: Have We Seen The Market's Top?

Financial news for GILD dated on 2014-09-09: Hearing Cleveland Research Says Gilead Recently Started Cutting Pricing 8% for Sovaldi

Financial news for GILD dated on 2014-09-08: Gilead Reports First-Line Combo Study of Ambrisentan, Tadalafil Met Primary Endpoint, Expecting to Submit Ambition Data by End of 2014

Financial news for GILD dated on 2014-09-06: CNBC's Stock Pops & Drops From September 5: Control4 Corp, Priceline Group Inc & More

Financial news for GILD dated on 2014-09-06: Allianz's Analyst Likes Biogen Idec Inc, Celgene Corporation & Gilead

Financial news for GILD dated on 2014-09-06: Fast Money Halftime Report Final Trade From September 5: American Eagle Outfitters, Delta Air Lines, Inc. & More

Financial news for GILD dated on 2014-09-05: A Word On Healthcare Mutual Funds, And One Sector's 'Fittest' Segment

Financial news for GILD dated on 2014-09-05: Markets Edge Lower; Zumiez Issues Weak

## Outlook

Financial news for GILD dated on 2014-09-05: Why Gilead Sciences, Inc. Is A Top Mutual Fund Holding

Financial news for GILD dated on 2014-09-02: Biotechnology, Oil And Brazil ETFs To Watch This Week

Financial news for GILD dated on 2014-08-30: Mike Khouw's Gilead Sciences Trade

Financial news for GILD dated on 2014-08-29: What You Need to Know About the Roche-InterMune Deal

Financial news for GILD dated on 2014-08-27: Biotech ETFs Hitting New Highs On Takeover News (FBT, PBE, ITMN)

Financial news for GILD dated on 2014-08-27: Seeing Very High Social Activity on Gilead Shares as Stock Crosses \$108 Level, Shares Up 2%

Financial news for GILD dated on 2014-08-27: #PreMarket Primer: Wednesday, August 27: Israel And Hamas To Resume Peace Talks In Cairo

Financial news for GILD dated on 2014-08-26: Deutsche Bank Has Added Gilead, Celgene to 'Short-Term Buy' List - Bloomberg

Financial news for GILD dated on 2014-08-26: #PreMarket Primer: Tuesday, August 26: US Gathers Intelligence In Syria

Financial news for GILD dated on 2014-08-25: InterMune's Roche Deal Sends Peer Group Up

Financial news for GILD dated on 2014-08-24: CNBC's Stock Pops & Drops From August 22

Financial news for GILD dated on 2014-08-18: #PreMarket Primer: Monday, August 18: Jackson Hole Draws Market Attention

Financial news for GILD dated on 2014-08-16: CNBC's Stock Pops & Drops From August 15

Financial news for GILD dated on 2014-08-15: Markets Close The Week On Negative Note As Ukraine Worries Mount

Financial news for GILD dated on 2014-08-15: Gilead Shares Rise in Premarket as UK's National Institute for Health and Care Excellence Recommends English Health System Pays for Sovaldi, Also Gets Favorable Ruling vs Roche in Arbitration

Financial news for GILD dated on 2014-08-14: Shares of Intercept Moving Higher; Report of Tweet Mentioning Potential Deal by Gilead being Passed Around, Totally Unconfirmed

Financial news for GILD dated on 2014-08-07: #PreMarket Primer: Thursday, August 7: Russia Set To Release A List Of Banned Goods

Financial news for GILD dated on 2014-08-07: Top 4 Stocks In The Biotechnology Industry With The Highest Revenue

Financial news for GILD dated on 2014-08-06: Why Investors Should Closely Watch Celgene

Financial news for GILD dated on 2014-08-04: TD Ameritrade Client Activity Jumped In July, Back To March Levels

Financial news for GILD dated on 2014-07-28: #PreMarket Primer: Monday, July 28: Tension Between U.S. And Israel On The Rise

Financial news for GILD dated on 2014-07-25: EU Medicines Agency Recommends Gilead Leukemia Drug Idelalisib

Financial news for GILD dated on 2014-07-24: Gilead Beats Q2 Views On Revenue Growth Lead By Sovaldi Drug

Financial news for GILD dated on 2014-07-23: Markets Mostly Higher As Earnings Season Continues To Impress

Financial news for GILD dated on 2014-07-23: Shares of Gilead Resume Trade, Trading Very Slightly Lower, Down ~0.5% from Close

Financial news for GILD dated on 2014-07-23: Gilead Reports Q2 Sovaldi Sales \$3.48B

Financial news for GILD dated on 2014-07-23: PREVIEW: Gilead Sciences to Resume

Trading at 4:30 PM ET

Financial news for GILD dated on 2014-07-23: Gilead Sciences, Inc. Sees FY2014 Sales \$21.0B-23.0B vs \$22.63B Est

Financial news for GILD dated on 2014-07-23: Gilead Sciences, Inc. Reports Q2 EPS of \$2.36 vs \$1.79 Est; Revenue of \$6.53B vs \$5.86B Est

Financial news for GILD dated on 2014-07-23: Gilead Halted Ahead of Earnings

Financial news for GILD dated on 2014-07-23: Statement from FDA Confirms Approval of Gilead's Zydelig

Financial news for GILD dated on 2014-07-23: FDA Statement Shows Approval for Gilead's Zydelig - Bloomberg

Financial news for GILD dated on 2014-07-23: Earnings Scheduled For July 23, 2014

Financial news for GILD dated on 2014-07-18: Investors Focus On Earnings Rather Than Geopolitical Tensions

Financial news for GILD dated on 2014-07-18: Biotech Enters Reporting Season With Large Caps Central To Sector Performance

Financial news for GILD dated on 2014-07-14: 2 Biotech Stocks That Crushed On Earnings

Financial news for GILD dated on 2014-07-11: Markets Close Higher Ahead Of Busy Earnings Season

Financial news for GILD dated on 2014-07-11: Stocks Hitting 52-Week Highs

Financial news for GILD dated on 2014-07-11: Wyden and Grassley Seek Details on Gilead's Solvaldi Pricing

Financial news for GILD dated on 2014-07-10: J.P. Morgan: Johnson & Johnson's Drug Segment May Beat Q2 Street Views

Financial news for GILD dated on 2014-07-07: FDA Warns Gilead on Marketing of Hepatitis B Drug Viread

Financial news for GILD dated on 2014-07-03: Citi Sees Plenty Of Q2 Earnings Beats Ahead In Biotech Sector

Financial news for GILD dated on 2014-07-02: Option Alert: Gilead Aug \$95 Call; 9,227 Contracts Traded vs 3,595 OI; Currently \$87.67

Financial news for GILD dated on 2014-06-30: UPDATE: Morgan Stanley Reiterates On Gilead Sciences On EM Sovaldi

Financial news for GILD dated on 2014-06-27: Gilead Submits NDA to Japan's Pharmaceutical and Medical Devices Agency for Sofosbuvir for Chronic Hepatitis C

Financial news for GILD dated on 2014-06-19: Gilead Shares Spiker Lower; May be Attributed to Congressional Probe into Sovaldi Pricing

Financial news for GILD dated on 2014-06-18: Advances In HIV, Hep C Treatments Could Spark Renewed Interest In Biotech Stocks

Financial news for GILD dated on 2014-06-16: Benzinga's M&A Chatter for Monday June 16, 2014

Financial news for GILD dated on 2014-06-15: Gilead Phase 3 Data Show Fixed-Dose Combination of Ledipasvir/Sofosbuvir Achieved 100 Percent Sustained Virologic Response Among Patients with Chronic Hepatitis C in Japan

Financial news for GILD dated on 2014-06-09: Are Gilead Shares Overreacting To Merck's Idenix Acquisition?

Financial news for GILD dated on 2014-06-09: Mid-Morning Market Update: Markets Edge Higher; Tyson Wins Bidding Battle To Buy Hillshire Brands For \$63/Share

Financial news for GILD dated on 2014-06-09: Hepatitis C Stocks Move After Idenix Rockets Up 235%

Financial news for GILD dated on 2014-06-09: Benzinga's Top #PreMarket Losers

Financial news for GILD dated on 2014-06-03: UPDATE: Gilead Reports Updated Phase 2 Results for Investigational GS-9973, Showed 49% Overall Response Rate with Est.

Progression-Free Survival Rate at 24 Weeks 70%

Financial news for GILD dated on 2014-06-03: Gilead Reports Updated Phase 2 Results for Investigational GS-9973, Showed 49% Overall Response Rate with Est. Progression-Free Survival Rate at 24 Weeks 70%

Financial news for GILD dated on 2014-06-02: Value Of U.S. Equity Buybacks In May Drops

Financial news for GILD dated on 2014-05-28: Option Alert: Gilead Jun \$87.5 Call; 7,432 Contracts Traded vs 3.026 OI; Currently \$82.41

Financial news for GILD dated on 2014-05-20: UPDATE: Gilead Reports Investigational GS-5806 Reduces Viral Load, Clinical Symptoms in Phase 2 RSV Study, Says Study Reached Primary, Secondary Endpoints

Financial news for GILD dated on 2014-05-20: Gilead Reports Investigational GS-5806 Reduces Viral Load, Clinical Symptoms in Phase 2 RSV Study, Says Study Reached Primary, Secondary Endpoints

Financial news for GILD dated on 2014-05-12: Breaking Biotech: Gilead's Phase 2 Study Results

Financial news for GILD dated on 2014-05-10: Gilead Phase 2 Study Shows Reduction in Atrial Fibrillation Burden with Investigational Combination of Ranolazine and Low-Dose Dronedarone

Financial news for GILD dated on 2014-05-09: Gilead Announces Phase 1 Data For Investigation Therapy

Financial news for GILD dated on 2014-05-07: Gilead Announces \$5B Buyback Plan

Financial news for GILD dated on 2014-04-25: U.S.-Russia Tensions Over Ukraine Could Make This An Interesting Weekend

Financial news for GILD dated on 2014-04-24: Biogen Raises Full-Year Earnings, But Is That The Entire Picture?

Financial news for GILD dated on 2014-04-23: Market Wrap For April 23: S&P 500 Ends Winning Streak, Apple Announces 7-for-1 Stock Split

Financial news for GILD dated on 2014-04-23: #Premarket Technical Update - Gilead Sciences Trading Higher

Financial news for GILD dated on 2014-04-23: Morning Market Movers

Financial news for GILD dated on 2014-04-23: How Did Analysts Get Gilead's Earnings Completely Wrong?

Financial news for GILD dated on 2014-04-23: Benzinga's Top #PreMarket Gainers

Financial news for GILD dated on 2014-04-23: ETF Outlook For Wednesday, April 23, 2014 (MGC, IYZ, TAN, BBH, GILD, T)

Financial news for GILD dated on 2014-04-23: Nomura Maintains Buy on Gilead Sciences, Inc., Raises PT to \$130.00

Financial news for GILD dated on 2014-04-22: Gilead Crushes On Earnings, Quickly Gives Up Gains

Financial news for GILD dated on 2014-04-22: Market Wrap For April 22: S&P Rises For Sixth Straight Day, Dow & Nasdaq Also Positive

Financial news for GILD dated on 2014-04-22: Gilead Beats Q1 Estimates, Stock Halted Briefly

Financial news for GILD dated on 2014-04-22: Gilead Sciences Shares Resume Trade, Up 5%

Financial news for GILD dated on 2014-04-22: Gilead Sciences Shares to Resume Trade at 4:30PM EDT

Financial news for GILD dated on 2014-04-22: Gilead Sciences, Inc. Reports Q1 EPS of \$1.48 vs \$0.92 Est; Revenue of \$5.0B, Up 98% YOY

Financial news for GILD dated on 2014-04-22: Gilead Sciences Halted Ahead of Earnings

Financial news for GILD dated on 2014-04-22: CAFC Says Gilead Has Lost Appeals Court Ruling Related to Patent Over Tamiflu



Financial news for GILD dated on 2014-04-22: Earnings Scheduled For April 22, 2014

Financial news for GILD dated on 2014-04-21: Gilead Sciences' New Drug Applications for Cobicistat and Elvitegravir for HIV Therapy Accepted by U.S. FDA

Financial news for GILD dated on 2014-04-21: Bloomberg Report Says CVS May Try to Slow the Uptake of Gilead's New Drug; Says CVS Wants Price Competition to Gilead's Hepatitis C Drug

Financial news for GILD dated on 2014-04-15: Gilead Receives FDA Orphan Status for Chronic Lymphocytic Leukemia - Bloomberg

Financial news for GILD dated on 2014-04-14: Markets Falling? Get Your Defense Ready

Financial news for GILD dated on 2014-04-11: US Stock Futures Slip Ahead Of Consumer Sentiment Report

Financial news for GILD dated on 2014-04-11: Gilead Announces Sovaldi Demonstrates Efficacy and Safety Among Chronic Hepatitis C Patients with Advanced Liver Disease

Financial news for GILD dated on 2014-04-10: Market Wrap For April 10: Wednesday's Rally Completely Forgotten

Financial news for GILD dated on 2014-04-10: Five Star Stock Watch: Gilead Sciences

Financial news for GILD dated on 2014-04-10: Natco Pharma Files to Block Grant Of India Patent On Gilead's Hepatitis C Drug Sovaldi -Reuters

Financial news for GILD dated on 2014-04-10: Nomura Maintains Buy on Gilead Sciences, Inc., Raises PT to \$121.00

Financial news for GILD dated on 2014-04-10: Gilead Announces Phase 2 Results for Investigational All-Oral Sofosbuvir-Based Regimens for Treatment of Chronic Hepatitis C

Financial news for GILD dated on 2014-04-08: Biotechs Struggling To Find A Bottom

Financial news for GILD dated on 2014-04-08: Morning Market Losers

Financial news for GILD dated on 2014-04-08: Benzinga's Top #PreMarket Losers

Financial news for GILD dated on 2014-04-08: Express Scripts Reports Spending on Hepatitis C Medications in US to Rise 1,800% by 2016

Financial news for GILD dated on 2014-04-07: UPDATE: TD Ameritrade Says IMX for Mar. Up to 5.87

Financial news for GILD dated on 2014-04-07: Gilead Sets US FDA Priority Review Designation for Ledipasvir/Sofosbuvir Fixed-Dose Combo Tablet, Sets PDUFA Date for Oct. 10th

Financial news for GILD dated on 2014-04-02: Gilead Says Results of Phase 3 Study of Sofosbuvir Confirm Efficacy, Safety

Financial news for GILD dated on 2014-04-02: Gilead's HepC Drug Sales May Be More Resilient Than Feared

Financial news for GILD dated on 2014-04-01: Despite S&P 500's New High, Stocks Face Challenges

Financial news for GILD dated on 2014-03-27: Market Wrap For March 27: Markets Lower Following Mixed Economic Data

Financial news for GILD dated on 2014-03-27: UPDATE: Gilead Sciences' LDV/SOF Receives Accelerated Assessment

Financial news for GILD dated on 2014-03-27: EMA Validates Gilead's Marketing Application for Ledipasvir/Sofosbuvir Fixed-Dose Combination Tablet for Genotype 1 Chronic Hepatitis C Infection

Financial news for GILD dated on 2014-03-27: Morgan Stanley's Top Biotech Pick is Biogen

Financial news for GILD dated on 2014-03-27: Morgan Stanley Initiates Coverage on Gilead Sciences, Inc. at Equal-weight, Announces \$75.00 PT

Financial news for GILD dated on 2014-03-26: Morgan Stanley Starts Gilead Sciences With Equal-Weight; \$75 PT

Financial news for GILD dated on 2014-03-24: Have We Seen The Top Of The Market?

Financial news for GILD dated on 2014-03-24: Idenix to Appeal Norway District Court Decision Regarding Patent Invalidity Case

Financial news for GILD dated on 2014-03-21: Market Wrap For March 21: Markets End Friday On A Negative Note, But Still Positive For The Week

Financial news for GILD dated on 2014-03-21: U.S. Lawmakers Ask For Briefing From Gilead Sciences on Price Of New Hepatitis C Drug Sovaldi

Financial news for GILD dated on 2014-03-14: Market Wrap For March 14: Ukraine Tension Drag Markets Lower

Financial news for GILD dated on 2014-03-14: US Stock Futures Edge Higher Ahead Of Consumer Sentiment Report

Financial news for GILD dated on 2014-03-14: Idenix Pharmaceuticals Files Patent Infringement Lawsuits Against Gilead Sciences in Europe

Financial news for GILD dated on 2014-03-10: UPDATE: TD Ameritrade's IMX Sentiment for Feb. Gains, Now at 5.74

Financial news for GILD dated on 2014-03-06: Market Wrap For March 6: Investors Find Positives In Jobless Claims

Financial news for GILD dated on 2014-02-26: Top 4 Large-Cap Stocks In The Biotechnology Industry With The Lowest PEG Ratio

Financial news for GILD dated on 2014-02-24: Constructing A Hedged Portfolio Around A Position In Priceline.com

Financial news for GILD dated on 2014-02-19: Gilead Sciences VP Bischofberger Sells 90,000 Shares -Form 4

Financial news for GILD dated on 2014-02-19: A High Expected Return Watch List

Financial news for GILD dated on 2014-02-10: Gilead Files for US Approval of Ledipasivir/Sofosbuvir Fixed-Dose Combo

Financial news for GILD dated on 2014-02-10: Three ETFs To Buy On The Pullback (PJP, SKYY, SPY)

Financial news for GILD dated on 2014-02-05: Market Wrap For February 5: Markets Unsure Of Which Direction To Take

Financial news for GILD dated on 2014-02-05: Stifel Nicolaus Maintains Buy on Gilead Sciences, Inc., Raises PT to \$92.00

Financial news for GILD dated on 2014-02-04: Gilead Sciences Falls Ever-So-Slightly After Q4 Earnings Beat

Financial news for GILD dated on 2014-02-04: Market Wrap For February 4: Investors And Traders Go Bargain Hunting

Financial news for GILD dated on 2014-02-04: From Gilead Call: CEO Martin Highlighting FDA Priority Review for Idelalisib in CLL

Financial news for GILD dated on 2014-02-04: Gilead Sciences, Inc. Sees FY2014 Product Sales \$11.30B-11.50B

Financial news for GILD dated on 2014-02-04: Gilead Sciences, Inc. Reports Q4 EPS of \$0.55 vs \$0.50 Est; Revenue of \$3.12B vs \$2.85B Est

Financial news for GILD dated on 2014-02-04: Baird Upgrades Gilead Sciences, Inc. to Outperform

Financial news for GILD dated on 2014-02-04: Nomura Maintains Buy on Gilead Sciences, Inc., Raises PT to \$119.00

Financial news for GILD dated on 2014-02-04: #PreMarket Primer for Tuesday, February 4: Will The Plunge Continue?

Financial news for GILD dated on 2014-01-31: Mylan Selected as Gilead's Exclusive Branded Medicines Business Partner for India

Financial news for GILD dated on 2014-01-29: Idenix to Challenge Decision by USPTO Patent Trial and Appeal Board in First Patent Interference

Financial news for GILD dated on 2014-01-29: Ian Estepan Tweet: Patent Office Website Indicates That \$GILD Has Prevailed In Interference Proceeding Between '572 Patent And \$IDIX '868 Application

Financial news for GILD dated on 2014-01-28: Deutsche Bank Boosts Target on Gilead to \$132, on Celgene to \$190, on Biogen to \$415, Says We Would Be Buyers on Weakness

Financial news for GILD dated on 2014-01-23: Deutsche Bank Adds Gilead to 'Short-Term Buy' List

Financial news for GILD dated on 2014-01-17: Gilead Announces EC Has Granted Marketing Authorization for Sovaldi

Financial news for GILD dated on 2014-01-16: Is The Market On Drugs?

Financial news for GILD dated on 2014-01-13: FDA Accepts NDA for Gilead's Idelalisib for Treatment of Refractory Indolent Non-Hodgkin's Lymphoma

Financial news for GILD dated on 2014-01-08: Nomura Initiates Coverage on Gilead Sciences, Inc. at Buy, Announces \$118.00 PT

Financial news for GILD dated on 2014-01-06: Targets on Gilead Raised from \$87 to \$96 at Citi, from \$80 to \$102 at UBS

Financial news for GILD dated on 2013-12-26: Rising Short Interest In Pharmacyclics, Other Biotechs (AMGN, GILD, PCYC)

Financial news for GILD dated on 2013-12-24: UPDATE: Idenix Pharmaceuticals Spokesperson Says IDX20963 Still on Hold; Preclinical Work is Ongoing to Characterize the Genotoxicity Signal in Single Ames in vitro Test; No Update on Litigation

Financial news for GILD dated on 2013-12-18: Market Wrap For December 18: Markets Surge Following the Fed's Taper Announcement

Financial news for GILD dated on 2013-12-18: JP Morgan Lifts Target on Gilead from \$85 to \$100, Maintains Overweight

Financial news for GILD dated on 2013-12-18: Gilead Sciences Says High Cure Rates Observed With Single Tablet Regimen May Eliminate Interferon And Ribavirin From Hcv Therapy For Genotype 1 Patients

Financial news for GILD dated on 2013-12-18: Gilead Issues SVR12 Rates from Three Phase 3 STudies, Says Ion-1 Rate 97.7%, NDA Submission Planned for Q1'14

Financial news for GILD dated on 2013-12-17: Slideshow: The Top 10 'Highs & Dives' Of S&P 500 Stocks In 2013

Financial news for GILD dated on 2013-12-16: Market Wrap For December 16: Dow Posts Triple Point Gain Ahead of Fed Meeting

Financial news for GILD dated on 2013-12-16: Gilead Announces Health Canada Notice of Compliance for Sovaldi for Treatment of Chronic Hepatitis C

Financial news for GILD dated on 2013-12-13: FDA Approves Gilead's Once-Daily Single Tablet HIV-1 Regimen Complera(r) for Patients Switching from a Stable Regimen; Also Approved by European Commission

Financial news for GILD dated on 2013-12-11: The One True Sector Bubble: Profits Here When It Crashes Soon

Financial news for GILD dated on 2013-12-10: Bloomberg Reporting Express Scripts' Miller in Phone Interview Said Aiming to Cut Costs for Hep C Drugs, Planning to Pit Gilead Against Other Drugmakers

Financial news for GILD dated on 2013-12-10: Stocks to Watch for December 10, 2013

Financial news for GILD dated on 2013-12-09: Market Wrap For December 9: Investors Digest Further Clues Hinting at An Upcoming Taper

Financial news for GILD dated on 2013-12-09: Moody's Revises Gilead Outlook to Positive on Sovaldi Approval

Financial news for GILD dated on 2013-12-09: USA TD Ameritrade's Investor Movement Index for Nov 5.42 vs 5.07 Prior

Financial news for GILD dated on 2013-12-09: Benzinga's Top #PreMarket Gainers

Financial news for GILD dated on 2013-12-08: Gilead Announces Phase 2 Study Results

for Idelalisib in Refractory Indolent Non-Hodgkin's Lymphoma at ASH

Financial news for GILD dated on 2013-12-07: Gilead Reports Positive Data from Interim Phase 2 Results for GS-9973 in Previously Treated Chronic Lymphocytic Leukemia

Financial news for GILD dated on 2013-12-06: Bloomberg First Word Reporting Gilead Has Won FDA Approval for Sofosbuvir

Financial news for GILD dated on 2013-12-02: Idenix Pharmaceuticals Files Patent Infringement, Interference Lawsuits Against Gilead Sciences

Financial news for GILD dated on 2013-11-27: UPDATE: Piper Jaffray Initiates Coverage on Gilead Sciences on Expected Attractive Returns

Financial news for GILD dated on 2013-11-27: 10 Stocks To Be Thankful For This Thanksgiving

Financial news for GILD dated on 2013-11-26: Piper Jaffray Reinstates Overweight on Gilead Sciences, Inc.

Financial news for GILD dated on 2013-11-22: UPDATE: Bank of America Increased Gilead Sciences PT

Financial news for GILD dated on 2013-11-22: EMA Says Gilead Sciences Granted Marketing Authorization for Sofosbuvir

Financial news for GILD dated on 2013-11-20: UPDATE: Citigroup Reiterates on Gilead Sciences on Positive Outlook

Financial news for GILD dated on 2013-11-20: Citigroup Maintains Buy on Gilead Sciences, Inc., Raises PT to \$87.00

Financial news for GILD dated on 2013-11-18: Gilead Says Idelalisib Significantly Reduced Rate of Disease Progression or Death in Phase 3 Trial, Met Primary, Secondary Endpoints

Financial news for GILD dated on 2013-11-18: UPDATE: Gilead Says Working on Resubmitting Vitekta to FDA as Single Agent

Financial news for GILD dated on 2013-11-18: European Commission Approves Gilead's Vitekta, HIV-1 Infection Treatment

Financial news for GILD dated on 2013-11-12: Gilead Sciences Leads In Rising Short Interest Among Biotechs

Financial news for GILD dated on 2013-11-04: J&J, Gilead Report HCV Combo Shows 93% SVR12 Rate Prior Null Responders, Says Medivir Showed No Benefit from Ribavirin, 12-Week Regimen Similar to 24

Financial news for GILD dated on 2013-11-04: Benzinga's Top #PreMarket Losers

Financial news for GILD dated on 2013-11-02: Gilead Announces Positive Phase 3 HCV Treatment Results in Patients Co-Infected With HIV

Financial news for GILD dated on 2013-11-02: Gilead Announces Promising Phase 2 HCV Treatment Results in Liver Transplant Patients

Financial news for GILD dated on 2013-11-01: Argus' Market Digest Summary

Financial news for GILD dated on 2013-10-30: Market Wrap for October 30: Fed Worries Push Stocks Lower, Facebook Earnings Raise Concerns

Financial news for GILD dated on 2013-10-30: Deutsche Bank Adds Gilead Sciences to 'Short-Term Buy' List

Financial news for GILD dated on 2013-10-30: UPDATE: BMO Capital Markets Reiterates on Gilead Sciences Following Solid 3Q13 Results

Financial news for GILD dated on 2013-10-29: Gilead Sciences, Inc. Reports Q3 EPS of \$0.52 vs \$0.48 Est; Revenue of \$2.78B vs \$2.72B Est

Financial news for GILD dated on 2013-10-25: Short Sellers Retreat From Biogen Idec, Move On Pharmacoclics (BIIB, BMRN, PCYC)

Financial news for GILD dated on 2013-10-16: Gilead's Stribild Demonstrates Durable Viral Suppression in Two Phase 3 Studies

Financial news for GILD dated on 2013-10-15: FDA Reporting Gilead Wins Orphan Drug

## Designation for Idealalisib

Financial news for GILD dated on 2013-10-11: Short Sellers Move On Amgen, Vertex (AMGN, PCYC, VRTX)

Financial news for GILD dated on 2013-10-09: UPDATE: Gilead to Stop Phase 3 Study 116 of Idelalisib in Chronic Lymphocytic Leukemia Early Because of Positive Risk-Benefit

Financial news for GILD dated on 2013-10-09: UPDATE: Gilead Says Planning to File Idelalisib in EU Later This Year

Financial news for GILD dated on 2013-10-09: Gilead Says Will Stop Phase 3 Study 116 of Idelalisib in CLL, Says Will Engage in Dialogue with FDA

Financial news for GILD dated on 2013-10-08: Biotech ETFs Plummeting (XBI, IBB, BBH)

Financial news for GILD dated on 2013-10-07: Playing Momentum With ETFs (PDP, PIE, MTUM)

Financial news for GILD dated on 2013-10-07: Shares of Gilead Bouncing Off Lows; Several Analysts Making Reassuring Comments

Financial news for GILD dated on 2013-09-27: Gilead Wins Orphan Drug Status for Lymphoma Treatment

Financial news for GILD dated on 2013-09-25: European Commission Gives Okay on Gilead's Tybost for HIV Therapy

Financial news for GILD dated on 2013-09-25: BioMarin, Celgene Lead Trend in Biotech Short Interest (BRMN, CELG, REGN)

Financial news for GILD dated on 2013-09-14: Alexion, Pharmacyclics Buck Trend in Biotech Short Interest (ALXN, CELG, PCYC)

Financial news for GILD dated on 2013-09-12: Some New ETFs Off To Impressive Starts

Financial news for GILD dated on 2013-09-11: UPDATE: Gilead Says Will File for EU Approval of Idelalisib in Q4

Financial news for GILD dated on 2013-09-11: Gilead Submits NDA to FDA for Idealalisib for Treatment of NHL

Financial news for GILD dated on 2013-09-05: Biotech Breakout Highlights Flawed ETF Thinking

Financial news for GILD dated on 2013-08-27: Short Interest In Celgene, Onyx Continues To Shrink (CELG, ONXX, VRTX)

Financial news for GILD dated on 2013-08-14: How Much Does It Cost To Develop A New Drug?

Financial news for GILD dated on 2013-08-07: AHF Wins Major Ruling against FDA on Gilead Prevention Pill

Financial news for GILD dated on 2013-08-02: Three Soaring, But Overlooked Health Care ETFs

Financial news for GILD dated on 2013-07-30: Three ETFs That Have Blown Past Their 200-Day Lines

Financial news for GILD dated on 2013-07-26: Short Interest in Pharmacyclics Plunges (AMGN, ONXX, PCYC)

Financial news for GILD dated on 2013-07-26: Baird Downgrades Gilead Sciences, Inc. to Neutral

Financial news for GILD dated on 2013-07-26: Atlantic Equities Upgrades Gilead Sciences to Overweight

Financial news for GILD dated on 2013-07-25: Gilead Sciences Rises After Q2 Report (GILD)

Financial news for GILD dated on 2013-07-25: Gilead Sciences, Inc. Reports Q2 EPS of \$0.50, Inline; Revenue of \$2.66B vs \$2.66B Est

Financial news for GILD dated on 2013-07-25: Economic Calendar for Thursday July 25, 2013

Financial news for GILD dated on 2013-07-22: Benzinga's Top Pre-Market Losers

Financial news for GILD dated on 2013-07-17: Kris Jenner of Rock Springs Capital Mentioning Vertex, Gilead, Pharmacyclics

Financial news for GILD dated on 2013-07-16: Benzinga's M&A Chatter for Tuesday July 16, 2013

Financial news for GILD dated on 2013-07-16: Gilead Not Commenting on Potential Bid for Onyx

Financial news for GILD dated on 2013-07-16: UPDATE: Amgen, Pfizer, Bristol-Myers Squibb, Gilead Among Companies that May Submit Bids for Onyx, According to Sources

Financial news for GILD dated on 2013-07-15: Health Care ETFs Looking Healthy Ahead of Earnings

Financial news for GILD dated on 2013-07-11: Short Interest Rises in Gilead Sciences, Onyx Pharmaceuticals (BIIB, GILD, ONXX)

Financial news for GILD dated on 2013-07-01: ETFs For an Onyx Takeover Battle

Financial news for GILD dated on 2013-06-26: Short Interest in Biogen Idec and Vertex Shrinks (BIIB, CELG, VRTX)

Financial news for GILD dated on 2013-06-17: Oppenheimer Reiterates Outperform Rating on Gilead Sciences Following Initial Idelalisib Ph.II Results

Financial news for GILD dated on 2013-06-17: Gilead Interim Phase 2 Data for Idelalisib Shows Response in Refractory Indolent Non-Hodgkin's Lymphoma

Financial news for GILD dated on 2013-06-13: Argus Research Upgrades Gilead Sciences, Inc. to Buy, Announces \$62.00 PT

Financial news for GILD dated on 2013-06-12: Gilead Shares Unaffected Following Headlines Viread Study Shows Reduced HIV Risk Among 49% of Patients

Financial news for GILD dated on 2013-06-12: Short Interest Falls in Vertex, Rises in Biogen Idec (VRTX, BIIB)

Financial news for GILD dated on 2013-06-10: Benzinga's Top Pre-Market Gainers

Financial news for GILD dated on 2013-06-07: Gilead Gets FDA Priority Review for Sofosbuvir for Hep C, Says PDUFA Date Dec. 8th

Financial news for GILD dated on 2013-05-29: Short Interest in Vertex Rises, in Biogen Idec Falls

Financial news for GILD dated on 2013-05-28: European Commission Approves Stribild(r), a New Single Tablet Regimen for the Treatment of HIV-1 Infection

Financial news for GILD dated on 2013-05-21: Gilead Receives MAA for Hep C Treatment

Financial news for GILD dated on 2013-05-15: Gilead Offers Response Data from Phase 2 Study of Idelalisib

Financial news for GILD dated on 2013-05-11: Short Interest in Vertex Rises, in Celgene Falls

Financial news for GILD dated on 2013-05-10: S&P Highlights Biotech ETFs

Financial news for GILD dated on 2013-05-03: Market Wrap for Friday, May 3: Stocks Jump on Strong Jobs Data

Financial news for GILD dated on 2013-05-03: Three Sector ETFs Up 20% or More YTD

Financial news for GILD dated on 2013-05-02: Gilead Sciences, Inc. Reports Q1 EPS of \$0.48 vs \$0.50 Est; Revenue of \$2.53B vs \$2.58B Est

Financial news for GILD dated on 2013-05-02: Benzinga Market Primer: Thursday, May 2

Financial news for GILD dated on 2013-05-01: Illumina and Other Bargain Biotech Stocks Worth a Look Now

Financial news for GILD dated on 2013-04-29: Gilead Receives CRL from FDA for Elvitegravir, Cobicistat

Financial news for GILD dated on 2013-04-28: Earnings Expectations for the Week of April 29

Financial news for GILD dated on 2013-04-28: A Look Ahead: This Week's ETFs to Watch

Financial news for GILD dated on 2013-04-26: Weekly Preview: Focus Shifts from Earnings to Economy

Financial news for GILD dated on 2013-04-26: Short Sellers Move into Celgene, Regeneron

Financial news for GILD dated on 2013-04-25: Gilead Hep-C Combo Cures 100% of Patients in Study, Results Presented in Amsterdam

Financial news for GILD dated on 2013-04-23: Piper Jaffray Maintains Overweight on Gilead Sciences, Inc., Raises PT to \$63.00

Financial news for GILD dated on 2013-04-23: Gilead, Bristol Hepatitis-C Drug Combination Suppresses Virus in Study, Helps Those Who Fail Other Drugs

Financial news for GILD dated on 2013-04-23: Gilead Presents Data from Phase 3 Studies of Sofosbuvir for Hepatitis C

Financial news for GILD dated on 2013-04-22: Gilead Sciences Target Boosted Sharply from \$48 to \$97 at Maxim

Financial news for GILD dated on 2013-04-22: Biotech Mutual Funds Show ETFs Are The Place to Be

Financial news for GILD dated on 2013-04-22: UPDATE: Morgan Stanley Raises PT on Gilead Sciences on Multiple Positive Factors

Financial news for GILD dated on 2013-04-22: Morgan Stanley Maintains Overweight on Gilead Sciences, Inc., Raises PT to \$65.00

Financial news for GILD dated on 2013-04-21: A Look Ahead: This Week's ETFs to Watch

Financial news for GILD dated on 2013-04-19: Weekly Preview: Earnings Season Continues, Apple In Focus

Financial news for GILD dated on 2013-04-19: Vertex News Lifts Biotech ETFs

Financial news for GILD dated on 2013-04-16: UPDATE: Deutsche Bank Raises PT on Gilead Sciences on Monthly HCV Market Model

Financial news for GILD dated on 2013-04-16: Deutsche Bank Maintains Buy on Gilead Sciences, Inc., Raises PT to \$69.00

Financial news for GILD dated on 2013-04-15: Leerink Swann Maintains Outperform on Gilead Sciences, Inc., Raises PT to \$70.00

Financial news for GILD dated on 2013-04-14: A Look Ahead: This Week's ETFs to Watch

Financial news for GILD dated on 2013-04-12: UBS Maintains Buy on Gilead Sciences, Inc., Raises PT to \$59.00

Financial news for GILD dated on 2013-04-11: ETF Showdown: A Pharma Fight

Financial news for GILD dated on 2013-04-11: Under The Hood: An Unheralded Biotech ETF

Financial news for GILD dated on 2013-04-10: Short Sellers Move Out of Amgen, Celgene, Pharmacyclics

Financial news for GILD dated on 2013-04-09: Gilead Hep C Drug Likely to be Launched in Q1 2014

Financial news for GILD dated on 2013-04-08: These Are the 100 Highest-Paid CEOs in Business Today

Financial news for GILD dated on 2013-04-08: Gilead Submits NDA to FDA for Sofosbuvir for Hep C

Financial news for GILD dated on 2013-04-05: Some Companies Aren't Evil... And Some Even Save Lives

Financial news for GILD dated on 2013-04-04: Benzinga's M&A Chatter for Thursday April 4, 2013

Financial news for GILD dated on 2013-04-04: Credit Suisse Maintains Outperform on Gilead Sciences, Inc., Raises PT to \$60.00

Financial news for GILD dated on 2013-04-04: Hearing Chatter Dan Loeb Has Taken Significant Stake in Gilead

Financial news for GILD dated on 2013-03-28: Biotech Breakout Boosting ETFs

Financial news for GILD dated on 2013-03-28: Stocks Hitting 52-Week Highs

Financial news for GILD dated on 2013-03-28: Short Sellers Dump Amgen, Focus on Celgene, Gilead Sciences

Financial news for GILD dated on 2013-03-27: Benzinga's Top Pre-Market Gainers

Financial news for GILD dated on 2013-03-26: Gilead Announces Update on Phase 3 Study of Oral Fixed-Dose Combination of Sofosbuvir and Ledipasvir for Genotype 1 Hepatitis C Patients

Financial news for GILD dated on 2013-03-25: Moving Averages Indicate These Sector ETFs Could be Stretched

Financial news for GILD dated on 2013-03-25: Mid-Afternoon Market Update: VrinetX Falls as Veeco Continues to Boost

Financial news for GILD dated on 2013-03-25: Mid-Day Market Update: Markets Turn Red, Apollo Group Surges On Upbeat Results

Financial news for GILD dated on 2013-03-25: Mid-Morning Market Update: Markets Rise On Cyprus Deal, Dollar General Posts Higher Profit

Financial news for GILD dated on 2013-03-25: Morning Market Losers

Financial news for GILD dated on 2013-03-25: Benzinga's Top Pre-Market Losers

Financial news for GILD dated on 2013-03-22: Gilead Confirms Positive CHMP Opinion for Stribild

Financial news for GILD dated on 2013-03-22: EMA Gives Positive Opinion's on Baxter's Hyqvia, ARIAD Pharma's Iclusig, Gilead's Stribild

Financial news for GILD dated on 2013-03-18: Citigroup Maintains Buy on Gilead Sciences, Inc., Raises PT to \$60.00

Financial news for GILD dated on 2013-03-17: Three Top Performing BRIC Stocks (CBPO, GSH, VIPS)

Financial news for GILD dated on 2013-03-15: Exploring No Man's Land ETFs

Financial news for GILD dated on 2013-03-15: Report of 14 Adults 'Cured' of HIV -NewScientist

Financial news for GILD dated on 2013-03-14: UPDATE: Oppenheimer Raises Gilead PT on Promising Oncology Pipeline

Financial news for GILD dated on 2013-03-14: Oppenheimer Maintains Outperform on Gilead Sciences, Inc., Raises PT to \$50.00

Financial news for GILD dated on 2013-03-12: Short Interest Swings in Biotech Stocks (AMGN, CELG, PCYC)

Financial news for GILD dated on 2013-03-11: Deutsche Bank Reiterates Buy Rating, \$48 PT on Gilead Sciences on IMS Weekly Script Analysis

Financial news for GILD dated on 2013-03-11: A Look Ahead: This Week's ETFs to Watch

Financial news for GILD dated on 2013-03-10: Study Shows Gilead's Ranexa Reduces Angina Frequency in Chronic Angina Patients With Type 2 Diabetes

Financial news for GILD dated on 2013-03-08: If Stocks Keep Soaring, Get to Know These Leveraged ETFs

Financial news for GILD dated on 2013-03-05: UPDATE: Piper Jaffray Raises PT to \$50 on Gilead Sciences on Positive Data

Financial news for GILD dated on 2013-03-05: Gilead Reports Full 24-Week Phase 2 Results for Once-Daily Single Tablet HIV Regimen Containing Novel TAF

Financial news for GILD dated on 2013-03-05: Piper Jaffray Maintains Overweight on Gilead Sciences, Inc., Raises PT to \$50.00

Financial news for GILD dated on 2013-03-05: AHF Seeking FDA Reversal on Gilead's HIV



Prevention Pill for Women

Financial news for GILD dated on 2013-03-04: An HIV Cure Is Great News For These Drug Manufacturers

Financial news for GILD dated on 2013-03-03: HIV Infected Baby 'Cured' with Aggressive Drug Treatment -NYT

Financial news for GILD dated on 2013-02-28: Short Interest Swings in Biotech Stocks (ALXN, AMGN, CELG)

Financial news for GILD dated on 2013-02-25: Gilead Shares Moving Higher as BofA Merrill Added to 'US 1 List'

Financial news for GILD dated on 2013-02-19: Gilead's Sofosbuvir Meets Primary Endpoint in Fourth Pivotal Phase 3 Study

Financial news for GILD dated on 2013-02-19: Credit Suisse Upgrades Gilead Sciences, Inc. to Outperform, Raises PT to \$55.00

Financial news for GILD dated on 2013-02-12: Short Interest Swings in Biotech Stocks (AMGN, CELG, ONXX)

Financial news for GILD dated on 2013-02-05: UBS Maintains Buy on Gilead Sciences, Inc., Raises PT to \$48.00

Financial news for GILD dated on 2013-02-05: Atlantic Equities Downgraded Gilead Sciences, Inc. to Neutral, Raised PT to \$41.00

Financial news for GILD dated on 2013-02-05: YM Biosciences Wins Final Court Order Approving Plan of Arrangement with Gilead

Financial news for GILD dated on 2013-02-05: Stocks Hitting 52-Week Highs

Financial news for GILD dated on 2013-02-05: Jefferies Maintains Hold on Gilead Sciences, Inc., Raises PT to \$40.00

Financial news for GILD dated on 2013-02-05: Stifel Nicolaus Maintains Buy on Gilead Sciences, Inc., Raises PT to \$49.00

Financial news for GILD dated on 2013-02-05: UPDATE: Gilead Posts Upbeat Q4 Results

Financial news for GILD dated on 2013-02-04: Gilead Sciences, Inc. Reports Q4 EPS of \$0.50 vs \$0.48 Est; Revenue of \$2.59B vs \$2.43B Est

Financial news for GILD dated on 2013-02-04: Morgan Stanley Reiterates Overweight Rating on Gilead Sciences on Phase III Data

Financial news for GILD dated on 2013-02-04: Piper Jaffray Reiterates Overweight Rating, \$44 PT on Gilead Sciences

Financial news for GILD dated on 2013-02-04: Gilead Announces Sustained Virologic Response Rates from Two Phase 3 Studies of Sofosbuvir

Financial news for GILD dated on 2013-02-04: US Stock Futures Flat Ahead Of Factory-Orders Data

Financial news for GILD dated on 2013-02-04: Earnings Scheduled For February 4, 2013

Financial news for GILD dated on 2013-01-30: UPDATE: Deutsche Bank Reiterates Buy Rating, Lowers PT on Gilead Sciences

Financial news for GILD dated on 2013-01-30: UBS Maintains Buy on Gilead Sciences, Inc., Raises PT to \$47.00

Financial news for GILD dated on 2013-01-30: Deutsche Bank Maintains Buy on Gilead Sciences, Inc., Lowers PT to \$48.00

Financial news for GILD dated on 2013-01-26: Short Interest Swings in Biotech Stocks (BIIB, CELG, VVUS)

Financial news for GILD dated on 2013-01-24: Friday January 25th Watchlist

Financial news for GILD dated on 2013-01-22: Morgan Stanley Sees Possible Near-Term Increase in M&A, Unveils 'Acquisition Likelihood Estimate Ranking Tool'

Financial news for GILD dated on 2013-01-15: One Biotech Stock Investors are Unfairly Ignoring

Financial news for GILD dated on 2013-01-07: 4 Health Care ETFs Your Broker Forgot to Mention

Financial news for GILD dated on 2013-01-07: Gilead Offers Update on Hep C Development Plans

Financial news for GILD dated on 2013-01-07: MacroGenics Enters License Agreement with Gilead Sciences to Develop and Commercialize Four DART Products

Financial news for GILD dated on 2013-01-03: Baird Initiates Coverage on Gilead Sciences, Inc. at Outperform, Announces \$86.00 PT

Financial news for GILD dated on 2012-12-28: Short Interest Swings in Biotech Stocks (CELG, GILD, REGN)

Financial news for GILD dated on 2012-12-18: UBS Maintains Buy on Gilead Sciences, Inc., Raises PT to \$87.00

Financial news for GILD dated on 2012-12-17: UPDATE: Bloom Burton Downgrades YM BioSciences to Hold Post Gilead Acquisition

Financial news for GILD dated on 2012-12-14: Piper Jaffray Maintains Overweight on Gilead Sciences, Inc., Raises PT to \$88.00

Financial news for GILD dated on 2012-12-13: Goldman Sachs Reinstates Neutral on Gilead Sciences, Inc., Announces \$81.00 PT

Financial news for GILD dated on 2012-12-12: Benzinga's M&A Chatter for Wednesday December 12, 2012

Financial news for GILD dated on 2012-12-12: J.P. Morgan Reiterates Overweight Rating on Gilead Sciences

Financial news for GILD dated on 2012-12-12: These ETFs Are Awash in 2013 Takeover Targets

Financial news for GILD dated on 2012-12-12: Short Interest Swings in Biotech Stocks (BIIB, CELG, VVUS)

Financial news for GILD dated on 2012-12-12: Morning Market Movers

Financial news for GILD dated on 2012-12-12: UPDATE: Gilead to Buy YM BioSciences for \$2.95/Share in Cash

Financial news for GILD dated on 2012-12-12: Gilead Sciences to Buy YM Biosciences for \$2.95/Share in Cash

Financial news for GILD dated on 2012-12-10: Gilead Board Approves Two-for-One Stock Split

Financial news for GILD dated on 2012-12-08: A Look at Fortune's Health Care Picks for 2013 (ALGN, FMS, GILD)

Financial news for GILD dated on 2012-12-04: Barclays Maintains Overweight on Gilead Sciences, Inc., Raises PT to \$76.00

Financial news for GILD dated on 2012-12-02: BioMarin, Prestige Brands and Other Top Performing Health Care Stocks in November

Financial news for GILD dated on 2012-12-01: RIM, Green Mountain and Other Top Performing Nasdaq Stocks in November

Financial news for GILD dated on 2012-11-27: EC Approves Gilead's Viread for HIV-1 Infection in Children, Adolescents

Financial news for GILD dated on 2012-11-27: Gilead Shares Continuing Higher After Teva Says Won't Offer Gilead Generics Til June 1st or Court Ruling

Financial news for GILD dated on 2012-11-27: Gilead Announces Sustained Virologic Response Rate of 78% from Phase 3 Study of Sofosbuvir

Financial news for GILD dated on 2012-11-15: Gilead Announces Results from Two Phase 3 Stribild HIV Studies

Financial news for GILD dated on 2012-11-14: UPDATE: BMO Capital Markets Reiterates Gilead Sciences at Outperform on Positive ELECTRON Data Results

Financial news for GILD dated on 2012-11-13: UPDATE: Deutsche Bank Raises PT to \$95 on Gilead Sciences on Latest Data

Financial news for GILD dated on 2012-11-13: UPDATE: Stifel Nicolaus Raises PT to \$85 on Gilead Sciences on HCV Data

Financial news for GILD dated on 2012-11-13: Stocks Hitting 52-Week Highs

Financial news for GILD dated on 2012-11-13: Stifel Nicolaus Maintains Gilead Sciences at Buy, Raises PT from \$80 to \$85

Financial news for GILD dated on 2012-11-13: Deutsche Bank Maintains Gilead Sciences at Buy, Raises PT from \$75 to \$95

Financial news for GILD dated on 2012-11-12: Mid-Afternoon Market Update: Markets Near Flat; J.C. Penney Falling Further

Financial news for GILD dated on 2012-11-12: Short Interest Swings in Biotech Stocks (AMGN, BIIB, VRTX)

Financial news for GILD dated on 2012-11-12: Mid-Day Market Update: Markets Slow Their Rally; JC Penney Spikes Lower

Financial news for GILD dated on 2012-11-12: Stocks Hitting 52-Week Highs

Financial news for GILD dated on 2012-11-12: Mid-Morning Market Update: Markets Continue Cautious Rally; Jefferies Acquired by Leucadia

Financial news for GILD dated on 2012-11-12: Benzinga's Top Pre-Market Gainers

Financial news for GILD dated on 2012-11-12: Gilead Sciences Rises 10% Pre-Market on Positive Hepatitis C Data

Financial news for GILD dated on 2012-11-12: Gilead Announces Positive Hepatitis C Data

Financial news for GILD dated on 2012-10-31: Gilead's Once-Daily Novel Prodrug for the Treatment of HIV Meets 24-Week Primary Objective in Phase 2 Study

Financial news for GILD dated on 2012-10-25: Short Interest Swings in Biotech Stocks (BIIB, GILD, VVUS)

Financial news for GILD dated on 2012-10-24: S&P Likes a Trio of Biotech ETFs

Financial news for GILD dated on 2012-10-24: UPDATE: Credit Suisse Reiterates Neutral Rating, Raises PT on Gilead Sciences

Financial news for GILD dated on 2012-10-24: UPDATE: Jefferies & Company Reiterates Hold Rating, Raises PT on Gilead Sciences

Financial news for GILD dated on 2012-10-24: BMO Capital Markets Maintains Gilead Sciences at Outperform, raises PT from \$67 to \$89

Financial news for GILD dated on 2012-10-24: Credit Suisse Maintains Gilead Sciences at Neutral, Raises PT from \$54 to \$65

Financial news for GILD dated on 2012-10-24: Jefferies & Company Maintains Gilead Sciences at Hold, Raises PT from \$55 to \$59

Financial news for GILD dated on 2012-10-23: Gilead Sciences Reports Q3 EPS \$1 vs \$0.94 Est; Revenues \$2.43B vs \$2.34B Est

Financial news for GILD dated on 2012-10-15: Barclays Maintains Gilead Sciences at Overweight, Raises PT from \$65 to \$73

Financial news for GILD dated on 2012-10-15: Short Interest Swings in Biotech Stocks (BIIB, CELG, GILD)

Financial news for GILD dated on 2012-10-08: Piper Jaffray Maintains Gilead Sciences at Overweight, Raises PT from \$69 to \$85

Financial news for GILD dated on 2012-10-03: Three Biotech Stocks Analysts Are Keen On (ARIA, MACK, GEVA)

Financial news for GILD dated on 2012-10-03: UBS Maintains Gilead Sciences at Buy, Raises PT from \$65 to \$80

Financial news for GILD dated on 2012-10-01: Bernstein Upgraded Gilead Sciences from Market Perform to Outperform

Financial news for GILD dated on 2012-09-27: Bank of America Maintains Gilead

Sciences at Buy, Raises PO from \$64 to \$86

Financial news for GILD dated on 2012-09-26: Short Interest in Biotech Firms Resumes (BIIB, GILD, ILMN, REGN)

Financial news for GILD dated on 2012-09-19: UPDATE: Deutsche Bank Reiterates Buy Rating, Raises PT on Gilead Sciences

Financial news for GILD dated on 2012-09-19: Long set-ups for Wednesday

Financial news for GILD dated on 2012-09-19: Deutsche Bank Maintains Gilead Sciences at Buy, Raises PT from \$68 to \$75

Financial news for GILD dated on 2012-09-17: Top Narrow Based Indexes For September 17

Financial news for GILD dated on 2012-09-17: Stocks Hitting 52-Week Highs

Financial news for GILD dated on 2012-09-17: JP Morgan Maintains Gilead Sciences at Overweight, Raises PT from \$70 to \$75

Financial news for GILD dated on 2012-09-14: Gilead Accelerates Expiration of Rights Pact

Financial news for GILD dated on 2012-09-13: Short Sellers Shy Away from Biotech Firms

Financial news for GILD dated on 2012-09-12: Gilead Receives Positive Mad Money/Jim Cramer Mention -CNBC

Financial news for GILD dated on 2012-09-12: Gilead Reiterates Its FY12 Forecast for Net Product Sales \$8.8-9B

Financial news for GILD dated on 2012-09-12: Gilead Sciences Begins Presentation at Morgan Stanley Conference

Financial news for GILD dated on 2012-09-05: Three Biotech Stocks Analysts Are Keen On (MDVN, GEVA, OPTR)

Financial news for GILD dated on 2012-08-30: UBS Maintains Gilead Sciences at Buy, Raises PT from \$61 to \$65

Financial news for GILD dated on 2012-08-28: UPDATE: Stifel Nicolaus Raises PT to \$68 on Gilead Sciences

Financial news for GILD dated on 2012-08-28: Stifel Nicolaus Maintains Gilead Sciences at Buy, Raises PT from \$65 to \$68

Financial news for GILD dated on 2012-08-28: Jefferies & Company Maintains Gilead Sciences at Hold, Raises PT from \$53 to \$55

Financial news for GILD dated on 2012-08-27: Gilead Quad Pill Wins FDA Approval to Treat Patients with HIV -Bloomberg

Financial news for GILD dated on 2012-08-27: Short Interest in Biotech Firms on the Rise

Financial news for GILD dated on 2012-08-24: Bristol-Myers' Trash is Gilead Sciences' Treasure

Financial news for GILD dated on 2012-08-17: Idenix Shares Plunge After Hepatitis Drug Study Put on Hold

Financial news for GILD dated on 2012-08-15: Deutsche Bank Maintains Gilead Sciences at Buy, Raises PT from \$65 to \$68

Financial news for GILD dated on 2012-08-13: Short Sellers Shy Away from Biotech Firms

Financial news for GILD dated on 2012-08-02: Barclays Upgrades Gilead Sciences from Equal-weight to Overweight

Financial news for GILD dated on 2012-08-02: Mylan Signs Agreement with Gilead to Accelerate Access to Generic Single and Fixed-Dose Combination ARVs Containing Emtricitabine

Financial news for GILD dated on 2012-08-02: Gilead Sciences Announces New Collaboration with Indian Partners to Reduce Manufacturing Cost and Improve Availability of Emtricitabine-Based Antiretroviral Therapy in Developing Countries

Financial news for GILD dated on 2012-08-02: Deutsche Bank Maintains Gilead Sciences at Buy, Raises PT from \$57 to \$65

Financial news for GILD dated on 2012-07-30: Possible Hepatitis C Outbreak Could Lift This ETF

Financial news for GILD dated on 2012-07-27: UPDATE: Jefferies Raises PT on Gilead Science from \$48 to \$53

Financial news for GILD dated on 2012-07-27: Stifel Nicolaus Maintains Gilead Sciences at Buy, Raises PT from \$55 to \$60

Financial news for GILD dated on 2012-07-27: Jefferies & Company Maintains Gilead Sciences at Hold, Raises PT from \$48 to \$53

Financial news for GILD dated on 2012-07-26: Gilead Sciences Reports Q2 EPS \$0.99 vs \$0.95 Est; Revenues \$2.41B vs \$2.29B Est

Financial news for GILD dated on 2012-07-24: Gilead's Once-Daily Single Tablet Regimen Complera(r) Maintains HIV Suppression Among Patients Switching From Protease Inhibitor-Based Regimens

Financial news for GILD dated on 2012-07-24: Gilead's Boosting Agent Cobicistat for HIV Therapy as Effective as Ritonavir in Pivotal Phase 3 Study

Financial news for GILD dated on 2012-07-16: UPDATE: U.S. Food and Drug Administration Approves Gilead's Truvada(r) for Reducing the Risk of Acquiring HIV

Financial news for GILD dated on 2012-07-16: Gilead Wins FDA Approval for Truvada to Prevent HIV Risk

Financial news for GILD dated on 2012-07-11: Glaxo HIV Drug Beats Gilead's Atripla In Study -IBD

Financial news for GILD dated on 2012-07-05: Small-Cap Corner: A Forgotten Biotech ETF

Financial news for GILD dated on 2012-06-29: Heating Positive Chatter in Achillion Pharmaceuticals

Financial news for GILD dated on 2012-06-28: Gilead Submits New Drug Application to U.S. FDA for Boosting Agent Cobicistat

Financial news for GILD dated on 2012-06-27: Gilead Submits New Drug Application to U.S. FDA for HIV Integrase Inhibitor Elvitegravir for Treatment-Experienced Patients

Financial news for GILD dated on 2012-06-18: European Medicines Agency Validates Gilead's Marketing Application for Elvitegravir for Treatment of HIV Infection

Financial news for GILD dated on 2012-06-13: Gilead Sciences Says Very Robust Pipeline in Phase 2, Phase 3

Financial news for GILD dated on 2012-06-13: Gilead Sciences Presentation Begins at William Blair Growth Stock Conference

Financial news for GILD dated on 2012-06-13: PREVIEW: Gilead Sciences, Scotts Miracle-Gro to Present at William Blair Growth Stock Conference at 9:00am

Financial news for GILD dated on 2012-06-08: FDA Delays Decision on Gilead's Truvada to Prevent HIV -Bloomberg

Financial news for GILD dated on 2012-05-21: The Definitive Biotech ETF Guide (IBB, XBI, FBT)

Financial news for GILD dated on 2012-05-16: J.P. Morgan Reiterates Overweight Rating, \$65 PT for Gilead Sciences

Financial news for GILD dated on 2012-05-15: Third Point Initiates Stake in Gilead Sciences, Hollyfrontier, Newell Rubbermaid, Potash

Financial news for GILD dated on 2012-05-15: S&P Bullish On Biotech ETFs (FBT, IBB, XBI)

Financial news for GILD dated on 2012-05-14: HIV Drug Maker Gilead Sciences Scores Two Wins

Financial news for GILD dated on 2012-05-11: UPDATE: FDA Advisory Committee Supports Approval of Gilead's Once-Daily Quad Single Tablet Regimen for HIV

Financial news for GILD dated on 2012-05-11: FDA Advisory Panel Votes 13-1 to Recommend Gilead's Quad

Financial news for GILD dated on 2012-05-11: From Earlier: FDA Advisory Committee Supports Approval of Gilead's Truvada(r) for Reducing the Risk of Acquiring HIV

Financial news for GILD dated on 2012-05-09: FDA Staff Saying Research Shows Gilead's Quad to Be Non-Inferior to Comparator Groups with Respect to Efficacy -Reuters

Financial news for GILD dated on 2012-05-09: UPDATE: Gilead's HIV Quad Drug Faces FDA Panel Review Friday

Financial news for GILD dated on 2012-05-01: Gilead Initiates Phase 3 Clinical Trial of GS-1101 for the Treatment of Chronic Lymphocytic Leukemia

Financial news for GILD dated on 2012-04-26: Gilead Sciences Reports Q1 EPS \$0.91 vs \$0.94 Est; Revenues \$2.21B vs \$2.20B Est

Financial news for GILD dated on 2012-04-19: Hedge Fund Shkreli Making Negative Comments on Gilead Sciences, Shorting Shares

Financial news for GILD dated on 2012-04-19: Notable Options Activity in Gilead Sciences Inc

Financial news for GILD dated on 2012-04-19: Benzinga's Top Pre-Market Gainers

Financial news for GILD dated on 2012-04-19: Financial Breakfast: Morning News Summary for April 19, 2012

Financial news for GILD dated on 2012-04-19: Gilead Sciences Rises 15% on Release of Phase 2 Hepatitis C Data

Financial news for GILD dated on 2012-04-19: From Earlier: Gilead Announces Early Sustained Virologic Response Rates for GS-7977 Plus Ribavirin in Genotype 1 Treatment-Naive Hepatitis C Patients

Financial news for GILD dated on 2012-04-04: Hearing UBS Positive on Gilead Sciences

Financial news for GILD dated on 2012-04-03: Brean Murray Carret Discusses Gilead's Potential Competitor

Financial news for GILD dated on 2012-03-15: UPDATE: Stifel Nicolaus Resumes Buy, \$57 PT on Gilead Sciences

Financial news for GILD dated on 2012-03-13: Idenix Pharmaceuticals Spokesperson Says Resolution in Patent Interference Claim Against Gilead Could Take Up to 2 Years

Financial news for GILD dated on 2012-03-13: Hearing Leering Says Gilead Will Have to Pay Licensing Fee to Idenix

Financial news for GILD dated on 2012-03-13: The Portfolio Bids Adieu to Gilead and Banco Itau

Financial news for GILD dated on 2012-03-09: Gilead Launching New Single Tablet AIDS Drug This Year

Financial news for GILD dated on 2012-03-07: Gilead Analyst: The Abstract Stated That Total Cholesterol and LDL Increases Are Significantly Lower for Quad. Some HIV Medicines Have Been Linked to an Increase in Cholesterol, Which Can Lead to Heart Attacks.

Financial news for GILD dated on 2012-03-07: Gilead's Quad Single Tablet Regimen for HIV Non-Inferior to Atripla in Pivotal Phase 3 Study

Financial news for GILD dated on 2012-03-07: Morgan Stanley Updates Gilead Sciences Model

Financial news for GILD dated on 2012-03-06: Researcher Says 8 Of The 9 "null" Hepatitis C Patients Who Have Reached 4 Weeks Post-Treatment In Trial Of Gilead's GS-7977 Have Relapsed -Reuters

Financial news for GILD dated on 2012-03-05: Hearing Goldman Sachs Reiterating Gilead Sciences as Top Pick for 2012, Making Positive Comments

Financial news for GILD dated on 2012-03-02: Option Alert: Gilead Sciences April 50 Call; Block Trade, 3,835 Contracts

Financial news for GILD dated on 2012-02-27: Deutsche Bank Reiterates Buy, \$57 PT on

## Gilead Sciences

Financial news for GILD dated on 2012-02-27: Morgan Stanley: 7977 Will Be Vital in All-Oral HCV Therapy

Financial news for GILD dated on 2012-02-24: UPDATE: Deutsche Bank Cuts Target to \$57 on Gilead Sciences

Financial news for GILD dated on 2012-02-23: JP Morgan Remains Bullish on Gilead Sciences

Financial news for GILD dated on 2012-02-22: Hearing Deutsche Bank Making Negative Comments on Gilead Sciences

Financial news for GILD dated on 2012-02-17: Friday Slide: Opportunity Or Red Flag For Biotech ETFs? (GILD, IBB, XBI)

Financial news for GILD dated on 2012-02-17: Gilead Analyst: The Gilead News is Positive for Vertex Investor Sentiment. It Casts Doubt Over the Thesis That Invicek's Market Share Will Go to Zero in 2014.

Financial news for GILD dated on 2012-02-17: Gilead Falls On Disappointing Hep C Drug Data; Analysts Remain Bullish

Financial news for GILD dated on 2012-02-17: UPDATE: Analyst Mark Schoenebaum Discusses Gilead Sciences on CNBC

Financial news for GILD dated on 2012-02-17: Gilead Sciences Negative Data Ripples through Biotech Field, Boosting Vertex, Achillion; Knocking Idenix

Financial news for GILD dated on 2012-02-17: Achillion Pharmaceuticals Spiking Higher on Gilead Hep C Data

Financial news for GILD dated on 2012-02-17: Deutsche Bank Sees Buying Opportunity on Gilead Share Weakness

Financial news for GILD dated on 2012-02-17: Vertex Pharmaceuticals Seeing Strength this Morning after Gilead's Negative Results

Financial news for GILD dated on 2012-02-17: Idenix Pharmaceuticals Seeing Weakness this Morning on Gilead's Negative Results

Financial news for GILD dated on 2012-02-17: Gilead Sciences Falls 23% Pre-Market on Disappointing Hep C Data

Financial news for GILD dated on 2012-02-17: Gilead Announces Data for Genotype 1 Null Responder Hepatitis C Patients Enrolled in ELECTRON Study; Viral Relapse Seen Post Treatment with GS-7977 Plus Ribavirin

Financial news for GILD dated on 2012-02-14: From Earlier: U.S. FDA Grants Priority Review for Truvada for Reducing the Risk of Acquiring HIV Infection

Financial news for GILD dated on 2012-02-10: Morgan Stanley Initiates Coverage on Gilead Sciences at Overweight, Announces PT of \$65

Financial news for GILD dated on 2012-02-06: Gilead Sciences Hits 52-Week High of \$54.90

Financial news for GILD dated on 2012-02-03: Gilead Sciences Soars On "Striking" Clinical Trial Data

Financial news for GILD dated on 2012-02-03: Gilead Sciences Surging on Clinical Trial Data

Financial news for GILD dated on 2012-02-03: UPDATE: JP Morgan Raises Target to \$65 on Gilead Sciences

Financial news for GILD dated on 2012-02-03: Gilead Sciences Hits 52-Week High of \$53.42

Financial news for GILD dated on 2012-02-03: Gilead Sciences up 10% Despite Lower Than Expected Q4 Profit

Financial news for GILD dated on 2012-02-03: Brean Murray Maintains Sell on Idenix

Financial news for GILD dated on 2012-02-03: UPDATE: Deutsche Bank Raises Target to \$66 on Gilead Sciences

Financial news for GILD dated on 2012-02-03: JP Morgan Raises PT on Gilead Sciences

to \$65

Financial news for GILD dated on 2012-02-02: Gilead Guides 2012 Product Sales \$8.6-8.8B

Financial news for GILD dated on 2012-02-02: Gilead Sciences Reports Q4 EPS \$0.97 vs \$1.05 Est; Revenues \$2.20B vs \$2.18B Est

Financial news for GILD dated on 2012-02-02: Gilead Sciences Hits 52-Week High of \$49.40

Financial news for GILD dated on 2012-02-01: Gilead Sciences Hits 52-Week High of \$49.06

Financial news for GILD dated on 2012-01-26: Brean Murray Carret & Co. Raises Gilead Sciences PT To \$60

Financial news for GILD dated on 2012-01-25: Gilead Sciences Hits 52-Week High of \$47.87

Financial news for GILD dated on 2012-01-24: Gilead Initiates Phase 2 Clinical Trial Evaluating GS-7340, A Low-Dose Novel Prodrug of Tenofovir for the Treatment of HIV

Financial news for GILD dated on 2012-01-24: BioLineRx Surges after Hep C License Agreement

Financial news for GILD dated on 2012-01-24: Gilead Sciences Hits 52-Week High of \$47.56

Financial news for GILD dated on 2012-01-19: Achillion's Hep C Pipeline Likely Can't Compete

Financial news for GILD dated on 2012-01-19: From Earlier: Gilead Sciences Announces U.S. Food and Drug Administration Approves New Formulations of Viread(r) for Use by Children Living With HIV

Financial news for GILD dated on 2012-01-18: J.P. Morgan Gives Gilead Sciences HIV Monthly Rx Update

Financial news for GILD dated on 2012-01-18: Gilead Sciences Hits 52-Week High of \$46.51

Financial news for GILD dated on 2012-01-17: 6 Stocks that worth watching

Financial news for GILD dated on 2012-01-17: Gilead Enters into \$1.25B, 5 Year Credit Pact; Funds Will Partially Cover Pharmasset Acquisition

Financial news for GILD dated on 2012-01-17: Gilead Sciences Hits 52-Week High of \$45.05

Financial news for GILD dated on 2012-01-10: Going Nuclear on Hepatitis C -- Is Idenix the Next Target?

Financial news for GILD dated on 2012-01-09: Just What The Doctor Ordered: 4 ETFs For Biotech M&A

Financial news for GILD dated on 2012-01-09: Forget Dendreon, Inhibitex is the New Biotech Success Story

Financial news for GILD dated on 2011-12-29: Top 4 Large-Cap Stocks In The Biotechnology Industry With The Highest Operating Margin

Financial news for GILD dated on 2011-12-28: Citigroup Reiterates Buy, \$49 Target on Gilead Sciences

Financial news for GILD dated on 2011-12-27: Best Biotech Stocks of 2011

Financial news for GILD dated on 2011-12-27: Citigroup Reiterates Buy, \$49 Target on Gilead Sciences

Financial news for GILD dated on 2011-12-20: Gilead Files European Marketing Application for the Quad, a Once-Daily Single-Tablet Regimen for the Treatment of HIV Infectio

Financial news for GILD dated on 2011-12-16: Wedbush Securities Drops Coverage on Pharmasset on Pending Gilead Acquisition

Financial news for GILD dated on 2011-12-16: Gilead Says it Remains Committed To Closing Pharmasset Acquisition -DJ



Financial news for GILD dated on 2011-12-16: JP Morgan Overweight on Gilead Sciences After Pharmasset QUANTUM Trial Announcement

Financial news for GILD dated on 2011-12-15: Gilead Sciences Submits Supplemental New Drug Application to U.S. Food and Drug Administration for Truvada

Financial news for GILD dated on 2011-12-09: Gilead Announces Two-Year Data From Pivotal Phase 3 Study of Elvitegravir, an Integrase Inhibitor for HIV

Financial news for GILD dated on 2011-12-08: Gilead Sciences and World Health Organization Establish New Five-Year Initiative to Prevent Deaths from Visceral Leishmaniasis

Financial news for GILD dated on 2011-12-07: Financial Breakfast: Morning News Summary for December 7, 2011

Financial news for GILD dated on 2011-12-07: Gilead Prices \$3.7 Billion of Senior Unsecured Notes

Financial news for GILD dated on 2011-12-05: Deutsche Bank Reiterates Buy, \$53 PT on Gilead

Financial news for GILD dated on 2011-12-05: Citi Reiterates Buy, \$49 PT on Gilead

Financial news for GILD dated on 2011-12-05: J.P. Morgan Reiterates Overweight On Gilead

Financial news for GILD dated on 2011-12-05: Gilead's Boosting Agent, Cobicistat, Meets 48-Week Primary Objective in Pivotal Phase 3 Study

Financial news for GILD dated on 2011-12-01: Pharmasset Seeing Weak Tape, Will \$11B Deal Go Through?

Financial news for GILD dated on 2011-11-29: Brean Murray Raises Inhibitex PT to \$19 From \$12

Financial news for GILD dated on 2011-11-28: Gilead Receives European Marketing Authorization for Eviplera

Financial news for GILD dated on 2011-11-28: Deutsche Bank Has Buy, \$53 PT On Gilead

Financial news for GILD dated on 2011-11-28: Investor Ideas' Biotech and Pharma Stock Investor Alert for Aethlon Medical, Vertex, Pharmasset

Financial news for GILD dated on 2011-11-28: Credit Suisse Downgrades Gilead Sciences to Neutral

Financial news for GILD dated on 2011-11-28: Goldman Sachs Adds Gilead Sciences to Conviction Buy List

Financial news for GILD dated on 2011-11-25: Investor Ideas' Hepatitis C Virus (HCV) Biotech and Pharma Stock Investor Alert

Financial news for GILD dated on 2011-11-23: Fast Money Picks For November 25th (EMB, GILD, PM, DE, TWI)

Financial news for GILD dated on 2011-11-23: Argus Downgrades Gilead Sciences to Hold

Financial news for GILD dated on 2011-11-22: Brean Murray Downgrades Pharmasset to "Hold"

Financial news for GILD dated on 2011-11-22: UPDATE: Bank of America Upgrades Gilead Sciences to Buy

Financial news for GILD dated on 2011-11-22: Bank of America Upgrades Gilead Sciences to Buy, PO Raised to \$55

Financial news for GILD dated on 2011-11-22: UPDATE: JP Morgan Maintains Overweight, Raises PT to \$55 on Gilead Sciences

Financial news for GILD dated on 2011-11-22: Piper Jaffray Reiterates Overweight Rating on Achillion Pharmaceuticals

Financial news for GILD dated on 2011-11-22: Canaccord Downgrades Pharmasset to Hold

Financial news for GILD dated on 2011-11-22: UBS Downgrades Pharmasset to Neutral

Financial news for GILD dated on 2011-11-22: BMO Capital Markets Upgrades Gilead

Sciences to Outperform

Financial news for GILD dated on 2011-11-22: JP Morgan Raises PT on Gilead Sciences to \$55

Financial news for GILD dated on 2011-11-22: Idenix and Spectrum Pharmaceuticals to Open Near 52-Week Highs

Financial news for GILD dated on 2011-11-21: Fast Money Picks For November 22nd (TOL, GILD, M, GFI, MS)

Financial news for GILD dated on 2011-11-21: Pharmasset to Pay Gilead \$331.9M Fee if Deal Terminated

Financial news for GILD dated on 2011-11-21: Pharmasset Agreed Not to Solicit Talks on Other Proposals

Financial news for GILD dated on 2011-11-21: Afternoon Movers; Healthcare Sector Up Significantly

Financial news for GILD dated on 2011-11-21: Hep-C Stocks Soar On M&A News

Financial news for GILD dated on 2011-11-21: What's Next for Hep C Drug Stocks Following Gilead's \$11B Pharmasset Buy?

Financial news for GILD dated on 2011-11-21: UPDATE: Piper Jaffray Downgrades Pharmasset to Neutral, PT Raised to \$137

Financial news for GILD dated on 2011-11-21: GILD Acquires VRUS

Financial news for GILD dated on 2011-11-21: Stocks Hitting 52-Week Highs

Financial news for GILD dated on 2011-11-21: Option Alert: Pharmasset December 100 Call Rises 17,300% on Takeover by Gilead Sciences

Financial news for GILD dated on 2011-11-21: Morning Market Movers

Financial news for GILD dated on 2011-11-21: Jim Cramer says Gilead "Staggeringly" Overpaid for Pharmasset

Financial news for GILD dated on 2011-11-21: Gilead Sciences Hits 52-Week Low of \$35.27

Financial news for GILD dated on 2011-11-21: J.P. Morgan Maintains Overweight Rating on Gilead Sciences

Financial news for GILD dated on 2011-11-21: Inhibitex Rises 29% Pre-Market on Gilead Buyout of Pharmasset

Financial news for GILD dated on 2011-11-21: Deutsche Bank Maintains Buy Rating on Gilead Sciences Following Pharmasset Acquisition

Financial news for GILD dated on 2011-11-21: Benzinga's Top Pre-Market Losers

Financial news for GILD dated on 2011-11-21: Benzinga's Top Pre-Market Gainers

Financial news for GILD dated on 2011-11-21: Gilead Participating in Merger Monday with Massive \$11B Deal

Financial news for GILD dated on 2011-11-21: Pharmasset Shares Surge In Pre-Market On Acquisition News

Financial news for GILD dated on 2011-11-21: Financial Breakfast: Morning News Summary for November 21, 2011

Financial news for GILD dated on 2011-11-21: Pharmasset Rises 85% Pre-Market on Gilead Sciences Buyout

Financial news for GILD dated on 2011-11-21: Pharmasset, Gilead Sciences Resume Trading

Financial news for GILD dated on 2011-11-21: Pharmasset, Gilead Sciences to resume trading at 7:30am

Financial news for GILD dated on 2011-11-21: Gilead Sciences to Acquire Pharmasset, Inc. for \$11 Billion

Financial news for GILD dated on 2011-11-16: JP Morgan Overweight on Positive Rx Data from Gilead Sciences

Financial news for GILD dated on 2011-11-15: End-of-Day Market Summary for November 15, 2011

Financial news for GILD dated on 2011-11-15: Gilead Sciences Finalizes Agreement with Tibotec Pharmaceuticals to Develop and Commercialize a Single-Tablet Regimen of Prezista with Emtriva, GS 7340 and Cobicistat

Financial news for GILD dated on 2011-11-15: Gilead Sciences Finalizes Agreement with Tibotec Pharmaceuticals to Develop and Commercialize a Single-Tablet Regimen of Prezista

Financial news for GILD dated on 2011-11-14: Third Point Entered Stakes in Yahoo, HollyFrontier Corp, Gilead Sciences, Warnaco Group and Gardner Denver; Exited Stakes in CIT Group, NXP Semiconductors, Pall Corp, Health Net, Safeway and Freeport-McMoran in Q3

Financial news for GILD dated on 2011-11-07: Gilead Sciences and Cardiovascular Research Foundation Initiate Phase 3 Clinical Trial with Ranolazine in Patients Who Have Undergone PCI with a History of Prior Chronic Angina

Financial news for GILD dated on 2011-11-05: Gilead Announces Positive Five-Year Data Showing Effect of Viread on Liver Fibrosis and Cirrhosis Caused by Chronic Hepatitis B

Financial news for GILD dated on 2011-10-27: Profit Up for Gilead Sciences

Financial news for GILD dated on 2011-10-27: Gilead Sciences Reports Q3 EPS \$1.02 vs \$1.01 Est; Revenues \$2.12B vs \$2.11B Est

Financial news for GILD dated on 2011-10-27: Gilead Submits New Drug Application to U.S. FDA for Once-Daily, Single-Tablet "Quad" HIV Regimen

Financial news for GILD dated on 2011-10-26: Bristol-Myers Squibb and Gilead Sciences Announce Licensing Agreement for Development and Commercialization of New Fixed-Dose Combination Pill for People Living with HIV

Financial news for GILD dated on 2011-10-25: Earnings Preview: Vertex Pharmaceuticals' EPS, Revenue Expected to Rise

Financial news for GILD dated on 2011-10-24: Gilead and GlobeImmune Announce License and Collaboration Agreement to Develop Therapeutic Vaccine Products for Treatment of Chronic Hepatitis B Infection

Financial news for GILD dated on 2011-10-24: Gilead Sciences Earnings Preview: Analysts Expect Higher EPS, Revenue

Financial news for GILD dated on 2011-10-19: Standpoint Research Downgraded Gilead Sciences to Hold

Financial news for GILD dated on 2011-10-06: Goldman Sachs Comments on Gilead Sciences

Financial news for GILD dated on 2011-10-06: Piper Jaffray Comments on Gilead Sciences' Licensing Agreement with Boehringer Ingelheim

Financial news for GILD dated on 2011-09-26: Top 4 Large-Cap Stocks In The Biotechnology Industry With The Lowest PEG Ratio

Financial news for GILD dated on 2011-09-19: Gilead's Second Pivotal Phase 3 Clinical Study of the Investigational Antiretroviral Quad Regimen Meets 48-Week Primary Objective

Financial news for GILD dated on 2011-09-16: Financial Breakfast: Morning News Summary for September 16, 2011

Financial news for GILD dated on 2011-09-16: Benzinga's Top Pre-Market Gainers

Financial news for GILD dated on 2011-09-16: Benzinga's Top Upgrades

Financial news for GILD dated on 2011-09-16: Goldman Sachs Upgrades Gilead Sciences To Buy, \$46 PT

Financial news for GILD dated on 2011-09-12: Citi Maintains Hold on Gilead Sciences

Financial news for GILD dated on 2011-09-04: Gilead Amends Study Design for Ongoing Hepatitis C Clinical Trials

Financial news for GILD dated on 2011-08-25: Piper Jaffray Looks Long at Gilead

## Sciences

Financial news for GILD dated on 2011-08-16: J.P. Morgan Adding Gilead Sciences To Focus List

Financial news for GILD dated on 2011-08-16: JP Morgan Adds Gilead Sciences To Analyst Focus list

Financial news for GILD dated on 2011-08-15: Hearing UBS Positive on Gilead Sciences

Financial news for GILD dated on 2011-08-15: Gilead's Antiretroviral Regiment Meets 48-Week Primary Objective in Phase 3 Study

Financial news for GILD dated on 2011-08-11: Brean Murray Carret & Co Revises EPS Estimates Of Gilead

Financial news for GILD dated on 2011-08-11: J.P. Morgan Reports On FDA Approval For GILD

Financial news for GILD dated on 2011-08-10: Gilead Sciences Resolves FDA Warning Letter Related to San Dimas Manufacturing Facility

Financial news for GILD dated on 2011-08-10: FDA Approves Gilead Sciences' Complera for HIV-1 Infection in Treatment-Naive Adults

Financial news for GILD dated on 2011-08-09: Gilead Sciences To Purchase Research and Manufacturing Facilities From Genentech

Financial news for GILD dated on 2011-08-08: Gilead Sciences to Purchase Biologics Process Research and Clinical Manufacturing Facility from Genentech

Financial news for GILD dated on 2011-08-02: AIDS Healthcare Foundation Hosts Protest & "Die-in" Over Gilead's AIDS Drug Prices

Financial news for GILD dated on 2011-07-27: Wednesday's S&P 500 Sector Recap: Hottest and Coldest Sectors

Financial news for GILD dated on 2011-07-27: UPDATE: JP Morgan Raises PT on Gilead Sciences from \$45 to \$50

Financial news for GILD dated on 2011-07-27: UPDATE: Oppenheimer Raises PT on Gilead Sciences to \$46

Financial news for GILD dated on 2011-07-27: JP Morgan Raises PT on Gilead Sciences To \$50

Financial news for GILD dated on 2011-07-27: Oppenheimer Raises PT On Gilead Sciences To \$46

Financial news for GILD dated on 2011-07-26: Gilead Sciences Reports Profit, Beats Estimates

Financial news for GILD dated on 2011-07-26: Gilead Sciences Reports Q2 EPS of \$1.00 vs. \$0.99 Est; Revenues \$2.14B vs. \$2.07B Est

Financial news for GILD dated on 2011-07-26: Notable Earnings After the Close: ACE, AMZN, GILD, CHRW, LVS, NSC, BWLD

Financial news for GILD dated on 2011-07-25: ISI Group Comments on Gilead Sciences

Financial news for GILD dated on 2011-07-25: Vertex Pharmaceuticals Earnings Preview: Analysts Expect Falling Revenue, Rising EPS Over Last Quarter

Financial news for GILD dated on 2011-07-21: Fifteen Health Care ETFs Trading Near 52-Week Highs

Financial news for GILD dated on 2011-07-21: Earnings Preview: Gilead Sciences EPS, Revenue Expected to Rise from Previous Quarter

Financial news for GILD dated on 2011-07-21: Gilead Sciences Hits New 52-Week High at \$42.94

Financial news for GILD dated on 2011-07-20: Gilead's Investigational Antiretroviral Elvitegravir Once Daily Non-Inferior to Raltegravir Twice Daily at 48 Weeks

Financial news for GILD dated on 2011-07-18: Support Held 07-18-2011

Financial news for GILD dated on 2011-07-18: WANTED: Buyers 07-18-2011

Financial news for GILD dated on 2011-07-18: J.P. Morgan Overweight On Gilead Sciences

Financial news for GILD dated on 2011-07-18: Options Brief: Gilead Sciences

Financial news for GILD dated on 2011-07-18: Bank of America Comments on Gilead Sciences After Research Results

Financial news for GILD dated on 2011-07-12: Oppenheimer Discusses Phase III Results From Gilead

Financial news for GILD dated on 2011-07-11: Deutsche Banks Reports Gilead Sciences 1Q To Miss

Financial news for GILD dated on 2011-06-29: UPDATE: Piper Jaffray Upgrades Gilead Sciences to Overweight

Financial news for GILD dated on 2011-06-29: Piper Jaffray Upgrades Gilead Sciences To Overweight, Raises PT To \$53

Financial news for GILD dated on 2011-06-28: Gilead Sciences Announces Agreement With Tibotec Pharmaceuticals to Develop and Commercialize a New Fixed-Dose Combination of Cobicistat and Prezista

Financial news for GILD dated on 2011-06-13: Health Care Sector Showing Strength

Financial news for GILD dated on 2011-06-13: Benzinga's Top Pre-Market Losers

Financial news for GILD dated on 2011-06-13: US Stock Futures Flat; Crude Oil, Gold Futures Drop

Financial news for GILD dated on 2011-06-13: Stocks To Watch For June 13

Financial news for GILD dated on 2011-06-10: Gilead Sciences Receives Subpoena from U.S. Department of Justice

Financial news for GILD dated on 2011-06-06: Gilead Reigns Supreme In HIV

Financial news for GILD dated on 2011-06-03: J.P. Morgan Overweight On Gilead Sciences After Meeting With Management

Financial news for GILD dated on 2011-05-23: Deutsche Bank Reports on Gilead Sciences

Financial news for GILD dated on 2011-05-18: GlaxoSmithKline and Isis Pharmaceuticals partnership shouldn't be overlooked as a long-term

Financial news for GILD dated on 2011-05-04: Mad Money Lightning Round: Cramer Advises Investors To Buy Gilead Sciences (GILD, NGG, NOG, AA, VOD)

Financial news for GILD dated on 2011-05-03: Deutsche Bank Comments On Gilead Sciences Client Dinner

Financial news for GILD dated on 2011-04-24: Top 5 S&P 500 worst performers for the week - IRM, GILD, HOG, KEY and DV

Financial news for GILD dated on 2011-04-21: UPDATE: Citi Raising Price Target On Gilead Sciences Inc (GILD)

Financial news for GILD dated on 2011-04-21: Jefferies Comments On Gilead Sciences 1Q11 Results

Financial news for GILD dated on 2011-04-21: J.P. Morgan Maintains Overweight on Gilead Sciences (GILD)

Financial news for GILD dated on 2011-04-21: Citigroup Raises PT On Gilead Sciences To \$44

Financial news for GILD dated on 2011-04-20: Gilead Sciences Reports EPS \$0.87 vs. \$0.97 Estimate; Revenues \$1.93B vs. \$2.04B Estimate (GILD)

Financial news for GILD dated on 2011-04-20: Gilead and MicroDose Therapeutx Announce License and Collaboration Agreement to Develop MDT-637 for Treatment of Respiratory Syncytial Virus

Financial news for GILD dated on 2011-04-15: Trend Continues to be Your Friend 04-15-2011

Financial news for GILD dated on 2011-04-11: J.P. Morgan Maintains Overweight on Gilead Sciences (GILD)

Financial news for GILD dated on 2011-04-04: Deutsche Bank Reiterates Buy Rating On GILD

Financial news for GILD dated on 2011-03-30: Yale and Gilead Sciences Announce Cancer Research Collaboration

Financial news for GILD dated on 2011-03-29: Drug Stocks Finally Make Their Move

Financial news for GILD dated on 2011-03-29: Wedbush Dropping Coverage Of Gilead Sciences

Financial news for GILD dated on 2011-03-29: Top 4 Large-Cap Stocks In The Biotechnology Industry With The Highest Operating Margin (GILD, AMGN, BIIB, CELG)

Financial news for GILD dated on 2011-03-28: Deutsche Bank Releases GILD Weekly IMS

Financial news for GILD dated on 2011-03-28: Mad Money Lightning Round: Cramer Likes Alcoa, Health Care REIT (AA, SPPI, PANL, PFE, GILD, CELG, MRK, ABT, AGNC, NLY, HCN)

Financial news for GILD dated on 2011-03-23: UBS Research Summary (AOL, CCL, CHD, GILD, RCL, SFSF)

Financial news for GILD dated on 2011-03-23: Gilead to Offer Senior Notes

Financial news for GILD dated on 2011-03-23: Gilead Sciences Files Automatic Mixed Securities Shelf

Financial news for GILD dated on 2011-03-23: Phase III Clinical Trial of Gilead's Investigational Elvitegravir Meets 48-Week Primary Objective

Financial news for GILD dated on 2011-03-18: Biotech Sector Snapshot HIV Drug Development

Financial news for GILD dated on 2011-03-17: Biotech/Pharma Sector Close-Up; Drug Resistance Potential for HIV Drugs; Can Medical Devices take over when drugs fail?

Financial news for GILD dated on 2011-03-17: Top 4 Large-Cap Stocks In The Healthcare Sector With The Lowest PEG Ratio (CELG, TEVA, GILD, GENZ)

Financial news for GILD dated on 2011-03-05: FDA Modifies Boxed Warning For Gilead Sciences Letairis Drug; Monthly Tests No Longer Required

Financial news for GILD dated on 2011-03-04: Running Late 03-04-2011

Financial news for GILD dated on 2011-03-04: FDA Modifies Boxed Warning For Gilead Sciences Letairis Drug; Monthly Tests No Longer Required

Financial news for GILD dated on 2011-03-04: How To Trade Biotech Stocks Better: Trading The NDAs (BIIB, AMGN, VVUS, GENZ, GILD)

Financial news for GILD dated on 2011-03-04: U.S. FDA Removes Warning about Potential Liver Injury from Boxed Warning of Prescribing Information for Gilead's Letairis

Financial news for GILD dated on 2011-03-02: Deutsche Bank Reports FDA Meta-Analysis On Abacavir Will Not Change Much For Gilead Sciences

Financial news for GILD dated on 2011-02-28: Gilead Sciences HIV Franchise Tracking Above Street Consensus Estimates

Financial news for GILD dated on 2011-02-22: Gilead Sciences to Acquire Calistoga Pharmaceuticals for \$375M

Financial news for GILD dated on 2011-02-18: ETF Showdown: A Biotech Battle

Financial news for GILD dated on 2011-02-10: Gilead Sciences Refiles New Drug Application with the FDA for Single-Tablet Regimen of Truvada and TMC278

Financial news for GILD dated on 2011-02-10: Gilead Sciences Refiles New Drug Application with the FDA for Single-Tablet Regimen of Truvada and TMC278

Financial news for GILD dated on 2011-02-09: J.P. Morgan Leaves Gilead Sciences Overweight Rating, \$45 PT Unchanged (GILD)

Financial news for GILD dated on 2011-02-07: Gilead Sciences Announces Notification of ANDA Filing for Tamiflu

Financial news for GILD dated on 2011-01-26: Gilead Beats by a Penny - Analyst Blog

Financial news for GILD dated on 2011-01-26: Gilead Beats by a Penny - Analyst Blog

Financial news for GILD dated on 2011-01-25: Gilead Sciences Down Despite Earnings Beat (GILD)

Financial news for GILD dated on 2011-01-25: Gilead Sciences Repurchases \$5B of Common Stock

Financial news for GILD dated on 2011-01-25: Gilead Sciences Announces Fourth Quarter and Full Year 2010 Financial Results

Financial news for GILD dated on 2011-01-25: Gilead Sciences Reports Q4 EPS of \$.95 vs. \$.94

Financial news for GILD dated on 2011-01-25: Gilead Sciences Receives Refuse to File Notification From U.S. FDA on New Drug Application for Single-Tablet Regimen of Truvada

Financial news for GILD dated on 2011-01-25: Earnings Preview: Abbott Labs - Analyst Blog

Financial news for GILD dated on 2011-01-25: Earnings Preview: Abbott Labs - Analyst Blog

Financial news for GILD dated on 2011-01-25: Earnings Scheduled For January 25 (MMM, YHOO, VZ, JNJ, KMB, JNPR, GILD, DD, NSC, COH, AKS, BLK, TRV, ALTR, DV)

Financial news for GILD dated on 2011-01-24: Earnings Preview: Gilead Sciences - Analyst Blog

Financial news for GILD dated on 2011-01-24: Earnings Preview: Gilead Sciences - Analyst Blog

Financial news for GILD dated on 2011-01-21: Priority Review for Vertex HCV Drug - Analyst Blog

Financial news for GILD dated on 2011-01-21: Priority Review for Vertex HCV Drug - Analyst Blog

Financial news for GILD dated on 2011-01-21: J.P Morgan Gives Update On BioTech Stocks (AMGN, BIIB, GILD)

Financial news for GILD dated on 2011-01-13: European Market May Open its Doors to This Biotech

Financial news for GILD dated on 2011-01-13: European Market May Open its Doors to This Biotech

Financial news for GILD dated on 2011-01-11: Jefferies: GILD Is Range-Bound Until There's Clarity On New Pipeline Assets

Financial news for GILD dated on 2010-12-23: Gilead Ends Letairis Trial for IPF - Analyst Blog

Financial news for GILD dated on 2010-12-23: Gilead Ends Letairis Trial for IPF - Analyst Blog

Financial news for GILD dated on 2010-12-23: Stocks To Watch For December 23 (MU, CROX, BBBY, GILD, MON)

Financial news for GILD dated on 2010-12-22: Bed, Bath & Beyond, Micron: After-Hours Trading

Financial news for GILD dated on 2010-12-22: 2011 Big-Cap Biotech Preview

Financial news for GILD dated on 2010-12-21: Gilead to Buy Arresto Biosciences - Analyst Blog

Financial news for GILD dated on 2010-12-21: Gilead to Buy Arresto Biosciences - Analyst Blog

Financial news for GILD dated on 2010-12-21: Big Pharma in Frenzy of Drug Deals

Financial news for GILD dated on 2010-12-20: Gilead Sciences Acquires Arresto Biosciences for \$225M

Financial news for GILD dated on 2010-12-16: DoJ declines to intervene in lawsuit against Gilead Sciences regarding Ranexa (GILD)

Financial news for GILD dated on 2010-12-15: Mad Money Lightning Round: Cramer Prefers EMC To Terremark Worldwide (TMRK, EMC, DWA, GILD, CELG, F)

Financial news for GILD dated on 2010-12-14: 'Mad Money Lightning Round': Ford Rumbles

Financial news for GILD dated on 2010-12-14: Pfizer Drug Withdrawn from Market - Analyst Blog

Financial news for GILD dated on 2010-12-14: Pfizer Drug Withdrawn from Market - Analyst Blog

Financial news for GILD dated on 2010-12-10: Wells Fargo Resumes Coverage On Gilead Sciences With \$48-52 Valuation Range

Financial news for GILD dated on 2010-12-06: ETFs For Biotech M&A Mania

Financial news for GILD dated on 2010-11-30: Merck Halts Isentress Study - Analyst Blog

Financial news for GILD dated on 2010-11-30: Merck Halts Isentress Study - Analyst Blog

Financial news for GILD dated on 2010-11-24: Vertex Eyes Telaprevir Approval - Analyst Blog

Financial news for GILD dated on 2010-11-24: Gilead Files NDA for Combo HIV Drug - Analyst Blog

Financial news for GILD dated on 2010-11-24: Gilead Files NDA for Combo HIV Drug - Analyst Blog

Financial news for GILD dated on 2010-11-24: Vertex Eyes Telaprevir Approval - Analyst Blog

Financial news for GILD dated on 2010-11-24: Gilead Files NDA for Combo HIV Drug - Analyst Blog

Financial news for GILD dated on 2010-11-24: Gilead Files NDA for Combo HIV Drug - Analyst Blog

Financial news for GILD dated on 2010-11-23: Gilead Drug Shown to Reduce Risk of HIV Infection - Study

Financial news for GILD dated on 2010-11-23: Gilead Drug Shown to Reduce Risk of HIV Infection - Study

Financial news for GILD dated on 2010-11-23: Gilead Sciences Submits New Drug Application to U.S. FDA for Once-Daily Single-Tablet Regimen for HIV

Financial news for GILD dated on 2010-11-16: UBS Initiates Buy Rating on Gilead Sciences

Financial news for GILD dated on 2010-11-10: Zacks Industry Outlook Highlights: Bayer, Sanofi-Aventis, Alcon, Gilead Sciences and Biogen Idec - Press Releases

Financial news for GILD dated on 2010-11-09: Pharma & Biotech Industry Outlook - Nov. 2010 - Zacks Analyst Interviews

Financial news for GILD dated on 2010-11-09: Pharma & Biotech Industry Outlook - Nov. 2010 - Industry Outlook

Financial news for GILD dated on 2010-11-05: Dr. Paul Berg to Retire from Gilead Sciences' Board of Directors

Financial news for GILD dated on 2010-11-02: NASDAQ Biotech Market Gainers; (BPAX), (CELG), (GILD) Stocks to Watch

Financial news for GILD dated on 2010-11-02: Deutsche Bank Reviews Gilead's Possible Safety Issues (GILD)

Financial news for GILD dated on 2010-11-01: Time To Buy Gilead Sciences (GILD)

Financial news for GILD dated on 2010-11-01: Gilead Sciences Upgraded to Outperform

Financial news for GILD dated on 2010-10-27: Zacks.com featured expert Kevin Matras highlights: Domino's Pizza, Inc., Gilead Sciences, Inc., Huntsman Corp., Domtar Corp. and Diodes Inc. - Press Releases



Financial news for GILD dated on 2010-10-27: Gilead Sciences (GILD) - Bull of the Day

Financial news for GILD dated on 2010-10-27: Zacks Bull and Bear of the Day  
Highlights: Gilead Sciences, Linear Technology, Biogen Idec, Elan and Novartis -  
Press Releases

Financial news for GILD dated on 2010-10-22: Gilead Sciences: Defying Gravity (GILD)

Financial news for GILD dated on 2010-10-21: Biotech Growth Stocks At A Reasonable Price (CBST, CEPH, GILD, TEVA)

Financial news for GILD dated on 2010-10-20: Antiviral Franchise Drives Gilead - Analyst Blog

Financial news for GILD dated on 2010-10-20: Gilead Rising On Heavy Volume After Earnings (GILD)

Financial news for GILD dated on 2010-10-20: Gilead Sciences, Inc. (NASDAQ: GILD)

Financial news for GILD dated on 2010-10-19: Gilead Sciences Exceeds Wall Street Estimates (GILD)

Financial news for GILD dated on 2010-10-19: Gilead Up After Reporting Mixed Quarter (GILD)

Financial news for GILD dated on 2010-10-19: Gilead Sciences Announces Third Quarter Results; EPS \$.83

Financial news for GILD dated on 2010-10-19: AAPL and Oil and 7.5% Levels, Oh My

Financial news for GILD dated on 2010-10-19: Markets Well Off Lows

Financial news for GILD dated on 2010-10-19: Earnings Scheduled For October 19 (GS, BAC, KO, YHOO, UNH, JNPR, SLM, NYT, HOG, JNJ, ITW, EMC, LMT, GILD, BK, MICC, STT, WDC, BSX, MNI, OXY, BTU)

Financial news for GILD dated on 2010-10-15: Jefferies & Company Lowers Estimates While Raising Price Target Of Gilead Sciences

Financial news for GILD dated on 2010-10-14: Ben Graham Buys in Pharma: Gilead and Teva (GILD, TEVA)

Financial news for GILD dated on 2010-10-14: J.P. Morgan Previews Gilead's Earnings (GILD)

Financial news for GILD dated on 2010-10-01: Betting on Biotech - Interview with Adam Feuerstein, Senior Columnist and Biotech Analyst of TheStreet.com

Financial news for GILD dated on 2010-09-28: Top 4 NASDAQ Stocks In The Healthcare Sector With The Highest ROE (TRIB, ALXN, GILD, USNA)

Financial news for GILD dated on 2010-09-17: Jefferies Reiterates Hold Rating on Gilead Sciences (GILD)

Financial news for GILD dated on 2010-09-14: Gilead Reports Positive Quad Data - Analyst Blog

Financial news for GILD dated on 2010-09-14: Jefferies Has Hold On Gilead (GILD)

Financial news for GILD dated on 2010-09-12: Mad Money Lightning Round: Cramer Doesn't Like Coal Stocks (LINE, RTN, GILD, YZC, BTU, WFC, JPM)

Financial news for GILD dated on 2010-09-09: Top 4 NASDAQ Stocks In The Biotechnology Industry With The Highest ROE (GILD, TLCR, TECH, AMGN)

Financial news for GILD dated on 2010-09-07: Gilead Files MAA for HIV Drug - Analyst Blog

Financial news for GILD dated on 2010-09-01: Gilead Provides Update on \$5 Billion Stock Repurchase (GILD)

Financial news for GILD dated on 2010-08-31: Benzinga's After Hours Gainers (STX, NFLX, WFMI)

Financial news for GILD dated on 2010-08-23: Generic Risk For Gilead's Hepsera - Analyst Blog

Financial news for GILD dated on 2010-08-16: Cautious Outlook On Biotech Stocks (GILD, DNDN, AMGN, CELG, BIIB, GENZ)

Financial news for GILD dated on 2010-08-04: Vertex Loss Narrows, Reaffirms Guidance - Analyst Blog

Financial news for GILD dated on 2010-08-03: UTHR Up on Lower Costs, Higher Revs - Analyst Blog

Financial news for GILD dated on 2010-07-28: Market Roundup (F, ADBE, BA, GOOG, GILD, CELG, FSLR)

Financial news for GILD dated on 2010-07-26: Gilead Repurchasing \$1 billion In Stock (GILD)

Financial news for GILD dated on 2010-07-25: Gilead - Not Your Run of the Mill Mid-Tier Pharma

Financial news for GILD dated on 2010-07-21: Near-Term Impact Of New Guidelines Unclear On GILD

Financial news for GILD dated on 2010-07-21: Afternoon Market Update (GILD, CYT)

Financial news for GILD dated on 2010-07-21: GILD Shares Reach Bottom Due To Unrealistically Bearish Street View: JP Morgan

Financial news for GILD dated on 2010-07-21: Benzinga's Top Downgrades (GILD, RICK, YHOO, CPLP)

Financial news for GILD dated on 2010-07-21: Benzinga's Top Pre-Market NASDAQ Losers (YHOO, STX, GILD, JASO)

Financial news for GILD dated on 2010-07-21: RBC Capital Downgrades GILD To Sector Perform

Financial news for GILD dated on 2010-07-20: Gilead Sciences Misses Estimates, Shares Fall 4% (GILD)

Financial news for GILD dated on 2010-07-19: J.P. Morgan Reiterates Overweight Rating On Gilead (GILD)

Financial news for GILD dated on 2010-07-19: Piper Jaffray Lowers Price Targets In Biotech Complex (BMRN, GENZ, GILD, CELG, ALXN, HGS1)

Financial news for GILD dated on 2010-07-13: Oppenheimer: Earnings Preview Of GILD, CELG, AMGN, GENZ

Financial news for GILD dated on 2010-07-13: Standpoint Research Initiates Coverage On Gilead Sciences (GILD)

Financial news for GILD dated on 2010-07-06: Top 4 Stocks In The Biotechnology Industry With The Highest Revenue Estimates (AMGN, GILD, GENZ, BIIB)

Financial news for GILD dated on 2010-06-30: Pharmaceutical ETFs on the Rise

Financial news for GILD dated on 2010-06-24: June 24, 2010: 21 Large Cap/Low PE Stocks

Financial news for GILD dated on 2010-06-15: Options Traders See Gilead Rallying (GILD)

Financial news for GILD dated on 2010-06-09: Citi Rates Gilead Sciences "Buy"

Financial news for GILD dated on 2010-06-08: Very Important Positions to Hedge Funds (AAPL, BIDU, CIT, QQQ, JPM, INTC, QCOM, XRX)

Financial news for GILD dated on 2010-06-03: Top 5 NASDAQ Stocks In The Biotechnology Industry With The Highest Profit Margins (QLTI, PDLI, TECH, GILD, AMGN)

Financial news for GILD dated on 2010-05-27: Mad Money Lightning Round: Jim Discusses HUN, GTE, GILD, GS, BAX, CHU, WHR, OC, QCOM

Financial news for GILD dated on 2010-05-19: J.P. Morgan Reiterates "Overweight" Rating on Gilead (GILD)

Financial news for GILD dated on 2010-05-18: J.P. Morgan Sees Upside For Gilead Sciences (GILD)

Financial news for GILD dated on 2010-05-12: US Stocks End Lower Yesterday After Soaring On Monday, Dow And S&P Down, Nasdaq Bucks Trend

Financial news for GILD dated on 2010-05-11: Gilead Sciences (GILD) Opts For Share Buyback

Financial news for GILD dated on 2010-05-11: Gilead Sciences Gaining On High Volume (GILD)

Financial news for GILD dated on 2010-05-11: Gilead To Purchase Back \$5 Billion Of Its Stock

Financial news for GILD dated on 2010-05-06: Top 5 NASDAQ Stocks In The Healthcare Sector With The Highest Sales (AMGN, TEVA, GILD, MYL, BIIB)

Financial news for GILD dated on 2010-04-22: Investors In Gilead Sciences (GILD) Should See Healthy Returns; Barron's

Financial news for GILD dated on 2010-04-22: Stock Market News for April 22, 2010 - Market News

Financial news for GILD dated on 2010-04-21: Benzinga's Top Pre-Market Losers (VITC, IGTE, CSIQ, KMGB, GILD)

Financial news for GILD dated on 2010-04-20: Gilead Sciences (GILD) First-Quarter Profit Up By 45%

Financial news for GILD dated on 2010-04-20: Benzinga's Top Pre-Market Losers (HGSI, XTSI, RYAA, GILD, CLNE)

Financial news for GILD dated on 2010-04-20: Benzinga's Top Pre-Market Losers (HGSI, XTSI, RYAA, GILD, CLNE)

Financial news for GILD dated on 2010-04-09: BIB, BIS: New Biotech 2x ProShares

Financial news for GILD dated on 2010-03-30: Low Volume From The Holiday Should Push These Key Market ETFs Higher

Financial news for GILD dated on 2010-03-26: Ascendere Long/Short Model Portfolio End of Day Update: March 25, 2010

Financial news for GILD dated on 2010-03-23: Before Jumping Into A Single Health Care Stock Consider This ETF

Financial news for GILD dated on 2010-03-23: Top 5 Large-Cap Stocks In The Biotechnology Industry With The Highest ROE (GILD, AMGN, CELG, BIIB, GENZ)

Financial news for GILD dated on 2010-03-23: Top 5 Large-Cap Stocks In The Biotechnology Industry With The Highest Cash (AMGN, CELG, GILD, BIIB, GENZ)

Financial news for GILD dated on 2010-03-23: Top 5 Large-Cap Stocks In Biotechnology Industry With Highest Gross Margins (CELG, BIIB, AMGN, GILD, GENZ)

Financial news for GILD dated on 2010-03-22: Investors Flock To Healthcare ETFs On Historic Reform

Financial news for GILD dated on 2010-03-21: How Will Obama-Care Play Into The Markets And ETFs?

Financial news for GILD dated on 2010-03-17: This Healthcare ETF (XLV) Is Seeing Above Average Call Buying

Financial news for GILD dated on 2010-03-09: Five Biotech ETFs, Which One Is Worth A Look?

Financial news for GILD dated on 2010-03-03: Jim Cramer Comments On PMCS, CSCO, VRTX, GILD, PAL

Financial news for GILD dated on 2010-03-02: Astellas Dips: OSI Pharmaceuticals Inc. Takeover Not Easy (OSIP, GILD)

Financial news for GILD dated on 2010-02-23: FDA Approves Gilead Sciences (GILD) Cystic-Fibrosis Treatment

Financial news for GILD dated on 2010-02-22: Gilead Sciences Gets A 'Sell' Rating (GILD)

Financial news for GILD dated on 2010-02-22: Benzinga's Top Downgrades (GILD, HME, CVE, SNMX, NETL)

Financial news for GILD dated on 2010-02-22: Benzinga's Top Pre-Market Losers (RIGL, FSLR, GILD, STP, GSK)

Financial news for GILD dated on 2010-02-18: Leerink Swann Reiterates Gilead Science (GILD) Outperform Rating

Financial news for GILD dated on 2010-02-17: Benzinga's Intraday Sector Leaders

Financial news for GILD dated on 2010-02-17: Healthcare Industry Update (CI, PFE, WLP, CEPH, CELG)

Financial news for GILD dated on 2010-02-16: GILD Reports Solid Numerical Data For Quad Combo Pill

Financial news for GILD dated on 2010-02-16: Calls Purchased in Gilead

Financial news for GILD dated on 2010-02-09: A Look At How Different Sectors Will Behave In 2010 (PG, KO, WMT, GSK, GILD, AZN, EXC, D, DUK)

Financial news for GILD dated on 2010-02-09: Lightning Round: NKE, GILD, V, CSCO Rock

Financial news for GILD dated on 2010-02-09: Analyst Shares Top Picks In Biotechnology Sector With CNBC (AMGN, ACOR, DNDN, GILD)

Financial news for GILD dated on 2010-02-09: Top 5 Top-Cap NASDAQ Stocks with Highest PEG Ratio (BRCM, CELG, GOOG, GILD, QCOM)

Financial news for GILD dated on 2010-01-27: GILD To Continue To Outpace Long-Term Street Estimates

Financial news for GILD dated on 2010-01-27: GILD Reports Stellar Reports For 4Q09, Powered By HIV Franchise

Financial news for GILD dated on 2010-01-27: Gilead Sciences Inc. (GILD) Gets Buy Rating From Deutsche Bank

Financial news for GILD dated on 2010-01-27: Benzinga's Top Pre-Market Gainers (YHOO, ALTR, SANM, KTCC, GILD, SIFY)

Financial news for GILD dated on 2010-01-26: Gilead Beats Wall Street Estimates (GILD)

Financial news for GILD dated on 2010-01-25: Stock Outlook for Gilead Sciences Inc (GILD)

Financial news for GILD dated on 2010-01-21: Bright 2010 Prospects For US Biotechnology (AMGN, BIIB, CELG, GENZ, GILD)

Financial news for GILD dated on 2010-01-18: Jim Cramer's Lightning Round (ALSK, AMGN, GILD, CELG, SNDK, T, VZ, TGB, GLD, HAS, NFLX)

Financial news for GILD dated on 2010-01-15: Mid Cap Biotechs May Outperform In 2010

Financial news for GILD dated on 2010-01-14: Top 5 Large-Cap Stocks In The Healthcare Sector With The Highest ROE (GSK, GILD, AZN, ACL, MRK)

Financial news for GILD dated on 2010-01-12: Tech ETFs: A Way Out Of Recession

Financial news for GILD dated on 2010-01-08: Activity In Genzyme (GENZ)

Financial news for GILD dated on 2010-01-06: Celgene's (CELG) 2010 Guidance To Set The Trend

Financial news for GILD dated on 2009-12-29: 31.8% Return Expected in Gilead Sciences, Further Upside Possible (GILD)

Financial news for GILD dated on 2009-12-23: Top 5 Large-Cap NASDAQ Stocks with Highest ROE (DELL, ESRX, FSLR, GILD, PAYX)

Financial news for GILD dated on 2009-12-22: Bookkeeping: Beginning Human Genome Sciences (HGSI) Position

Financial news for GILD dated on 2009-12-21: Human Genome Sciences (HGSI) Appears Ready to Breakout of 2 Month Base

Financial news for GILD dated on 2009-12-11: Top 5 Large-Cap NASDAQ Stocks with Best ROA (GILD, BIDU, FSLR, MSFT, CTSH)

Financial news for GILD dated on 2009-12-11: Top 5 Large-Cap NASDAQ Stocks with Best ROE (GILD, PAYX, ESRX, BIDU, MSFT)

Financial news for GILD dated on 2009-11-11: Deutsche Bank maintains "buy" rating on GILD

Financial news for GILD dated on 2009-11-11: Top Franklin Templeton Funds - Mutual Fund Education

Financial news for GILD dated on 2009-11-05: Time To Make A Long-Term Bet On Healthcare (XLV)

Financial news for GILD dated on 2009-11-02: Morgan Stanley's (MS) Swine Flu Pandemic Trades (AMZN, BCRX, CAL, EXPE, GILD, MMM, MS, SFD)

Financial news for GILD dated on 2009-10-02: Cramer Says Buy Citigroup, GILD, ETP, CELG and sell ANN, GERN

Financial news for GILD dated on 2009-09-11: Deutsche Bank Analyst Likes Genzyme (GENZ), Gilead (GILD) And Amgen (AMGN)

Financial news for GILD dated on 2009-08-17: TheFortuneFinancial.com Free Market Research on CVBF, ESRX, CTAS, FUQI, JAZZ and GILD